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GENERAL INTRODUCTION 
 
Injuries are among the leading causes of death and disability in the world, often affecting young people.1 
In road traffic alone, about 1.25 million people die each year on the world's roads and millions more 
sustain non-fatal injuries.2,3 In Europe, yearly more than 230,000 people die and about 5.7 million 
people are hospitalised due to an intentional (e.g. self-harm, assault) or unintentional injury.4 Injury may 
lead to great personal suffering and economic costs. Almost all injury survivors experience some level 
of short-term or long-term impairment or disability,5 which affects their health-related quality of life 
(HRQL)5 and frequently inhibits them to return to full employment.6 In addition, survivors of injury may 
require specialised emergency care and long-term rehabilitation. 
An important severe injury that often affects young people is a traumatic brain injury (TBI). TBI, 
especially the more severe cases, can have a significant and long-term impact on a person's life and 
imposes a substantial economic burden on individuals and society.7,8 According to the World Health 
Organisation, TBI is predicted to surpass many diseases as a major cause of death and disability by the 
year 2020.9,10 
The number of survivors of severe injuries has rapidly risen,1 due to major advances in trauma systems, 
amongst others. This resulted in a shift in attention from mortality towards disability. Policymakers and 
clinicians are recognising the importance of quantifying the health impact and costs of injuries in order 
to identify, measure, value, and compare the costs and consequences of prevention strategies and 
treatments. This information enables them to prioritise prevention and provides essential input for the 
development of treatment guidelines. Consequently, insight into the incidence, trends, risk groups, 
costs, disease burden, and impact of an injury on patients’ health is essential in order to compare the 
burden of injuries between patient subgroups and with other diseases, optimise health care policy and 
prevention, and develop effective health care and rehabilitation services. 
The papers in this thesis deal with the incidence, health-related quality of life, psychiatric consequences 
and economic consequences of TBI, and address the methodological challenges in assessing outcome 
after injury, including TBI. 
This chapter will introduce some concepts related to the assessment of the health impact and costs of 
injuries, and consequently will address the research questions and outline of this thesis. 
 
1.1 TRAUMATIC BRAIN INJURY 
 
Traumatic brain injury (TBI) occurs when a sudden trauma causes damage to the brain. One commonly 
used definition of TBI is from an international expert group on TBI (Box 1.1).11 
Annually, 10 million people worldwide sustain a TBI that warrants some form of health care (incidence 
rate 144 per 100,000).1 In Europe, approximately 2.5 million people experience a TBI each year, of 
whom 1 million are admitted to the hospital and 75,000 die.12 Overall, males are about twice as likely 
as females to experience a TBI,13 and show overall higher mortality rates than females.14 Additionally, 
TBI often involves young children, young adults and the elderly.13 Motor vehicle-related crashes and 
falls are the most common events leading to a TBI.13 
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Box 1.1 Definition of traumatic brain injury (TBI) 
TBI is defined as an alteration in brain function, or other evidence of brain pathology, caused by an 
external force.11 An alteration in brain function is defined as one of the following clinical signs: any 
period of loss of or a decreased consciousness; any loss of memory for events immediately before 
or after the injury; neurologic deficits such as muscle weakness, loss of balance and coordination, 
disruption of vision, change in speech and language, or sensory loss; any alteration in mental state 
at the time of the injury such as confusion, disorientation, slowed thinking, or difficulty with 
concentration. Other evidence of brain pathology may include visual, neuro-radiologic, or laboratory 
confirmation of damage to the brain. Caused by an external force may include any of the following 
events: the head being struck by an object; the head striking an object; the brain undergoing an 
acceleration/deceleration movement without direct external trauma to the head; a foreign body 
penetrating the brain; forces generated from events such as a blast or explosion; or other force yet 
to be defined.11 
 
TBI survivors often experience a substantial burden of functional, physical, emotional, cognitive, 
behavioral, and/or social disability,15,16 which disrupts the lives of victims and relatives and imposes huge 
costs to individuals and society.17-19 
Symptoms of TBI can be classified as mild, moderate, or severe, depending on the extent of the damage 
to the brain. The majority (70–80%) of TBI cases involve mild TBI,13 often comprising a concussion. 
Although classified as ‘mild’, individuals with mild TBI may suffer from several physical impairments (e.g. 
headaches, dizziness, visual disturbances), cognitive problems (e.g. attention deficits, memory 
problems), and/or emotional or behavioral problems (irritability, anxiety, depression).16,20 Moderate or 
severe TBI often occurs due to penetrating injuries or more severe shaking of the brain inside the bony 
skull, compressing and stretching the fragile nerve cells in the brain. These injuries may result in 
contusion (bleeding), bruising, swelling, and/or tearing of the brain tissue and blood vessels, leading to 
a loss of consciousness of several minutes or a prolonged unconscious state or coma.21  
After a TBI, as swelling decreases and blood flow and brain chemistry improve, the function of the brain 
usually improves. TBI, however, often results in long-term or lifelong disability.15 In the US, almost half 
of all hospitalised TBI survivors22 and about 2% of the US population15 experience TBI-related long-term 
or lifelong disability, which drastically reduced their HRQL23,24 and complicated recovery and 
rehabilitation.25 
Over the past decades, the number of survivors of severe TBI has rapidly grown due to major advances 
in trauma systems,1 amongst others. However, the disability due to TBI has not appreciably reduced.26 
This has resulted in a shift in attention from mortality towards disability of TBI survivors. 
 
1.2 OUTCOME AFTER INJURY 
 
Historically, the medical community was oriented towards clinical outcomes, such as mortality and side 
effects of treatments.27 The escalation of health care expenditures in the 1970s and 1980s,28 amongst 
others,  induced a need for mechanisms to reduce these cost increases and a need for accountability 
for expenses and health outcome.27 As a consequence, there has been an increased interest in 
expanding the objective clinical outcomes with assessments of subjective patient-reported outcomes 
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and the measurement of economic outcomes.27 This resulted in the development of a model that  
classifies health outcomes along three dimensions: clinical outcome, functional outcome, and economic 
outcome.29 
The model can be translated to measure outcome after injury (Figure 1.1). In this thesis, clinical 
outcomes comprise the medical events that occur as a result of injury (e.g. hospital admission) and the 
objective outcome after injury as assessed by physicians. Functional outcomes are the consequences of 
injuries on a patient’s health-related quality of life (HRQL). Economic outcomes include the direct, 
indirect, and intangible costs of injuries. 
 
Figure 1.1 Measuring outcome after injury 
 
 
Integrated knowledge on the clinical outcomes, functional outcomes, and costs of injuries are essential 
to gain insight into the total impact of injuries, to identify high-risk groups and in its turn to set priorities 
for prevention and trauma care. So far, most efforts on assessing the outcome after injury, including 
TBI, have been limited to either its clinical outcome,13 functional outcome,30 or costs.7,31 By focusing on 
all three dimensions, the papers in this thesis provide insight into the medical events and the objective 
outcome after injury (clinical outcome), the impact of an injury on a patient’s life and specifically the 
psychiatric consequences (functional outcome), and the associated costs of injuries (economic 
outcome).  
 
Clinical outcome 
Injuries frequently warrant some form of specialised emergency care. This may involve consulting a 
general physician, treatment at the emergency department or intensive care, and/or admission to the 
hospital. Most injury patients, especially those who experienced a TBI, also require additional treatment 
after hospital discharge and often require rehabilitation services for the rest of their life. Rehabilitation 
aims to help injury patients to achieve the highest possible level of physical, mental, and social 
functioning. 
In case of TBI, these levels of functioning are often objectively assessed by physicians using the Glasgow 
Outcome Scale Extended (GOSE).26,32 The GOSE classifies outcome into an 8-point scale from 1 (dead) 
to 8 (complete recovery), using eight questions covering consciousness, independence at home, major 
Clinical 
outcome
Economic 
outcome
Health 
outcomes 
research
Functional 
outcome
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social roles, and return to normal life.33 However, a criticism of scales such as the GOSE is that they fail 
to capture the subjective perspective (e.g. HRQL) of injury patients.34  
 
Functional outcome 
Health care and prevention strategies have the ultimate goal to restore or preserve functioning and 
well-being related to health.35 Functional outcome addresses not only activities of daily living but also 
the other aspects that constitute quality of life.36 Quality of life expresses an overall sense of well-being, 
comprising aspects of happiness and satisfaction with life as a whole.37  
 
Health-related quality of life 
The concept of health-related quality of life (HRQL) has evolved since the 1980s and refers to a wide 
range of aspects of life that affect health (Box 1.2).38 
 
Box 1.2 Definition of health-related quality of life (HRQL) 
HRQL reflects an individual’s perception of how an illness and its treatment affect physical, mental 
and social aspects of his or her life.39 HRQL measurement is aimed to quantify the degree to which 
the medical condition (e.g. injury) impacts the individual’s life in a valid and reproducible way.40 
 
HRQL is generally measured with questionnaires (e.g. the SF-36 or EQ-5D) consisting of a number of 
questions on several domains of functioning (e.g. physical health, mental health, pain, mobility, self-
care, cognition, and social functioning).38 By means of HRQL measures patients can indicate whether 
and to which extend they have problems on one or several of these domains. 
Some HRQL instruments generate a single summary score (or utility score) that represents the total 
health status of a person on a scale that usually extends from 0 (death) to 1 (full health), although 
negative scores representing states worse than death are possible.38 This way, HRQL measures can be 
used to quantify the gap between measured and perfect HRQL or the net change in HRQL over time.38  
HRQL has been recognised as an important outcome after injuries, as it provides well-standardised 
information on the recovery patterns and frequency, nature, severity and duration of the functional 
consequences of injuries.41 This information is needed to quantify the impact of injuries on population 
health over time. Additionally, HRQL measures enable comparison of health outcome after injury with 
other diseases, pre-injury health state and the general population, and their outcome can be used in 
economic evaluations.38 
 
Psychiatric consequences 
The psychiatric consequences of injury have already been acknowledged since the 1940s.42 Several of 
these first studies investigated the mental problems occurring as a consequence of head injuries and 
burn injuries.42-44 To date, mental health has been recognised as an important component of HRQL after 
injury. However, little is known about to what extent patients with TBI are diagnosed with mental health 
problems after their injury, what the risk factors are for developing these psychiatric problems, and 
what the impact of these problems is on patients’ recovery. 
Research showed that a significant proportion of injury survivors is diagnosed with psychiatric disorders, 
with major depression and post-traumatic stress disorder (PTSD) being the most commonly diagnosed 
12 | General introduction 
and studied disorders.10 Notable variation exists in the prevalence rates of these disorders following TBI. 
For example, depression prevalence rates after injury have been assessed that vary from 8% to 60% 
shortly after injury, and 9% to 31% up to one year after the injury.45 PTSD prevalence rates have been 
reported that range from 18% to 42% within the first half year after injury, and 2% to 33% after one 
year.45  
Overall, psychiatric consequences are found to play an important role in the development and 
maintenance of long-term disability in injury survivors and have a substantial effect on their physical 
health, functioning, HRQL and capacity to work,46,47 imposing high costs to both individuals and society. 
 
Economic outcome 
Injuries, especially TBI, are a major cause of health care costs in the Western world. In Europe, the 
medical costs of hospital treated injuries is estimated to be at least 78 billion Euro per year.4 In case of 
TBI, the annual lifetime costs of patients requiring medical treatment add up to an estimated 406 billion 
US dollars (about 431 Euro) in the US17 and an estimated 147 million US dollars in New Zealand.18 The 
majority (80%) of these costs is attributed to lifetime lost productivity, while a relatively minor share 
(20%) is estimated for medical costs. 
Most of the assessments of the economic costs of injuries are based on the cost of illness approach (Box 
1.3). 
 
Box 1.3 Definition of cost of illness 
The cost of illness approach was formalised in the 1960s, and divides the economic consequences 
of illnesses into direct costs, indirect costs, and intangible costs.48,49 Direct costs include the expenses 
incurred because of the illness (e.g. medical care in hospitals and rehabilitation centers).48 Indirect 
costs represent the value of lost production because of reduced working time or impaired 
performance at the workplace.48 Intangible costs comprise the costs of pain and disability that 
cannot be directly measured in monetary form.48 Generally, direct and indirect costs are summed 
to provide the overall cost the illness imposed on society.49 
 
The papers in this thesis describe the direct health care costs, indirect productivity costs, and estimates 
of the total costs of injuries. These cost estimates provide a measure that enables comparison of the 
economic consequences of several types of injury with different injury severity and health care need. 
An overview of the costs of injuries by socio- and injury-related demographics easily provides insight 
into the opportunity for savings and needs for preventive action or treatment strategies. This 
information is essential for setting priorities in injury prevention and trauma care, and allocating 
resources in health care. 
 
1.3 METHODOLOGICAL CHALLENGES 
 
Injury, especially TBI, is characterised by a heterogeneous patient population of all ages and with a wide 
variety of causes, severity levels, outcome, and recovery patterns. This heterogeneity in patients and 
outcomes makes health outcomes research in the area of injuries challenging, and puts specific 
demands on the methodology of assessing outcome after injury. 
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The most important challenges in the outcome assessment of injuries, and especially TBI, comprise the 
difficulties in obtaining ratings from patients with severe injury, cognitive impairments, and those of 
very young age.50 These patients might not be able to self-report on their HRQL, and in certain 
conditions proxy-report might be useful. Additionally, a large variation of measures and instruments 
exists to quantify the health impact of injuries.51 Especially in TBI, there has been much debate on the 
use of generic instruments and/or measures that have been developed for TBI specifically, in order to 
measure all relevant domains of functioning (e.g. cognitive functioning).50 
 
Other challenges in the field of injuries involve the measurement of pre-injury health status, the shift in 
outcome assessment from mortality towards disability, and the assessment of change in health status 
due to an injury, which will be addressed in the second part of this thesis. 
In order to produce valid estimates of the health impact of injuries and the decrease in HRQL due to an 
injury, information on the patient’s pre-injury health status is needed. This information is, however, 
often not available due to the difficulty to prospectively collect information on the patients’ pre-injury 
health status. To date, it is not clear which alternative methods should be used to measure and 
incorporate the pre-injury HRQL of injury patients to estimate the change in health status. 
Moreover, it remains challenging to obtain information on the consequences of injury and assessing the 
outcome of injuries beyond mortality. Most trauma registries document information on the acute phase 
of hospital care and in-hospital mortality, but not on the consequences of non-fatal trauma. 
Additionally, information on the medical events after trauma is often registered in different databases, 
which generally all have their own purposes (e.g. injury prevention, trauma care evaluation, providing 
death statistics). As a consequence, none of these databases provides the full picture of medical events 
resulting from injury. Linkage of data from multiple sources may overcome these problems and may be 
used to obtain insight into the consequences of injury. 
Finally, different methods exist to quantify the consequences of injury, for example, the burden of 
disease. To estimate the years lived with disability due to an injury, disability weights are needed. 
Disability weights can be obtained from existing sets of disability weights, or derived from HRQL data 
from individual injury patients. Although both methods have their advantages and disadvantages, little 
is known about the differences between the disabilities weights derived by both methods and their 
effect on estimations of the change in health status. 
 
1.4 GUIDELINES 
 
Insights into the health- and economic impact of injuries is essential for the development of treatment 
guidelines. The trauma care for patients with injuries, especially TBI, is often complex and 
multidisciplinary. As a consequence, guidelines, protocols and care pathways have been developed to 
reduce variation in practice, improve quality of care, and ensure that evidence-based care is optimally 
implemented (Box 1.4). 
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Box 1.4 Guidelines 
Guidelines incorporate the current best evidence in making decisions about the care of individual 
patients. This way, guidelines enable the integration of the best available external clinical evidence 
from systematic research and consensus recommendations made by a panel of experts, with 
individual clinical expertise and patient values.52,53 
 
The proportion of patients treated according to these guideline recommendations is generally low,54-56 
showing substantial variation in guideline adherence between centers56,57 and medical condition,58 
amongst others. Consequently, patients may not receive evidence based care or receive unnecessary 
care. The studies included in this thesis specifically assess the guidelines adherence in TBI, and in the 
pain management of injury patients in the chain of emergency care. 
 
1.5 AIM AND OUTLINE OF THIS THESIS 
 
The main aim of this thesis is to expand our knowledge on the incidence and health- and economic 
impact of injuries and TBI in specific, and the possible improvements of outcome assessment in the field 
of injuries. We will apply an integrated approach of assessing all three domains of health outcomes 
research to identify important risk groups as input for prevention strategies. 
The aim of this thesis was operationalised in the following research questions: 
1. What are the incidence, health impact and costs of TBI, and which risk groups in TBI can be 
identified? 
2. How can the assessment of outcomes after injury be improved? 
3. What is the impact of TBI on HRQL, and what is the prevalence of psychiatric disorders after TBI? 
4. What is the extent of adherence to guidelines in injury patients? 
 
This thesis consists of four parts. Part I (Chapter 2 and 3) addresses research question 1 and describes 
the incidence, health impact, and costs of TBI, and thereby provides insight into the risk groups in TBI. 
Chapter 2 provides estimates of the incidence, costs and disease burden of TBI in the Netherlands, using 
an integrated approach which enables detection of important risk groups in TBI. As bicyclists are one of 
the main risk groups in TBI, Chapter 3 addresses the incidence and costs of bicycle-related TBI across 
various age groups, and in comparison to all injuries from cycling. 
Part II (Chapter 4 and 5) addresses the methodological issues in assessing outcome after injury, and 
aims to answer research question 2. Chapter 4 provides an overview of the current measures to assess 
pre-injury HRQL and the differences in pre-injury HRQL scores between measures. Chapter 5 provides 
insight into the opportunities of expanding trauma registries that generally contain only clinical 
outcomes, with follow-up data on the functional and economic outcomes after injury. In Chapter 6, two 
methods to derive disability weights of TBI are compared which are used to estimate the years lived 
with disability after TBI. 
Part III (Chapter 7 to 10) examines the outcome after TBI. Chapter 7 assesses the recovery pattern 
differences between mild, moderate, and severe TBI and examines the relationship between objective 
functional impairment and subjective HRQL. Chapter 8 provides an overview of the prevalence and risk 
factors of anxiety and depression following TBI. Chapter 9 elaborates on the predictors and prediction 
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models of major depression and posttraumatic stress disorder after TBI. In Chapter 10, the impact of 
depression and posttraumatic stress symptoms on functional outcome and HRQL of patients with TBI is 
assessed. These chapters aim to answer research question 3. 
Part IV (Chapter 11 and 12) addresses the adherence to guidelines in injury patients, and aims to answer 
research question 4. Chapter 11 quantifies the guideline adherence in TBI, explores the factors 
influencing adherence, and examines the associations between guideline adherence and outcome. In 
Chapter 12 the compliance of current practice with a guideline on the pain management for trauma 
patients in the chain of emergency care is assessed, and the early and initial pain management for adult 
trauma patients in emergency care is evaluated. 
These parts are followed by the general discussion, which summarises the main findings of the papers 
in this thesis, answers the four research questions, and consequently addresses the methodological 
considerations, practical implications and recommendations for future research. 
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ABSTRACT 
 
Background Traumatic brain injury (TBI) is a major cause of death and disability, leading to 
great personal suffering and huge costs to society. Integrated knowledge on epidemiology, 
economic consequences and disease burden of TBI is scarce but essential for optimising 
health care policy and preventing TBI. This study aimed to estimate incidence, cost-of-illness 
and disability-adjusted life years (DALYs) of TBI in the Netherlands. 
 
Methods This study included data on all TBI patients who were treated at an Emergency 
Department (ED - National Injury Surveillance System), hospitalised (National Medical 
Registration), or died due to their injuries in the Netherlands between 2010–2012. Direct 
health care costs and indirect costs were determined using the incidence-based Dutch Burden 
of Injury Model. Disease burden was assessed by calculating years of life lost (YLL) owing to 
premature death, years lived with disability (YLD) and DALYs. Incidence, costs and disease 
burden were stratified by age and gender. 
 
Results TBI incidence was 213.6 per 100,000 person years. Total costs were €314.6 (USD 
$433.8) million per year and disease burden resulted in 171,200 DALYs (on average 7.1 DALYs 
per case). Men had highest mean costs per case (€19,540 versus €14,940), driven by indirect 
costs. 0–24-year-olds had high incidence and disease burden but low economic costs, 
whereas 25–64-year-olds had relatively low incidence but high economic costs. Patients aged 
65+ had highest incidence, leading to considerable direct health care costs. 0–24-year-olds, 
men aged 25–64 years, traffic injury victims (especially bicyclists) and home and leisure injury 
victims (especially 0–5-year-old and elderly fallers) are identified as risk groups in TBI. 
 
Conclusions The economic and health consequences of TBI are substantial. The integrated 
approach of assessing incidence, costs and disease burden enables detection of important risk 
groups in TBI, development of prevention programmes that target these risk groups and 
assessment of the benefits of these programmes.  
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2.1 INTRODUCTION 
 
Traumatic brain injury (TBI) – defined as an alteration in brain function, or other evidence of brain 
pathology, caused by an external cause1 – is a leading cause of morbidity, disability, and mortality 
worldwide. In Europe, the annual incidence rate of hospitalised and fatal TBI is about 235 per 100,000 
person years.2 TBI survivors almost all experience some level of impairment or disability,2 which 
drastically reduces their health-related quality of life (HRQL).3,4 
In addition to the often long-term impact of TBI on a person’s life, the economic consequences of TBI 
for both individuals and society are substantial.5,6 TBI patients require specialised pre-hospital care, 
transport, in-hospital (emergency) care, and often long-term rehabilitation. Survivors of more severe 
TBI are often unable to return to full employment.7,8 TBI therefore leads to significant direct health care 
costs in terms of pre-hospital care, emergency care, hospitalisation, long-term outpatient care and 
rehabilitation, and indirect costs due to loss of productivity. The total direct and indirect costs of TBI 
occurring in Europe were estimated to €33 billion (approximately USD $45.4 billion).9 
Most efforts on assessing the impact of TBI have been limited to either its epidemiology,2,10,11 costs5,6,9,12-
18 or disease burden.17,19,20 Integrated knowledge on epidemiology, economic consequences and disease 
burden of TBI is scarce but essential for optimising health care policy, allocating scarce resources, 
preventing TBI, and developing effective health care and rehabilitation services. Up till now, an insight 
of the total population impact of TBI is lacking. The purpose of this study was to 1) estimate the 
incidence, cost-of-illness and disability-adjusted life years (DALYs) of TBI in the Dutch population, and 2) 
detect important risk groups in TBI. 
 
2.2 METHODS 
 
Data sources 
This surveillance-based study included data on all patients with TBI treated at an emergency department 
(ED) and/or admitted to hospital in the Netherlands in the period 2010–2012. TBI cases were extracted 
from the Dutch Injury Surveillance System (LIS)21 and the National Hospital Discharge Registry (LMR),22 
to include data of TBI patients treated at the ED and hospitalised TBI patients respectively. 
LIS is an ongoing monitoring system which records data of all unintentional and intentional injured 
patients who attend the ED. LIS is based upon the registration of 13 hospitals in the Netherlands (12–
15% coverage) that are considered to be representative for the total Dutch injury-related ED visits. To 
generate national estimates of the injury-related ED visits in the Netherlands, an extrapolation factor 
was calculated in which the number of ED treatments due to injury registered by the participating 
hospitals is multiplied by the quotient of the number of hospital admissions due to injury in the 
Netherlands divided by the number of hospital admissions due to injury registered in the participating 
hospitals.23 The required data on the number of hospital admissions due to TBI in the Netherlands is 
obtained from the LMR, which collects data from all Dutch hospitals regarding patient information from 
hospital admission to discharge. 
In this study, data from LIS was used to assess socio-demographic (age at injury and sex), injury (type of 
injury, external cause of injury, multiple injury), and health care related characteristics (hospitalisation 
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and length of stay). To avoid double counting, only the LMR was used to obtain data of hospitalised 
patients on the type of injury (ICD-9-codes) and for costs calculations. 
 
Definition of TBI 
For patients treated at the ED, TBI was defined as having a “Concussion” or “Other skull – brain injury” 
in at least one of the three injuries that can be recorded in LIS. This study therefore included all cases 
in which TBI was registered as first, second or third injury. In case of multiple injuries, an hierarchy 
derived from the literature was used to determine the most severe injuries.24 This hierarchy prioritised 
spinal cord injury over skull or brain injury (except concussions), hip fracture, and other lower extremity 
fractures, respectively. 
For hospitalised patients, TBI was defined using the International Classification of Diseases, ninth 
revision (ICD-9-CM). This study included ICD-9-codes related to concussion (850), fractures (800–801, 
803, 804), lesion (851–854), late effects (905, 907), nerve injury (950), and unspecified head injury 
(959). 
 
Cost-of-illness 
Short- and long-term direct costs (e.g. health care costs) and indirect costs (e.g. productivity loss) of TBI 
were calculated with use of the incidence-based Dutch Burden of Injury Model.23,25 This model 
calculates patient numbers, health care consumption, and related costs for predefined patient groups 
that are homogenous in terms of health service use. Data on health care consumption was obtained 
from the LIS and LMR database, rehabilitation centers (LIVRE), nursing homes (SIVIS), and a patient 
follow-up survey conducted in 2007–2008.23,26,27 
Direct health care costs of TBI were calculated by multiplying incidence by health care volumes (e.g. 
length of stay), transition probabilities (e.g. probability of hospital admission), and unit costs (e.g. costs 
per day in hospital). All unit costs were estimated according to national guidelines for health care 
costing,28 reflecting real resource use (Table 2.1). 
Indirect costs of TBI were calculated for all TBI patients in the working age 15 to 64 years treated at the 
ED or hospitalised, based on information on work absence and return to work from the patient follow-
up questionnaire conducted in 2007–2008.23,26,27 
In order to compare the costs of TBI in the Netherlands with previous cost studies conducted in other 
countries and at varying points in time, all costs estimates were adjusted for inflation with use of the 
Consumer Price Index29-31 and converted into 2012 Euros (as at 31 December 2012 €1.00 = USD 
$1.3203). 
 
Burden of TBI 
The national disease burden of TBI was measured using the disability-adjusted life year (DALY), a 
summary measure of population health.32 To calculate the burden of disease, information on premature 
mortality, and morbidity and disability due to non-fatal health outcome is combined into one single 
number. This number represents the health gap between the current state of a population’s health 
compared to an ideal situation where individuals would live to the standard life expectancy in full health, 
i.e. free of disease and disability. DALYs are the sum of the years of life lost due to premature mortality 
(YLLs) and years lived with disability (YLDs). 
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Table 2.1 Unit costs (2012) 
 Resource Unit costs 
General Practitioner Practice consultation €33.70 
 Consultation by telephone €16.90 
 Home visit €67.40 
 Referral patient treated at the ED €35.00 
 Referral hospitalised patient €44.00 
 Follow-up care patient treated at the ED €33.70 
 Follow-up care hospitalised patient €37.80 
Ambulance Emergency journey €538.20 
 Scheduled journey €206.20 
Hospital Attendance of ED Injury specific fees1 
 Hospitalisation general hospital €460.40/day 
 Hospitalisation academic hospital €629.00/day 
 Intensive care €1,751.50/day 
 Day care €310.30/day 
 Outpatient department visit €178.10/visit 
 Medical procedures Reimbursement fees 
Long-term care Nursing home €264.60/day, 138.80/day care 
 Rehabilitation €469.10/day 
 Physiotherapy €38.00/treatment 
Home care Domestic care €30.60/hour 
 Care €39.10/hour 
 Nursing €67.60/hour 
 Nursing & care €46.40/hour 
Labor costs 15–19 year €13.50/hour 
(including VAT) 20–24 year €24.70/hour 
 25–29 year €32.80/hour 
 30–34 year €39.30/hour 
 35–39 year €43.30/hour 
 40–44 year €45.40/hour 
 45–49 year €46.80/hour 
 50–54 year €48.50/hour 
 55–59 year €49.70/hour 
 60–64 year €50.70/hour 
 Overall mean €40.90/hour 
1 Unit costs for attendance of emergency department are calculated per type of injury in an annually unit cost study indexing the tariffs per 
minute of nurses, physicians and specialists. ED: emergency department; VAT: value added tax. 
 
YLLs were calculated by multiplying the number of deaths at each age by a standard life expectancy at 
that age. The number of deaths at each age were calculated with use of the average European case-
fatality rate of 11%; about 3% in-hospital and 8% out-of-hospital.2,33 To allow for international 
comparisons, the life expectancy was calculated using the Coale-Demeny model West life tables, with a 
life expectancy at birth of 80 years for males and 82.5 years for females.34 
YLDs were calculated in three steps.35 First, data was gathered on the incidence, age and sex distribution 
of patients treated at the ED or hospitalised due to TBI. Second, the incidence data was divided into the 
injury categories “Concussion” and “Skull-brain injury” of the EUROCOST classification system.36 Finally, 
the grouped incidence data was combined with the disability weights and durations developed within 
the framework of the European INTEGRIS (Integration of European Injury Statistics) study.35 Registered 
cases were multiplied with the 1-year disability weight, the proportion of lifelong consequences 
(Concussion: 4% ED, 21% hospitalised; Skull-brain injury: 13% ED, 23% hospitalised) and the duration 
(life expectancy at age of injury, by sex). The mean 1-year disability weights included the temporary and 
lifelong consequences for cases seen in EDs and those recorded in hospital discharge registers for both 
concussions (Temporary: 0.015 ED, 0.100 hospitalised; Lifelong: 0.151) and skull-brain injuries 
(Temporary: 0.090 ED, 0.241 hospitalised; Lifelong: 0.323). To compare the impact of TBI with that of 
other injuries, YLDs for the other injuries were also calculated with disability weights obtained from the 
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INTEGRIS study. The disability weights were derived from empirical follow-up data on the health-related 
quality of life of individual trauma patients, and adjusted for population norms, age and gender.35  
 
Data and statistical analysis 
All statistical analyses were carried out using the statistical package SPSS for Windows, version 21 (IBM 
SPSS Statistics, SPSS Inc, Chicago, IL). Descriptive statistics were used to provide insight in the 
characteristics of TBI patients. Continuous variables were described by presenting the median and 
interquartile range. Incidence rates per 100,000 person years were calculated using population data 
from Statistics Netherlands.37 A value of p<0.05 was used to determine statistical significance. All data 
reported in this article are national estimates. 
 
2.3 RESULTS 
 
Incidence  
In the period 2010–2012, annually 34,681 patients visited the ED due to TBI (Table 2.2), comprising 
about 4% of the total injury-related ED visits per year in the Netherlands. The overall incidence rate of 
ED visits due to TBI was 213.6 per 100,000 person years, 241.9 for males and 175.3 for females 
respectively. Incidence rates were highest in children (268.2), young adults (271.6) and older patients 
in the age of 75–84 years (307.6) or 85 and older (578.2). 
The majority of patients sustained a TBI because of a home and leisure injury (47.9%) or traffic injury 
(33.5%). Patients that sustained a TBI due to a traffic accident often concerned bicyclists (56.9%) and 
passenger vehicle occupants (16.5%). Home and leisure injuries often concerned a fall among 0–5-year-
olds and elderly patients (aged 60 years and older). ED visits due to TBI often included the diagnoses 
concussion (44.7%), intracranial injury of other or unspecified nature (25.5%) and cerebral laceration or 
contusion (9.8%). Almost one in three TBI patients were treated for more than one injury and more than 
half of the patients were hospitalised, most frequently for 1 or 2 days (61.7% of the hospitalised 
patients). 
 
Cost-of-illness   
The estimated total costs of TBI in the Netherlands was €314.6 million per year (Table 2.3). Total direct 
health care costs (€158.6 million) were comparable to indirect costs (€155.9 million), whereas in the 
working population per case mean direct health care costs were more than 3 times lower than the 
indirect costs. 
Overall, the mean total costs per case were €18,030, and were higher for men (€19,540) than for 
women (€14,940). This difference is mostly driven by the difference in indirect costs per TBI patient 
(males €15,416; females €10,257; p<0.001). The estimated total amount of omitted work days among 
TBI patients with paid employment was 44 days per case, and significantly differed between men (mean 
46 days) and women (mean 38 days) (p<0.001). Both direct and indirect costs per TBI patient increased 
with the length of hospital stay. 
The average direct costs per case increased with age (Figure 2.1). Mean direct costs per case were 
higher (up to €950) for men than for women in the ages up to 74 years, while in individuals aged over 
75 years women had much higher mean direct costs per case (up to € 3,210) than men. Indirect costs 
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(applicable to individuals aged 15–64 years old) also increased with age, and were higher (up to €6,280) 
for men than for women. 
 
Table 2.2 Incidence and characteristics of traumatic brain injuries in the Dutch population (2010-2012)1 
 Dutch Injury 
Surveillance System 
n=3,762 (%) 
National estimate 
n=34,681 (%) 
Incidence 
(per 100,000) 
Total: 213.6 
Gender    
Male 2,162 (57.5) 19,937 (57.5) 241.9 
Female 1,600 (42.5) 14,744 (42.5) 175.3 
Age    
0–14 846 (22.5) 7,793 (22.5) 268.2 
15–24 601 (16.0) 5,538 (16.0) 271.6 
25–44 714 (19.0) 6,584 (19.0) 148.7 
45–64 789 (21.0) 7,281 (21.0) 156.1 
65–74 332 (8.8) 3,062 (8.8) 211.4 
75–84 287 (7.6) 2,648 (7.6) 307.6 
85+ 192 (5.1) 1,775 (5.1) 578.2 
Accident category, type of road user    
Home and leisure 1,806 (48.0) 16,628 (47.9)  
Traffic 1,256 (33.4) 11,616 (33.5)  
Pedestrian 66 (5.3) 613 (5.3)  
Bicyclist 706 (56.9) 6,522 (56.9)  
Moped occupant 151 (12.2) 1,406 (12.3)  
Motor vehicle/scooter occupant 63 (5.1) 575 (5.0)  
Passenger vehicle occupant 205 (16.5) 1,898 (16.5)  
Other 49 (4.0) 455 (4.0)  
Unknown 16 148  
Sport 307 (8.2) 2,824 (8.1)  
Occupational 109 (2.9) 1,003 (2.9)  
Assault 247 (6.6) 2,269 (6.5)  
Self-mutilation 18 (0.5) 171 (0.5)  
Other 19 (0.5) 172 (0.5)  
Type of brain injury2,3    
Concussion  8,983 (44.7)  
Fracture    
Vault  317 (1.6)  
Base  1,319 (6.6)  
Other/unqualified  330 (1.6)  
Multiple fractures  130 (0.6)  
Lesion    
Cerebral laceration/contusion  1,977 (9.8)  
Subarachnoid/sub-/extradural hemorrhage  1,598 (7.9)  
Other/NFS intracranial hemorrhage  262 (1.3)  
Intracranial injury, other/NFS nature  5,116 (25.5)  
Late effects    
Musculoskeletal and connective tissue  46 (0.2)  
Nervous system  18 (0.1)  
Nerve injury    
Optic nerve and pathways  3 (<0.1)  
Unknown  14,581 (42.0)  
Number of injuries    
1 injury 1,065 (28.3) 9,766 (28.2)  
2 injuries 2,033 (54.0) 18,773 (54.1)  
≥3 injuries 664 (17.7) 6,142 (17.7)  
Hospitalisation    
Not admitted 1,633 (43.5) 15,024 (43.4)  
Unknown 8 70  
1–3 days 1,424 (70.4) 13,146 (70.4)  
≥4 days 597 (29.6) 5,529 (29.6)  
N days unknown 106 982   
1 Mean number per year in the period 2010–2012. 
2 Traumatic brain injury diagnoses (ICD-9 codes): Concussion: Concussion (850): Cranial fracture: Fracture of vault of skull (800); Fracture of 
base of skull (801); Other and unqualified skull fractures (803); Multiple fractures involving skull or face with other bones (804): Lesion: 
Cerebral laceration and contusion (851); Subarachnoid, subdural, and extradural hemorrhage after injury (852); Other and unspecified 
intracranial hemorrhage after injury (853); Intracranial injury of other and unspecified nature (854): Late effects: Late effects of 
musculoskeletal and connective tissue injuries (905); Late effects of injuries to the nervous system (907): Nerve injury: Injury to optic nerve 
and pathways (950): Head injury, unspecified (959, n=0). 
3 Data on injury type (ICD) only known for hospitalised patients in the LMR database (National estimate: n=20,100). 
28 | Epidemiology of traumatic brain injury 
Table 2.3 Cost-of-illness by hospitalisation and gender (2010-2012) 
 Hospitalisation 
Direct costs 
per case1 
Indirect costs 
per case1 
Total costs 
per case1 
Total costs (€) 
Total 0–7 days 3,584 12,454 16,040 234,259,230 
 >7 days 9,854 21,431 31,280 64,608,290 
 Total 4,361 13,668 18,030 314,592,930 
Men 0–7 days 3,413 14,116 17,530 149,815,870 
 >7 days 8,809 22,216 31,020 41,805,590 
 Total 4,128 15,416 19,540 202,953,300 
Women 0–7 days 3,812 9,479 13,290 84,443,360 
 >7 days 11,433 18,638 30,070 22,802,690 
 Total 4,680 10,257 14,940 111,639,630 
1 Mean costs per case: indirect costs per case are presented as an average of only the working population (15 to 65 years). 
 
Figure 2.1 Mean direct and indirect costs per case and total costs by age and gender (2010–2012) 
 
 
Disability-adjusted life years 
TBI resulted in 52,998 YLD and 118,207 YLL respectively, amounting to 171,205 DALYs (on average 7.07 
DALYs per TBI patient, Table 2.4). Overall, 69% of the total burden was caused by premature mortality. 
The burden due to permanent (lifelong) disability was high compared with temporary (short-term) 
disability. Men were responsible for 59% of the total burden of TBI, and had higher YLDs, YLLs and DALYs 
per case than women (YLD per case: 2.29 in men vs 2.05 in women; YLL per case: 4.97 vs 4.76; DALY per 
case: 7.27 vs 6.81). Mean YLD decreased with age in both men and women, and was highest among 0–
14-years-olds (Figure 2.2). 
 
Table 2.4 Total temporary and lifelong years lived with disability, years of life lost and disability-adjusted life-
years per 1-year interval (2010–2012) 
 
 YLD ED visits YLD hospital admission  
N Temporary Lifelong Temporary Lifelong YLL 
Total 
DALYs1 
DALYs 
per case 
Men 13,877 56 1,077 2,098 28,603 69,022 100,856 7.27 
Women 10,330 47 941 1,470 18,706 49,185 70,348 6.81 
         
Concussion 12,580 54 1,023 897 13,540 
118,207 171,205 7.07 
Skull-brain injury 11,631 50 995 2,670 33,769 
Total 24,211 104 2,018 3,567 47,309 118,207 171,205 7.07 
1 Disability-adjusted life-years (DALYs) per year. 
YLD: years lived with disability; ED: emergency department; YLL: years of life lost. 
0
2
4
6
8
10
12
14
16
18
20
0-14 15-24 25-44 45-64 65-74 75-84 85+
C
o
st
s 
p
e
r 
ca
se
 (
E
u
ro
 x
 1
,0
0
0
)
Age (years)
Direct costs - men
Direct costs - women
Indirect costs - men
Indirect costs - women
Total costs / €10,000 - men
Total costs / €10,000 - women
Chapter 2 | 29 
 
Figure 2.2 Mean years lived with disability by age and gender (2010–2012) 
 
YLD: years lived with disability. 
 
TBI in comparison to other injury categories 
In the period 2007–2011, TBI accounted 10% of the total YLDs and 12% of the lifelong YLDs caused by 
all injuries in the Netherlands (data not shown). Concussion and skull-brain injury both were ranked in 
the top 5 of injuries with highest total YLDs, after fractures of the knee or lower leg, ankle, and foot or 
toes (Table 2.5). Skull-brain injury accounted for the highest YLDs per case after spinal cord injury: 2.89 
and 14.68 respectively (data not shown). 
 
Table 2.5 Top ten injuries with highest disability in the Netherlands by accident category (2007–2011)1 
Rank Home and leisure Traffic Sport Occupational Total 
1 Fract ankle Fract knee/lower leg Fract knee/lower leg Fract foot/toes Fract knee/lower leg 
2 Fract foot/toes Skull-brain injury Fract ankle Fract knee/lower leg Fract ankle 
3 Fract knee/lower leg Concussion Fract foot/toes Fract ankle Fract foot/toes 
4 Concussion Fract ankle Lux/dist ankle/foot Spinal cord injury Skull-brain injury 
5 Skull-brain injury Spinal cord injury Lux/dist knee Skull-brain injury Concussion 
6 Hip fract Fract foot/toes Concussion Complex arm/hand Spinal cord injury 
7 Spinal cord injury Hip fract Fract wrist Lux/dist ankle/foot Hip fract 
8 Fract upper arm Fract shoulder Skull-brain injury Concussion Lux/dist ankle/foot 
9 Lux/dist ankle/foot Fract upper arm Fract upper arm Lux/dist knee Fract upper arm 
10 Fract wrist Fract upper leg Fract shoulder Open wound Lux/dist knee 
1 Ranked by total years lived with disability (YLD) for short- and long-term disability. 
Fract: fracture; Lux/dist: luxation/distortion.; Complex arm/hand: complex soft tissue arm/hand. 
 
2.4 DISCUSSION 
 
The purpose of this paper was to estimate the incidence, cost-of-illness and disability-adjusted life years 
(DALYs) of TBI in the Netherlands. Our study revealed that TBI imposes a substantial economic and 
disease burden (on average 7.1 DALYs per TBI patient) on the Dutch population, accounting for more 
than 4% of injury-related ED visits, 9% of the injury-related costs and 10% of the injury-related YLDs in 
the Netherlands. 
The integrated approach of our study showed that the incidence and burden of disease among children 
and young adults aged 0–24 years is high, whereas the economic consequences for this group were low 
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due to relatively shorter hospitalisation and almost no indirect costs (Figure 2.3). The reverse is shown 
in the 25–64-year-olds, who have relatively low incidence and high economic costs, driven by loss of 
productivity. Older patients aged 65+ had highest incidence of TBI, leading to considerable direct health 
care costs, and a relatively low disease burden. 
 
Comparison of results to other studies 
Incidence  
Our estimated incidence rate of ED treated, hospitalised and fatal TBI for the Netherlands of about 214 
per 100,000 person years was lower than the estimated rate of hospitalised and fatal TBI for Europe of 
about 235 per 100,000 persons years.2 This difference may partly be explained by the time period 
covered in the studies. The European rate was derived from studies with data over 1974 to 2000, with 
incidence rates ranging from 150 to 300 per 100,000 person years,2 whereas our study included data 
from 2010 to 2012. Compared to the US, the Dutch estimated incidence rates of ED visits, hospital 
admissions and deaths are considerably lower. It is estimated that the incidence of TBI in the US is 577 
per 100,000 person years in 2006,38 comprising about 1,365,000 ED visits (81%), 275,000 
hospitalisations (16%) and 52,000 deaths (3%). However, other population-based studies suggest that 
the incidence of TBI in the US is somewhat lower, between 180 to 250 per 100,000 person years in 1965 
to 1996.2,11 
Consistent with prior research,2,38 TBI incidence was higher among men than women, and highest 
among children and older people. Whereas motor vehicle accidents and falls were the most common 
mechanisms of injury in previous studies in Europe2 and the US,6,17,38 our sample showed a high number 
of ED treatments among bicyclists in the traffic setting. Cycling is a very popular form of transport and 
recreation in the Netherlands, as up to 28% of all trips nationwide are made by bicycle.39 The popularity 
of cycling however also imposes a high burden on society, due the large number of (brain) injuries 
among cyclist.40-42 Bicycle helmets are not compulsory in the Netherlands and are only commonly used 
among road cyclist, mountain bikers and young children. 
 
Figure 2.3 Economic and disease burden of traumatic brain injury in the Netherlands (2010–2012) 
 
YLD: years lived with disability. 
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Cost-of-illness 
TBI accounted for 9% of total costs of all injuries in the Netherlands (about €3.5 billion). The direct 
health care costs of TBI are on average €4,300 per case. This is in line with the outcomes of a previous 
study on the costs of all types of injuries in the Netherlands in 2004 that estimated the average direct 
health care costs of skull and brain injury cases at €3,100.12 This is approximately €4,100 when 
converting 2004 Euros to 2012 Euros using consumer price index.  
Compared to other European countries our estimation of direct health care costs of TBI are somewhat 
higher:5 from €2,700 in whole Europe, to €2,930 in Germany, €3,490 in Spain and €3,453 in Sweden 
after adjustment for inflation up to 2012. Estimates from the US are however more than two times the 
estimates in our present study: about €23,500 acute hospital charges per TBI,15 €6,200 per TBI in 
Missouri,17 and €8,500 to €35,000 for mild to severe hospitalised patients6 - all scaled to 2012 price 
levels and 2012 Euro. These differences can partly be explained by differences in cost calculations. The 
European cost calculations were limited to inpatient costs while the current study included also 
extramural health care costs, and most US studies used charges instead of unit costs. Although the 
methodology of cost calculations varied considerably, our study confirms that indirect costs of TBI are 
far higher than direct health care costs of TBI,9,17,43,44 costs of TBI are higher among men than women 
and increase with age 5 and that the costs increase with the length of hospital stay.6 The latter suggests 
that the economic burden of TBI varies considerably by TBI severity.  
Overall, TBI imposes a high economic burden on society and, together with hip fracture, is a leading 
source of hospital costs13 and direct health care costs12 in the Netherlands due to high health care costs 
per patient. 
 
Disability-adjusted life years 
TBI accounted for 10% of total YLD and 12% of the lifelong YLD caused by all injuries in the Netherlands, 
due to lifelong consequences in a relative young patient group. TBI resulted in both high temporary and 
lifelong YLD among road traffic injuries and home and leisure injuries, as confirmed in the literature.19,45 
TBI is one of the leading causes of disease burden compared to other injuries and diseases in the 
Netherlands. TBI imposes a disease burden comparable to that of depression, diabetes, and lung cancer, 
which are all in the top 10 diseases with highest total DALY in the Netherlands.46 
Mean YLD decreased with age and was highest among children (0–14 years). This can partly be explained 
by the use of the expected number of years of life remaining as the duration of TBI in the YLD calculation. 
This method assumes that a proportion of the TBI patients will live with disability outcomes for the 
remainder of their expected lifetime. Therefore the duration used in the YLD calculation equaled the 
life expectancy at age based on the Coale-Demeny model West life tables;34 in our sample on average 
45 years in men and 43 in women. This may have led to a higher estimate of the years lived with disability 
after TBI in comparison to the use of a fixed average duration for TBI. 
 
Limitations 
The number of deaths due to TBI in the Netherlands could not be generated from national death 
statistics, because these are only available for specific diseases (e.g. type of cancer, cardiovascular 
diseases) or injuries specified by cause (e.g. traffic accidents, falls, drowning, self-mutilation). Therefore, 
the YLL component of the total DALY was estimated with use of the European average case fatality rate 
32 | Epidemiology of traumatic brain injury 
of TBI, derived from 18 studies. This overall case fatality rate was on average about 11 per 100 persons 
with TBI; about 3% in-hospital and 8% out-of-hospital deaths among patients with TBI.2,33 Due to the 
use of the average European overall case fatality rate, the number of YLLs and thereby the disease 
burden of TBI may be over- or underestimated. However, actual case fatality rates and disease burden 
of TBI may be even higher due to higher excess mortality in the long-term.47-49 In order to improve the 
YLL and disease burden estimates of TBI and other injuries and diseases in the Netherlands, specific 
(long-term) mortality data should be registered and available for future research. 
Other limitations concern the classification of TBI and the calculation of costs. TBI patients treated at 
the ED were registered as having a “Concussion” or “Other skull – brain injury”. No additional data was 
available on ICD-codes, AIS-codes or a Glasgow Outcome Scale to uniformly determine TBI; data that 
was available for the majority of the hospitalised patients. 
The ICD-9 codes used to determine the type of TBI among hospitalised patients slightly differed from 
those recommended by the Center for Disease Control (CDC),50 in that this study also included the late 
effects of TBI (ICD-9 codes 905, 907, 950). These late effects however comprise far less than 1% of all 
hospitalised traumatic brain injuries in the Netherlands, and therefore will not complicate comparison 
of our results to those of other studies in which the CDC ICD-9 codes for TBI were used. 
The cost-of-illness of TBI may have been overestimated because of the use of a patient follow-up survey 
to obtain information on health care consumption and labor status. Comparison of the hospital 
discharge data and the patient follow-up data indicated that there is a higher response among the more 
severe injured patients. This may lead to an overestimation of the costs and disease burden of TBI. 
On the other hand, our estimation of indirect costs of TBI comprised only costs of lost work productivity 
for TBI patients of working age. Other potential sources of indirect costs, such as the work productivity 
and finances of families and caregivers were not incorporated in this study. Previous research showed 
that TBI imposes a significant level of financial burden on families and caregivers,51,52 which is directly 
related to the severity of TBI.51 Total indirect costs of TBI will therefore be far higher than estimated in 
this study, particularly among children and elderly with caregivers in the working age. 
Our study is limited to TBI patients that were treated at the ED or admitted to hospital. Patients who 
consulted a GP were not included in our overview. Hence, incidence rates, cost-of-illness and burden of 
TBI may be even higher.53 According to registries from Dutch general practice, in 2012 about 7,600 
persons contacted their General Practitioner (GP) or after-hours General Practitioner Co-operation 
(GPC) due to TBI.54 Assuming that direct health care costs of GP visits are on average €39 per contact 
(Table 2.1; mean costs for practice or telephone consultation, and home visit), and the indirect costs 
and disease burden of TBI will not be larger than that of ED-treated patients, they will add about 7–8% 
only to our cost estimate and about 1–2% only to our DALY estimate. 
 
Recommendation for future research 
The results of our study reveal that TBI imposes a relatively high economic and health impact compared 
to all injuries and diseases in the Netherlands. TBI is a growing worldwide problem, as recent reports 
suggest a rapid increase in ED visits and hospitalisations resulting from traumatic brain injury, especially 
fall-related TBI in older adults55-57 and traffic-related TBI.58,59 
There is a need for prevention programmes targeting on the reduction of incidence and severity of TBI. 
On the bases of our study, we conclude that especially children and young adults aged 0–24 years, men 
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aged 25–64 years and traffic injury victims (in the Netherlands especially bicyclists) and home and 
leisure injury victims are an important target for intervention. In the working population, screening for 
risk of problems to return to work and immediate rehabilitation after TBI may help to minimise lost 
productivity.60 
Future research should examine how helmet use among cyclists can be increased. Bicycle helmets have 
shown to be highly effective in preventing head, brain, and facial injuries to cyclist.61,62 Previous research 
in Canada showed that helmet legislation may be an effective tool in the prevention of childhood 
bicycle-related head injuries.63 
Overall, future research on the population impact of TBI in terms of costs and disease burden should 
also include patients who receive no treatment or out-of-hospital treatment (e.g. from a GP or by sports 
trainers). 
 
Conclusions  
This study provided comprehensive population-based estimates on the epidemiology, costs and disease 
burden (in DALYs) of ED-treated and hospitalised persons with TBI over 2010–2012 in the Netherlands. 
The study included all age groups, all TBI severities, and both patients treated at the ED and hospitalised 
patients. 
The economic and health consequences of TBI are substantial. Prevention programmes are needed to 
reduce incidence and severity of TBI. The integrated approach of assessment of incidence, costs and 
disease burden (in DALYs) of TBI enables the detection of all important risk groups in TBI. 
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ABSTRACT 
 
Background The main cause of death and serious disability in bicycle accidents is traumatic 
brain injury (TBI). The aim of this population-based study was to assess the incidence and costs 
of bicycle-related TBI across various age groups, and in comparison to all bicycle-related 
injuries, to identify main risk groups for the development of preventive strategies. 
 
Methods Data from the National Injury Surveillance System and National Medical Registration 
was used for all patients with bicycle-related injuries and TBI who visited a Dutch emergency 
department (ED) between 1998 and 2012. Demographics and national, weighted estimates of 
injury mechanism, injury severity and costs were analysed per age group. Direct health care 
costs and indirect costs were determined using the incidence-based Dutch Burden of Injury 
Model. 
 
Results Between 1998 and 2012, the incidence of ED treatments due to bicycle-related TBI 
strongly increased with 54%, to 43 per 100,000 persons in 2012. However, the incidence of 
all bicycle-related injuries remained stable, from 444 in 1998 to 456/100,000 in 2012. 
Incidence of hospital admission increased in both TBI (92%) and all injuries from cycling (71%). 
Highest increase in incidence of both ED treatments and hospital admissions was seen in 
adults aged 55+. The injury rate of TBI per kilometre travelled increased (44%) except in 
children, but decreased (–4%) for all injuries, showing a strong decrease in children (–36%) 
but an increase in men aged 25+, and women aged 15+. Total costs of bicycle-related TBI were 
€74.5 million annually. Although bicycle-related TBI accounted for 9% of the incidence of all 
ED treatments due to cycling, it accounted for 18% of the total costs due to all bicycle-related 
injuries (€410.7 million). Children and adolescents (aged 0–24) had highest incidence of ED 
treatments due to bicycle-related injuries. Men in the working population (aged 15–64) had 
highest indirect costs following injuries from cycling, including TBI. Older cyclists (aged 55+) 
were identified as main risk group for TBI, as they had highest ED attendance, injury rate, 
injury severity, admission to hospital or intensive care unit, and costs. 
 
Conclusions Incidence of ED treatments due to cycling are high and often involve TBI, imposing 
a high burden on individuals and society. Older cyclists aged 55+ were identified as main risk 
group for TBI to be targeted in preventive strategies, due to their high risk for (serious) injuries 
and ever-increasing share of ED visits and hospital admissions.  
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3.1 INTRODUCTION 
 
Cycling is a popular form of transport and recreation worldwide, and especially in the Netherlands, 
where there are more bicycles than residents.1,2 In the Netherlands, cycling is a common mode of 
transport among all age groups and socio-economic classes, in both urban and rural areas.2 The 
Netherlands has a good cycling infrastructure with cyclists enjoying segregated cycle facilities and 
protected intersections.2,3 Despite the high levels of road safety, in the Netherlands (with 16.7 million 
inhabitants) approximately 350,000 injuries occur due to cycling each year.4 
Traumatic brain injury (TBI) is the main cause of mortality and severe morbidity among bicycle 
accidents,5-12 which is most often seen in children,7,8,10 adolescents8 and older adults.7,8,11,13 Almost all 
survivors of TBI experience some level of impairment or disability,14 which drastically reduces their 
health-related quality of life,15,16 increases their requirement of specialised health care,17 and often 
restricts adults in returning to full employment.18,19 TBI therefore imposes significant direct health care 
costs in terms of pre-hospital care, emergency care, hospitalisation, long-term outpatient care and 
rehabilitation, and indirect costs due to loss of productivity.20 
Although the literature on the epidemiology and consequences of bicycle-related TBI is growing, by our 
knowledge, detailed population-based information on the costs of bicycle-related TBI is scarce and often 
limited for use in studies on the cost-effectiveness of bicycle helmet campaigns or laws.21-23 Such 
information is however vital for the development of prevention programmes that are aimed at patient 
groups at greater risk of TBI. This article presents the results of a population-based study in the 
Netherlands. It provides demographics and national, weighted estimates of the injury mechanism, injury 
severity and costs, by age group, of all patients with bicycle-related injuries and TBI in specific, who 
visited Dutch emergency departments (EDs). The purposes of this study were to 1) assess the incidence, 
direct costs and indirect costs of bicycle-related TBI between 1998 and 2012 across various age groups, 
2) compare these estimates with all bicycle-related injuries treated in Dutch EDs between 1998 and 
2012, and 3) identify main risk groups to develop preventive strategies that target bicycle-related TBI. 
 
3.2 METHODS 
 
Study setting 
This retrospective study included data on all patients with bicycle-related injuries treated at Dutch EDs 
and/or hospitalised between 1998 and 2012. Data on ED treatments due to bicycle-related TBI was 
obtained from the Dutch Injury Surveillance System (LIS).24 Data on hospital admissions was obtained 
from the National Hospital Discharge Registry (LMR).25 
LIS is an ongoing monitoring system which records data of all unintentional and intentional injured 
patients who attend the ED. LIS is based upon the registration of 13 hospitals in the Netherlands (12–
15% coverage), that are considered to be representative for the total Dutch injury-related ED visits.24 
The LMR contains data from all Dutch hospitals regarding patient information from hospital admission 
to discharge.25 
National, weighted estimates of bicycle-related TBI presenting to Dutch EDs were derived by calculating 
an extrapolation factor. This factor multiplies the number of ED treatments due to bicycle-related injury 
registered by the participating hospitals, by the quotient of the number of hospital admissions due to 
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bicycle-related injury divided by the number of hospital admissions due to bicycle-related injury 
registered in the participating Dutch hospitals.26 
Data from the LIS databank was used to assess socio-demographic (age at injury and sex), injury (type 
of injury besides TBI, injury mechanism), and health care related characteristics (hospitalisation and 
length of stay). The LMR was used to obtain data on hospitalisation and injury severity (MAIS: maximum 
abbreviated injury scale). 
 
Definitions 
A bicycle-related injury was defined as an injury sustained to the cyclist either during cycling or getting 
on or off a bicycle. A cyclist was defined as a user of a non-motorised two wheeled vehicle, and also 
included electrically assisted bicycles, road bikes, mountain bikes and cyclo-cross bicycles. 
TBI was defined as having a concussion (ICD10 code S06.0) or other skull-brain injury (S02.0–1, S02.7, 
S02.9, S06.1–9, S04.0–9, S07.1–9, T02.0, T04.0) in one of the three injuries that can be recorded in LIS. 
This study included all bicycle-related TBI that were registered as first, second or third injury. 
 
Cost-of-illness 
Direct costs (e.g. health care costs) and indirect costs (e.g. productivity loss) of bicycle-related injuries 
and TBI were calculated with use of the incidence-based Dutch Burden of Injury Model.26,27 
Direct health care costs were calculated by multiplying incidence by health care volumes (e.g. length of 
stay), transition probabilities (e.g. probability of hospital admission), and unit costs (e.g. costs per day 
in hospital). Health care volumes were estimated with use of age- and injury-specific data from the LIS 
and LMR database, rehabilitation centres (LIVRE), nursing homes (SIVIS), and a patient follow-up survey 
conducted in 2007–2008.26,28,29 All unit costs were estimated according to national guidelines for health 
care costing,30 reflecting real resource use (Appendix Table 3.A). 
Indirect costs were calculated for all patients in the working age 15 to 65 treated at the ED or 
hospitalised, based on age- and injury- specific estimates on work absence and return to work from the 
patient follow-up questionnaire conducted in 2007–2008.26,28,29 A full description of the calculation of 
the cost per hour worked, based on data from the patient follow-up survey, has been published 
elsewhere.31,32 
All costs estimates were converted into 2012 Euros (as at 31 December 2012 €1.00 = USD $1.3203). The 
direct and indirect costs of bicycle-related TBI were compared with the costs of all bicycle-related 
injuries treated at Dutch EDs, including TBI. 
 
Data and statistical analysis 
All statistical analyses were carried out using the statistical package SPSS for Windows, version 21 (IBM 
SPSS Statistics, SPSS Inc., Chicago, IL). Descriptive statistics were used to provide insight in the 
characteristics of injured cyclists. Continuous variables were described by presenting the median and 
interquartile range. Chi square statistics were used for between-group comparisons on injury 
mechanism variables. Univariate logistic regression analysis was used to explore the association 
between patient demographics and injury mechanism with regard to a diagnosis of TBI and the severity 
of TBI. Secondly, multivariate logistic regression analysis (enter method) including socio-demographics 
(block 1) and injury mechanism (block 2) was used to further identify independent predictors of bicycle-
related TBI and TBI severity. 
Chapter 3 | 41 
 
Incidence rates per 100,000 person years were calculated for men and women separately, using 
population data from the Dutch Central Bureau of Statistics.33 Data on cycle use, as measured by the 
average annual number of kilometres travelled per cyclist, was obtained by age groups from the Dutch 
National Travel Survey.34 To overcome differences in age group classifications, data from the Dutch 
National Travel Survey (0–11; 12–17; 18–24; 25–29; followed by 10-year age groups until 75+) was 
divided into the age groups of this study. Injury rate of bicycle-related TBI and all bicycle-related injuries 
per kilometre travelled was calculated by age group, by dividing the number of cyclists with respectively 
TBI and all injuries in each age group by the total number of kilometres travelled within that age group. 
The overall growth in the number of ED visits, hospital admissions, cycle use, and injury rate was 
calculated for 2012 in percentages relative to the year 1998. A value of p<0.05 was used to determine 
statistical significance. All data reported in this article are national estimates. 
 
3.3 RESULTS 
 
Incidence and trends 
Between 1998 and 2012, the incidence of ED treatments due to bicycle-related TBI increased with 54% 
from 28 to 43 per 100,000 persons (Figure 3.1A). The highest increase was seen in adults aged 55+ 
(151%), though incidence decreased in girls aged 0–14 (–6%; Appendix Figure 3.A (A and B). The 
incidence of hospital admissions due to bicycle-related TBI increased in all age groups (92% from 14 to 
28/100,000 in 2012 – Figure 3.1C), with also highest increase in adults aged 55+ (186% – data not 
shown). 
 
Figure 3.1 Absolute number of ED treatments (A and B), hospital admissions (C and D), and incidence (per 
100,000 person-years) for bicycle-related TBI (A and C) and all bicycle-related injuries (B and D) in the Dutch 
population (1998–2012) 
A  B 
   
C  D 
   ED: emergency department. 
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In contrast to the strong increase of bicycle-related TBI between 1998 and 2012, the incidence of ED 
treatments of all bicycle-related injuries remained stable from 444/100,000 in 1998 to 456/100,000 in 
2012 (Figure 3.1B). However, we see a decrease in children (–30%), but increase in adults aged 55+ 
(43%) and especially in 75+ year-old women (89%; Appendix Figure 3.A (C and D)). Similar to bicycle-
related TBI, the incidence of hospital admissions due to all bicycle-related injuries increased in all age 
groups (71% from 50 to 85/100,000 – Figure 3.1D), and especially in adults aged 55+ (93% – data not 
shown). 
In the same period, cycle use increased with only 14% (on average 13% in men and 16% in women). 
Cycle use in those aged 15–54 remained stable over time (0% to +5%), however strongly increased in 
adults aged 55+ (on average 56% in 55–74, and 68% in 75+ – data not shown). 
Between 1998 and 2012, the injury rate of TBI per kilometre travelled increased with on average 44% 
from 0.34 per million kilometres travelled in 1998 to 0.49 in 2012 (48% in men, 41% in women). Like 
the incidence rates, injury rates of TBI per kilometre travelled decreased in children (–12%) but 
increased in all other age groups (from 34% in 25–54 to 125% in 75+), with highest increase in the 
elderly aged 75+ (141% in men, 121% in women). In the same period, the overall injury rate of all bicycle-
related injuries decreased (–4%, from 5.40 to 5.19 per million kilometres travelled) due to a decrease 
in children (–36%) and men aged 15–24 (–10%), but increased in all other age groups with highest 
increase in men aged 55–74 (44%) and women aged 75+ (49% – data not shown). 
 
Cause of injury 
In 2012, 7,190 bicycle-related TBI were treated at Dutch EDs (43/100,000 persons), comprising 9% of 
all 76,325 bicycle-related injuries (456/100,000; Table 3.1). Half of the patients with bicycle-related TBI 
were injured due to a fall or single bicycle crash (51%). Collisions with a 4-wheeled vehicle (26% of all 
causes) often involved a passenger car (86% of all collisions). Collision with a passenger car was most 
common in children (26% of all causes in this age group), adolescents aged 15–24 (30%), and elderly 
cyclists aged 75+ (26%). Almost two third of all collisions with a 2-wheeled vehicle (16% of all causes) 
comprised a collision with another cyclist (73%). This was the most common cause in children (14% of 
all causes in this age group) and adults aged 55–74 (14%). 
 
Table 3.1 Injury mechanism of bicycle-related TBI (2012) 
 
 
0–14 
(%) 
15–24 
(%) 
25–54 
(%) 
55–74 
(%) 
75+ 
(%) 
Total 
TBI 
(%) 
Total all bicycle- 
related injuries 
(%) 
N (N) 1,215 1,010 2,169 2,095 701 7,190 76,325 
Traffic (N, %) 
1,206 
(99.3) 
963 
(95.3) 
2,102 
(97.0) 
2,095 
(100.0) 
701 
(100.0) 
7,066 
(98.3) 
74,752 
(98.0) 
Fall (single bicycle crash) 45.0 43.0 54.4 54.8 49.4 50.7 63.2 
Collision with 4-wheeled vehicle1 28.9 37.8 22.6 21.6 29.3 26.3 13.7 
Collision with 2-wheeled vehicle2 16.0 13.3 15.4 17.4 18.3 16.1 12.7 
Collision with obstacle3 / pedestrian / animal 3.3 5.9 7.6 6.2 3.0 5.7 5.0 
Fall out of child seat 6.8 – – – – 1.2 0.4 
Fall when getting on or off the bicycle 0.0 0.0 0.0 0.0 0.0 0.0 0.3 
Entrapment between bicycle spokes / wheel 0.0 0.0 0.0 0.0 0.0 0.0 4.8 
Not specified/unknown (N) 115 95 348 321 96 975 12,870 
Sport (N, %) 9 (0.7) 47 (4.7) 47 (2.2) 0 (0.0) 0 (0.0) 1.4 1,232 (1.6) 
Other (N, %) 0 (0.0) 0 (0.0) 18 (0.8) 0 (0.0) 0 (0.0) 0.3 316 (0.4) 
1 Including passenger cars, buses, pick-up trucks, trucks and trams. 
2 Including bicycles, mopeds and motor cycles. 
3 Including tree, wall, stationary car (door), (light) pole or edge of sidewalk. 
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In contrast to all bicycle-related injuries, bicycle-related TBI less often involved a fall (Chi2=242.2, 
p<0.001), but more often were caused by a collision with a 4-wheeled vehicle (Chi2=1018.8, p<0.001; 
OR 2.7, 95%CI [2.2–3.3], p<0.001), 2-wheeled vehicle (Chi2=92.9, p<0.001; OR 1.6, 95%CI [1.3–2.0], p < 
0.001), or obstacle (Chi2=17.5, p<0.001; OR 1.5, 95%CI [1.2–1.9], p=0.001), or by a fall out of a child seat 
(Chi2=151.3, p<0.001; OR 6.6, 95%CI [4.6–9.3], p<0.001 – Appendix Table 3.B). 
 
Patient characteristics and outcome 
Incidence of ED treatments due to bicycle-related TBI was highest in older cyclists aged 55–74 
(57/100,000 persons) and 75+ (59/100,000, Table 3.2). In contrast, incidence of ED treatments due to 
all injuries from cycling were highest in children aged 0–14 (540/100,000), and adolescents aged 15–24 
(623/100,000). In both bicycle-related TBI and all bicycle-related injuries, lowest incidence was reported 
in cyclists aged 25–54 (32/100,000 and 340/100,000). Elderly cyclist (75+) had the highest injury rate 
per kilometre travelled of both TBI and all injuries from cycling (annual injury rate of respectively 1.45 
and 12.64 per million kilometres travelled). Bicycle-related TBI patients were significantly older than all 
injured cyclists (mean age 43 (SD 24.2) versus 39 (SD 24.0), p<0.001), and more likely to be male (55% 
versus 51%, p<0.001). 
 
Over half (59%) of the ED treatments due to bicycle-related TBI comprised a concussion, and one third 
(30%) a skull-brain injury. Concussions were often caused by a fall (48.1% concussion versus 33.9% skull-
brain injury; Chi2=124.7, p<0.001; OR of severe TBI 0.4, 95%CI [0.3–0.7], p<0.001), or a collision with an 
obstacle (5.4% versus 4.3%; Chi2=4.1, p<0.04; OR 0.5, 95%CI [0.3–0.8], p=0.003), whereas a collision 
with a 4-wheeled vehicle often led to skull-brain injuries (33.5% versus 18.1% concussion; Chi2=204.1, 
p<0.001 – Appendix Table 3.B). 
 
In 11% of the ED treatments due to bicycle-related TBI, patients had a primary injury other than TBI. 
These injuries often involved upper extremity fractures (40%, common in all age groups), facial fractures 
(17%, only in patients aged 15–74), and internal organ injury (10%, common in all age groups except 
the elderly). In contrast, all bicycle-related injuries often comprised superficial injury (31%), and 
fractures to the upper (26%) or lower extremity (9%). 
 
Bicycle-related TBI often represented severe injuries (MAIS 2+, 98%), whereas all bicycle-related injuries 
often comprised minor or moderate injuries (MAIS 1–2, 76%). According to the MAIS, 482 of all cyclists 
(4%) died in the hospital because of their injuries, the majority comprising bicycle-related TBI (452, 94%; 
total in-hospital mortality rate in bicycle-related TBI: 14%). 
In both bicycle-related TBI and all bicycle-related injuries, injury severity (type of injury and MAIS), 
hospitalisation, days of hospitalisation, and IC admission increased with older age. However, those 
diagnosed with TBI were more often warranted admission to a hospital (64% versus 19%). Although 
patients with bicycle-related TBI had a shorter length of hospital stay than all bicycle-related injuries (on 
average 2.3 days (SD 0.74) versus 2.4 (SD 0.73)), they were more often admitted to the intensive care 
(IC; 7% versus 1%). 
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Table 3.2 Characteristics of bicycle-related TBI (2012) 
 
 
0–14 
(%) 
15–24 
(%) 
25–54 
(%) 
55–74 
(%) 
75+ 
(%) 
Total 
TBI (%) 
Total all bicycle-
related injuries (%) 
N (N (%)) 
1,215 
(16.9) 
1,010 
(14.0) 
2,169 
(30.2) 
2,095 
(29.1) 
701 
(9.7) 
7,190 
(100) 
76,325 
Incidence rate (per 100,000) 41.9 49.3 31.5 56.6 58.8 43.0 456.2 
Cycle use1 (billion km) 2.7 2.7 5.5 3.3 0.5 14.7 14.7 
Injury rate2 0.45 0.38 0.39 0.63 1.45 0.49 5.19 
Sex        
Men 57.7 48.1 61.6 53.1 49.4 55.4 50.5 
Women 42.3 51.9 38.4 46.9 50.6 44.6 49.5 
Type of injury        
Traumatic brain injury        
Concussion 70.0 62.0 59.1 53.6 53.3 59.2 5.6 
Skull-brain injury 23.8 25.0 29.3 34.0 41.3 30.3 2.9 
Other injury3        
Facial fracture 0.0 28.7 15.2 18. 0 0.0 16.9 2.1 
Facial injury, other 0.0 0.0 0.0 0.0 0.0 0.0 6.1 
Spine, vertebrae 0.0 0.0 7.8 10.7 0.0 6.6 1.1 
Internal organ injury 19.6 7.0 19.3 3.4 0.0 10.3 0.9 
Rib/thorax fracture 0.0 0.0 0.0 14.2 51.4 7.8 1.2 
Upper extr. fracture 19.6 21.7 53.9 39.5 48.6 40.4 25.5 
Upper extremity, other 0.0 0.0 0.0 0.0 0.0 0.0 4.6 
Hip fracture 0.0 0.0 0.0 14.2 0.0 5.2 2.5 
Lower extr.fracture 0.0 20.9 3.7 0.0 0.0 5.0 9.2 
Lower extremity, other 60.9 14.7 0.0 0.0 0.0 6.6 3.9 
Superficial injury 0.0 7.0 0.0 0.0 0.0 1.3 30.6 
Other 0.0 0.0 0.0 0.0 0.0 0.0 3.9 
Injury severity4        
MAIS 1 1.0 1.7 2.3 1.7 2.5 1.8 15.3 
MAIS 2 85.1 69.0 67.2 52.3 48.1 64.4 60.9 
MAIS 3 4.7 9.5 13.4 16.1 13.0 11.9 18.2 
MAIS 4 2.8 7.1 5.1 12.0 18.0 8.3 2.1 
MAIS 6 6.5 12.6 12.1 18.0 18.3 13.5 3.5 
Unknown (N) 0 0 1 0 0 0 360 
Hospitalisation5        
Hospital admission 58.5 58.3 60.8 68.8 78.6 64.1 18.6 
Number of hospital days6 2 (2–2.75) 2 (1–3) 2 (2–3) 3 (2–3) 3 (2–3) 2 (2–3) 3 (2–3) 
1 day 15.8 33.3 23.4 9.7 6.7 17.2 14.4 
2 days 59.2 38.1 34.7 30.5 28.9 36.9 27.6 
≥3 days 25.0 28.6 41.8 59.8 64.4 45.9 58.0 
IC admission 3.0 4.7 6.9 8.9 8.0 6.6 1.1 
1 Cycle use (annual number of kilometres travelled) per age group: relevant for both bicycle-related TBI and all bicycle-related injuries. 
2 Annual injury rate per million kilometres: calculated by dividing the number of cyclists with TBI or all injuries from cycling in each age group, 
by the annual number of kilometres travelled. 
3 Bicycle-related TBI: primary injury besides TBI. 
4 Data on MAIS only known for hospitalised patients in the LMR database (all injuries: n=14,177; TBI: n=3,357). 
5 Hospital admission or IC admission for one day or more after arrival at emergency department. 
6 Data is displayed as median, with the first and third quartile given within brackets. 
Km: kilometres, MAIS: maximum abbreviated injury score, IC: intensive care. 
 
Cost-of-illness 
Total costs of bicycle-related TBI in the Netherlands were €74.5 million annually, comprising 18% of the 
costs of all bicycle-related injuries (€410.7 million). Total costs per patient were far higher in bicycle-
related TBI (€19,620 per patient) than in all bicycle-related injuries (€10,130 per patient, Figure 3.2). 
This is due to both higher mean direct costs (€4,940 versus €2,610 per patient) and mean indirect costs 
(€14,680 versus €7,530 per patient), because TBI patients were more often warranted to the hospital 
and intensive care, and were longer absent from work (on average 46 versus 24 work days in all injuries). 
The direct costs and indirect costs (only applicable to the working population aged 15 to 65 years) per 
patient increased with age (Figure 3.2). 
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Figure 3.2 Age-related costs per case for bicycle-related TBI (A) and all bicycle-related injuries (B) in 2012 
A  B 
 
 
In both TBI (Table 3.3) and all injuries from cycling, the mean indirect costs per case were up to three 
times higher than the mean direct costs per case. Also, in both groups, total costs per case were higher 
in men than in women (TBI: €21,290 versus €17,120 per patient; all injuries: €11,160 versus €8,840 per 
patient). Men had higher indirect costs per case than women (TBI: €16,520 versus €11,990 per patient; 
all injuries: €8,850 versus €5,940 per patient), because they had to omit more days from work than 
women (TBI: 47 versus 44 work days; all injuries: 26 versus 21 work days). 
Indirect costs per case due to bicycle-related TBI were highest in men in the working population (aged 
15–64), and overall in adults aged 45–64 (on average €20,350 in men and €15,320 in women). Direct 
costs per case due to bicycle-related TBI were highest in cyclists aged 65+ (on average €8,530 per 
patient in men and €8,850 per patient in women). 
 
Table 3.3 Costs of bicycle-related TBI (2012) 
 Age (years) N 
Direct costs 
per case1 
Indirect costs 
per case1 
Total costs 
per case1 
Total costs TBI 
Total 0–14 1,215 2,400 – 2,400 2,734,650 
 15–24 1,010 3,280 6,780 10,050 6,741,570 
 25–44 1,299 3,890 14,300 18,190 18,467,500 
 45–64 2,047 4,730 18,400 23,120 32,000,700 
 65+ 1,617 8,690 – 8,690 14,594,180 
 Total 7,190 4,940 14,680 19,620 74,538,610 
Men 0–14 701 2,700 – 2,700 1,825,610 
 15–24 486 3,750 7,802 11,550 3,630,390 
 25–44 813 3,682 15,261 18,940 12,336,920 
 45–64 1,169 4,438 20,350 24,790 20,130,920 
 65+ 813 8,527 – 8,530 7,158,850 
 Total 3,983 4,770 16,520 21,290 45,082,680 
Women 0–14 514 1,950 – 1,950 909,040 
 15–24 524 2,820 5,930 8,750 3,111,180 
 25–44 486 4,233 12,502 16,740 6,130,590 
 45–64 879 5,091 15,320 20,410 11,869,790 
 65+ 804 8,852 – 8,850 7,435,330 
 Total 3,207 5,140 11,990 17,120 29,455,920 
1 Mean costs per case: indirect costs are only applicable to the working population (15 to 65 years). 
 
3.4 DISCUSSION 
 
Cycling is a popular form of transport and recreation in the Netherlands. Although cycling improves 
fitness and health, it is not without risks. The purpose of this paper was to assess the incidence and 
costs of bicycle-related traumatic brain injury across various age groups, and compared them with data 
on all bicycle-related injuries treated at Dutch EDs between 1998 and 2012. We conclude that incidence 
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of ED treatments due to cycling are high (456/100,000 persons) and often involve TBI (9%; 43/100,000). 
Between 1998 and 2012, the incidence of ED treatments due to bicycle-related TBI strongly increased, 
while this incidence due to all bicycle-related injuries remained stable. The incidence of hospital 
admissions, however, increased in both TBI and all injuries from cycling. In the same period, the injury 
rate of TBI per kilometres travelled increased in all age groups (44%) except children (–12%), whereas 
the overall injury rate of all injuries decreased (–4%) especially in children (–36%). Although bicycle-
related TBI accounted for 9% of the incidence of all ED treatments due to cycling, it accounted for 18% 
(€74.5 million) of the total costs due to all bicycle-related injuries (€410.7 million). Both direct and 
indirect costs per patient were far higher for cyclists diagnosed with TBI than all injuries from cycling, as 
TBI patients had more severe injuries, were more often admitted to a hospital or intensive care, and 
were longer absent from work. Our study identified children and adolescents aged 0–24 to have the 
highest incidence of ED treatments due to bicycle-related injuries. Although incidence of all bicycle-
related injuries and TBI was relatively low in cyclists aged 25–54, men in the working population (age 
15–64) had highest indirect costs due to their loss of productivity. Older cyclists aged 55+ were 
identified as main risk group for TBI, as they represented highest ED attendance, injury severity, 
admission to hospital or intensive care unit, and economic costs. 
The strength of our study lies in the detailed data on demographics, injury mechanism, injury severity 
(MAIS) and costs of bicycle-related injuries treated at Dutch EDs. Our study therefore provides 
population-based weighted estimates of the incidence and costs of injuries among all types of cyclists 
(sports and non-sports) in the Netherlands. In addition, our data provides insight into the trends of ED 
treatments and hospital admissions due to injuries from cycling over a period of 15 years. In contrast to 
cost estimations in previous studies, our cost-of-illness assessment included both direct and indirect 
costs, which were calculated with use of information on real health care volumes, work absence and 
return to work obtained from patient follow-up surveys. 
 
Incidence and trends 
Our estimated incidence of 456 ED treatments per 100,000 persons due to injuries from cycling was 
much higher than previously reported population-based incidence of ED treatments elsewhere in the 
world; <1/100,000 persons in Tanzania35 and Sweden,8 10 in Iran,36 50 in Canada,37 80 in France,6 and 
163 in the United States.38 This higher Dutch incidence is most likely caused by the more frequent use 
of bicycles and therefore higher risk of bicycle-related injuries in the Netherlands than in other 
countries: in the Netherlands one third of all journeys are made by bike.33 In contrast, in other European 
countries approximately 2–20% of all journeys are made by bike.2 In car-oriented countries such as 
Canada and the United States, only 1% of daily trips are made by bike.39 
The finding that bicycle-related TBI accounted for 9% of all bicycle-related injuries, is lower than the 
proportion of head injuries reported in other studies, namely 22–35% in the USA, Sweden, and 
Finland.5,10,11 This difference in proportion is likely explained by the disparity in TBI definition. Whereas 
this study only included patients diagnosed with traumatic brain injury, other studies included all head 
injuries (including facial fractures, and open wounds or superficial injuries to the head). In addition, the 
difference in proportion of head injuries may be explained by differences in cycling populations, as in 
the abovementioned Northern European countries cycling levels remain high, even among the elderly.40 
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Our study showed a strong increase in the incidence of ED treatments due to bicycle-related TBI 
between 1998 and 2012. In this period, the number of hospital admissions due to bicycle-related TBI 
and all injuries from cycling increased in all age groups in the Netherlands. Such findings have also been 
reported for adolescents (aged 13–17) and adults (aged 18+) without head injuries in Alberta, Canada.41 
The increase in hospital admissions in the Netherlands is likely explained by an increase in injury severity 
of patients visiting an ED, as the number of patients with multiple injuries and the number of patients 
admitted to the intensive care increased over time. In addition, estimates of the Global Burden of 
Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) showed a constant increase in the number 
of years lived with disability (YLDs – the non-fatal component of disability adjusted life-years (DALYs)) 
from pedal cycling in Western Europe, approximately 30% from 1990 to 2010.42 
 
Patient characteristics and outcome 
Our finding that in all age groups the majority of bicycle-related TBI and all bicycle-related injuries were 
caused by a fall or collision with a motor vehicle is in line with results of other studies.6-10,43 
Our study indicated that the incidence of ED treatments due to bicycle-related TBI are highest in adults 
aged 55+, which is in line with previous studies that reported that older cyclists tended to have a higher 
risk of (serious) injuries from cycling than the younger age groups.7,8,11,13 This confirms our finding that 
bicycle-related TBI imposed far more severe injuries (98% MAIS 2+) than all bicycle-related injuries. In 
our sample, the majority (76%) of all bicycle-related injuries involved minor or moderate injuries (MAIS 
1-2), which is in line with other findings in injured cyclists.5,12 The difference in injury severity between 
TBI and all injuries from cycling may explain the fact that we found far higher hospital admission rates 
in cyclists diagnosed with TBI (64%) than in all injured cyclists (19%). 
 
Direct and indirect costs 
Total direct and indirect costs of bicycle-related injuries treated at EDs were €10,130 per patient, which 
was higher than estimates in other European countries: €3,180 in Finland5 and €4,290 in Sweden11 after 
adjustment for inflation up to 2012. Although the Finnish study estimated the same costs and included 
both costs of treatment and labour absenteeism, the Swedish study estimated only the costs of out- 
and inpatient care in older adults (65+ years). However, a study in Norway estimated costs of health 
care and lost output per cyclist injured or killed, similar to estimates in our study: ranging from €1,470 
for minor injuries (AIS1) to €19,610 for moderate injuries (AIS2)12 after adjustment for inflation up to 
2012. 
In addition to previous studies, we found the total costs of survivors of bicycle-related TBI to be even 
higher (on average €19,620 per patient), because these TBI patients were more often warranted to the 
hospital and intensive care, and were longer absent from work (on average 46 days). Our estimates 
were higher than those of head injured cyclists used for cost-effectiveness of bicycle helmet campaigns 
or laws, estimating acute medical treatment costs as being €64 per patient,22 and direct medical costs 
of hospitalisation as being €1,310 in children aged 5–12, €1,350 in adolescents aged 13–18, and €1,130 
in adults aged 18+.23 
According to our study, in both bicycle-related TBI and all injuries from cycling, the mean indirect costs 
per case were up to three times higher than the mean direct costs per case, and higher in men than in 
women (on average 3–5 more omitted workdays). Previous research on minor bicycle accidents in 
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Belgium, also indicated productivity loss to be the most important component of total cost due to 
cycling injuries.44 The difference in omitted workdays and indirect costs between men and women can 
be explained by the fact that in the Netherlands many women, especially mothers, work part-time: 75% 
of women aged 25 to 54 with dependent children work part-time, compared to only 26% in France.45 
 
Limitations 
The epidemiology and costs of bicycle-related TBI and all bicycle-related injuries reported in this study 
are conservative since they represent only injury patients who were treated at the ED and/or 
hospitalised. Estimates of the Dutch Consumer and Safety Institute indicate that for every injured cyclist 
treated at the ED, 1 to 2 consulted a general practitioner, and 2 did not seek medical care.4 Hence, the 
actual incidence and cost-of-illness due to bicycle-related TBI and all bicycle-related injuries may be 
even higher. It should also be noted that this study could not provide complete information on mortality 
among injured cyclists, because national death statistics are only available for specific diseases or 
specific injury mechanisms. However, information on the injury severity (MAIS) showed that 482 (4%) 
of all cyclists died (MAIS 6) in the hospital because of their injuries. The majority of these patients 
(n=452, 94%) was diagnosed with TBI. According to the MAIS, total in-hospital mortality rate in bicycle-
related TBI was 14%. Overall mortality rates are expected to be even higher, because the MAIS only 
provides information on the in-hospital mortality. 
The incidence of bicycle-related TBI and all injuries from cycling were not kilometre-adjusted. However, 
we did include information on cycle use and the injury rate of both bicycle-related TBI and all injuries 
from cycling per kilometre travelled. This data showed that between 1998 and 2012, cycle use increased 
in the Netherlands. In the same period, the injury rate of bicycle-related TBI increased (except in 
children), whereas the overall injury rate of all bicycle-related injuries decreased. 
A final limitation of our study is that since helmet use is not registered in the LIS database, the effects 
of helmet use could not be studied. 
 
Implications for prevention 
This study showed older cyclists (aged 55+ years) to have a higher risk of (serious) injuries from cycling 
than younger cyclists, both with respect to incidence and injury rate, and identified them as an 
important risk group for TBI. However, so far, prevention strategies in the Netherlands have been mainly 
focussing on children and the use of bicycle-helmets in these young and vulnerable cyclists. This has led 
to an increase in the purchase and/or use of bicycle helmets in children.46-48 Efforts to increase helmet 
use may have been effective, as our study showed a 30% decrease in ED treatments due to all bicycle-
related injuries and a 12% decrease in the injury rate of TBI per kilometre travelled in 0–14-year olds 
between 1998 and 2012, and a 6% decrease in ED treatments due to bicycle-related TBI in girls aged 0–
14. Also, preliminary results of a campaign in the southern part of the Netherlands, in which free bicycle 
helmets are provided to all children in primary schools, indicate that after the implementation of this 
campaign the number of young cyclists with TBI decreased.46 The latter provides further support for the 
effectiveness of community based helmet promotion programmes. 
Bicycle helmets may also be of use among older cyclists. In the Netherlands, nowadays, helmet use is 
not mandatory and is unusual among most cyclists. Bicycle helmets are only used during sports among 
road cyclists and mountain bikers, and by young children. However, it has been shown in other countries 
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that bicycle helmets reduce the incidence, proportion and severity of head injuries among helmet 
users.5,9,36,49,50 
Finally, as older cyclists showed higher injury rates of TBI per kilometre travelled compared to other age 
groups, and increased cycling is expected to increase TBI in the older age groups, prevention strategies 
should target on education and training for the physical vulnerable elderly in traffic, especially those 
using electrical bicycles. Our finding that both the number of ED treatments due to injuries from cycling 
and injury rate per kilometre travelled increased in adults aged 55+, may be caused by the increasing 
popularity of electrically assisted bicycles1,51,52 in this age group.53 In 2011, 13% of all ED treatments due 
to bicycle-related injuries in the Netherlands involved users of an electrical bicycle, often aged 60+ 
(72%).54 Although injury characteristics seemed similar, in contrast to users of classical bikes, elderly 
users of electrical bikes were more often injured due to a fall (18% versus 12%). A possible explanation 
could be the weight of the electrical bicycle, which the elderly indicated to be too high.54 Also, results 
of a recent study on the road safety implications of the use of electric bicycles in the Netherlands 
suggest that users of electric bicycles are more at risk of having a crash that requires treatment at an 
ED than users of classical bicycles.55 Further research is needed to minimise the risk and maximise the 
health benefits for users of electric bicycles. Overall, education and training for the elderly, and 
improvements in the cycle infrastructure, may reduce the injury severity, ED attendance, and 
hospitalisation of elderly cyclists. 
 
Conclusions 
This study examined the incidence and costs of bicycle-related TBI and compared them with data on all 
bicycle-related injuries treated at Dutch EDs between 1998 and 2012. We found that incidence of ED 
treatments due to cycling are high and often involve TBI, imposing a high burden on individuals and 
society. Older cyclists aged 55+ were identified as main risk group for TBI to be targeted in preventive 
strategies, due to their high risk for (serious) injuries and ever-increasing share of ED visits and hospital 
admissions.  
 
REFERENCES 
 
1. BOVAG RAI Foundation. [Mobility in Figures 'Two-wheelers' 2013/2014]. Amsterdam: Stichting BOVAG RAI Mobiliteit;2013. 
2. Ministry of Transport and Fietsberaad. Cycling in the Netherlands. The Hague and Utrecht: Ministry of Transport 
and Expertise Centre for Cycling Policy;2009. 
3. Godefrooij T. Segregation or Integration for Cyclists? The Dutch Approach. In: Tolley RS, ed. The Greening of Urban Transport. 
Second edition ed. New York: John Wiley & Sons; 1997:229-238. 
4. Consumer and Safety Institute. Fact sheet: bicycle accidents. Amsterdam2011. 
5. Airaksinen N, Lüthje P, Nurmi-Lüthje I. Cyclist Injuries Treated in Emergency Department (ED): Consequences and Costs in 
South-eastern Finland in an Area of 100 000 Inhabitants. Ann Adv Automot Med. 2010;54:267-274. 
6. Amoros E, Chiron M, Thélot B, Laumon B. The injury epidemiology of cyclists based on a road trauma registry. BMC Public 
Health. 2011;11:653. 
7. Chen WS, Dunn RY, Chen AJ, Linakis JG. Epidemiology of nonfatal bicycle injuries presenting to United States emergency 
departments, 2001-2008. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 
Jun 2013;20(6):570-575. 
8. Eilert-Petersson E, Schelp L. An epidemiological study of bicycle-related injuries. Accid Anal Prev. May 1997;29(3):363-372. 
9. Hefny AF, Eid HO, Grivna M, Abu-Zidan FM. Bicycle-related injuries requiring hospitalization in the United Arab Emirates. 
Injury. Sep 2012;43(9):1547-1550. 
10. Rivara FP, Thompson DC, Thompson RS. Epidemiology of bicycle injuries and risk factors for serious injury. Injury prevention 
: journal of the International Society for Child and Adolescent Injury Prevention. Jun 1997;3(2):110-114. 
11. Scheiman S, Moghaddas HS, Björnstig U, Bylund PO, Saveman BI. Bicycle injury events among older adults in Northern 
Sweden: a 10-year population based study. Accid Anal Prev. Mar 2010;42(2):758-763. 
12. Veisten K, Saelensminde K, Alvaer K, et al. Total costs of bicycle injuries in Norway: correcting injury figures and indicating 
data needs. Accid Anal Prev. Nov 2007;39(6):1162-1169. 
50 | Epidemiology of traumatic brain injury 
13. Stone M, Broughton J. Getting off your bike: cycling accidents in Great Britain in 1990-1999. Accid Anal Prev. Jul 
2003;35(4):549-556. 
14. Tagliaferri F, Compagnone C, Korsic M, Servadei F, Kraus J. A systematic review of brain injury epidemiology in Europe. Acta 
Neurochir (Wien). Mar 2006;148(3):255-268; discussion 268. 
15. Andelic N, Hammergren N, Bautz-Holter E, Sveen U, Brunborg C, Roe C. Functional outcome and health-related quality of 
life 10 years after moderate-to-severe traumatic brain injury. Acta Neurol Scand. Jul 2009;120(1):16-23. 
16. Dijkers MP. Quality of life after traumatic brain injury: a review of research approaches and findings. Arch Phys Med Rehabil. 
Apr 2004;85(4 Suppl 2):S21-35. 
17. Berg J, Tagliaferri F, Servadei F. Cost of trauma in Europe. European journal of neurology : the official journal of the European 
Federation of Neurological Societies. Jun 2005;12 Suppl 1:85-90. 
18. Holtslag HR, Post MW, van der Werken C, Lindeman E. Return to work after major trauma. Clinical rehabilitation. 
2007;21(4):373-383. 
19. Radford K, Phillips J, Drummond A, et al. Return to work after traumatic brain injury: cohort comparison and economic 
evaluation. Brain injury. 2013;27(5):507-520. 
20. Scholten AC, Haagsma JA, Panneman MJ, van Beeck EF, Polinder S. Traumatic brain injury in the Netherlands: incidence, 
costs and disability-adjusted life years. PLoS One. 2014;9(10):e110905. 
21. Hansen P, Scuffham PA. The cost-effectiveness of compulsory bicycle helmets in New Zealand. Aust J Public Health. Oct 
1995;19(5):450-454. 
22. Kopjar B, Wickizer TM. Age gradient in the cost-effectiveness of bicycle helmets. Prev Med. May 2000;30(5):401-406. 
23. Taylor M, Scuffham P. New Zealand bicycle helmet law--do the costs outweigh the benefits? Injury prevention : journal of 
the International Society for Child and Adolescent Injury Prevention. Dec 2002;8(4):317-320. 
24. Meerding WJ, Polinder S, Lyons RA, et al. How adequate are emergency department home and leisure injury surveillance 
systems for cross-country comparisons in Europe? Int J Inj Contr Saf Promot. Mar 2010;17(1):13-22. 
25. Van der Stegen R, Ploemacher J. Discription of methods for statistics by diagnoses in time by using the LMR (1981–2005). 
The Hague: Statistics Netherlands (CBS). 2009;9. 
26. Consumer and Safety Institute. The Dutch Burden of Injury Model. Amsterdam: Consumer and Safety Institute;2005. 
27. Mulder S, Meerding WJ, Van Beeck EF. Setting priorities in injury prevention: the application of an incidence based cost 
model. Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention. Mar 2002;8(1):74-
78. 
28. Haagsma JA, Polinder S, Olff M, Toet H, Bonsel GJ, van Beeck EF. Posttraumatic stress symptoms and health-related quality 
of life: a two year follow up study of injury treated at the emergency department. BMC psychiatry. 2012;12:1. 
29. Polinder S, van Beeck EF, Essink-Bot ML, et al. Functional outcome at 2.5, 5, 9, and 24 months after injury in the Netherlands. 
The Journal of trauma. Jan 2007;62(1):133-141. 
30. Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic 
evaluations. Pharmacoeconomics. 2002;20(7):443-454. 
31. de Putter CE, Selles RW, Polinder S, Panneman MJ, Hovius SE, van Beeck EF. Economic impact of hand and wrist injuries: 
health-care costs and productivity costs in a population-based study. J Bone Joint Surg Am. May 2012;94(9):e56. 
32. Meerding WJ, Mulder S, van Beeck EF. Incidence and costs of injuries in The Netherlands. Eur J Public Health. Jun 
2006;16(3):272-278. 
33. Population data. 2013. www.cbs.nl. Accessed February 19, 2014. 
34. Mobility of persons. SWOV Institute for Road Safety Research; 2014. http://www.swov.nl/UK/Research/Cijfers/Cijfers_ 
Mobiliteit-UK.htm. 
35. Zimmerman K, Mzige AA, Kibatala PL, Museru LM, Guerrero A. Road traffic injury incidence and crash characteristics in Dar 
es Salaam: a population based study. Accid Anal Prev. Mar 2012;45:204-210. 
36. Karkhaneh M, Naghavi M, Rowe BH, Hagel BE, Jafari N, Saunders LD. Epidemiology of bicycle injuries in 13 health divisions, 
Islamic Republic of Iran 2003. Accid Anal Prev. Jan 2008;40(1):192-199. 
37. Konkin DE, Garraway N, Hameed SM, et al. Population-based analysis of severe injuries from nonmotorized wheeled 
vehicles. Am J Surg. May 2006;191(5):615-618. 
38. Thompson DC, Thompson RS, Rivara FP. Incidence of bicycle-related injuries in a defined population. American journal of 
public health. Nov 1990;80(11):1388-1390. 
39. Buehler R, Pucher J. Trends in Walking and Cycling in Western Europe and the United States. 2012. 
40. Pucher J, Buehler R. Cycling for everyone: lessons from Europe. Transportation Research Record: Journal of the 
Transportation Research Board. 2008;2074(1):58-65. 
41. Karkhaneh M, Rowe BH, Saunders LD, Voaklander DC, Hagel BE. Trends in head injuries associated with mandatory bicycle 
helmet legislation targeting children and adolescents. Accid Anal Prev. Oct 2013;59:206-212. 
42. The Global Burden of Disease (GBD) Visualizations: GBD Compare. Institute for Health Metrics and Evaluation; 2013. 
http://vizhub.healthdata.org/gbd-compare/. 
43. Kraus JF, Fife D, Conroy C. Incidence, severity, and outcomes of brain injuries involving bicycles. American journal of public 
health. Jan 1987;77(1):76-78. 
44. Aertsens J, de Geus B, Vandenbulcke G, et al. Commuting by bike in Belgium, the costs of minor accidents. Accid Anal Prev. 
Nov 2010;42(6):2149-2157. 
45. OECD. Closing the Gender Gap - Act Now. Paris: OECD publishing;2012. 
46. Consumer and Safety Institute and Institute for Road Safety Research (SWOV). [Factsheet 'Coole kop, helm op!']. Consumer 
and Safety Institute and Institute for Road Safety Research (SWOV);2012. 
47. Goldenbeld C, Van Vugt M, H. Increase of bicycle helmet use in the Netherlands. Tijdschrift voor Gezondheidswetenschappen 
(TSG). 2003;81(1):18-23. 
48. Villamor E, Hammer S, Martinez-Olaizola A. Barriers to bicycle helmet use among Dutch paediatricians. Child Care Health 
Dev. Nov 2008;34(6):743-747. 
49. Olivier J, Walter SR, Grzebieta RH. Long term bicycle related head injury trends for New South Wales, Australia following 
mandatory helmet legislation. Accid Anal Prev. Jan 2013;50:1128-1134. 
50. Thompson DC, Rivara FP, Thompson R. Helmets for preventing head and facial injuries in bicyclists. Cochrane Database Syst 
Rev. 2000(2):CD001855. 
Chapter 3 | 51 
 
51. Kühn M. Safety Aspects of High-Speed Pedelecs. Berlin: German Insurers Accident Research;2012. 
52. Papoutsi S, Martinolli L, Braun CT, Exadaktylos AK. E-bike injuries: experience from an urban emergency department-a 
retrospective study from Switzerland. Emerg Med Int. 2014;2014:850236. 
53. Hendriksen I, Engbers L, Schrijver J, van Gijlswijk R, Weltevreden J, Wilting J. [Electric Bicycles; Market Research and an 
Exploration of Future Potential]. Leiden: Netherlands Organisation for Applied Scientific Research (TNO);2008. 
54. Consumer and Safety Institute. [Fact sheet: National Injury Surveillance System 2012]. Amsterdam: Consumer and Safety 
Institute;2013. 
55. Schepers JP, Fishman E, den Hertog P, Wolt KK, Schwab AL. The safety of electrically assisted bicycles compared to classic 
bicycles. Accid Anal Prev. Sep 16 2014;73C:174-180. 
 
APPENDIX 
 
Table 3.A Unit costs (2012) 
 Resource Unit costs 
General Practitioner Practice consultation €33.70 
 Consultation by telephone €16.90 
 Home visit €67.40 
 Referral patient treated at the ED €35.00 
 Referral hospitalised patient €44.00 
 Follow-up care patient treated at the ED €33.70 
 Follow-up care hospitalised patient €37.80 
Ambulance Emergency journey €538.20 
 Scheduled journey €206.20 
Hospital Attendance of ED Injury specific fees1 
 Hospitalisation general hospital €460.40/day 
 Hospitalisation academic hospital €629.00/day 
 Intensive care €1,751.50/day 
 Day care €310.30/day 
 Outpatient department visit €178.10/visit 
 Medical procedures Reimbursement fees 
Long-term care Nursing home €264.60/day, 138.80/day care 
 Rehabilitation €469.10/day 
 Physiotherapy €38.00/treatment 
Home care Domestic care €30.60/hour 
 Care €39.10/hour 
 Nursing €67.60/hour 
 Nursing & care €46.40/hour 
Productivity loss 15–19 year €13.50/hour 
(including VAT) 20–24 year €24.70/hour 
 25–29 year €32.80/hour 
 30–34 year €39.30/hour 
 35–39 year €43.30/hour 
 40–44 year €45.40/hour 
 45–49 year €46.80/hour 
 50–54 year €48.50/hour 
 55–59 year €49.70/hour 
 60–64 year €50.70/hour 
 Overall mean €40.90/hour 
1 Unit costs for attendance of emergency department are calculated per type of injury in an annually unit cost study indexing the tariffs per 
minute of nurses, physicians and specialists. ED: emergency department; VAT: value added tax. 
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Table 3.B Predictors of bicycle-related TBI and TBI severity1 
 OR 95%CI p-value 
Bicycle-related TBI2    
Age3 1.01 1.01–1.01 <0.05 
Male gender 1.33 1.27–1.40 <0.05 
Fall (single bicycle crash) 0.95 0.77–1.16 0.601 
Collision with 4-wheeled vehicle4 2.67 2.17–3.30 <0.05 
Collision with 2-wheeled vehicle5 1.63 1.32–2.01 <0.05 
Collision with obstacle6, pedestrian or animal 1.48 1.18–1.86 <0.05 
Fall out of child seat 6.56 4.64–9.26 <0.05 
TBI severity7    
Age3 1.01 1.01–1.02 <0.05 
Male gender 1.11 1.00–1.23 0.059 
Fall (single bicycle crash) 0.43 0.29–0.66 <0.05 
Collision with 4-wheeled vehicle4 1.24 0.82–1.88 0.317 
Collision with 2-wheeled vehicle5 0.55 0.36–0.85 <0.05 
Collision with obstacle6, pedestrian or animal 0.49 0.31–0.79 <0.05 
Fall out of child seat 1.46 0.79–2.72 0.231 
1 Analysis based on stepwise multivariate regression analysis with socio-demographics (age and gender) as step 1; and injury mechanism as 
step 2. 
2 Bicycle-related TBI versus all bicycle-related injuries. 
3 Continuous variable. 
4 Including passenger cars, buses, pick-up trucks, trucks and trams. 
5 Including bicycles, mopeds and motor cycles. 
6 Including tree, wall, stationary car (door), (light) pole or edge of sidewalk. 
7 Concussion versus skull-brain injuries. 
OR: odds ratio; 95%CI: 95% confidence interval; IC: intensive care. 
 
Figure 3.A Absolute number of ED treatments and incidence (per 100,000 person-years) for bicycle-related 
TBI (A and B) and all bicycle-related injuries (C and D) in the Dutch population (1998–2012) 
Data is shown for men (A and C) and women (B and D). 
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ED: emergency department. 
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ABSTRACT 
 
Background Insight into the change from pre- to post-injury health-related quality of life 
(HRQL) of trauma patients is important to derive estimates of the impact of injury on HRQL. 
Prospectively collected pre-injury HRQL data is, however, often not available due to the 
difficulty to collect this data before the injury. We performed a systematic review on the 
current methods used to assess pre-injury health status and to estimate the change from pre- 
to post-injury HRQL due to an injury. 
 
Methods A systematic literature search was conducted in EMBASE, MEDLINE, and other 
databases. We identified studies that reported on the pre-injury HRQL of trauma patients. 
Articles were collated by type of injury and HRQL instrument used. Reported pre-injury HRQL 
scores were compared with general age- and gender-adjusted norms for the EQ-5D, SF-36 
and SF-12. 
 
Results We retrieved results from 31 eligible studies, described in 41 publications. All but two 
studies used retrospective assessment and asked patients to recall their pre-injury HRQL, 
showing widely varying timings of assessments (soon after injury up to years after injury). 
These studies commonly applied the SF-36 (n=13), EQ-5D (n=9) or SF-12 (n=3) using 
questionnaires (n=14) or face-to-face interviews (n=11). Two studies reported prospective 
pre-injury assessment, based on prospective longitudinal cohort studies from a sample of 
initially non-injured patients, and applied questionnaires using the SF-36 or SF-12. The 
recalled pre-injury HRQL scores of injury patients consistently exceeded age- and gender-
adjusted population norms, except in a limited number of studies on injury types of higher 
severity (e.g. traumatic brain injury and hip fractures). All studies reported reduced post-injury 
HRQL compared to pre-injury HRQL. Both prospective studies reported that patients had 
recovered to their pre-injury levels of physical and mental health, while in all but one 
retrospective study patients did not regain the reported pre-injury levels of HRQL, even years 
after injury. 
 
Conclusions So far, primarily retrospective research has been conducted to assess pre-injury 
HRQL. This research shows consistently higher pre-injury HRQL scores than population norms 
and a recovery that lags behind that of prospective assessments, implying a systematic 
overestimation of the change in HRQL from pre- to post-injury due to an injury. More 
prospective research is necessary to examine the effect of recall bias and response shift. 
Researchers should be aware of the bias that may arise when pre-injury HRQL is assessed 
retrospectively or when population norms are applied, and should use prospectively derived 
HRQL scores wherever possible to estimate the impact of injury on HRQL. 
Chapter 4 | 59 
 
4.1 INTRODUCTION 
 
Insight into the change from pre- to post-injury health status of trauma patients is important in order 
to derive population estimates of the impact of injury on health-related quality of life (HRQL). However, 
prospectively collected information on the pre-injury HRQL of injury patients is difficult to obtain. 
This has led researchers to use alternative methods to assess the contrast between pre-injury and post-
injury HRQL, such as use of patient recall or retrospective baseline scores. In other words, pre-injury 
HRQL that is assessed after sustaining the injury. However, retrospective baseline scores of pre-injury 
health status are potentially subject to bias.1,2 Patients may remember their pre-injury HRQL as better 
or worse than it actually was (recall bias).1 Moreover, patients’ perception on HRQL may change after 
the injury, due to a change in internal standards or values (response shift).3 This change in perception 
of HRQL after the injury may also affect the retrospectively assessed pre-injury HRQL. 
Other methods are the application of general population norms (i.e. using normative values from the 
general population as a reference point for the health status before the injury), or the use of a matched 
non-injured comparison group as a baseline to assess the reduction in health due to the injury. The 
application of population norms or a matched non-injured comparison group may lead to an inaccurate 
estimate of the change in health status as injured people may differ from the general non-injured 
population.4,5 Research indicated that injured people have a higher prevalence of comorbidity, 
hospitalisation and health service utilisation prior to their injury in comparison to non-injured people.4 
This suggests that pre-injury health status is worse compared to population norms and conflicts with 
the reported better pre-injury health status compared to the general population.5-7 On the other hand, 
the injured population might be healthier and more likely to participate in activities, exposing them to 
a higher risk of injuries.8 
 
The current systematic review identifies the methods that are used to assess pre-injury health status of 
trauma patients and to estimate the change from pre- to post-injury HRQL due to an injury. Moreover, 
bias that may occur from these methods is examined, by comparing the reported pre-injury HRQL scores 
with population norms. The objectives of this study are to 1) assess the methods which are used to 
measure pre-injury HRQL, 2) compare the reported pre-injury HRQL scores with general age- and 
gender-adjusted norms, 3) study the pre-injury HRQL scores per HRQL instrument and injury type, 4) 
examine the change between pre- and post-injury HRQL in injury patients, and 5) formulate 
recommendations for future studies on (pre-injury) HRQL. 
 
4.2 METHODS 
 
Relevant studies were identified through systematic literature searches in the databases EMBASE, 
MEDLINE (via Ovid SP), Cochrane Central, Pubmed, Web of Science, SCOPUS, PsycINFO, CINAHL, Lilacs, 
Scielo, ScienceDirect, and ProQuest. Grey literature was examined via Google Scholar. Search strategies 
were developed in consultation with a search expert, and included a combination of subheadings and 
text words (Appendix A). Reference lists and citation indices of the included papers and relevant reviews 
were inspected to identify additional relevant citations.  
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Study selection 
We included studies that assessed the pre-injury HRQL of injury patients, published in English in peer-
reviewed journals until July 6 2015. We included studies on general injury populations, as well as injury 
specific studies (e.g. traumatic brain injury or hip fractures). There was no restriction in the methods of 
patient selection used in the studies (e.g. samples drawn from to the ED, hospital or outpatient 
programmes). HRQL was conceptualised as an individual’s perception of how an illness and its 
treatment affect physical, mental and social aspects of his/her life.9 Studies that assessed only some 
domains of HRQL (e.g. functional status, activities of daily living, mobility, mental health) were excluded. 
We included studies that assessed the HRQL of patients before the injury, whether assessed before the 
injury or retrospectively. Studies that solely used population norms, as a substitute of pre-injury HRQL, 
were excluded. For studies using data from the same study sample, one study was chosen as reference 
study by giving priority to the study that focused on reporting pre-injury HRQL summary scores or utility 
scores (e.g. instead of percentage of problems per HRQL domain). 
 
Data extraction and methodological quality  
The first review author (AS) screened all titles and abstracts and deleted obviously irrelevant papers. 
Two independent review authors (AS and SP) screened the remaining citations on title and abstract and 
those obtained in full text. Results from both reviewers were compared by a third review author (JH) 
and any disagreement was be resolved by discussion between the three authors. 
We extracted information on the participants (age, gender), injury (type, severity, and mechanism), the 
assessment of pre-injury HRQL (instrument, procedure, and timing) and recovery of injury patients 
(change between pre- and post-injury HRQL). 
The methodological quality of the studies was evaluated with four elements of the STROBE checklist10 
which were most relevant to the quality of reported pre-injury HRQL by injury type: setting, participants, 
data sources/measurement and study size. In addition, risk of bias was assessed using items from the 
Research Triangle Institute item bank for observational studies on attrition bias (Impact missing data 
adequately assessed) and reporting bias (No important primary outcomes missing).11 
 
Statistical analysis 
Pre-injury HRQL scores from the study samples were compared with norm scores derived from the 
general population. Norms by age and sex groups of the EQ-5D (UK population),12 SF-3613 and SF-1214 
(US population) were used to calculate age- and gender-adjusted norms based on the demographics in 
the study samples. 
Heterogeneity between pre-injury HRQL scores was assessed with the Q-statistic and I2-statistic, using 
a random-effects model in a Microsoft Excel spreadsheet.15 The Q-statistic is a Chi2-test for 
heterogeneity, which assesses whether observed differences in results are compatible with chance 
alone. A significant Q (low p-value) indicates heterogeneity among the effect sizes and a variation in 
effect sizes that is beyond chance.16 The I²-statistic describes the percentage of variation across studies 
that is due to heterogeneity rather than chance, with an I2 value of ≤25% indicating low heterogeneity, 
and ≥50% indicating substantial heterogeneity.17 
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4.3 RESULTS 
 
Literature search 
The extensive search strategy identified 2,286 unique titles of potentially relevant articles (Figure 4.1). 
Screening of the titles and abstracts resulted in a selection of 383 articles that appeared to meet all 
selection criteria. After screening and selection of the full text papers, we retrieved 31 studies described 
in 41 publications. The main reasons for exclusion were not measuring pre-injury health status, not 
reporting on injuries or only reporting part of the outcomes on HRQL. 
 
Study characteristics 
Of the 31 studies included in our systematic review, most were conducted in the US (n=8),18-25 Australia 
(n=5),5,26-29 and Canada (n=5)30-34 (Table 4.1). Eight studies measured the pre-injury HRQL of patients 
with a hip fracture,24,30,34-39 followed in frequency by extremity injury (n=6),19,23,32,37,40,41 general injury 
(n=5)7,29,31,42,43 and traumatic brain injury (TBI, n=4).22,25,27,44 Sample sizes of the studies varied widely, 
ranging between 3433 and 2,8427 participants, with most studies having sample sizes between 100 and 
600 (n=17). The majority of the participants were males (>50% men in 20 out of the 31 studies). The 
nine studies that included more women than men18,23,30,34,36,38,39,45,46 often focused on hip fractures 
(n=5),30,34,36,38,39 or reported on the outcomes after a motor vehicle crash of a longitudinal (annual) 
survey (n=2).18,46 The mean age of the participants in the included studies ranged between 1019 and 
8730, with an average of 30 to 54 in half (n=16) of the studies and 75+ in six of the 31 included studies. 
Four studies measured the pre-injury HRQL for children and adolescents,19,22,25,31 of which the author 
names are indicated in bold in Table 4.1 
 
Figure 4.1 Study selection 
 
5,351 records identified
through database searching
250 additional records identified 
through other sources
2,286 unique records
383 full-text articles assessed for 
eligibility
342 articles excluded
252 part of HRQL
26 type of injury
22 no pre-injury HRQL
20 study design
12 intervention/treatment
5 no HRQL scores
3 no injury
2 language
1,903 records excluded
31 eligible studies identified,
described in 41 publications
5,601 records identified 3,315 duplicates removed
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Methodological quality 
Over half (n=19) of the 31 articles included in our review reported on attrition. Most studies faced 
several problems in the participation of eligible patients, as patients refused to participate (n=15), could 
not be contacted (n=6), did not complete the HRQL assessment (n=6), had died (n=5), or were not able 
to respond to the questionnaires (e.g. due to the consequences of the trauma, n=3). Overall, response 
rates ranged from 60% to 98% in 17 of the 22 studies that reported on response rates. 
Limited variation existed in the selection of samples between the studies. Most patients were recruited 
during or after a treatment in a (pediatric) hospital (n=21), while others were selected from a specialised 
burn center (n=2),20,28 sports center (n=1),23 or nursing home facility (n=1).30 
In four out of the 31 studies, the measurement of pre-injury HRQL was one of the primary aims,7,8,18,46 
while in all other studies pre-injury HRQL scores were used to assess the change in HRQL after the injury 
or to validate HRQL instruments. 
 
Methods to measure pre-injury HRQL 
The 36-item Short-Form (SF-36, n=14)21,24,26-29,32-34,40,41,45,46,53 was the most frequently used instrument 
to assess the pre-injury HRQL of injury patients, followed by the EuroQol-5 Dimension Questionnaire 
(EQ-5D, n=9),7,30,31,35-39,42 and the SF-12 (n=4)5,18,23,43 (Table 4.1). The remaining studies used the Pediatric 
Quality of Life Inventory (PedsQL, n=3),19,22,25 or a combination of the EQ-5D and SF-36 (n=1).44 The 
majority of the studies assessed the participants’ pre-injury HRQL by using a questionnaire 
(n=16)8,18,20,22-24,27,28,31-33,35,37,41,44-46 or a face-to-face interview (n=11).7,8,21,25,29,30,34,36,38-40 At follow-up, 
most studies used questionnaires (n=17)18,23,24,27,28,31-33,35,37,39-41,44-46,53 followed by the use of telephone 
interviews (n=10).19,21,22,25,26,30,34,36,42,43 
All but two studies in this review retrospectively assessed the pre-injury HRQL of patients, by asking 
them to recall their HRQL before the injury occurred. Only two studies provided prospectively collected 
pre-injury health status of participants18,46 (articles in bold and italics in Table 4.1): the Medical 
Expenditure Panel Survey (MEPS)18 and the Seguimiento Universidad de Navarra (SUN)46 cohort. These 
studies used data from longitudinal cohort studies in which participants who were initially non-injured 
were followed for several years, by means of questionnaires comprising the SF-3646 or SF-1218. In 
addition, only one of the included studies measured the recalled pre-injury health status of trauma 
patients and not their post-injury HRQL,5 while all other studies measured both pre- and post-injury 
HRQL. 
Pre-injury scores were often reported as assessed ‘soon after’ injury or admission (n=12), in-hospital or 
‘soon after’ discharge (n=5),8,21,29,34,36 at inclusion or initial contact/visit (n=5),23,25,32,37,45 within 6 months 
after ED discharge (n=2),7,43 or years after injury (n=2).42,44 The focus of the questionnaire and/or 
interviews (i.e. a specified period prior to the injury) was often not specifically defined (e.g. ‘before the 
injury’, n=15) or not reported (n=2).28,38 The studies that specified the period of their pre-injury 
assessment used a day before injury (n=1),31 ‘just’ before injury (n=1),30 a week before injury 
(n=4),8,25,39,45 the previous week (n=2),23,29 or the month or 4 weeks before injury (n=3).20,24,26 
Most studies (n=16) made a comparison of pre-injury HRQL between injury patients or with controls 
(e.g. TBI vs no TBI),18,19,25,27,37,44,46 between subgroups (e.g. by age, gender, ethnicity),5,22,29,36,39 or 
between survival or recovery status (e.g. survived vs dead, recovered vs not recovered).7,24,30,39 In 
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addition, twelve studies compared the participants’ pre-injury health status with general population 
norms.7,8,20,21,23,28,29,33,39,40,43,45 
 
Comparison of pre-injury HRQL between injury patients and with population norms 
Within-study comparisons between retrospectively collected pre-injury HRQL and general population 
norms indicated that self-reported pre-injury HRQL scores were consistently higher than population 
norm scores (n=3).7,29,54 Three studies found that scores were higher in either the physical domains 
(n=3)20,21,28 or mental domains (n=1)20 or in certain age or sex groups (n=1).8 Five studies found no 
differences between the recalled pre-injury HRQL and population norms (n=5)33,39,40,43,45 (Table 4.2). 
The self-reported pre-injury HRQL scores also exceeded the calculated age- and gender-adjusted 
population norm scores on the EQ-5D7,37-39,42,44 (Figure 4.2), as well as the physical and mental domains 
of the SF-36 and SF-12 (Figure 4.3). Exceptions were injury types of higher severity, including elderly hip 
fracture patients (aged 80+ years),30,35,36 or patients with a motor vehicle injury,18,46 vertebral fracture,33 
or TBI.27 
Within-study comparisons of pre-injury HRQL between injury patients or with controls showed that 
patients that injured due to a motor vehicle injury or that sustained a TBI have significantly lower mental 
health at baseline18,27,44,46 and lower scores across all HRQL domains46 compared to those without a 
motor vehicle injury or TBI (Table 4.2). Higher pre-injury HRQL was found in those who survived than 
those who eventually died during follow-up (significant differences found on the SF-36 PF, RP and GH,24 
no significant differences found between EQ-5D scores30) and in those recovered than those not 
recovered at follow-up (not significant).7 
 
Pre-injury HRQL scores per HRQL instrument and injury type 
There was a large variation in the presentation of the pre-injury HRQL of patients (Table 4.2). Most 
studies reported the total scale scores on the EQ-5D (n=10)7,30,31,35-39,42,44 or PedsQL (n=3).19,22,25 The 
studies that used the SF-36 or SF-12 often presented the physical (PCS) and mental component scores 
(MCS) (n=10),8,18,27-29,32,33,43,44,54 while some studies provided an oversight of all domain scores without 
summary scores.20,21,24,34,41 
Pre-injury HRQL scores varied between patients with a hip fracture, ranging from 0.56 in an operatively 
managed sample of primarily 80+ year old females36 to 0.80 in a hospitalised sample of women aged 
45+.37 Highest pre-injury EQ-5D scores were seen in study populations who experience a TBI,44 major 
trauma,42 unintentional injury7 or wrist or vertebral fracture37 (mean EQ-5D 0.94, SD 0.04) while lowest 
pre-injury EQ-5D scores were reported in hip fracture populations30,35-39 (mean EQ-5D 0.71, SD 0.10); 
two-sample t(9)=5.01, 95% confidence interval (CI) [0.13-0.34], p=0.001. Overall, pre-injury EQ-5D 
scores decreased with age, from 0.99 in populations with a mean age of 40 years (SD 21)44 to 0.56 in 
those aged 80+ years.30,35,36  
Patients with a vertebral injury reported lowest pre-injury PCS (SF-36, PCS 49),33 while those with 
orthopedic injury reported highest pre-injury PCS scores (SF-36, PCS 59).26 Lowest pre-injury MCS on 
both the SF-36 (MCS 47)46 and SF-12 (MCS 49)18 was reported in the two studies that prospectively 
assessed the pre-injury HRQL of participants before the occurrence of a motor vehicle injury. Overall, 
rather similar pre-injury HRQL scores were reported in all studies, showing low heterogeneity (PCS: 
I2=12%, MCS: I2=7%), with generally better pre-injury PCS than MCS (mean 54.6 vs 52.9).  
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Change between pre- and post-injury HRQL 
Most studies used a longitudinal design (n=23) with multiple follow-up measurements over time (n=18), 
often measuring post-injury HRQL at 3 months, 6 months and/or 12 months. All studies showed a 
decrease in post-injury HRQL compared to their pre-injury levels of HRQL (Table 4.2). Looking at the EQ-
5D, only one out of the 12 studies showed full recovery to pre-injury HRQL at one year after the injury,38 
while the other studies still reported reduced levels of HRQL post-injury. Looking at the SF-36 and SF-
12, injuries showed to have the highest impact on the physical component of HRQL (reduction in PCS 
with 15 to 30 points from pre-injury to first post-injury assessment) compared to the mental component 
of HRQL (reduction in MCS with 5 to 9 points).23,27,29,32 At the final follow-up measurement, both 
prospective studies showed almost full recovery to pre-injury HRQL levels on the PCS and full recovery 
on the MCS,18,46 while only one retrospective study showed such recovery on the PCS54 or MCS.28 
 
4.4 DISCUSSION 
 
This systematic review summarised the methods that were used to assess pre-injury health status and 
to estimate the change from pre- to post-injury HRQL. All but two of the 31 studies in our review used 
retrospective assessment (recall) to assess pre-injury HRQL. The studies most often applied the SF-36, 
followed by the EQ-5D or SF-12, by means of questionnaires or face-to-face interviews. Recalled pre-
injury HRQL scores consistently exceeded general population norms, except in a limited number of 
studies on injury types of higher severity (e.g. traumatic brain injury and hip fractures). All studies 
reported reduced post-injury HRQL compared to pre-injury HRQL. Both prospective studies reported 
that patients had recovered to their pre-injury levels of physical and mental health, while in all but one 
retrospective study patients had not returned to their reported pre-injury levels of HRQL, even years 
after the injury. 
Prospective assessment is the preferred method to determine pre-injury HRQL as it is not subject to 
bias that may occur due to experiencing an injury. In our review, only two out of the 31 studies used 
prospective assessment of pre-injury HRQL. These studies used longitudinal data from the Medical 
Expenditure Panel Survey (MEPS) among the US general population18 and the Seguimiento Universidad 
de Navarra (SUN) cohort comprising university graduates in Navarra, Spain.46 Both prospective studies 
reported lowest pre-injury mental health on the SF-36 (MCS 47)46 as well as SF-12 (MCS 49)18 of all 
studies in our review, which otherwise all used retrospective assessment. 
Our review shows that the retrospectively assessed pre-injury HRQL systematically differed from the 
age- and gender-adjusted norms we calculated based on population data on the EQ-5D, SF-36, and SF-
12. Despite the use of different HRQL instruments, recalled pre-injury HRQL scores in our review 
consistently exceeded these adjusted population norms. An exception to this were samples including 
patients with a hip fracture,30,35,36,39 motor vehicle injury,18,46 vertebral fracture33 or TBI,27 that reported 
poorer pre-injury HRQL than our calculated adjusted norms. These injury patients are likely to be less 
healthy than their counterparts,18,27,44,46 in terms of socio-economic status,18 comorbidity18,55 or frailty 
and older age.12,55,56 
The difference between retrospectively assessed pre-injury HRQL and population norm scores might be 
caused by several reasons. 
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Recall bias may have influenced the outcomes of the retrospective assessment, as patients may have 
remembered their pre-injury HRQL differently than it actually was.1,57,58 Patients may, for example, have 
overestimated their health status before the injury, resulting in higher recalled pre-injury HRQL than 
seen in the general population. 
Response shift might have occurred, as patients’ perception of HRQL may have changed due to the 
injury and a change in health.3 After having had experience with poor HRQL, patients may have inflated 
the rating of their health status before the injury.59 
Nevertheless, some researchers argue for the use of retrospective assessment of pre-injury HRQL, as 
this method applies one internal standard of HRQL values (reference point) in the assessment of both 
pre-injury HRQL and post-injury HRQL.3,59 According to them, such a reference point is essential for the 
interpretation of the change from pre- to post-injury HRQL, since patients may have changed their 
judgement of HRQL due to new insights since the injury (e.g. although a patient has a serious injury, 
he/she has seen others who are far worse off), or patients have become used to their new health state. 
However, both recall bias and response shift might result in an overestimation of the pre-injury HRQL 
by patients. This is underpinned by our finding that, even years after the injury, in all but one 
retrospective study patients had not returned to their reported levels of pre-injury PCS and MCS, while 
recovery to pre-injury HRQL levels was seen in both prospective studies. 
Moreover, selection bias may have threatened the validity of the findings from the studies included in 
our review, as the study populations were often not randomly selected from the injury population for 
which the findings are reported.60 For example, studies had excluded patients with pre-existing 
morbidities (e.g. physical illness, cognitive impairment), as it was anticipated that these patients would 
be difficult to follow-up. Exclusion of patients with impairments before the injury may have increased 
the overall pre-injury HRQL scores of these study samples, as healthier participants were recruited. 
In contrast, attrition bias may have decreased the overall pre-injury HRQL scores measured in the 
studies, as a higher proportion of the non-participants were less educated,26 cognitive impaired,38 victim 
of intentional injury,5 shorter hospitalised21 and had lower injury severity,28,29,44 less pain,34 better 
mental health.34 These factors are all expected to be associated with better HRQL and incorporation of 
these patients would have resulted in higher pre-injury HRQL scores. Additionally, pre-injury HRQL levels 
may have increased after loss of follow-up, resulting in higher pre-injury HRQL in the final study sample 
with complete response compared to the eligible study sample.32 
Finally, retrospectively assessed pre-injury HRQL scores may differ from the population norms as injury 
populations may differ from the general population. The findings of the retrospective assessments 
(recall) in our review suggest that injured populations are generally healthier than the general 
population. Previous studies reported that, as injured populations might be healthier, they are more 
likely to participate in activities, exposing them to a higher risk of injuries.8 However, the comparisons 
of injury patients with matched controls in our review showed injury patients to be less healthy than 
their counterparts, as they reported significantly lower pre-injury mental health than controls18,27,44,46 
and lower scores across all HRQL domains.46 Previous research showed that injury patients had a higher 
occurrence of comorbidity, higher admission rates to the hospital, higher health service utilisation and 
a lower socio-economic status prior to their injury in comparison to uninjured people.4,18 It is argued 
that the general population has not been exposed to a similar injury experience as the injury population, 
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which emphasises the use of retrospective assessments over the application of general population 
norms to estimate the impact of injury on HRQL.49 
 
Strengths and limitations 
Our review included studies on the pre-injury HRQL from children, adolescents and adult patients, with 
various injury types, using a range of HRQL instruments. Moreover, this review compared the reported 
pre-injury HRQL scores with general population norms, calculated for each study based on the reported 
mean age and gender distribution of the study sample, to identify bias that may occur from the different 
methods to asses pre-injury HRQL.  
There are limitations to this review that need to be addressed. First, there was no restriction in the 
methods of patient selection used in the studies. Therefore, the studies in this review included samples 
retrieved from a variety of injury settings (e.g. hospital or outpatient programmes). Their conclusion 
may not be applicable to injury patients from other injury settings. However, most studies selected their 
patients during or after treatment in a (pediatric) hospital or specialised treatment center, which may 
enhance the generalisability of their results to patient populations with similar case-mix. 
Second, the review included studies with patient samples from a broad range of injury types and injury 
severity levels, which may have complicated the comparability of the results between studies. 
Nonetheless, this way we were able to provide a full oversight of the pre-injury health status of injury 
patients and the differences in pre-injury HRQL between injury types. 
In addition, there are limitations to the studies included in our review. First, more than half of the 
included studies had difficulties in recruiting research participants, as patients often could not be 
contacted, had died, refused to participate, or did/could not complete questionnaires. The studies often 
reported limited generalisability of their results due to differences between the eligible patients and 
study participants, loss to follow-up, their limited number of subjects, and recruitment of participants 
from a single center. 
In some studies pre-injury HRQL was assessed after a long period of time since the injury, for example 
several months up to years after the injury.7,42,44 This longer time frame may have increased the recalled 
pre-injury HRQL scores,31 as these studies also reported the highest pre-injury HRQL scores on the EQ-
5D (0.94-0.99) compared to the studies that used shorter time frames. However, these three studies 
assessed the HRQL of a relatively young injury population. Moreover, no differences were found 
between the time frame and pre-injury HRQL on the SF-36 and SF-12.  
Finally, unfortunately not all studies reported the HRQL scores in the text or tables (e.g. only in graphs). 
After contacting the authors, in three publications HRQL scores had to be manually obtained from the 
graphs presented in the article.36,40,45 This may have resulted in some small differences in the levels of 
pre- and/or post-injury HRQL. 
 
Recommendations for future research 
Our review clearly showed that recalled pre-injury HRQL systematically exceeded population norms. 
These differences in pre-injury HRQL may generate different estimates of the change in HRQL from pre- 
to post-injury due to an injury.  
Researchers should use prospectively derived pre-injury HRQL scores wherever possible to estimate the 
impact of injury on HRQL. If it is not feasible to prospectively assess the pre-injury health status of 
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trauma patients, researchers should be aware of the bias that may arise when pre-injury HRQL is 
assessed retrospectively or when population norms are applied. Overall, more research is needed to 
examine the effect of recall bias and response shift on the reported levels of pre-injury HRQL among 
trauma patients, in which different methods to assess pre-injury HRQL are compared and within-study 
comparisons between reported pre-injury HRQL and population norms are made. 
In general, when assessing pre-injury HRQL, researchers should carefully consider and specify the timing 
of the assessment of pre-injury HRQL and the period of the pre-injury assessment. The time period 
shows to be one of the essential factors influencing patient recall, as recall bias is generally worse when 
asking for a recall over longer periods.61 A short time frame within the injury and retrospective 
assessment of pre-injury HRQL may increase recall and may increase the correlation between pre- and 
post-injury measures.31 This implies that pre-injury HRQL should be assessed as soon as possible after 
the injury, preferably within the first week after the injury.62 Whether or not the measurement of pre-
injury HRQL is the primary purpose of studies, publications on the measurement of HRQL should include 
information on the applied methods to measure HRQL. 
Levels of pre-injury HRQL also may have been influenced by the use of telephone interviews. In our 
review, the highest or one of the highest pre-injury HRQL on the EQ-5D,42 SF-36 (PCS and MCS)26 or SF-
1243 were reported by studies that had conducted telephone interviews to assess the pre-injury levels 
of HRQL. Previous research indicated that telephone-administered questionnaires provide higher HRQL 
scores than self-administered questionnaires.63-65 Preferably, the same method should be used for the 
assessment of both pre-injury and post-injury HRQL throughout the study, at all post-injury HRQL 
measurements and among all individuals. 
Researchers should choose a validated HRQL instrument that showed good performance in the type of 
injury under study, and that is sensitive to changes in HRQL and differentiates well between health 
states. In order to assess the change from pre- to post-injury HRQL, the same HRQL instrument should 
be applied throughout the study. Preferably, a HRQL instrument should be chosen for which national 
age- and gender-adjusted population norms are available. In order to enable comparison of the impact 
of injuries on HRQL between studies, injury types and other diseases, it is recommended to report the 
pre- and post-injury HRQL scores for specific age and sex groups, which correspond to the age and sex 
distribution of the norm groups for the applied instrument.  
Finally, to examine the change in HRQL due to the injury, a longitudinal design is recommended with 
multiple follow-up measurements over time (e.g. at 1–3 months, 3–6 months, and 6–24 months post-
injury).62 
 
Conclusions 
So far, primarily retrospective research has been conducted to assess pre-injury HRQL. This research 
shows consistently higher pre-injury HRQL scores than population norms and a recovery that lags 
behind that of prospective assessments, implying a systematic overestimation of the change in HRQL 
from pre- to post-injury due to an injury. More prospective research is necessary to examine the effect 
of recall bias and response shift. Researchers should be aware of the bias that may arise when pre-injury 
HRQL is assessed retrospectively or when population norms are applied, and should use prospectively 
derived HRQL scores wherever possible to estimate the impact of injury on HRQL. 
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ABSTRACT 
 
Background Trauma-related mortality has rapidly dropped over the past decades. Most 
trauma registries document information on the acute phase of hospital care and in-hospital 
mortality, but not on the consequences of non-fatal trauma. This pilot provides insight into 
the opportunities of expanding the trauma registry with extensive follow-up data. The aim of 
our study was to assess the  hospitalisation, health care costs, productivity costs and health-
related quality of life (HRQL) by injury type and injury severity, and to identify injury types with 
highest impact.  
 
Methods We linked data of trauma patients (aged 16+) hospitalised between 2007–2008 from 
the Dutch National Injury Surveillance System, Trauma Registry, and patient follow-up survey. 
Socio-demographic and trauma-related characteristics, hospitalisation, health care costs (in-
hospital and after discharge), return to work and associated productivity costs, and HRQL (EQ-
5D) were analyzed by injury type and injury severity score (ISS). 
 
Results Injury patients with ISS 9–15 (moderate) showed higher mean costs than patients with 
ISS≥16 (severe), mainly due to their longer admission to a nursing home or revalidation center 
and high need for home care; health care costs (€13,440/patient, IQR €6,030 to €22,020 vs 
€8,800, IQR €6,710 to €9,710: p=0.001), productivity costs (€23,720/patient, IQR €16,800 to 
€32,670 vs €20,920, IQR €17,900 to €24,960: not significant). Injury patients with ISS 9–15 
also reported poor HRQL at 2.5 months post-injury (EQ-5D 0.56), comparable to that of 
patients with ISS 25+ (EQ-5D 0.49). Isolated hip fractures (100% ISS<16) were among the injury 
types with the highest mean health care costs (€19,740/patient vs €8,630/patient in other 
injuries, p<0.001), with patients reporting poor HRQL (EQ-5D 0.48). 
 
Conclusions The integrative approach of assessing the consequences of non-fatal trauma 
revealed that injury patients with ISS 9–15 had one of the highest impact on both individuals 
and society. Our findings emphasise the importance of documenting the consequences of all 
hospitalised trauma cases in trauma registries and incorporating these outcomes in the 
evaluation of trauma care to obtain insight into the quality of survival after trauma and to 
compare the consequences of trauma across patient subgroups. 
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5.1 INTRODUCTION 
 
Injuries are a major public health problem, yearly leading to more than 5.7 million hospitalisations and 
230,000 deaths in Europe,1 and over 560,000 deaths in high-income countries.2 In order to evaluate and 
improve the care delivered to individual trauma patients, the results of trauma care are documented in 
trauma registries.3 Trauma registries generally contain information on patient demographics, pre-
hospital care and transport, emergency department and in-hospital treatment, diagnosis, in-hospital 
mortality, and patient discharge destination.3 These databases generally focus on severe trauma (e.g. 
hospitalised trauma patients, or only those with severe injuries).3 
Trauma registries were initially developed to reduce preventable mortality. Therefore, they generally 
document information on the acute phase of hospital care and focus on mortality as main patient 
outcome. In order to compare mortality rates between trauma groups, risk adjustment models are used 
to adjust for the differences in baseline risk of death between trauma patients. A key element in these 
risk adjustment models is the severity of the injury, which is often measured with the Injury Severity 
Score (ISS).4 
During the last decades, however, trauma-related mortality has rapidly dropped due to advances in 
trauma care,5 amongst others. As more and more trauma patients survive, mortality does no longer 
provide the true quality indicator of trauma systems. Although survival after injury may further improve, 
largest gains will come from improved outcome of survivors.6 Therefore, there is an increased interest 
in other trauma outcomes such as the costs of medical care use, productivity costs due to the absence 
from work, and the health-related-quality of life (HRQL) of injury survivors. Nevertheless, trauma 
registries generally provide very limited information on the post-hospital care of patients other than 
their discharge destination.3 
Moreover, although the injury severity scoring tools like the ISS were developed to predict mortality 
after injury,7 many studies still use these threat-to-life measures in their assessment of the long-term 
consequences after injury, whether as threshold for inclusion (e.g. ISS>15) or as predictor of outcome.8 
Assessment of the outcomes of trauma other than mortality is important to obtain insight into the 
recovery of patients following trauma, the quality of survival after trauma, and to compare the (long-
term) consequences of trauma across patient subgroups. The current study therefore provides insight 
into the opportunities of expanding the trauma registry with follow-up data on the long-term 
consequences of non-fatal injuries among hospitalised trauma patients. In a pilot, we therefore linked 
data of adult trauma patients hospitalised between 2007–2008 from the Dutch National Injury 
Surveillance System, the Dutch Trauma Registry, and a patient follow-up survey. 
We aim to 1) assess the hospitalisation, health care costs, productivity costs and HRQL by injury type 
and ISS, and 2) identify injury types with highest impact. 
 
5.2 METHODS 
 
Study design 
In a pilot, we linked data from the Dutch National Injury Surveillance System (LIS), the Trauma Registry 
(TR) of the Regional Emergency Health care Network Nijmegen (AZO, The Netherlands), and a patient 
follow-up survey of the LIS (Figure 5.1).9,10  
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The LIS is an ongoing monitoring system which focuses on injury prevention and records data of all 
injured patients who attend the emergency department (ED). It is based upon the registration of 13 
hospitals throughout the Netherlands (12–15% coverage), and registers detailed information on the 
cause and mechanism of injuries, patient characteristics, type of injury, and hospitalisation. 
The TR focuses on the quality of trauma care and provides data on the (pre)hospital treatment of 
hospitalised trauma patients and the epidemiology of the trauma population. It is an important tool for 
trauma evaluation and improvement of trauma care. The TR contains detailed information on trauma 
patients admitted to the hospital within 48 hours after the ED treatment and registers their Abbreviated 
Injury Scale (AIS) revised 1990, update 98 (AIS-98),11 length of stay in hospital, admission to intensive 
care, and in-hospital mortality. 
During the period February 1, 2007 to January 31, 2008 a patient follow-up survey was sent to a random 
sample of patients registered in LIS,9 to collect information on socio-demographics and data on the 
consequences of trauma in terms of health care consumption and associated health care costs, return 
to work and associated productivity costs, and the HRQL of patients at 2.5 months after trauma.  
Four hospitals of the TR of AZO also participated in the LIS: Radboud university medical center, Nijmegen 
(Level I trauma center, 950 beds); Canisius-Wilhelmina hospital, Nijmegen (Level II, 650 beds); Gelderse 
Vallei hospital, Ede (Level II, 510 beds); Maasziekenhuis Pantein hospital, Boxmeer hospital (Level III, 
190 beds).  
 
Figure 5.1 Data in the national Injury Surveillance System, the Trauma Registry, and the patient follow-up 
survey 2007–2008 
 
 
 
 National Injury Surveillance System: information used on patient details, injury type, length of stay, intensive care (IC). 
 Trauma Registry: information used on injury severity (ISS). 
 Patient follow-up survey: information used on health care consumption, return to work, HRQL (EQ-5D). 
 
Study participants 
This pilot included data of hospitalised patients aged 16+ years, who were injured due to unintentional 
injury or interpersonal violence and were registered in both LIS and the TR, and responded to the 2.5 
month patient follow-up survey. 
 
Linkage of data 
Data of the TR and patient follow-up survey (respondents of first questionnaire) was linked to the LIS 
data, using data that was not reducible to individual patients (e.g. date of arrival at ED, patient’s age in 
months, patient’s sex and detailed cause-of-injury. Informed consent was obtained from the patients 
Accident ED treatment Hospital admission 2 
months
5 
months
12 
months
24 
months
Cause
Mechanism
Patient details Length of stay, IC, discharge
Length of stay, IC, discharge
In-hospital mortality
Trauma care
Diagnosis (AIS)
Patient details
Pre-hospital care
Injury: Setting, cause, mechanism
Patient: Education, co-morbidity, household composition
Costs: Healthcare consumption, return to work
Outcome: Health-related quality of life (EQ-5D, HUI)
T I M E
Injury type
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participating in the patient follow-up survey. Ethical approval for the linkage of data was obtained from 
the ethical committee of the Radboudumc. 
 
Injury severity 
Information on injury severity was obtained from the TR. Abbreviated Injury Scale (AIS) codes were 
assigned to all injuries by a trained staff member using information from patient medical records. The 
AIS describes the type of injury, affected body region, and injury severity in a 7-digit code for each injury 
the patient has sustained.12 The AIS ranges from 1 (minor injury) to 6 (nonsurvivable).11 The AIS scores 
of patients with multiple injuries were combined into a single score, with use of the maximum AIS 
(MAIS)13 and Injury Severity Score (ISS).7 The MAIS was computed as the highest AIS score off all 
injuries.13 In case of multiple injuries with the same AIS, an algorithm was applied, giving priority to head 
injuries, followed by injuries to the spine, extremity, and thorax/abdomen.13 Like the AIS, the MAIS 
ranges from 1 (minor injury) to 6 (nonsurvivable). Additionally, the ISS was computed by allocating AIS 
scores to six body regions and taking the sum of squares for the highest AIS score in each of the three 
most severely injured body regions.7 The ISS ranges from 1 (minor injury) to 75 (nonsurvivable). The ISS 
was categorised as mild (<9), moderate (9–15), severe (16–24), and profound (25+).14   
 
Injury type 
The type of injury was obtained from LIS in which up to three injuries can be recorded. In case of multiple 
injuries, like with the MAIS, the most severe injury was determined by giving priority to head injuries, 
followed by injuries to the spine, extremity, and thorax/abdomen.13 Injuries were classified into 8 main 
injury groups: head injury (including injuries to face/neck), spine injury, thorax/abdomen injury, upper 
extremity injury, hip fracture (AIS 8518083 (2%), 8518103 (19%), and 8518123 (79%)),15 lower extremity 
injury (excluding hip fracture), superficial injury (including open wound), and other injury (burns, 
unspecified). 
 
Health care and productivity costs 
Information on the health care consumption was obtained from LIS (short-term) and the patient follow-
up survey (long-term). Short- and long-term direct health care costs and indirect productivity costs of 
injuries were calculated with use of the incidence-based Dutch Burden of Injury Model.16,17 This 
prediction model is based on the incidence of injuries treated in emergency departments, as recorded 
in LIS. The prediction model is used to calculate the health care consumption within the hospital and 
after discharge, and related costs for predefined patient groups that are homogenous in terms of health 
service use (e.g. age, gender, injury type/location and injury severity/mechanism).17 Data on health care 
consumption (in-hospital and after discharge) was obtained from LIS, the National Hospital Discharge 
Registry, rehabilitation centers (LIVRE), nursing homes (SIVIS), and a patient follow-up survey conducted 
in 2007–2008.9,10,16,17 
The length of stay in hospital (LOS) and admission to the Intensive Care (IC) were determined using the 
LIS database (missing values were obtained from the TR). 
Direct costs of all health care consumption within the hospital and after discharge were computed by 
multiplying incidence by health care volumes (e.g. length of stay)  and unit costs (e.g. costs per day in 
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hospital). Unit costs were estimated according to national guidelines for health care costing18 reflecting 
real resource use (Appendix Table 5.A). 
Indirect productivity costs were calculated for all hospitalised trauma patients in the working population 
(aged 15 to 64 years), using the same prediction model based on information on return to work from 
the patient follow-up questionnaire.9,10,16 People with paid jobs were asked questions related to work 
absence, absence duration, and return to work, which were strongly related to the ‘usual activities’ 
dimension of the EQ-5D but are more detailed.19 
 
Health-related quality of life 
HRQL was measured 2.5 months after trauma using the EQ-5D by means of the patient follow-up 
survey.9,10 The EQ-5D defines health along five domains (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression) with each three levels of severity (no/moderate/extreme 
problems).20 EQ-5D summary scores, ranging from 0 (dead) to 1 (full health), were calculated with the 
Dutch tariff based on time-trade-off preferences from the general Dutch population.21 The EQ-5D is a 
feasible and valid instrument for the measurement of functioning in trauma patients, and is well able 
to describe a heterogeneous trauma population and to discriminate among specific injuries.10,19,22,23 
 
Statistical analysis 
Analysis of variance (ANOVA) and Chi-square statistics (dichotomous variables) were used for between-
group comparisons. A value of p<0.05 was used to determine statistical significance. 
Linear regression analysis was used to assess which factors were predictors of HRQL (EQ-5D) at 2.5 
months after trauma. We included the socio-demographic factors gender (male/female), age 
(continuous), a dummy-coded variable for low (reference)/middle/higher education, household 
composition (alone/not alone), and comorbidity (continuous), and the trauma-related characteristics 
injury type (head yes/no, etc.), and ISS (continuous). Variables associated with outcome (p<0.20 in 
univariable analysis) were included in stepwise multivariable linear regression analyses.24,25 All statistical 
analyses were carried out using the statistical package SPSS for Windows, version 21 (IBM SPSS 
Statistics, SPSS Inc, Chicago, IL). 
 
5.3 RESULTS 
 
Study population 
Linkage of data resulted in 1,995 hospitalised patients treated between 2007 and 2008 who were 
registered in both the LIS and TR (Appendix Table 5.B). Of these patients, 891 (45%) were invited for 
participation in a patient follow-up survey. In total, 411 (46%) patients responded to the 2.5 month 
follow-up survey, and formed the basis of our pilot. No significant differences on socio-demographic 
characteristics and injury characteristics were found between responders and non-responders to the 
follow-up survey. 
The 411 participants in our pilot were on average 57 years old (SD 21.6), and 48% were men (Table 5.1). 
About one third of the patients had one or more comorbid disease(s) (39%). Frequently reported causes 
of injury were home and leisure accidents (53%) or traffic accidents (30%). Most patients had a single 
injury (68%), with a moderate injury severity (43% MAIS3/ISS9) with an average ISS of 8.7 (SD 7.2). Lower 
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extremity injury (excluding hip fractures; n=126, 31%) was the most common injury type, followed by 
an upper extremity injury (16%), head injury (16%), or hip fracture (15%). 
 
Table 5.1 Patient demographics, injury mechanism and injury severity by injury type (%) 
 
 
Total Head Spine 
Thorax/ 
Abdomen 
Upper 
Extremity 
Hip 
Fracture 
Lower 
Extremity 
Superficial Other 
N (%) 
411 
(100) 
64 
(15.6) 
26 
(6.3) 
31 
(7.5) 
66 
(16.1) 
61 
(14.8) 
126 
(30.7) 
30 
(7.3) 
7 
(1.7) 
Patient demographics          
Age at injury 
(mean, SD) 
57 
(21.6) 
50.8 
(21.3) 
60.4 
(21.2) 
47.8 
(22.5) 
55.9 
(20.3) 
76.0 
(12.6) 
55.2 
(21.4) 
56.3 
(20.3) 
47.4 
(22.5) 
Sex (male) 48.4 54.7 42.3 58.1 50.0 26.2 51.6 46.7 100 
Comorbid diseases          
None 61.1 73.4 50.0 71.0 65.2 37.7 63.5 56.7 85.7 
1 24.3 15.6 38.5 19.4 13.6 36.1 26.2 30.0 14.3 
≥2 14.6 10.9 11.5 9.7 21.2 26.2 10.3 13.3 0.0 
Injury mechanism          
Home and leisure 52.6 39.1 65.4 41.9 48.5 78.7 54.0 33.3 42.9 
Traffic 30.2 42.2 23.1 35.5 33.3 18.0 22.2 56.7 28.6 
Occupational 4.9 6.3 3.8 0.0 7.6 0.0 6.3 6.7 0.0 
Sport 10.5 6.3 7.7 12.9 10.6 3.3 16.7 3.3 28.6 
Intentional 81.9 6.3 0.0 9.7 0.0 0.0 0.8 0.0 0.0 
Injury severity          
Multiple injury          
1 67.5 26.6 73.1 58.1 50.0 96.7 81.7 76.7 85.7 
2 19.1 32.8 23.1 19.4 30.3 3.3 13.5 16.7 14.3 
≥3 13.4 40.6 3.8 22.6 19.7 0.0  (4.8 6.7 0.0 
MAIS (median, IQR) 
3 
(2–3) 
3 
(2–4) 
2 
(2–2) 
2 
(2–3) 
3 
(2–3) 
3 
(3–3) 
2 
(2–3) 
2 
(1–2.5) 
2.5 
(1.3–3) 
ISS (median, IQR) 
9 
(4–9) 
9 
(5–
17) 
4 
(4–8) 
9 
(4–16) 
9 
(4–10) 
9 
(9–9) 
5 
(4–9) 
4 
(1–7) 
6.5 
(1.8–15) 
ISS 1–8 45.3 45.5 79.2 45.2 41.0 1.7 54.1 75.9 50.0 
ISS 9–15 45.3 25.5 16.7 25.8 55.7 98.3 40.2 24.1 25.0 
ISS 16–24 4.9 9.1 0.0 22.6 3.3 0.0 3.3 0.0 25.0 
ISS 25+ 4.4 20.0 4.2 6.5 0.0 0.0 2.5 0.0 0.0 
Unknown (N) 27 9 2 0 5 3 4 1 3 
IQR: interquartile range. 
Head: including head, face and neck; Lower extremity injury: excluding hip fractures; Superficial injury: open wounds, superficial injuries; 
Other injury: burns, unspecified. 
 
Patient characteristics by injury type 
Patients with a hip fracture were more likely to be older than patients with other injuries (mean age 76 
vs 54 years, F=60.6, df=1, p<0.001), female (74% vs 48%, Chi2=14.1, p<0.001), live alone (58% vs 28%, 
Chi2=19.0, p<0.001), and have comorbidity (62% vs 35%, Chi2=16.4, p<0.001). 
In contrast, patients with thorax/abdomen injury were more likely to be younger (mean age 48 vs 58 
years in other injuries, F=6.8, df=1, p=0.010), male (58% vs 48%), without comorbidity (71% vs 60%), 
and to have multiple injuries (42% vs 32%), though the latter differences were not significant. 
Patients with head injuries were assigned highest injury severity (ISS median 9, interquartile range (IQR) 
5–17) followed by thorax/abdomen injuries (median 9, IQR 4–16), whereas lowest injury severity was 
assigned to patients with superficial injuries (median 4, IQR 1–7). 
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Consequences of non-fatal trauma 
Hospitalisation 
Highest mean length of stay (LOS) in hospital was documented in patients with skull-brain injuries (on 
average 20 days), a fracture of the upper leg (12 days), or a hip fracture (12 days, Table 5.2). Lowest 
mean LOS was seen in patients with hand/finger injury (on average 1–2 days), a concussion (2 days), a 
luxation/distortion of the knee, ankle or foot (2–3 days), or superficial injuries (3–4 days).  
IC admission was highest among patients with a head injury (28%), especially those with a skull-brain 
injury (n=18, 62% admitted, mean ISS 23.5, SD 15.1), followed by thorax/abdomen injuries (19%). 
 
Health care and productivity costs 
Expanding the data of the TR with follow-up data from the patient survey indicated that highest mean 
direct health care costs were seen in patients with a fracture of the upper leg (on average €20,800, 
interquartile range (IQR) €12,630 to €25,150) and those with a hip fracture (€19,740, IQR €15,650 to 
€23,800 vs €8,630/patient, IQR €4,380 to €10,880 in other injuries: F=136.6, df=1, p<0.001, Table 5.2). 
These patients with an upper leg fracture or hip fracture showed a higher need for home care in the 
first 2.5 months post-injury than other injuries (on average 1.9 weeks vs 1 week, F=8.9, df=1, p=0.003; 
for on average 2 hours/week vs 0.8 h/w, F=9.8, df=1, p=0.002). 
Although the incidence of patients with an isolated hip fracture in the working population was low 
(n=10), these patients lost on average the highest number of work days (on average 107 days, (SD 2.8) 
vs 70 days (SD 20.2) in other injuries) and accordingly showed highest mean productivity costs (€35,380, 
IQR €32,180 to €38,910 vs €20,860/patient, IQR €15,870 to €26,270 in other injuries: F=28.0, df=1, 
p<0.001). Overall, hip fractures accounted for 15% of our hospitalised study sample but accounted for 
28% of the total direct health care costs and 38% of the total productivity costs. 
Lower extremity injury (excluding hip fractures) accounted for the highest total direct health care costs 
(€1.2 million, 32% of total direct costs), mainly due to their high incidence (31% of our study sample).  
Highest mean total costs per patient were seen in patients with a fracture to the knee/lower leg (on 
average €30,290, IQR €20,540 to €39,800), foot/toes (€29,790, IQR €20,670 to € 41,830), upper leg 
(€28,300, IQR €23,660 to €27,000), spine (€27,580, IQR €18,620 to €38,020) or pelvis (€27,580, IQR 
€18,640 to €38,240), followed by hip fractures (€26,540, IQR €22,020 to €26,230). Overall, total direct 
and indirect costs were the highest in hip fractures (€1.4 million) and other lower extremity injuries 
(€2.9 million), together accounting for 52% of the total costs due to injuries (compared to 46% of the 
study sample). 
 
Health-related quality of life (HRQL) 
There was a wide variety of EQ-5D scores per injury severity level (Figure 5.2), indicating low injury 
severity but poor HRQL and vice versa, especially in patients with ISS 9–15. Patients with ISS 9–15 
reported lower HRQL (EQ-5D 0.56) than patients with more severe injuries coded with ISS 16–24 (EQ-
5D 0.63). Respondents with ISS<16 (indicating minor to moderate injury severity) but poor HRQL (EQ-
5D<0.30, n=44) often involved females (84%), aged 60+ (77%), diagnosed with a hip fracture (27%) or 
other lower extremity injury (30%). Univariable regression revealed age, gender, education, 
comorbidity, living alone, diagnosis of hip fracture, and ISS to be significantly related to HRQL (all 
p<0.002). 
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After adjusting for confounders in the multivariable model, older age, female gender, lower education, 
higher comorbidity, and higher ISS were found to statistically significantly predict lower EQ-5D scores 
at 2.5 months post-injury (F(5, 348)=22.45, p<0.001, R2=0.24). 
Lowest HRQL at 2.5 months after trauma was reported by patients with a fracture of the upper arm 
(EQ-5D 0.36), a pelvic fracture (EQ-5D 0.48) or hip fracture (100% ISS<16, EQ-5D 0.49, Figure 5.3). Hip 
fracture patients specifically reported significantly more problems than other injuries on mobility (93% 
vs 58%, Chi2=27.6, df=1, p<0.001), self-care (71% vs 40%, Chi2=19.5, df=1, p<0.001), usual activities (88% 
vs 73%, Chi2=6.2, df=1, p=0.007), anxiety/depression (48% vs 32%, Chi2=5.3, df=1, p=0.017), and 
cognition (37% vs 26%, Chi2=3.5, df=1, p=0.047). In contrast, patients with thorax/abdomen injury 
reported one of the highest HRQL (71% ISS<16, EQ-5D 0.74), comparable to the HRQL of patients with 
superficial injuries (100% ISS<16, EQ-5D 0.71). 
Looking at the EQ-5D domains (Appendix Figure 5.A (A)), a substantial number of respondents with ISS 
1–8 and ISS 9–15 reported to have problems on mobility (ISS 1–8: 56%; ISS 9–15: 74%), self-care (34%; 
83%) usual activities (68%; 83%), pain/discomfort (74%; 76%) and anxiety/depression (21%; 43%). 
Respondents with ISS<16 reported more problems than those with ISS≥16 on multiple domains, though 
these differences were not significant (Appendix Figure 5.A (B)). This indicated that, although ISS<16 
indicates minor to moderate severity, these injuries had a substantial impact on the patient’s HRQL. 
 
Figure 5.2 EQ-5D summary scores at 2.5 months after injury by ISS category 
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Figure 5.3 EQ-5D summary sores at 2.5 months after injury by injury type and ISS category 
 
Head: including head, face and neck; Lower extremity injury: excluding hip fractures; Superficial injury: open wounds, superficial injuries; 
Other injury: burns, unspecified. 
 
Injuries with highest impact 
Comparison of the consequences of trauma (from LIS and the patient follow-up survey) by injury 
severity (obtained from the TR) revealed a generally linear pattern, with minor injuries (ISS 1–8) showing 
the lowest impact on all measures towards severe injuries (ISS 25+) showing the highest impact (Figure 
5.4). Patients with ISS 25+ had the highest mean LOS (on average 26 days, SD 17.7), and lowest HRQL 
(EQ-5D 0.49). 
 
Figure 5.4 Mean length of stay in hospital, costs, and HRQL by injury severity 
 
* Mean productivity costs per case are presented as an average of only the working population (in our sample aged 16 to 65 years). In 
patients aged 65 and older, mean total costs per case only comprised the direct health care costs. 
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The integrative assessment of the consequences of trauma, however, also highlighted the major impact 
of trauma in patients with ISS 9–15. Although these injuries were given moderate severity by the AIS-
coding system, patients with ISS 9–15 had significant higher mean health care costs compared to 
patients with ISS≥16 (on average €13,440, IQR €6,030 to €22,020 vs €8,800/patient, IQR €6,710 to 
€9,710: F=11.2, df=1, p=0.001) as well as higher mean productivity costs (on average €23,720, IQR 
€16,800 to €32,670 vs €20,920/patient, IQR €17,900 to €24,960: F=1.8, df=1, not significant). Patients 
with ISS 9–15 specifically were longer admitted to a nursing home or rehabilitation center than patients 
with ISS≥16 (on average 25.4 days vs 11.5 days; F=3.4, df=1, not significant). In addition, patients with 
ISS 9–15 reported one of the poorest outcomes on the EQ-5D (EQ-5D 0.56), comparable to the HRQL 
of patients with ISS 25+. 
 
5.4 DISCUSSION 
 
Trauma registries generally focus mainly on mortality as the main patient outcome. To show the 
opportunities of expanding the trauma registry with follow-up data on the consequences of trauma, we 
linked data of the National Injury Surveillance System, a trauma registry, and a patient follow-up survey. 
Assessment of the consequences of trauma beyond mortality is important to obtain insight into 
patients’ recovery after trauma, their quality of survival, and to compare the (long-term) outcomes of 
trauma across patient subgroups. By linkage of data from multiple sources, we were able to combine 
information of a heterogeneous sample of adult injury patients and on a broad spectrum of outcome 
measures. Our integrative approach revealed injuries with ISS 9–15 to have one of the highest impact 
on individuals and society. 
According to the results of our pilot study, injury patients with ISS 9–15 (moderate severity) showed 
higher mean health care costs (p=0.001) and productivity costs (not significant) than patients with 
ISS≥16 (severe injury). Moreover, the HRQL of injury patients with ISS 9–15 was generally poor and 
comparable to that of patients with ISS 25+. Patients with an isolated hip fracture (100% ISS<16) showed 
one of the highest mean health care costs and also reported one of the poorest HRQL at 2.5 months 
post-injury. Overall, the ISS insufficiently classified injuries according to their probable degree of 
functional problems after trauma. 
 
Limitations 
This pilot study was restricted to patients hospitalised in one of the four hospitals participating in both 
LIS and the TR, which included Level I, II, and III trauma centers situated in the eastern part of the 
Netherlands with rural and (sub)urban catchment areas. The characteristics of our study population 
were, however, comparable to the national trauma population registered in the Dutch trauma registry 
between 2007 and 2008 in terms of treatment at a trauma center with level I to III, age (mean 57 ± SD 
21.6 in our sample vs 52 ± SD 28 in the total national sample), gender (48% males vs 50%), injury severity 
(median ISS 9, IQR 4–9 vs median 9), length of hospital stay (in both samples on average 8 days), and 
admission to the intensive care (6.6% vs 6.8%).26 This indicates that the results of our study are 
generalisable to the Dutch trauma population. 
Another limitation of this study was the response rate for the 2.5 month follow-up survey (46%), 
primarily due to the use of postal questionnaires and the limited opportunities to increase response 
rates (i.e. no contact information available to the researchers). The low response rates may have led to 
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selection bias, and under- or overestimation of the consequences of injury. However, comparison of 
the characteristics of responders and non-responders to the 2.5 month follow-up survey showed no 
significant differences in patient and injury characteristics. 
Additionally, our pilot study only included trauma patients with a response to the 2.5 month follow-up 
survey, and therefore did not comprise the outcomes of trauma patients who had died due their injuries 
in the period before the first follow-up assessment. We therefore may have missed the high health care 
costs of injury patients who died after a long stay in the hospital and/or IC. This may have led to an 
underestimation of the consequences of injuries in our study, especially the severe ones. However, 
according to the Dutch national trauma registry, the overall in-hospital mortality rate of injury patients 
is low; about 3% in 2007–2008 and 2% in recent years.26 In addition, missing of these consequences of 
fatal injuries may have had limited impact on our results, as mortality not only occurs in patients with 
injuries of high injury severity (e.g. ISS≥16), but also in patients with a low injury severity score (e.g. hip 
fracture patients, ISS<16)27. It is however recommended to, shortly after the injury, assess the 
consequences of all hospitalised trauma patients documented in the trauma registries, in order to 
obtain full insight into the impact of injuries. 
Moreover, information on injury severity was obtained from AIS codes assigned by a trained staff 
member. The AIS coding system is known to be rater-subjective, especially in case of patients with 
multiple injuries, leading to considerable variations in AIS codes between raters for identical injuries.28-
30 However, the AIS codes in our study were assigned by a single rater, which is expected to enhance 
the comparability of the severity rating of injuries included in our sample. 
In addition, no risk adjustment was used in the assessment of the hospitalisation or costs after injury. 
Research showed that there are many other factors which influence the outcome after injury, for 
example including patients’ health status before the injury, age, or injury severity.8,31 Unfortunately, in 
this pilot study, we were not able to collect information on the pre-injury HRQL of patients. However, 
we did use a multivariable model to assess the predictors of poor HRQL after injury, which indicated 
age, gender, education, comorbidity, and ISS to be independent predictors of lower EQ-5D scores post-
injury. 
Finally, although the EQ-5D showed to be a feasible and valid instrument for the measurement of 
functioning in injury patients,10,19,22,23 it lacks a cognitive dimension and is in some populations 
outperformed by other measures.22,32 We therefore included a separate item on cognitive ability. 
Preferably, the EQ-5D should be combined with other instruments when used in patient-related 
outcome measurement. 
 
The future of trauma registries 
Our study provides directions for the development of trauma registries, showing the opportunities of 
expanding these registries and document data on the consequences of non-fatal trauma. 
As trauma registries were originally designed to monitor and improve the quality of care delivered to 
trauma patients3, in-hospital mortality is generally the only available and easy accessible patient 
outcome in these databases. Mortality comprises a relatively rare outcome among all trauma patients 
and does no longer provide the true quality indicator of trauma systems. As a consequence, trauma 
registries that focus on mortality as the main patient outcome have become outdated. 
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Consequently, the outcomes of non-fatal trauma have increasingly become important. Trauma 
survivors often experience some level of impairment or disability after their trauma. The economic 
consequences of injuries are substantial, as survivors of severe trauma often require specialised health 
care and long-term rehabilitation and are in some cases unable to return to full employment. Insight 
into the economic consequences, and impact of a trauma on patients’ health outcome is essential for 
optimising health care policy and prevention, and developing effective health care and rehabilitation 
services. 
More specifically, patient-reported outcome measures (e.g. HRQL instruments) can be used in clinical 
decision making after the acute phase of trauma care. For instance, HRQL information may enable 
clinicians to detect unrecognised problems, monitor the impact of a trauma and the provided trauma 
care, and may also lead to improvements in the patient’s health status and/or satisfaction with trauma 
care.33 
Our study highlights that data on the consequences of non-fatal trauma should be integrated in the 
evaluation of health care delivered to trauma patients, and should be documented in trauma registries. 
Worldwide, the first trauma registry to measures the long-term outcomes of trauma survivors after 
discharge is the Victorian State Trauma Registry (VSTR) in Australia. The VSTR routinely collects 
information on the long-term functional status, work disability, and HRQL of trauma patients over 2 
years post-discharge,34 reaching follow-up rates of over 80% using telephone interviews.35 Results from 
the VSTR indicate that even years after injury survivors of major trauma still experience impairments 
due to the injury, as only one fourth of all patients returned to their pre-injury level of function after 
two years of follow-up.36 In line with our findings, data from the VSTR also indicated that patients with 
abdominal injury showed high levels of recovery and as well as highest return to work or study after 
injury.36 
Like other trauma registries, the VSTR focuses on the more severe injuries and major trauma patients 
(e.g. ISS≥16).3,34 Our results, however, indicated that the highest impact on both individual patients and 
society was found in injuries coded with ISS 9–15 (indicating moderate severity). It is therefore 
recommended to broaden the inclusion criteria of trauma registries by including all hospitalised trauma 
patients (as in the Dutch National Trauma Registry26 and the National Trauma Data Bank® of the US).37 
Information on the health outcome of patients could be gathered and documented for all patients on 
discharge using questionnaires. The EuroSafe Group has developed guidelines for the conduction of 
follow-up studies measuring trauma-related disability, and recommended the use of the EQ-5D in 
combination with the Health Utilities Index mark 3.38 These instruments were thought to include most 
of the relevant health domains for trauma patients, when measuring the consequences of non-fatal 
trauma.38 Another instrument that is frequently used among trauma patients is the 36-item Short Form 
health survey (SF-36).8,39 The SF-36 and EQ-5D both have shown to be able to discriminate between the 
health status of patients with different types of injuries.8 More specific, disability and activity limitations 
after injury can be assessed with use of the World Health Organisation Disability Assessment Schedule 
(WHODAS);40 a self-administered instrument which captures six major life domains and a summary 
score of functioning and disability.40 The WHODAS has been shown to be a reliable and valid instrument, 
with scores highly correlated with scores on physical component score (PCS) of the SF-36.40 However, 
in contrast to the EQ-5D, the SF-36 and WHODAS may be too time-consuming for patients to fill out, 
which may negatively affect the response rates. Therefore, the shorter SF-12 health survey can be used, 
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which like the SF-36, captures information about the mental and physical HRQL,41 and is applied in the 
VSTR.34 
Some trauma registries, like the Dutch trauma registry, have implemented the Utstein Template for 
uniform reporting of data following trauma,42 in which besides the 30-day mortality also the Glasgow 
Outcome Scale (GOS) is recorded; an objective measure to assess the recovery of trauma patients.43 An 
extended version of the GOS is used in the Australian VSTR,34 the GOSE, which classifies patients into 
eight levels of function from death to full recovery.44 However, a criticism of scales such as the GOSE is 
that they fail to capture the subjective perspective of trauma patients.45  
In practice, hospitals could send follow-up questionnaires to all hospitalised patients registered in the 
trauma database, in order to provide information on the long-term consequences of trauma of all 
patients. It may however be costly and time-consuming to contact all registered trauma patients, to 
obtain their informed consent, and to collect their response to the follow-up questionnaires. Previous 
research indicated that the use of telephone interviews may increase response and reduce the costs of 
data collection.46 Moreover, (part of) the HRQL assessment could be incorporated into the daily care 
provided within the hospital and/or outpatient setting (e.g. during contact with the clinician). In 
addition, the burden of follow-up measurement may be reduced by drawing random samples from all 
registered trauma patients to obtain a representative sample of the treated trauma population. 
Moreover, due the high share of Internet users worldwide (82% of individuals in developed countries),47 
web-based and mobile phone technologies (e.g. online questionnaires or use of smartphone apps) may 
be used for set up and follow-up of a cohort of injury patients, creating significant cost and time savings 
in comparison to traditional research methods.48 
Besides assessing the HRQL of trauma patients, these assessments of outcomes after trauma should 
also include items on the health care consumption, and return to work or normal activities after trauma. 
Depending on the length of stay of individual trauma patients, follow-up measurement of all these items 
is advised at 1 month (acute treatment phase, range 0–8 weeks), 2 months (rehabilitation phase, range 
1–3 months), 4 months (adaptation phase, range 3–6 months), and 12 months (stable end situation, 
range 6–24 months) after the trauma.38 To produce estimates of the decrease in HRQL due to the 
trauma, it is recommended to retrospectively assess the preinjury HRQL of trauma patients within the 
first week after the injury.38 
 
Conclusions 
The integrative approach of assessing the consequences of non-fatal trauma revealed that injury 
patients with ISS 9–15 had one of the highest impact on both individuals and society. Our findings 
emphasise the importance of documenting the consequences of all hospitalised trauma cases in trauma 
registries and incorporating the outcomes of non-fatal trauma in the evaluation of trauma care to obtain 
insight into the quality of survival after trauma and to compare the consequences of trauma across 
patient subgroups. 
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APPENDIX 
 
Table 5.A Unit costs (2012) estimated according to national guidelines for health care costing 
 Resource Unit costs 
General Practitioner Practice consultation €33.70 
 Consultation by telephone €16.90 
 Home visit €67.40 
 Referral patient treated at the ED €35.00 
 Referral hospitalised patient €44.00 
 Follow-up care patient treated at the ED €33.70 
 Follow-up care hospitalised patient €37.80 
Ambulance Emergency journey €538.20 
 Scheduled journey €206.20 
Hospital Attendance of ED Injury specific fees1 
 Hospitalisation general hospital €460.40/day 
 Hospitalisation academic hospital €629.00/day 
 Intensive care €1,751.50/day 
 Day care €310.30/day 
 Outpatient department visit €178.10/visit 
 Medical procedures Reimbursement fees 
Long-term care Nursing home €264.60/day, 138.80/day care 
 Rehabilitation €469.10/day 
 Physiotherapy €38.00/treatment 
Home care Domestic care €30.60/hour 
 Care €39.10/hour 
 Nursing €67.60/hour 
 Nursing & care €46.40/hour 
Labor costs 15–19 year €13.50/hour 
(including VAT) 20–24 year €24.70/hour 
 25–29 year €32.80/hour 
 30–34 year €39.30/hour 
 35–39 year €43.30/hour 
 40–44 year €45.40/hour 
 45–49 year €46.80/hour 
 50–54 year €48.50/hour 
 55–59 year €49.70/hour 
 60–64 year €50.70/hour 
 Overall mean €40.90/hour 
1 Unit costs for attendance of emergency department are calculated per type of injury in an annually unit cost study indexing the tariffs per 
minute of nurses, physicians and specialists. ED: emergency department; VAT: value added tax. 
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Table 5.B Study population (aged 16 years and older) 
Hospital Level1 
National Injury 
Surveillance 
System2 
Trauma 
Registry3 
Linked 
files4 
Follow-up 
survey5 
Response 
Radboud university medical center, Nijmegen I 975 750 747 309 91 
Canisius-Wilhelmina hospital, Nijmegen II 918 474 413 186 152 
Gelderse Vallei hospital, Ede II 1,088 477 424 194 78 
Maasziekenhuis Pantein hospital, Boxmeer III 532 431 411 202 90 
Total  3,513 2,132 1,995 891 411 
1 Trauma center level, from Level-I (highest) to Level-III (lowest). 
2 Number of hospitalised patients (16+ years) registered in the LIS. 
3 Number of hospitalised patients (16+ years) registered in the TR. 
4 Number of hospitalised patients (16+ years) registered in both the LIS and TR. 
5 Number of hospitalised patients (16+ years) with linked files who were sent a follow-up survey. 
 
 
Figure 5.A Prevalence of limitations (moderate or severe) of the EQ-5D health domains by ISS category 
Data is shown by the four ISS categories (A) and ISS<16 versus ISS≥16 (B). 
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ABSTRACT 
 
Background The disability-adjusted life year (DALY) measures the burden of disease, which 
serves as crucial input for policy decisions. Disability weights are necessary to estimate DALYs. 
The aims of this study were to 1) quantify differences between two methods to derive 
disability weights for traumatic brain injury (TBI), and 2) compare DALY estimations calculated 
with both sets of disability weights given the same TBI incidence data. 
 
Methods HRQL disability weights were assessed using SF-36 data from a postal survey among 
996 TBI patients 6 and 12 months after attending the emergency department of a hospital. 
Differences between health-related quality of life (HRQL) and existing Global Burden of 
Disease (GBD) study disability weights were calculated by TBI severity class (mild, moderate, 
severe). The GBD 2013 and HRQL disability weights were applied to the same incidence data 
to assess YLD due to TBI in the Netherlands to estimate the burden of TBI. 
 
Results The findings showed that the GBD and HRQL disability weights for TBI were in the same 
order of magnitude apart from the disability weight for severe TBI, where long-term 
consequences were weighted 2.5 times more severe according the GBD. When the HRQL 
disability weights were used, the majority (62%) of the total number of DALYs were lost due 
to mild TBI, whereas with the GBD disability weights 51% of the total number of DALYs were 
lost due to mild TBI. 
 
Conclusions We conclude that differences are small between the disability weights and YLD 
estimations derived in a standard way or from empirical HRQL follow-up data from individual 
TBI patients.  
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6.1 INTRODUCTION 
 
The disability-adjusted life year (DALY) measures the burden of disease, i.e. it is a time-based measure 
that aggregates the total health loss due to mortality, morbidity and disability at population level into a 
single index by summarising a) years of life lost due to premature death (YLL), and b) years lived with 
disability (YLD).1 This allows comparison of the size of a certain health problem to comparable data of 
other health problems and this feature makes the DALY very suitable for guiding decision-making on 
prevention and control.2,3 Landmark studies that used the DALY are the Global Burden of Disease and 
Injury (GBD) 1996 study and its subsequent updates.  
An essential component for DALY calculations is the disability weight. The disability weight is a scaling 
factor that expresses the impact of a disease with a value ranging from 0, indicating best possible health 
state, to 1, indicating worst possible health state.4 By multiplying the disability weight of a condition by 
its incidence and its average duration (or prevalence in case of chronic disease), the healthy time lost 
due to living with disability (YLD) is calculated.  
Disability weights are derived by a panel of judges that value a number of health states and these health 
state valuations are then used to calculate disability weights for the health states.5 These judges may 
be patients, proxies, health experts or lay people from the population. Up till now few panel studies 
have been conducted, of which the GBD disability weighs studies,6-8 the Dutch Disability Weights (DDW) 
study,9 Integrated Burden of Injury (IBIS) study10 and INTEGRIS11 disability weights are of significance for 
traumatic brain injury (TBI) and its consequences.  
An important difference between these existing sets of TBI disability weights is the subdivision into TBI 
categories, ranging from one category to six categories. For instance, the set of GBD 1996 disability 
weights included one disability weight for intracranial injury, which was applied to concussion, 
moderate and severe brain injury, whereas the set of GBD 2013 disability weights included five disability 
weights for TBI. An overview of existing sets of TBI disability weights and the subdivision into TBI 
categories is shown in Appendix Table 6.A and 6.B. 
However, a disadvantage of the application of standard disability weights is that these disability weights 
may be unable to capture the heterogeneity within a certain injury group. In other words, there may be 
a misfit between the epidemiological data that is used for the YLD calculations and the disability weight 
that is applied to the epidemiological data, leading to an underestimation of the burden of TBI. 
Consequently, increasingly, researchers conclude that, in case of injury, disability weights derived from 
health-related quality of life (HRQL) data from individual trauma patients are the preferred option.12-15 
Deriving HRQL disability weights consists of two steps. First patients report their own health state with 
a generic health state classification (e.g. EQ-5D, Health Utilities Index, Short Form(SF)-36).16 Combined 
with previously population elicited attribute weights these responses render a HRQL summary score. 
Subsequently, the HRQL summary score of the cases is converted to a disability weight.  
Using HRQL data to derive disability weights has the advantage that disability weights can be linked to 
epidemiological injury data more precisely, provided that a logical and homogeneous grouping of 
patients is used.11 In case of TBI a logical and homogeneous grouping would be the Glasgow Outcome 
Scale Extended (GOSE). GOSE is a functional measurement scale with eight categories that has been 
designed for TBI specifically.17 GOSE has demonstrated good construct and discriminant validity and is 
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a widely used instrument to describe outcome in a group of TBI cases.18,19 However, the GOSE 
classification has not yet been used to assess disability weights for TBI.  
The aims of this study were to 1) generate HRQL disability weights for TBI by severity level measured by 
GOSE level based on  SF-6D data of a cohort of TBI patients, 2) quantify differences between (a) HRQL 
disability weights and (b) GBD 2013 disability weights, and 3) compare YLD estimations calculated with 
both sets of disability weights given the same incidence data. 
 
6.2 METHODS 
 
Cohort of TBI patients 
The data for this study was obtained from the Radboud University Brain Injury Cohort Study (RUBICS).20-
22 RUBICS is a prospective observational cohort study on the association between demographic and 
clinical variables, posttraumatic complaints, and functional outcome. The RUBICS database included 
data of all patients with TBI admitted to the emergency department (ED) of the Radboud University 
Nijmegen Medical Centre (RUNMC), a level I trauma center. The RUBICS database recorded socio-
demographic variables, cause of injury, the Abbreviated Injury Scale (AIS), Glasgow Coma Scale (GCS), 
Abbreviated Injury Scale of the Head (AISH) score, Injury Severity Score (ISS) and health care that was 
provided. Of the 3,888 patients with TBI admitted to the ED of the RUNMC between June 2003 and June 
2010 were eligible for inclusion. Of these patients, 2,286 were sent a questionnaire. For this study, all 
patients with TBI aged 18 years and older were selected from the RUBICS database. For more details on 
the RUBICS, see Scholten and colleagues.23 
 
Glasgow Outcome Scale Extended 
The GOSE scores functional outcome with eight questions covering consciousness, independence inside 
and outside the home, major social roles (work, social and leisure activities, family and friendships), and 
return to normal life.24 Aggregating these questions results in an 8-point scale that classifies functional 
outcome from 1 (dead) to 8 (complete recovery). The GOSE was assessed using a structured interview 
during regular visits to the outpatient clinic or during consultation by telephone.17 Assessment of the 
GOSE often took place at 6 and 12 months post-injury. If GOSE scores at 6 months post-TBI were missing, 
the 6 month GOSE was composed by taking the mean of GOSE scores assessed at 5 or 7 months, or at 
4 or 8 months. In case of missing GOSE scores at 12 months post-TBI, the 12 month GOSE was composed 
by taking the mean of GOSE scores assessed at 11 or 13 months, or at 10 or 14 months. 
 
Health-related quality of life data 
HRQL data was collected by postal questionnaires at 6 and 12 months after injury. The questionnaires 
included items regarding socio-demographics (age, sex, educational level and household composition),  
clinical outcome and HRQL determined with the 36-item Short-Form Health Survey (SF-36).25 The SF-36 
is one of the HRQL instruments recommended by the TBI consensus groups.26 The SF-36 is a 36-item 
questionnaire that covers eight domains of health status: physical functioning (PF), role limitations 
related to physical health problems (RP), bodily pain (BP), general health perception (GH), vitality (VT), 
social functioning (SF), role limitations related to emotional problems (RE), and mental health (MH).25 
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The SF-36 has been used previously to evaluate HRQL in TBI patients.27,28 For each domain, a summation 
of item responses is linearly transformed into a score ranging from 0–100.  
 
Converting SF-36 data into disability weights 
Assessing HRQL disability weights requires two steps. Firstly, patients described their health state by 
choosing a functional level for each attribute of the HRQL instrument. Using tariff weights for the 
separate attributes, the reported functional level on the attributes is then converted into a utility weight 
which usually fits within the 0–1 range. The method of scoring the SF-36 is not based on preferences, 
and therefore cannot be used directly as a single utility score which is needed to construct disability 
weights. Single utility scores were obtained by deriving SF-6D utility scores out of the SF-36. The SF-6D 
reduces the eight dimensions of the SF-36 to six dimensions by excluding the general health item and 
combining both role limitation dimensions.29 The reduced and less complex SF-6D defines 249 health 
states, which were valued by a representative sample of 611 members of the UK general population 
using standard gamble.30,31 Preference data from this study was used in a SF-6D algorithm. The SF-6D 
algorithm was applied to responses to the SF-36 generating SF-6D utility scores for each TBI patient, 
ranging from full health (1) to death (0). 
The second step in assessing HRQL disability weights is to convert the utility weights into disability 
weights. The method that we applied to convert SF-6D utility scores to disability weights (dw) is as 
follows: dw = SF-6Dpopulation – SF-6Dpatient 
In this formula, the SF-6D utility score of the general population of a country (HRQL<1) is used as the 
baseline in the calculation of the disability weight of the health state. With this formula, it is possible to 
adjust for the effects of age and/or sex on HRQL. We used the population norm scores for the SF-6D for 
the UK.32 
 
GBD 2013 disability weights 
For the GBD 2013 study a Disability Weights Measurement study was carried out using household 
sample surveys in five countries (Bangladesh, Indonesia, Peru, Tanzania, USA) supplemented by an 
open-access online survey and a web-survey that was held among a representative sample of the 
general population of four European countries (Hungary, Italy, the Netherlands and Sweden).7,33,34 The 
primary mode of data collection was via a simple paired comparison question in which respondents 
were asked to consider two hypothetical individuals, each with a particular health condition described 
briefly in terms of its main functional consequences and symptoms, and to indicate which of the two 
individuals they would regard as being healthier. An additional type of question asked respondents to 
compare the population health benefits in two different hypothetical health programmes, and this 
information was used to anchor the results from the paired comparison data such that all weights were 
located on a scale between zero and one. This resulting in a set of 235 disability weights based on the 
responses from 61,890 people in 167 countries.7,33,34 The GBD 2013 includes five disability weights for 
TBI 1) concussion; 2) minor TBI, long-term consequences; 3) moderate TBI, long-term consequences; 4) 
severe TBI, short-term consequences; 5) severe TBI, long-term consequences.  
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Mapping of disability weights and calculating Disability-Adjusted Life Years 
The injury severity classes were grouped post hoc according to the GOSE categories (GOSE 2–3: severe 
disability; GOSE 4–5: moderate disability; GOSE 6–7: minor disability; GOSE 8: no disability) (Table 6.1).  
 
Table 6.1 Mapping of TBI severity classes, duration and severity distribution of TBI cases according to GOSE  
GBD disability weight GOSE points Duration 
Severity distribution of cases 
from the RUBICS study 
Short-term consequences    
No disability 8 - 42.3% 
Concussion 6–7 <12 months 43.2% 
Moderate disability, short-term consequences 4–5 <12 months 13.9% 
Severe disability, short-term consequences 2–3 <12 months 0.7% 
Long-term consequences    
No disability  8 - 56.7% 
Minor disability,  long-term consequences 6–7 ≥12 months 14.6% 
Moderate disability, long-term consequences 4–5 ≥12 months 2.2% 
Severe disability, long-term consequences 2–3 ≥12 months 0.5% 
 
To estimate the burden of TBI. the GBD 2013 and HRQL disability weights have been applied to the same 
incidence data to assess YLD due to TBI in the Netherlands. Incidence data on all patients with TBI 
treated at an ED and/or admitted to hospital in the Netherlands in the period 2010–2012 was extracted 
from the Dutch Injury Surveillance System (LIS)35 and the National Hospital Discharge Registry (LMR)36 
to include data of TBI patients treated at the ED and hospitalised TBI patients respectively. See Scholten 
and colleagues for more details on the incidence of TBI in the Netherlands.37  The distribution of the TBI 
severity level (assessed by GOSE points) of RUBICS cases was calculated using the RUBICS dataset (Table 
6.1). This distribution was then applied to incidence data on all patients with TBI treated at an ED and/or 
admitted to hospital in the Netherlands. Apart from incidence data and disability weights, duration is 
needed to assess YLDs. Duration of injury is the period of time that there is disability due to the injury. 
In our conceptual model we distinguish between short-term and long-term consequences of TBI. Short-
term consequences are the consequences that a TBI patient experiences immediately after until 364 
days after sustaining the TBI. Long-term consequences are the consequences that a patients 
experiences one year after injury. In our study, the short- and long-term consequences of TBI are 
captured with the 6 month and 12 months follow-up study respectively. 
  
Data and statistical analysis 
For analysis of the data the Statistical Package for the Social Sciences version 21 was used (SPSS Inc, 
Chigaco, Ill). The SF-36 and SF-6D summary scores can be calculated if all items are completed. If one 
or two items were missing, the item was estimated using a hot deck imputation technique. The missing 
data was then imputed by the estimated values.38 If more than two of the SF-36 items were missing, 
data was not imputed. 
Differences between HRQL and GBD disability weights and ratios were calculated by TBI severity class 
(minor, moderate, severe). The intraclass correlation coefficient was calculated to test if the ranking 
based on the mean HRQL and GBD disability weights of the TBI health states were associated.   
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6.3 RESULTS 
 
Respondents 
The response rates were 44% (n=996) at 6 months and 17% (n=386) at 12 months post-injury (Table 
6.2). Of the TBI patients that completed the patient surveys 6 months after attending the ED 63% was 
male and mean age was 44 years old. The majority (80%) of TBI patients had a GCS score ≥13. After 
visiting the ED, 60% of the respondents were admitted to hospital and 17% were admitted to the IC. 
 
Table 6.2 Characteristics of the study population  
 6 month follow-up 12 month follow-up 
N 996 386 
Patient demographics   
Age1 44 [27–57] 47 [28–58] 
Male sex 628 (63.1%) 232 (60.1%) 
Injury characteristics   
ISS1  9 [5–18] 10 [5–22] 
AISH   
Head AIS 0–1 208 (20.9%) 73 (18.9%) 
Head AIS 2–3 602 (60.4%) 234 (60.6%) 
Head AIS 4–5 186 (18.7%) 79 (20.5%) 
Admitted to hospital 596 (59.8%) 263 (68.1%) 
GCS   
Mild (GCS≥13) 797 (80.0%) 282 (73.1%) 
Moderate (GCS=9–12) 50 (5.0%) 22 (5.7%) 
Severe (GCS≤8) 149 (15.0%) 82 (21.2%) 
1 Data is displayed as median, with the first and third quartile given within brackets. 
 
HRQL disability weights 
Table 6.3 shows that the HRQL disability weight increases with increasing level of GOSE. Mean 6 month 
HRQL disability weights ranged from 0.04 (GOSE 7; lower good recovery) to 0.254 (GOSE 3; lower severe 
disability). Mean 12 month HRQL disability weights ranged from 0.08 (GOSE 7; lower good recovery) to 
0.263 (GOSE 3; lower severe disability). 
 
Table 6.3 Mean HRQL disability weights by GOSE category 
GOSE 
6 month follow-up 12 month follow-up 
N 
SF-6D 
mean 
SF-6D 
SD 
DW SD N 
SF-6D 
mean 
SF-6D 
SD 
DW SD 
2 0 NA NA NA NA 0 NA NA NA NA 
3 4 0.541 0.051 0.254 0.09 4 0.542 0.075 0.263 0.07 
4 43 0.607 0.070 0.185 0.09 6 0.625 0.109 0.210 0.04 
5 90 0.635 0.091 0.167 0.09 14 0.593 0.112 0.202 0.10 
6 170 0.663 0.087 0.137 0.08 49 0.642 0.105 0.149 0.10 
7 196 0.760 0.112 0.040 0.11 70 0.719 0.114 0.079 0.12 
N: number of respondents; SF-6D mean: mean SF-6D utility weight; SD: standard deviation; DW: disability weight (0 indicates best possible 
health state and 1 indicates worst possible health state); NA: not available. 
 
Comparison of HRQL and GBD 2013 disability weights  
Figure 6.1 shows a Bland-Altman plot of the GBD and HRQL disability weights. Table 6.4 shows that 
absolute differences and SF-6D/GBD disability weights ratio increased with increasing level of severity. 
Correlation coefficients between SQM and APM disability weights were high, intraclass correlation was 
0.65 (p=0.166). The GBD and HRQL disability weights are in the same order of magnitude, apart from 
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the disability weight for severe TBI, long-term consequences for which the GBD disability weights is 2.5 
times higher. 
 
Figure 6.1 Comparison of GBD and HRQL disability weights for TBI 
 
Each point represents the TBI disability weight per GOSE category. 
DW: disability weight; 0 indicates best possible health state and 1 indicates worst possible health state. 
  
Table 6.4  TBI disability weights derived with the HRQL and GBD disability weights measurements study  
TBI health state HRQL DW GBD DW ∆1 Ratio 
Short-term     
Concussion 0.085 0.110 –0.03 0.8 
Severe traumatic brain injury, short-term  0.254 0.214 0.04 1.2 
Long-term     
TBI, long-term consequences, minor  0.113 0.094 0.02 1.2 
TBI, long-term consequences, moderate  0.199 0.231 –0.03 0.9 
TBI, long-term consequences, severe  0.265 0.637 –0.37 0.4 
1 ∆: absolute difference between SQM and APM disability weights. 
DW: disability weight; 0 indicates best possible health state and 1 indicates worst possible health state. 
 
Comparison of YLD estimations 
Annually, 34,682 patients visited the ED due to TBI in the Netherlands. Table 6.5 shows the YLD 
estimations calculated with (a) the set of HRQL disability weights and (b) the set of GBD disability 
weights. Application of the HRQL disability weights resulted in 102,381 YLDs (short-term TBI: 2,725 YLDs; 
long-term: 99,656 YLDs), whereas application of the GBD disability weights resulted in 108,732 YLDs 
(short-term TBI: 2,682 YLDs; long-term: 106,050 YLDs).  
As shown in Figure 6.2, with the application of HRQL disability weights, the majority (62%) of the total 
number of YLDs were lost due to mild TBI, whereas with the GBD disability weights 52% of the total 
number of YLDs were lost due to mild TBI. 
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Table 6.5 YLD estimations calculated with (a) the set of SF-6D disability weights and (b) the set of GBD disability 
weights 
GOSE category Incidence Duration (years) HRQL DW YLD HRQL DW GBD DW YLD GBD DW 
Short-term (<12 months) 
2 0 1 NA 0 0.214 0 
3 771 1 0.254 196 0.214 165 
4 2,253 1 0.185 417 0.110 248 
5 4,565 1 0.167 762 0.110 502 
6 7,292 1 0.137 999 0.110 802 
7 8,774 1 0.04 351 0.110 965 
8 11,027 1 0 0 0 0 
Total 34,682     2,725   2,682 
Long-term (≥12 months) 
2 0 47.9 NA 0 0.637 0 
3 534 47.9 0.263 6,727 0.637 16,294 
4 1,067 47.9 0.21 10,733 0.231 11,806 
5 2,075 47.9 0.202 20,077 0.231 22,960 
6 4,743 47.9 0.149 33,851 0.094 21,356 
7 7,470 47.9 0.079 28,267 0.094 33,634 
8 18,793 47.9 0 0 0 0 
Total 34,682     99,656   106,050 
Total    102,381   108,732 
DW: disability weight; 0 indicates best possible health state and 1 indicates worst possible health state. 
YLD: years lived with disability. 
 
Figure 6.2 YLDs due to mild, moderate and severe TBI, calculated with GBD and HRQL disability weights 
 
DW: disability weight; 0 indicates best possible health state and 1 indicates worst possible health state. 
YLD: years lived with disability. 
 
6.4 DISCUSSION 
 
The results showed that the ranking of both sets of disability weights were concordant and that the 
HRQL and GBD disability weights for TBI were in the same order of magnitude, apart from the disability 
weight for severe TBI long-term consequences for which the GBD disability weight was 2.5 times more 
severe. 
In many areas of medicine, disability weights are not tailored to incidence or prevalence. Disability 
weights for certain health outcomes may not be available or not ‘appropriate’. If, for example, the 
health status of the population is less or more severe than the health status represented by the 
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‘disability weights’ used in the formula the linkage between the incidence data and functional outcomes 
is flawed. 
This problem is amplified in case of TBI. TBI encompasses a variety of consequences and recovery 
patterns ranging from mild and short-term to severe and lifelong. To assess the burden of TBI, the Global 
Burden of Disease (GBD) study developed a set of five disability weights.7  Application of these disability 
weights means that TBI incidence data, classified into many ICD codes, have to be collapsed into five 
groups to link the data to the disability weights. Important to note for instance is that there was no GBD 
disability weight for short-term consequences of moderate TBI (14% of TBI patients) and we applied the 
disability weight for concussion to these cases, resulting in an underestimation of the YLD of the short-
term consequences of moderate TBI. 
More and more researchers conclude that the fit between injury incidence data and disability weights 
is improved if disability weights are derived from empirical HRQL follow-up data from individual trauma 
patients.12-14 An advantage of using disability weights based on empirical HRQL follow-up data is that 
the HRQL disability weights are able to capture the heterogeneity within an injury group. However, the 
results of our study showed that although disability weights based on HRQL data provides solutions for 
problems with the GBD disability weights, it also has limitations. 
Firstly, the HRQL disability weights might be contaminated by comorbidity, since one in four TBI patients 
from our sample suffered from comorbid disorders.23 This means that the disability weights based on 
empirical HRQL follow-up data might reflect the impact of the TBI plus one or more comorbid diseases. 
Apart from this, HRQL may be affected by age and sex of the respondent, follow-up time, type of 
instrument that is used to measure HRQL, etc.  
A second aspect that might affect HRQL disability weights is adaptation to the health state. Especially in 
case of chronic conditions, such as long-term consequences of TBI, adaptation to the health state plays 
an important role, because this may cause TBI patients to perceive their health state as less severe after 
living with the condition for some time.39 This may be an explanation for the relatively low HRQL 
disability weights for severe TBI compared to the HRQL disability weights for moderate and mild TBI. 
Another explanation for the relatively low HRQL disability weights for severe TBI may be the use of self-
report HRQL data to assess disability weights for TBI patients. TBI patients had to fill out the SF-36, which 
is lengthy and has complex questions. It has been debated whether TBI patients have the ability to 
provide useful and complete answers to complex questions.40 The more complex HRQL instruments, 
such as the SF-36, have been shown to be difficult to complete by the general populations,41 let alone 
for TBI patients who may have cognitive problems. The use of self-report SF-36 questionnaires may have 
led to an underestimation of impact on functional outcome and HRQL, since patients with a higher 
degree of cognitive problems may have not been able to fill in the questionnaire. Comparison of the 
response rate of patients with a GSC>8 and GSC≤8 in the RUBICS dataset showed that latter group of 
patients were significantly less likely to respond to the 6 month follow-up questionnaire. Also, the low 
response rates at 6 and 12 month follow-up may have led to selection at the two follow-up moments 
of the study. 
Furthermore, the HRQL disability weight for severe TBI is based on a small number of patients (n=4).  
This underlines the challenge of using HRQL data to assess disability weights, namely that the number 
of patients per grouping needs to be relatively large to derive a HRQL disability weight for the whole 
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spectrum of patients within the grouping. This may be difficult in case of less frequently occurring injury, 
such as severe TBI.  
The YLD of TBI assessed in the current paper is twice as high as the YLD reported in a previous study on 
the incidence and burden of disease in the Netherlands.37 This difference can be explained by 
differences in several aspects of the YLD calculation. Firstly, our study used a more detailed subdivision 
of TBI (six categories versus two categories), different sets of disability weights and a longer duration of 
long-term consequences of TBI. This translates into a higher YLD per case (3.0–3.1 YLD per case in the 
current study versus 1.5 YLD per case in Scholten and colleagues).37  
A limitation of our YLD calculations is that we applied information on the distribution of GOSE level of 
the TBI cases seen in one academic hospital to all TBI cases in the Netherlands. This academic hospital 
functions as a tertiary referral hospital. This may result in a relatively high proportion of more severe 
cases of TBI, which limits extrapolation to all TBI in the Netherlands.  
 
Conclusions 
Taking the results of our study, with little difference between the disability weights and YLD estimations, 
and the limitations of disability weights derived from empirical HRQL follow-up data from individual TBI 
patients, we conclude that using the GBD disability weights to assess the burden of TBI is the preferred 
option. 
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Table 6.B GBD disability weights, health state description and severity classes according to GOSE and 
duration 
GBD disability weight7 GBD Health state description7 GOSE points Duration 
No disability – 8 - 
Concussion 
has headaches, dizziness, nausea and difficulty 
concentrating 
6–7 <12 months 
Minor TBI, 
long-term consequences 
has episodes of headaches, memory problems, and 
difficulty concentrating. 
6–7 >12 months 
Moderate TBI, 
long-term consequences 
has frequent headaches, memory problems, difficulty 
concentrating, and dizziness. The person is often anxious 
and moody.  
4–5 >12 months 
Severe TBI, 
short-term 
consequences 
cannot concentrate and has headaches, memory problems, 
dizziness, and feels angry. 
2–3 <12 months 
Severe TBI, 
long-term consequences 
cannot think clearly and has frequent headaches, memory 
problems, difficulty concentrating and dizziness. The person 
is often anxious and moody, and depends on others for 
feeding, toileting, dressing and walking.   
2–3 >12 months 
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ABSTRACT 
 
Background The Glasgow Outcome Scale Extended (GOSE) is the established functional 
outcome scale to assess disability following traumatic brain injury (TBI), however does not 
capture the patient’s subjective perspective. Health-related quality of life (HRQL) does 
capture the individual’s perception of disability after TBI, and has therefore been recognised 
as an important outcome in TBI. In contrast to GOSE, HRQL enables comparison of health 
outcome across various disease states and with healthy individuals. We aimed to assess 
functional outcome, HRQL, recovery, and predictors of 6 and 12 month outcome in a 
comprehensive sample of patients with mild, moderate or severe TBI, and to examine the 
relationship between functional impairment (GOSE) and HRQL. 
 
Methods A prospective cohort study was conducted among a sample of 2,066 adult TBI 
patients who attended the emergency department (ED). GOSE was determined through 
questionnaires or structured interviews. Questionnaires 6 and 12 months after ED treatment 
included socio-demographic information and HRQL measured with Short-Form Health Survey 
(SF-36; reflecting physical, mental and social functioning) and Perceived Quality of Life Scale 
(PQoL; measuring degree of satisfaction with functioning). 
 
Results 996 TBI survivors with mild, moderate or severe TBI completed the 6 month 
questionnaire. Functional outcome and HRQL after moderate or severe TBI was significantly 
lower than after mild TBI. Patients with moderate TBI showed greatest improvement. After 
one year, the mild TBI group reached outcomes comparable to population norms. TBI of all 
severities highly affected SF-36 domains physical and social functioning, and physical and 
emotional role functioning. GOSE scores were highly related to all SF-36 domains and PQoL 
scores. Female gender, older age, comorbidity and high ISS were strongest independent 
predictors of decreased HRQL at 6 and 12 months after TBI. 
 
Conclusions HRQL and recovery patterns differ for mild, moderate and severe TBI. This study 
indicates that GOSE, although clinically relevant, fails to capture the subjective perspective of 
TBI patients, which endorses the use of HRQL as valuable addition to established instruments 
in assessing disability following TBI. Influence of TBI severity on recovery, together with female 
gender, older age, comorbidity and high ISS should be considered in long-term follow-up and 
intervention programmes.  
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7.1 INTRODUCTION 
 
Traumatic brain injury (TBI) is a leading cause of death and long-term disability, particularly in young 
adults. TBI can cause assorted impairments and disabilities in functional, physical, emotional, cognitive, 
and social domains which drastically reduce health-related quality of life (HRQL).1,2 Because of major 
improvements in trauma care, the number of survivors of severe TBI has rapidly grown.3 However, the 
disability due to TBI has not appreciably reduced.4 This has resulted in a shift in attention from mortality 
towards disability of TBI patients. 
Disability following TBI is often assessed by functional measurement scales that have been designed for 
TBI specifically, e.g. the Glasgow Outcome Scale (GOS) and the GOS Extended (GOSE).4,5 The GOS is a 
descriptive outcome scale with 5 categories. Five categories are believed to be too few to represent the 
wide range of mental and physical disability a patient can suffer following TBI.6,7 Therefore, the GOS was 
extended to 8 categories, by dividing 3 categories into a lower and upper one. The GOSE is more 
sensitive to change than the GOS,6,8 is quick to administer, can be applied to all cases, and has clinically 
relevant categories. These practical advantages have led to its widespread adoption in early 
management studies and clinical trials. However, one criticism of scales such as the GOSE is that they 
fail to capture the subjective perspective (e.g. HRQL) of TBI patients.8 
HRQL reflects an individual’s perception of how an illness and its treatment affect physical, mental and 
social aspects of his/her life.9 HRQL has been recognised as an important outcome in TBI, because it 
provides well-standardised information on recovery patterns and frequency, nature, and predictors of 
disabilities.10 In contrast to the GOSE, HRQL measures enable comparison of health outcome after TBI 
with other diseases and the general population, and their outcome in terms of an health status on a 
scale from 0 (death) to 1 (perfect health) scale can be used in economic evaluations. Research has 
shown that even years after injury, many TBI patients still report significantly lower HRQL than the 
general population.1,2,11-14 Most studies however, focus on recovery after mild15-17 or moderate and 
severe1,12,13,18,19 TBI. HRQL and recovery pattern differences between mild, moderate and severe TBI are 
not often studied. 
Large variation exists in the use of HRQL instruments to quantify the impact of TBI on population health 
over time. The most widely used instrument to estimate HRQL after TBI is the 36-Item Short-Form (SF-
36) Health Survey;20 a multidimensional questionnaire, reflecting features of health including physical, 
mental, and social functioning. Another HRQL instrument that has previously been used in TBI,21,22 is the 
Perceived Quality of Life Scale (PQoL); a measure of the degree to which the individual is satisfied with 
his/her functioning, or global life satisfaction.23 Findings from earlier studies suggest similar SF-36 and 
PQoL patterns after TBI.7,21,24 
Due to the heterogeneity of TBI patients and their wide array of short- and long-term recovery patterns, 
accurate measurement of HRQL and the impact of all severities of TBI over time is needed. Furthermore, 
more insight is needed in the assessment of HRQL following TBI as a potential addition to established 
instruments, such as the GOSE. Therefore, the current study focused on HRQL after mild, moderate and 
severe TBI, and on the relationship between functional outcome measured with GOSE and HRQL 
measured with the SF-36 (including all domains) and PQoL. 
The objectives of the present prospective cohort study were to 1) assess the functional outcome (GOSE), 
HRQL (SF-36 and PQoL), and recovery patterns at 6 and 12 months after mild, moderate and severe TBI, 
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2) assess the relationship and discrepancies between GOSE and HRQL for all TBI severity levels, and 3) 
test socio-demographic and injury-related characteristics as predictors for suboptimal functioning after 
TBI. 
 
7.2 METHODS 
 
Study design 
Data for the present study was obtained from the Radboud University Brain Injury Cohort Study 
(RUBICS).25-27 RUBICS is a prospective observational cohort study on the association between 
demographic and clinical variables, posttraumatic complaints, and functional outcome of patients with 
brain injury. This study encompassed multiple outcome measures (GOSE, SF-36 and PQoL) of patients 6 
and 12 months after mild, moderate and severe TBI. 
Between 1998 and 2010, patients admitted to the emergency department (ED) of the Radboud 
University Nijmegen Medical Centre (RUNMC), a level I trauma centre, with a diagnosis of mild, 
moderate or severe TBI were included in the RUBICS database. TBI was defined as an acute insult to the 
brain caused by an external physical force.28 Mild and moderate TBI were defined by an ED Glasgow 
Coma Scale (GCS) score of, respectively, 13–1529 and 9–1230 after initial resuscitation at the ED or an 
admission GCS of, respectively, 13–15 and 9–12 followed by sedation and intubation during 
resuscitation for a non-neurological cause. Severe TBI was characterised by an ED GCS ≤831 after 
resuscitation. Clinical data registered by a neurologist and/or neurosurgeon in the ED was collected by 
a research nurse and entered into the RUBICS database. The RUBICS database comprised demographic 
data, trauma mechanism, hospitalisation, clinical injury variables, and comorbidities. Comorbidity was 
defined as the presence of any co-existing medical diseases or disease processes additional to the injury 
that the injury patients sustained. The following diseases were assessed as comorbid disease: asthma, 
chronic bronchitis, chronic non-specific lung disease (not questioned), heart disease, diabetes, back 
hernia or chronic backache, osteoarthritis, rheumatoid arthritis, and cancer. Further, Abbreviated Injury 
Scale of the Head (AISH) revised 1990 (AIS-90),32 Injury Severity Score (ISS), and GOSE were recorded. 
 
Study participants 
In the current study, all patients, aged 16 years and older, with mild, moderate and severe TBI, admitted 
to the ED of RUNMC, between June 2003 and June 2010, who completed the 6 month questionnaire, 
were selected from the RUBICS database. Exclusion criteria were no informed consent, alcohol or drug 
abuse or dementia, unknown address, and inability to speak or write Dutch. Furthermore, patients who 
died within 6 months were excluded. Written informed consent was obtained from all participating 
patients. 
 
Functional outcome measure 
The GOSE scores functional outcome with eight questions covering consciousness, independence at 
home, major social roles (work, social and leisure activities, family and friendships), and return to normal 
life.33 It results in an 8-point scale classifying functional outcome from 1 (dead) to 8 (complete recovery). 
GOSE scores were determined using a structured interview during regular visits to the outpatient clinic 
or during consultation by telephone.34 Patients not visiting the outpatient clinic were sent a GOSE 
Chapter 7 | 125 
 
questionnaire by regular mail, and when not returned a reminder was sent.35 Finally, we attempted to 
reach all non-responding patients by telephone to acquire an outcome score. Assessment often took 
place at 6 (70%) and 12 (66%) months post-injury. Outcomes obtained within a 2 months range were 
also accepted if no outcome at exactly 6 or 12 months was available. Patients with a GOSE score of 1 
(dead) were excluded from this study. 
 
Health-related quality of life measures 
HRQL was determined using the SF-36 (Version 1) and PQoL. Patients were asked to fill in a 
questionnaire, which included the HRQL measurements at 6 and 12 months post-injury. 
The SF-36 is the most frequently used HRQL instrument in TBI and showed positive results for internal 
consistency and validity in a TBI population.36,37 It is a 36-item questionnaire that covers eight domains 
of health status: physical functioning (PF), role limitations related to physical health problems (RP), 
bodily pain (BP), general health perception (GH), vitality (VT), social functioning (SF), role limitations 
related to emotional problems (RE), and mental health (MH).38 For each domain, a summation of item 
responses is linearly transformed into a score ranging from 0 to 100. Physical (PCS) and mental summary 
scores (MCS) are calculated by standardising patients’ scores, by subtracting Dutch subscale means 
from each individual’s subscale scores and dividing the result by Dutch standard deviation to generate 
Z-scores.39 In order to facilitate international comparison,40 Z-scores are multiplied by United State (US) 
subscale factor coefficients for PCS and MCS and summed over all eight subscales into PCS and MCS 
sums. Both sums were re-scaled into T-scores, with a mean of 50 and standard deviation of 10 for the 
US norm population.40 Missing values at 6 and 12 months of 10.8% and 10.7% of the respondents were 
replaced by the mean value of the respondents’ completed items in the same scale, provided that at 
least 50% of the items within that scale had been completed.38 
The PQoL was initially developed as a cognitive appraisal of life satisfaction for patients after intensive 
medical care.41 It has been used for adults with chronic neurologic disability21,42 and showed good 
internal reliability in a TBI population.22 PQoL measures the degree to which the individual is satisfied 
with his/her functioning on an 11-point scale ranging from 0 (extremely dissatisfied) to 10 (extremely 
satisfied). It consists of 19 items in 3 domains (physical, cognitive and social), assessing 10 areas of 
functioning including physical health, thinking and remembering, family relationships, community 
participation and leisure, work and income, and meaning and purpose of life. PQoL scores may be 
considered a measure of global life satisfaction, with PQoL <7.5 ‘‘Dissatisfied’’ and PQoL >7.5 
‘‘Satisfied’’.23 A previous study showed that the PQoL scores in adults without chronic conditions, range 
between 8.3 and 8.5.42 We used the mean score (range of 0 to 10) in our analyses. Because PQoL scores 
can only be computed in case of complete information on all items, missing values of 11.4% respondents 
at both 6 and 12 months were estimated by hot deck imputation per domain if at least 50% of the items 
within that domain had been completed, using the reported values of respondents with similar scores 
on the items that were reported in that domain.43 
 
Data and statistical analysis 
Analysis of variance (ANOVA), Chi-square statistics (dichotomous variables), and Student’s t tests 
(continuous variables) were used for between-group comparisons on socio-demographic and injury-
related variables, and the influence of AISH (<3 versus ≥3) on HRQL in patients with mild TBI. A paired t 
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test was used to evaluate the difference between 6 and 12 month patients’ SF-36 scores. The 
relationship between GOSE and HRQL was determined by comparing the mean SF-36 domain scores 
and PQoL scores across GOSE categories using ANOVA (degrees of freedom = 5). Correlations were 
analysed with Spearman’s r. Additional analyses were done to look for discrepancies between GOSE and 
HRQL outcomes, comparing patients with and without poor functional outcome (defined as GOSE ≤4) 
with high SF-36 domain scores (defined per SF-36 domain score as higher than or equal to third quartile 
of overall domain score), or patients with and without good functional outcome (defined as GOSE ≥7) 
with low SF-36 domain scores (defined per SF-36 domain score as lower than or equal to first quartile 
of overall domain score). A value of p<0.05 was used to determine statistical significance. 
Socio-demographic and injury-related characteristics were tested as predictors of HRQL measured with 
the SF-36 domains and PQoL score 6 and 12 months after TBI in a simple linear regression analysis. We 
included the socio-demographic variables gender (male/female), age (continuous), a dummy-coded 
variable for primary/secondary (reference), higher and academic education, and comorbidity 
(continuous). The injury-related variables were a dummy-coded variable for GCS 13–15 (mild TBI, 
reference), GCS 9–12 (moderate TBI), and GCS 3–8 (severe TBI), ISS (continuous), and AISH (continuous). 
Variables associated with outcome (p<0.20 in the univariable analysis) were included in stepwise 
multivariable linear regression analyses.44,45 Analysis of the variance inflation factor (VIF) showed low 
VIF-values (all VIFs<1.9), indicating that higher order collinearity was not problematic in this study. None 
of the variables showed high correlations between each other (all variables r<0.7). 
All statistical analyses were carried out using the statistical package SPSS for Windows, version 21 (IBM 
SPSS Statistics, SPSS Inc, Chicago, IL). 
 
7.3 RESULTS 
 
Patient characteristics 
Between June 2003 and June 2010, 4,576 patients with TBI of 16 years old and older were admitted to 
the ED of the Radboud University Nijmegen Medical Centre (Figure 7.1). Of these patients, 688 were 
excluded from the database due to inability to speak Dutch, or death. Mortality for mild, moderate and 
severe TBI was, respectively, 4.1%, 17.2%, and 35.7%. Of the 3,888 eligible patients, 1,602 did not 
receive a first questionnaire due to various reasons (e.g. dementia, unknown address). Of the 2,286 TBI 
patients that received a 6 month questionnaire, 996 (44%) completed the 6 month questionnaire, of 
whom 386 (39%) filled in the 12 month questionnaire. 
Of the 996 respondents, 797 had mild (80%), 50 moderate (5%) and 149 severe (15%) TBI (Table 7.1). 
The median age of the respondents was 44 years and 63% were male. Respondents with severe TBI 
were significantly younger than respondents with mild or moderate TBI (median age 39 years versus 45 
years and 47 years, F=5.5, df=2, p=0.004). Respondents with moderate TBI more often were female 
(56%, F=6.4, df=2, p=0.002). 
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Figure 7.1 Flow chart of patient inclusion throughout the study 
 
 
Respondents who also filled in the 12 month follow-up questionnaire (74% mild, 6% moderate and 21% 
severe TBI) had a significantly higher head AIS-score (F=4.6, df=1, p=0.033), GCS score (F=21.4, df=1, 
p<0.001), and were significantly more often admitted to hospital (Chi2=17.6, p<0.001) and more often 
admitted to the Intensive Care (IC; Chi2=6.2, p=0.009) than non-respondents. Furthermore, comparison 
of the characteristics of responders and non-responders to the 12 month follow-up survey showed that 
respondents who filled in both the 6 and 12 month questionnaire were older and more likely to be 
female, though these differences were not significant. 
 
Functional outcome and HRQL for mild, moderate and severe TBI 
According to the GOSE scores, at 6 and 12 months 36% and 23% of all respondents had an unfavourable 
outcome (GOSE ≤6). GOSE was significantly lower for respondents with moderate or severe TBI than for 
those with mild TBI (6 months F=53.1, 12 months F=28.3, df=2, both p<0.001, Table 7.2). The majority 
of the respondents (54% and 55% at 6 and 12 months, respectively) reported on the SF-36 a higher PCS 
than MCS. Respondents with moderate or severe TBI had significantly lower outcomes than mild TBI on 
PCS, physical functioning, role physical, social functioning and role emotional (F=8.5–20.4, df=2, all 
p<0.001). 
All SF-36 domains showed improvement over time after mild, moderate and severe TBI (Figure 7.2), 
except mental health for respondents with severe TBI. Individual patients’ scores revealed significant 
improvement for only mild and moderate TBI, on the domains physical functioning, role physical, bodily 
pain, social functioning and PCS (t(340–378)= –5.10 to –3.52, 95%CI [–11.70 to –2.23, –4.14 to –0.81]; 
all p<0.001), and lowest change for all severities on general health, vitality, mental health and MCS. 
Respondents with moderate TBI showed greatest improvement over time. This group went from lowest 
6 month scores on all SF-36 domains except physical functioning, to higher 12 month scores than severe 
TBI on all SF-36 domains except social functioning and role emotional, and even higher 12 month scores 
than mild TBI on physical functioning, general health and vitality. 
  
TBI patients (16+ years) atmitted to RUNMC 
between June 1 2003 and June 30 2010
N=4576
Eligible patients
N=3888
6 month follow-up
N=996
12 month follow-up
n=386
688 patients excluded
(445 patients died
243 patients unable to speak Dutch or foreigner)
Study sample
N=2286
1602 patients not sent a questionnaire
(reasons: no study at the time, unwillingness to 
participate, address unknown, dementia)
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Table 7.1 Characteristics of the study population 
 
All 
Severe 
(GCS≤8) 
Moderate 
(GCS=9-12) 
Mild 
(GCS≥13) 
N 996 149 (15.0) 50 (5.0) 797 (80.0) 
Gender (male) 628 (63.1) 107 (71.8) 22 (44.0) 499 (62.6) 
Age1 (years) 44 (27–57) 39 (22.5–54.5) 47 (27–61.3) 45 (28–57) 
Education     
Primary education 34 (3.4) 4 (2.7) 5 (10.0) 25 (3.1) 
Secondary education 515 (51.7) 114 (76.5) 35 (70.0) 366 (45.9) 
Higher professional education 143 (14.4) 20 (13.4) 5 (10.0) 118 (14.8) 
Academic education 95 (9.5) 4 (2.7) 3 (6.0) 88 (11.0) 
Unknown 209 (21.0) 7 (4.7) 2 (4.0) 200 (25.1) 
Injury mechanism     
Road traffic accidents 493 (49.5) 94 (63.1) 24 (48.0) 375 (47.1) 
Fall  330 (33.0) 34 (22.8) 22 (44.0) 273 (34.3) 
Sports 93 (9.3) 9 (6.0) 2 (4.0) 82 (10.3) 
Assault 47 (4.7) 4 (2.7) 0 (0.0) 43 (5.4) 
Other/unknown 34 (3.4) 8 (5.4) 2 (4.0) 24 (3.0) 
Injury severity     
ISS1 9 (5–18) 29 (20–38) 20.5 (10–29) 6 (4–14) 
AISH1 2 (2–3) 4 (3–5) 4 (2–4) 2 (2–2) 
Head AIS 3 152 (15.5) 43 (29.7) 10 (20.4) 99 (12.5) 
Head AIS 4 123 (12.5) 45 (31.0) 16 (32.7) 62 (7.9) 
Head AIS 5 63 (6.4) 41 (28.3) 10 (20.4) 12 (1.5) 
Comorbidity2     
No pre-existing disease 489 (49.1) 98 (65.8) 26 (52.0) 365 (45.8) 
1 comorbid disease 135 (13.6) 23 (15.4) 13 (26.0) 99 (12.4) 
2 comorbid diseases 43 (4.3) 6 (4.0) 3 (6.0) 36 (4.5) 
3 or more comorbidities 52 (5.2) 4 (2.7) 2 (4.0) 43 (5.4) 
Unknown 277 (27.8) 18 (12.1) 5 (10.0) 254 (31.9) 
Hospitalisation3     
Hospital admission 597 (59.9) 144 (96.6) 46 (92.0) 407 (51.1) 
Number of days hospitalised1 6 (2–14) 17.5 (7.3–32) 11 (6–20.5) 3 (1–8) 
IC admission 167 (16.8) 118 (79.2) 14 (28.0) 35 (4.4) 
Number of days on IC1 4 (2–10) 6 (2–10.3) 6 (2–16.3) 2 (1–5) 
1 Data is displayed as median, with the first and third quartile given within brackets. 
2 Comorbidity is defined as the presence of any co-existing medical diseases or disease processes additional to the injury that the injury 
patients sustained. The following diseases were assessed as comorbid disease: asthma, chronic bronchitis, chronic non-specific lung disease 
(not questioned), heart disease, diabetes, back hernia or chronic backache, osteoarthritis, rheumatoid arthritis, and cancer. 
3 Hospital or IC admission for one day or more after arrival at emergency department. 
 
At one year follow-up, only respondents with mild TBI reached outcomes comparable to the Dutch 
population norm on all the SF-36 domains. Comparison of patients’ scores with the Dutch general norm 
showed that mild, moderate and severe TBI all highly affected the domains physical functioning, role 
physical, social functioning, and role emotional. 
PQoL scores showed that, at 6 and 12 months 40% and 37% of all respondents were dissatisfied with 
their functioning (PQoL<7.5). Mean PQoL scores ranged from 7.4 and 7.3 after severe or moderate TBI 
to 7.6 after mild TBI, compared to mean PQoL scores of 8.3 to 8.5 measured in adults without chronic 
conditions.42 Of the 346 respondents who filled in both 6 and 12 month PQoL, 50% reported a decreased 
PQoL over time (from 8.0 to 7.1). In total, at 6 and 12 months 31 (4.0%) and 12 (3.2%) respondents 
scored at the scale ceiling. 
Additional analyses on multiple organ injury showed no statistical difference in SF-36 or PQoL scores 
between respondents with or without polytrauma besides TBI, except for SF-36 physical functioning at 
6 months (t(885)=2.36, 95%CI [0.86, 9.66]; p=0.019). The GOSE also showed statistical difference 
between respondents with and without polytrauma at 6 months (t(963)=3.11, 95%CI [0.11, 0.50]; 
p=0.002). 
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Figure 7.2 SF-36 at 6 and 12 months for mild, moderate and severe TBI 
6 months 12 months 
  
 
SF-36: Short-Form-36; PF: physical functioning; RP: role physical; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: 
role emotional; MH: mental health; Dutch norm scores from Aaronson and colleagues (1998) 
 
HRQL compared to GOSE levels 
The mean 6 and 12 month SF-36 scores were generally appropriately ordered for each GOSE category 
(Figure 7.3). There was a particularly strong relationship between the GOSE and the SF-36 domains 
physical functioning (r=0.62, p<0.001), role physical (r=0.68, p<0.001) and social functioning (r=0.61, 
p<0.001). The mean scores of all eight SF-36 domains significantly increased with higher GOSE 
categories at 6 months (F=43.2–163.8, df=5, all p<0.001) and 12 months (F=10.8–46.3, df=5, all 
p<0.001). The PQoL also showed a significant increase with higher GOSE categories at 6 months (F=53.7, 
df=5, p<0.001) and 12 months (F=29.5, df=5, p<0.001). 
 
Figure 7.3 Comparison of SF-36 domain scores and PQoL with GOSE 6 months after TBI 
 
* Significant increase of domain score with more favourable GOSE category (multiple ANOVA, all p<0.001). 
Mean (error bars: 95% confidence interval [CI]) SF-36 domain scores, and Perceived Quality of Life (PQoL) plotted against Glasgow 
Outcome Score – Extended (GOSE) category; 3: Lower severe disability; 4: Upper severe disability; 5: Lower moderate disability; 6: Upper 
moderate disability; 7: Lower good recovery; 8: Upper good recovery; SF-36: Short-Form-36; PF: physical functioning; RP: role physical; BP: 
bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role emotional; MH: mental health. 
 
  
40
45
50
55
60
65
70
75
80
85
90
PF RP BP GH VT SF RE MH
40
45
50
55
60
65
70
75
80
85
90
PF RP BP GH VT SF RE MH
Total Severe Moderate Mild Dutch norm scores
0
1
2
3
4
5
6
7
8
9
10
0
10
20
30
40
50
60
70
80
90
100
PF RP BP GH VT SF RE MH
P
Q
o
L 
sc
o
re
P
Q
o
L 
sc
o
re
P
Q
o
L 
sc
o
re
P
Q
o
L 
sc
o
re
M
e
an
 s
co
re
 (
9
5
%
 C
I)
M
e
an
 s
co
re
 (
9
5
%
 C
I)
M
e
an
 s
co
re
 (
9
5
%
 C
I)
M
e
an
 s
co
re
 (
9
5
%
 C
I)
SF-36 domain
3-4
5
6
7
8
PQoL
GOSE
*          * *             *        *        *             *            *             *  
Chapter 7 | 131 
 
Additional analysis on discrepancies between GOSE and SF-36 showed that at 6 months a small number 
of patients reported high SF-36 domain scores while having a low GOSE score, ranging from no 
differences on the social functioning domain to 3.1% on bodily pain and 3.2% on the role emotional 
domain. Patients more often reported low SF-36 domain scores at 6 months while having a high GOSE 
score, with smallest differences on the role physical domain (8.3%) and largest differences on general 
health (24.8%), mental health (25.1%) and vitality (31.1%). High SF-36 domain scores while having a low 
GOSE score was significantly related to injury-related characteristics and more common among patients 
with more severe TBI according to the GCS (in general health and vitality; t(792–828)=3.96 to 4.24, 
95%CI [0.20 to 0.24, 0.60 to 0.66]; both p<0.001), higher ISS (in bodily pain, vitality, role emotional and 
mental health; t(782–876)= –6.60 to –4.87, 95%CI [–13.70 to –11.32, –7.36 to –4.80]; all p<0.001) and 
higher AISH (in bodily pain, general health and mental health; t(828–876)=–4.46 to –2.18, 95%CI [–1.10 
to –0.63, –0.42 to –0.03]; all p<0.05). The reporting of low SF-36 domain scores while having a high 
GOSE score was significantly related to socio-demographic characteristics and more often occurred 
among females (in bodily pain, general health and vitality; Chi2=4.4–9.5, all p<0.05), older patients (in 
physical functioning and bodily pain; t(831–885)=–4.78 to –2.29, 95%CI [–15.56 to –6.71, –6.50 to –
0.59]; all p<0.05), less educated patients (in bodily pain; Chi2=11.3, p=0.003) and patients with multiple 
comorbid diseases (in all SF-36 domains except social functioning, role emotional and mental health; 
t(594–640)=–3.71 to –2.35, 95%CI [–1.58 to –0.53, –0.45 to –0.05]; all p<0.02). 
 
Predictors for HRQL after TBI 
At 6 months, females tended to have lower outcome on all SF-36 domains, except general health and 
role emotional (both not significant), as well as lower PCS, MCS and PQoL (t(764–978)=2.09 to 4.79, 
95%CI [0.06 to 4.20, 0.63 to 12.72]; all p<0.05, Table 7.3). Older respondents showed lower outcome 
on all SF-36 domains, except vitality, social functioning, mental health and MCS (t(764–978)=–5.93 to –
2.03, 95%CI [–13.83 to –0.64, –6.95 to –0.09]; all p<0.05). Respondents with comorbid diseases tended 
to have lower outcome on all SF-36 domains, except role emotional and mental health, as well as lower 
PCS and PQoL (t(651–705)=–8.29 to 0.47, 95%CI [–28.78 to –1.63, –17.52 to 3.08]; all p<0.005). The 
more severe injured patients (higher ISS) showed lower outcome on all SF-36 domains, PCS, MCS and 
PQoL (t(763–976)=–9.03 to –2.37, 95%CI [–31.23 to –0.78, –20.08 to –0.22]; all p<0.02). 
After one year (data not shown), females still had lower outcome on the presented items, with 
exception of SF-36 physical functioning, role physical, PCS and PQoL (t(361–381)=1.99 to 3.80, 95%CI 
[0.02 to 4.02, 4.72 to 12.64]; all p<0.05). Older respondents still showed lower outcome on physical 
functioning, general health and PCS (t(361–378)=–3.09 to –3.56, 95%CI [–13.47 to –5.11, –3.87 to –
0.87]; all p<0.01). Respondents with comorbidity still showed lower outcome on all SF-36 domains, 
except social functioning, role emotional and mental health, as well as lower PCS and PQoL (t(317–
336)=–5.93 to –2.35, 95%CI [–31.86 to –1.70, –13.36 to –0.47]; all p<0.05). In contrast to lower outcome 
on all 6 month items, after one year, respondents with higher ISS scores showed lower outcome on only 
SF-36 domains physical functioning, role physical, social functioning and role emotional (t(370–380)=–
3.87 to –2.17, 95%CI [–25.38 to –10.52, –8.28 to –0.53]; all p<0.05). 
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7.4 DISCUSSION 
 
The purpose of this paper was to assess HRQL and recovery patterns at 6 and 12 months after mild, 
moderate and severe TBI to examine the relationship between GOSE and HRQL, and to test predictors 
for suboptimal functioning after TBI. We found that TBI of all severities strongly affected functional 
outcome and HRQL, with only patients with mild TBI reaching outcomes comparable to general 
population norms at one year follow-up. In line with our expectations, HRQL and recovery patterns 
differed after mild, moderate and severe TBI. GOSE scores were highly related to all SF-36 domains and 
PQoL scores. Female gender, older age, comorbidity and high ISS were strongest independent 
predictors of decreased HRQL at 6 and 12 months after TBI. 
In contrast to most other studies, this study examined HRQL in a comprehensive sample of TBI patients 
of all severity levels. Surprisingly, at 6 months moderate TBI patients scored lower on almost all SF-36 
domains and reported lower PQoL scores than severe TBI. This intriguing trend toward greater difficulty 
after moderate TBI than after severe TBI was also reported in other studies.21,46,47 A possible explanation 
for this finding may be that survivors of severe injuries perceive some of their problems as less difficult, 
or their appreciation of being alive might outweigh their concerns about functioning. Those with 
moderate injuries would both have problems and be distressed about them.21 
SF-36 patterns at 6 and 12 months for all 3 severities reflect those reported in earlier studies on HRQL 
after TBI.20 All SF-36 domain scores for all 3 TBI severities increased over time, suggesting improvement 
on the whole spectrum of HRQL after mild, moderate and severe TBI. However, comparison of SF-36 
outcome at one year follow-up with Dutch population norms39 revealed outcomes in line with studies 
in which HRQL was lower for TBI patients than for the general population.2,11-13 This study used Dutch 
population norms, which vary from US population norms.40 The Dutch population reported lower 
physical domain scores and higher mental domain scores than the US population, with largest 
differences in the domains role physical (–4.2; Dutch: 77.0 vs US: 81.2) and vitality (+7.1; Dutch: 68.2 vs 
US: 61.1).39,40 Comparison of patients’ scores with the US population norms, however, revealed the 
same outcomes, in that TBI of all severities strongly affected HRQL and that only patients with mild TBI 
reached outcomes comparable to the general population at one year follow-up. The latter was also 
indicated in a study of MacKenzie and colleagues, in which trauma patients with an AISH of 2, considered 
as mild TBI, reached outcomes at one year follow-up comparable to the US population norms on all SF-
36 domains, except bodily pain and general health.48  
Our study also provided insight in the assessment of HRQL following TBI as a potential addition to GOSE. 
The significant relationship of increasing scores with more favourable GOSE category across all SF-36 
domains confirms results of earlier studies.8,36 This study was the first to examine the relationship 
between GOSE and PQoL, which also showed a significant increase with higher GOSE categories. 
Analysis on discrepancies between GOSE and SF-36 showed that at 6 months only a few patients 
reported high HRQL while having poor functional outcome, which was significantly more common 
among patients with more severe TBI in terms of GCS, ISS and AISH (especially in bodily pain, general 
health and mental HRQL domains). However, on some HRQL domains up to one third of the patients 
reported low HRQL while having good functional outcome, which significantly more often occurred 
among females, older patients, less educated patients, and patients with multiple comorbid diseases 
(especially physical HRQL domains). Our study therefore indicates that although functional outcome 
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(measured with the GOSE) is highly associated with HRQL, the discrepancies between GOSE and HRQL 
endorse the use of HRQL as valuable addition to established instruments in assessing disability following 
TBI. HRQL measures have the advantages over instruments like the GOSE, that they capture the 
individual’s perception of disability following TBI, enable comparison of health outcome across various 
disease states and with healthy individuals, and can be used in economic evaluations. 
Subsequent to initiation of our study, a disease specific HRQL measure for TBI, the Quality of Life after 
Brain Injury (QOLIBRI), has been developed.49 It captures the individuals’ well-being and satisfaction, 
and provides a profile of HRQL in 6 domains together with an overall score. The QOLIBRI consists of 37 
items and measures physical, psychological (emotional and cognitive), social and functional changes 
typical of TBI.49 The QOLIBRI seems a promising instrument to measure HRQL after TBI with good 
correlation with the GOSE and providing additional information to the SF-36.50 
Additionally, we tested predictors for suboptimal functioning 6 and 12 months after TBI. Female gender 
was the most striking. Multiple studies have reported poorer outcomes after TBI among females.51-53 A 
possible explanation for this finding may be disruption of hormone production after injury in females.53 
However, the mechanism behind gender differences in outcome after TBI is not entirely clear. 
The presented results made no distinction between outcome after TBI with or without additional 
multiple organ injury. Our study showed no statistical difference in SF-36 or PQoL scores between 
respondents with or without polytrauma besides TBI, except for SF-36 physical functioning at 6 months. 
The GOSE, which according to our findings was strongly related to SF-36 physical functioning, also 
showed statistical difference between respondents with and without polytrauma at 6 months. Similar 
results with regard to SF-36 have previously been reported,54,55 suggesting outcome after TBI is not 
influenced by polytrauma. 
Apart from these promising findings, there are some potential validity problems with administering 
HRQL measurement questionnaires to patients with cognitive impairments.56 In severely impaired 
persons, awareness of cognitive and other deficits may be reduced. Therefore, measuring a construct 
such as HRQL in persons with cognitive deficits via self-rated questionnaires represents a major 
methodological challenge. However, recent research indicated that although lack of awareness is 
expected among people with severe TBI soon after the injury, most people with TBI, even those with 
severe functional limitations, are aware of those deficits 6 months after injury and rate their satisfaction 
accordingly.57 
In our study, the severity of TBI was defined by the GCS. Although the GCS is the established instrument 
to define TBI severity, a small sample of patients with mild TBI in our study had an AISH 3 or higher. The 
severity of these injuries however did not affect HRQL, except the SF-36 domains role physical and role 
emotional. The higher scores of patients with an AISH 3 or higher on these role functioning scales may 
be influenced by the use of SF-36 version 1, which has dichotomous response choices instead of the 
five-level response choices in version 2. During the preparation of this study, a validated Dutch SF-36 
version 2 was not yet available. 
It is a limitation that this study was restricted to TBI patients of one hospital. The results do not 
necessarily apply to patients treated at other Dutch hospitals. A national multicentre study comparing 
the outcome of TBI patients could possibly improve the understanding of HRQL and the impact of all 
severities of TBI over time. 
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Finally, this study had to cope with a low response rate of 39% at 12 month follow-up. Comparison of 
the characteristics of responders and non-responders to the 12 month follow-up survey showed that 
respondents who filled in both the 6 and 12 month questionnaire were older and more likely to be 
female, though these differences were not significant. The low response rates may have led to selection 
bias and in its turn to under- or overestimation of the functional outcome and HRQL after TBI. Despite 
the low response rate, a strength of our study is that we used a relatively large study sample, with even 
386 participants at 24 months. 
 
Conclusions  
TBI of all severities strongly affects HRQL, leading to lower HRQL of TBI patients compared to the general 
population. HRQL and recovery patterns differ for mild, moderate and severe TBI. This study indicates 
that the GOSE, although clinically relevant, fails to capture the subjective perspective of TBI patients, 
which endorses the use of HRQL as valuable addition to established instruments in assessing disability 
following TBI. Influence of TBI severity on recovery, together with female gender, older age, comorbidity 
and high ISS should be considered in long-term follow-up and intervention programmes. 
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ABSTRACT 
 
Background This review examined pre- and post-injury prevalence of, and risk factors for, 
anxiety disorders and depressive disorders after traumatic brain injury (TBI), based on 
evidence from structured diagnostic interviews. 
 
Methods A systematic literature search was conducted in EMBASE, MEDLINE, Cochrane 
Central, PubMed, PsycINFO, and Google Scholar. We identified studies in civilian adults with 
TBI reporting on the prevalence of anxiety and depressive disorders using structured 
diagnostic interviews and assessed their quality. Pooled pre- and post-injury prevalence 
estimates of anxiety disorders and depressive disorders were computed. 
 
Results A total of 34 studies described in 68 publications were identified, often assessing 
anxiety disorders (n=9), depressive disorders (n=7), or a combination of disorders (n=6). 
Prevalence rates of psychiatric disorders varied widely. Pooled prevalence estimates of 
anxiety and depressive disorders were 19% and 13% before TBI and 21% and 17% in the first 
year after TBI. Pooled prevalence estimates increased over time and indicated high long-term 
prevalence of Axis I disorders (54%), including anxiety disorders (36%) or depressive disorders 
(43%). Females, those without employment, and those with a psychiatric history before TBI 
were at higher risk for anxiety and depressive disorders after TBI. 
 
Conclusions We conclude that a substantial number of patients encounter anxiety and 
depressive disorders after TBI, and that these problems persist over time. All health care 
settings should pay attention to the occurrence of psychiatric symptoms in the aftermath of 
TBI to enable early identification and treatment of these disorders and to enhance the 
recovery and quality of life of TBI survivors.  
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8.1 INTRODUCTION 
 
Traumatic brain injury (TBI) often imposes long-term consequences that complicate recovery and 
rehabilitation.1 A significant proportion of TBI survivors is diagnosed with psychiatric disorders, with 
post-traumatic stress disorder (PTSD) and major depression (MD) being the most commonly diagnosed 
and studied disorders.1-3 
Anxiety disorders and depressive disorders have a major impact on functional outcome of patients with 
TBI, and drastically reduce their health-related quality of life (HRQL).4-9 Because of the high incidence of 
TBI and the common diagnosis of anxiety and depressive disorders post-TBI, this pathology imposes 
substantial disease burden and economic consequences to both individuals and society. 
Early identification and treatment of psychiatric disorders in patients with TBI may improve their 
outcome, psychosocial functioning, and HRQL.10,11 For early prevention and treatment, insight in the 
prevalence of and risk factors for anxiety and depressive disorders is needed. 
Anxiety and depressive disorders can be diagnosed with use of standard criteria such as the Diagnostic 
and Statistical Manual of Mental Disorders (DSM)12 or the International Statistical Classification of 
Diseases and Related Health Problems (ICD).13 These criteria specify clinical disorders (so-called Axis I 
disorders in DSM) that represent acute symptoms that need treatment. Axis I disorders include a wide 
range of psychological diagnostic categories, for example, substance use, schizophrenia, psychotic 
disorders, dementia, and so on. Common Axis I disorders include anxiety disorders (generalised anxiety 
disorder (GAD), acute stress disorder (ASD), panic disorder, agoraphobia, specific phobia, social phobia, 
obsessive-compulsive disorder (OCD), and PTSD), and depressive disorders (dysthymia, bipolar disorder, 
and MD). 
Previous reviews on psychiatric outcomes post-TBI reported a wide range of anxiety and depressive 
disorders among TBI survivors,3,14-17 and large variation in prevalence rates.3,15,17 These reviews found 
prevalence rates of anxiety as high as 70%15 and rates of depressive disorders varying from 25% to 
50%.3,18 The existing reviews, however, focused solely on post-TBI prevalence rates of PTSD,17,19,20 
anxiety disorders,15 or depressive disorders18,21 or included studies with prevalence rates based on both 
self-report measures and structured diagnostic interviews.18,22 Research, however, indicated that self-
reports from TBI patients may be unreliable because of the overlap between psychiatric symptoms and 
disorders, memory deficits associated with TBI, and evidence that TBI patients tend to underestimate 
their functional problems.10,15 In contrast to self-reports, the use of structured diagnostic interviews 
enables the clinical examination for the presence of psychiatric disorders according to standard criteria 
such as the DSM or ICD.23 Use of these criteria in structured diagnostic interviews leads to more accurate 
prevalence estimates compared to self-report measures.18,24 Self-report measures may provide an 
overestimation of psychiatric disorders post-TBI, given that they do not take into account the pre-
existing or comorbid conditions of TBI patients and enable patients to report more symptoms by 
prompting them with specific questions.25,26 
The current review was conducted to improve our knowledge on psychiatric outcomes post-TBI, which 
may enable early identification and treatment of these psychiatric disorders and may enhance the 
recovery and HRQL of patients with TBI. This review provides a full oversight of the prevalence of and 
risk factors for anxiety and depressive disorders in civilian adults with TBI, based on evidence from 
structured diagnostic interviews. The current study therefore analyzed existing research that has 
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examined the 1) pre- and/or post-injury prevalence of clinically diagnosed anxiety and depressive 
disorders post-TBI and/or 2) risk factors influencing the development of anxiety and depressive 
disorders post-TBI. 
 
8.2 METHODS 
 
Relevant studies were identified through systematic literature searches in the databases EMBASE, 
MEDLINE, Cochrane Central, PubMed, and PsycINFO. Grey literature was examined by Google Scholar. 
Search strategies were developed in consultation with a search expert and included a combination of 
subheadings and text words (Appendix 8.A). Reference lists and citation indices of the included papers 
and relevant reviews were inspected to identify additional relevant citations. We restricted searches to 
English-language articles, published in peer-reviewed journals until November 2, 2015. 
 
Study selection 
Study design – We included retrospective and prospective cohort studies, cross-sectional studies, and 
case-control studies. Reviews, case reports, editorials, and intervention studies were excluded. 
Participants – Studies were included if they were conducted in civilian adults (16+ years) with TBI. 
Studies including a mixed population (e.g. all trauma patients) were only included if they analyzed their 
results for TBI patients separately. TBI was defined as an alteration in brain function or other evidence 
of brain pathology, caused by an external cause.27 There was no restriction in the diagnosis of TBI (e.g. 
self-reported) or severity of TBI. There was also no restriction in the methods of patient selection (e.g. 
samples drawn from the emergency department (ED) or hospital, referral clinics, or outpatient 
programmes). 
Psychiatric disorders – We included studies that examined all Axis I disorders or reported on the 
prevalence of at least one of the underlying anxiety disorders (including GAD, ASD, panic disorder, 
agoraphobia, specific phobia, social phobia, OCD, and PTSD) or depressive disorders (dysthymia, bipolar 
disorder, and MD) – see Table 8.1. All information on risk factors for anxiety or depressive disorders 
(from uni- or multivariable analysis) were extracted from the included studies. 
Structured diagnostic interviews – We included studies that used structured diagnostic interviews for 
the diagnosis of disorders (see Table 8.2). Studies solely using self-report measures (e.g. checklist or 
rating scales) or other measures to determine disorders (e.g. told by doctor, own classification system) 
were excluded. 
Multiple publications – To avoid double counting of prevalence rates, we identified publications that 
were related to the same sample of patients. For studies using data from an overlapping sample, one 
study was chosen as reference study by giving priority to the largest sample size (e.g. whole sample 
instead of specific age group or injury mechanism), the assessment of most disorders (e.g. Axis I over 
solely PTSD), and the focus on reporting prevalence rates (instead of predictors of disorders, or their 
impact on outcome). Information from all articles was used for analysing the risk factors for psychiatric 
disorders post-TBI. 
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Table 8.1 Overview of anxiety disorders and depressive disorders according to the DSM-5* 
Disorder Definition Symptoms Duration 
Axis I    
 Clinical disorders Acute symptoms that need treatment  
Anxiety    
Generalised 
anxiety 
disorder (GAD) 
Excessive anxiety and 
worry about a number of 
events or activities  
Restlessness or feeling keyed up or on edge; 
being easily fatigued; difficulty concentrating or 
mind going blank; irritability; muscle tension; 
sleep disturbance 
Occurring more 
days than not and 
for ≥6 months 
Acute stress 
disorder (ASD) 
Exposure to 
actual/threatened death, 
serious injury, or sexual 
violation 
Intrusion; negative mood; dissociation; 
avoidance; arousal 
3 days to 1 month 
after trauma 
exposure 
Panic disorder Recurrent unexpected 
panic attacks (abrupt 
surge of intense fear or 
discomfort) 
Palpitations; sweating; shaking; shortness of 
breath; choking; chest pain; nausea; dizziness; 
chills or heat sensations; numbness or tingling; 
derealisation; fear of losing control; fear of dying 
≥1 attack followed 
by ≥1 month of 
persistent worry, 
or maladaptive 
change in 
behavior 
Agoraphobia Marked fear or anxiety 
about using public 
transportation; being in 
open or enclosed spaces, 
outside of the home 
alone, in a crowd; 
standing in line 
Fear or anxiety; avoidance of situation Persistent, 
typically lasting ≥6 
months 
Specific phobia Marked fear or anxiety 
about an object or 
situation 
Immediate fear or anxiety; avoidance of object or 
situation 
Persistent, 
typically lasting ≥6 
months 
Social phobia Marked fear or anxiety 
about ≥1 social situations 
with exposure to possible 
scrutiny by others 
Fear to act in a way or show anxiety symptoms 
that will be negatively evaluated; avoidance of 
social situations 
Persistent, 
typically lasting ≥6 
months 
Obsessive-
compulsive 
disorder (OCD) 
Presence of obsessions, 
compulsions, or both 
Experience and ignorance or suppression of 
recurrent and persistent thoughts, urges, or 
images; repetitive behaviors or mental acts 
Time-consuming 
(>1h/day) or 
interfere with 
functioning 
Post-traumatic 
stress disorder 
(PTSD) 
Direct experience or 
witnessing traumatic 
event, exposure to 
aversive details or 
involved friends or family 
Persistent re-experiencing of event; avoidance of 
stimuli; negative alterations in cognitions and 
mood associated with event; alterations in 
arousal and reactivity 
>1 month, 
interfere with 
functioning 
Depression    
Dysthymia Persistent depressive 
disorder 
Poor appetite/overeating; 
insomnia/hypersomnia; low energy/fatigue; low 
self-esteem; poor concentration/difficulty making 
decisions; feelings of hopelessness 
Occurring for 
most of the day, 
for more days 
than not, for ≥2 
years 
Bipolar 
disorder 
Current or past 
hypomanic episode and 
major depressive episode 
Inflated self-esteem or grandiosity; diminished 
need for sleep; more talkative than usual or 
pressure to keep talking; racing thoughts 
Interfere with 
functioning 
Major 
depression 
(MD) 
 Depressed mood; diminished interest/pleasure; 
significant weight loss/gain; 
insomnia/hypersomnia; agitation/retardation; 
fatigue/loss of energy; worthlessness/guilt; 
diminished ability to think/ concentrate; 
recurrent thoughts of death, suicidal ideation 
Most of the day, 
nearly every day, 
interfere with 
functioning 
* Obtained from: American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders, (DSM-5®). American 
Psychiatric Pub. 
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Table 8.2 Structured diagnostic interviews 
Disorder Interview Criteria Assessment 
Anxiety and depression 
 CIDI28 
Composite International Diagnostic 
Interview 
DSM/ICD Trained lay interviewers 
 DIS29 Diagnostic Interview Schedule DSM Trained lay interviewers 
 MINI30 
Mini International Neuropsychiatric 
Interview 
DSM/ICD Trained lay interviewers 
 SADS-L31 
Schedule for Affective Disorders and 
Schizophrenia-Lifetime 
DSM 
Trained psychiatrists / 
psychologists 
 SCAN/PSE32 
Schedules for Clinical Assessment in 
Neuropsychiatry 
(or Present State Examination) 
DSM/ICD 
Trained interviewers 
(clinicians) 
 SCID33 
Structured Clinical Interview for DSM 
Disorders 
DSM 
Mental health 
professional 
ASD     
 ASDI34 Acute Stress Disorder Interview DSM Trained lay interviewer 
PTSD     
 CAPS35 Clinician-Administered PTSD Scale DSM Trained subprofessionals 
 PSS36 PTSD Symptom Scale DSM Trained lay interviewers 
 PDS Post-traumatic Diagnostic Scale DSM Trained lay interviewers 
 PTSD-I37 Posttraumatic Stress Disorder Interview DSM Trained subprofessionals 
ASD: acute stress disorder; DSM: Diagnostic and Statistical Manual of Mental Disorders; ICD: International Statistical Classification of 
Diseases and Related Health Problems; PTSD: posttraumatic stress disorder. 
 
Data extraction and risk of bias assessment  
The first review author (AS) screened all titles and abstracts and deleted obvious irrelevant citations. 
After initial selection, the reviewer (AS) screened the remaining citations on title and abstract and full-
text. Any doubt on inclusion was resolved by consulting a second author (JH). Two reviewers (AS and 
MC) extracted data and assessed the risk of bias of the included studies. Any discrepancies were 
resolved by discussion or consulting a third author (SP).  
We extracted information on the participants (age, gender, injury severity, and injury mechanism), and 
the assessment (interview, procedure, and timing), prevalence (before and/or after TBI), and risk factors 
(assessed and significant variables) for the studied psychiatric disorders. For each study, risk of bias was 
assessed using items on attrition bias (management of loss to follow-up) and reporting bias (primary 
outcomes missing) from the Research Triangle Institute item bank for observational studies,38 
complemented by items on the assessment of psychiatric disorders (e.g. inter-rater reliability, or 
assessor blinded to psychiatric history, medical file history, and/or hospitalisation variables of 
participants), study limitations, and statements on causality. 
 
Statistical analysis 
TBI severity was assessed and categorised into severity levels (mild, minor, moderate, severe) with use 
of the classification methods reported in the studies. TBI severity can be classified with use of the 
Glasgow Coma Scale (GCS),39 which is often categorised into mild or minor (GCS 13–15), moderate (GCS 
9–12), and severe TBI (GCS 3–8).40 Additionally, the American Congress of Rehabilitation Medicine 
(ACRM) defined mild TBI as a traumatically induced physiological disruption of brain function with a loss 
of consciousness (LOC) of approximately 30 minutes or less, an initial GCS of 13–15 after 30 minutes, 
and posttraumatic amnesia (PTA) not greater than 24 hours.41 
Pooled prevalence estimates per disorder were determined for three time points: before TBI (pre-
injury), during the first year (first year), and after one year (>1 year). A step-by-step guide was followed 
to perform a meta-analysis using a random-effects model in a Microsoft Excel spreadsheet.42 This meta-
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analysis using Microsoft Excel showed to achieve results comparable with that of using Comprehensive 
Meta-Analysis Software, a commercial software package specifically developed to conduct meta-
analyses.42 If studies reported prevalence rates equal to 0%, a prevalence rate of 0.1% was used in our 
calculations. Studies with a sample size of fewer than 30 patients were excluded from the calculation of 
pooled prevalence estimates to minimise outlier estimates resulting from small sample sizes. 
Additionaly, studies that used a sample with self-reported TBI43,44 or retrospective recall over decades 
post-injury to assess the prevalence of disorders preceding TBI (pre-injury)45 or the year after injury (first 
year)45 were excluded from the calculation of pooled prevalence estimates, as suggested by the 
Cochrane Collaboration.46 When only a small number of studies (n≤2) reported on the prevalence of a 
disorder, no pooled prevalence estimates were calculated for that disorder.  
Heterogeneity was assessed with the Q-statistic and I2-statistic. The Q-statistic is a Chi2-test for 
heterogeneity, which assesses whether observed differences in results are compatible with chance 
alone. A significant Q (low p-value) provides evidence of heterogeneity among the effect sizes and 
indicates that the variation in effect sizes is beyond chance.47 The I²-statistic describes the percentage 
of variation across studies that is to heterogeneity rather than chance.48 An I2 value of 25% or lower is 
associated with low heterogeneity, 50% is associated with moderate heterogeneity, and 75% or higher 
is associated with high heterogeneity.48 
 
8.3 RESULTS 
 
Literature search 
In January 2015, a total of 4,800 unique titles of potentially relevant articles were identified through the 
extensive search strategy (Figure 8.1). In November, the search strategy was updated and an additional 
539 new, unique titles of potentially relevant articles were identified. Screening of the titles and 
abstracts resulted in a selection of 291 articles that appeared to meet all selection criteria. After 
screening and selection of the full text papers, we retrieved 34 studies described in 68 publications. The 
main reasons for exclusion were not using a structured interview, not reporting about TBI patients 
(separately), or not reporting prevalence rates. Twelve out of the 34 included studies were multiple 
publications on the same sample of patients, with the number of related studies ranging from 1 
(n=5)2,43,44,49,50 to 7 (n=1).51 The 34 studies formed the basis of our review. 
 
Study characteristics 
Of the 34 studies, most were conducted in Australia (n=9),2,5,52-58 followed by the United States 
(n=8),43,44,51,59-63 the United Kingdom (n=4),24,49,64,65 and Canada (n=3)11,66,67 (Table 8.3 and Appendix 
Table 8.A). Sample sizes varied widely, ranging between 1668 and 47656 participants. The majority of the 
participants were males (except in 3 studies with 40–46% males),64,66,69 with an average age of 29–42 
years (in 27 out of the 34 studies). Traffic accidents comprised over half of all causes in 16 of the 22 
studies that reported on injury mechanism. 
TBI severity was often classified using the GCS (n=15),5,44,49-51,53,54,59-61,66,68,70-72 the definition of mild TBI 
by the ACRM (n=8),11,55-58,63,67,73 or the duration of PTA (n=3).24,52,64 Fifteen studies included all TBI 
severity levels, and 12 only mild TBI. 
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Axis I disorders (n=11),2,5,43-45,49,50,54,58,70,74 ASD and/or PTSD (n=9),24,52,53,55,56,64,65,69,75 (major) depression 
(n=7),11,51,60-62,67,73 and a combination of anxiety disorders and depressive disorders (n=6)57,59,63,66,68,72 
were the most frequently studied disorders per sample. The three studies on ASD also assessed PTSD, 
and only included patients with mild TBI (n=3).52,56,64 In contrast, 15 of the remaining 31 studies included 
all TBI severity levels in their assessment of Axis I disorders, PTSD, (major) depression, or both anxiety 
disorders and depressive disorders. 
The most frequently used structured interview was the Structured Clinical Interview for DSM Disorders 
(SCID, n=15),5,11,43,44,50,54,59-62,67,68,73,74,76 followed by the Clinician-Administered PTSD Scale (CAPS, 
n=6),2,24,55,56,58,65 Schedules for Clinical Assessment in Neuropsychiatry / Present State Examination 
(SCAN/PSE, n=5),45,49,51,60,70 and/or Mini International Neuropsychiatric Interview (MINI, n=3).2,57,58 Axis 
I disorders were often assessed with the SCID (n=6),5,43,44,50,54,74 or SCAN/PSE (n=3).45,49,70 ASD and/or 
PTSD were diagnosed with use of a range of interviews, including the CAPS (n=4),24,55,56,65 Acute Stress 
Disorder Interview (ASDI, n=2),52,64 and PTSD Symptom Scale (PSS, n=2),64,69 whereas depressive 
disorders were commonly assessed with use of the SCID (n=8).11,59-62,67,68,73 Five studies used multiple 
instruments in their assessment of Axis I disorders (MINI and CAPS),2,58 ASD and PTSD (ASDI and PSS64 
or Composite International Diagnostic Interview (CIDI)52), and MD (SCAN/PSE and SCID).60 Eleven studies 
reported that the interviews were conducted by one trained (neuro) psychiatrist or psychologist. 
 
Figure 8.1 Study selection 
 
 
7,582 records identified through 
database searching
200 additional records identified 
through other sources
4,800 unique records
291 full-text articles assessed for 
eligibility
223 excluded
115 no structured interview
50 no TBI
33 no prevalence
14 study design
8 no anxiety/depression
1 no civilians
1 no adults
1 duplicate paper
3 additional articles identified 
through reference lists
4,515 records excluded
34 eligible studies identified, 
described in 68 publications
7,782 records identified 2,982 duplicates removed
3 additional articles identified 
after search update
539 new, unique records
after search update
763 records identified
after search update
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Risk of bias 
Overall, 21 of the 34 studies reported on attrition and faced problems of patients who refused to 
participate (n=17, 8–58% of study sample),2,45,50,52-58,64,68,70,73-76 patients who could not be contacted 
(n=11, 2–58%),2,5,45,50,52,53,64,65,70,73,75 and patients who deceased or did not attend appointments (n=6, 
3–36%).45,49,50,60,73,76 According to these studies, participants often did not differ from those who did not 
participate. A few studies, however, showed differences in age (participants were older2,57,60 or 
younger69,75 compared to non-responders), and TBI severity (participants had higher2,75 or lower53 TBI 
severity level compared to non-responders). 
With respect to patient selection, two of the 34 studies included patients with self-reported TBI (not 
medically documented),43,44 and in another 16 studies participants were drawn from a variety of settings 
like specialty referral clinics or outpatient programmes. 
Only six out of the 34 studies provided information on the inter-rater reliability of the structured 
diagnostic interviews, which ranged between 80% (n=2)44,61 and 100% (n=4).2,54-56 
 
Prevalence rates 
Prevalence rates of anxiety and depressive disorders were assessed retrospectively (pre-injury, 
n=15),5,43-45,51,54,57,58,61,63,66,70,73,74,76 and at approximately 3 months (n=8),2,57-60,62,64,68 6 months 
(n=8),52,53,60,65,67-69,74 1 year (n=10),2,5,44,45,49,55,60,62,70,75 or more than one year post-TBI (n=12)24,43-
45,50,54,61,63,66,72,73,76 (Figure 8.2). Of the 12 studies with long-term follow-up, six studies had follow-up 
periods between 1 and 3 years,44,50,54,63,72,76 five studies comprised periods of 5–8 years post-
TBI,24,43,61,66,73 and one study 31 years post-TBI.45 
 
Overall, a wide range of prevalence rates was reported for Axis I disorders, anxiety disorders and 
depressive disorders (Table 8.4). 
 
Figure 8.2 Time points at which prevalence of psychiatric disorders was assessed 
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Pre-injury 
In total, 14 of the 15 studies that assessed the history of psychiatric disorders pre-TBI used the same 
diagnostic interview to assess the pre- and post-injury disorders, while one study used questions to 
assess the personal history of psychiatric disorders.105 The 15 studies showed widely varying prevalence 
rates of pre-injury Axis I disorders (5–54%, with 40–54% in 5 out of 8 studies),5,43,58,70,74 anxiety disorders 
(13–41%), and depressive disorders (0–50%, with 17–27% in 5 of the 9 studies reporting on pre-injury 
rates),5,44,54,57,58 irrespective of TBI severity. The 15 studies also reported varying pre-injury rates of the 
other disorders: GAD 0–14%, panic 0–11%, agoraphobia 0–13%, specific phobia 0–8%, social phobia 2–
11%, OCD 0–11%, PTSD 0–18%, dysthymia 0–4%, bipolar disorder 0–5%, MD 0–23%, and absence of 
ASD (0%, n=1).80 A history of dysthymia or bipolar disorders preceding TBI was rarely reported. A few 
studies reported absence of disorders (a prevalence rate of 0%), which may be explained because of 
the assessment of disorders after a long period of time,6,45,54 the measure used for diagnosis of disorders 
(PSE),51,105 or inclusion of only patients with severe TBI,6 with causes other than motor vehicle accident 
(MVA),70 or those admitted to a rehabilitation hospital.80 Additionally, two studies that assessed Axis I 
disorders in patients with mild TBI generally reported relatively high prevalence rates of all disorders, 
which may be related to their measures used for diagnosis of the disorders (MINI/CAPS).2,58 
 
Post-injury 
In the first year post-TBI, prevalence rates of Axis I disorders ranged from 10–34% in mild TBI, to 5–47% 
in studies with all TBI severity levels. Additionally, substantial prevalence rates were reported of post-
injury anxiety disorders (13–32%), especially ASD (14–21% in 3 of the 5 studies)52,64,91 and PTSD (12–
32% in 12 of the 17 studies),2,44,52,53,55,58,59,64,65,69,74,75 or depressive disorders (5–52%, 11–35% in 6 of the 
8 studies),5,44,49,57,58,62 especially MD (7–63%, 15–29% in 6 of the 11 studies).2,11,51,59,60,80 MD tended to 
be more frequently diagnosed in patients with more severe TBI, given that 8–18% of the patients with 
mild TBI received this diagnosis versus 7–63% in patients with all TBI severity levels. 
Even years post-TBI, patients were diagnosed with psychiatric disorders, with prevalence rates of Axis I 
disorders as high as 40% (more than 10 years post-TBI)45 and 65% (3 years post-TBI).54 Prevalence of 
anxiety ranged from 9–50% after on average 1.5–5 years of follow-up,44,50,54,66,72 and rates for depressive 
disorders were up to 21–57% after follow-up periods of on average 1.5–3 years.44,50,54,72 Long-term 
prevalence rates were almost all higher than (or equal to) the rates before TBI, in all studies that 
measured both pre-injury and long-term prevalence of psychiatric disorders.6,43-45,54,61,63,66,73,76 
Although the prevalence of dysthymia  after TBI was generally low (0–3% in 5 of the 8 studies),43,45,54,58,80 
a few studies also reported a prevalence rate of 0% (absence of disorder) for GAD, social phobia, PTSD, 
and bipolar disorder. These studies, however, had a long follow-up period (more than 30 years post-
TBI),45 a small sample size (n=16),68 or included solely patients admitted to neurosurgery68 or a TBI 
rehabilitation clinic.63 
 
Pooled prevalence estimates 
Figure 8.3 provides an overview of the overall pooled prevalence estimates per disorder by time point 
(also see Appendix Table 8.B). Highest variation in prevalence rates across studies were seen before TBI 
in agoraphobia (moderate heterogeneity: I2=66%, p=0.05), and depressive disorders (high 
heterogeneity: I2=82%, p<0.01). Highest pooled prevalence rates were retrieved for Axis I disorders 
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(n=5, 38% pre-TBI; n=6, 32% in the first year; n=3, 54% after one year), including anxiety disorders (n=6, 
19%; n=5, 21%; n=3, 36%), and depressive disorders (n=8, 13%; n=10, 17%; n=3, 43%). Overall, the 
pooled prevalence rates increased over time in all disorders, except panic disorder, PTSD, and dysthymia 
(slight decrease).  
 
Figure 8.3 Forest plot of pooled prevalence rates per psychiatric disorder 
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Axis I also includes disorders other than anxiety or depressive disorders (e.g. substance use, schizophrenia, psychotic disorders, dementia, 
etc. 
 
Risk factors 
In total, 30 articles assessed risk factors for psychiatric disorders, including 24 (71%) of the 34 reference 
studies and 6 related articles.2,50,52,54,83,84 The most often assessed risk factors were age (n=22), gender 
(n=19), education (n=18), marital or relationship status (n=12), and TBI severity or GCS (n=14). Other 
frequently studied factors were personal history of psychiatric disorders preceding TBI (n=11), 
employment, ethnicity, duration of PTA, and time post-injury (all n=10), history of alcohol or substance 
abuse before TBI (n=6), and involvement in litigation (n=6). Females,43,44,75,85 those without 
employment,5,60,86,93 and those with a history of psychiatric disorders5,43,49,51,60,74,75,80,84-87,89,99,103,107 or 
substance abuse pre-TBI11,49,75,87,99 were at higher risk for psychiatric disorders post-TBI (Table 8.5). 
Location of the brain lesion showed to be related to the risk of depressive disorders.51,60,62,100,102 Further, 
psychiatric disorders were associated with worse outcomes on measures like the Glasgow Outome Scale 
(GOS),49,87 Mini-Mental State Examination (MMSE),49,87 or complications such as post-concussion 
symptoms/disorder (PCS/PCD)59,92,97 and memory of the traumatic event.65,74,76 Contrasting findings 
were reported with respect to patients age, showing an increased risk of psychiatric disorders in 
older5,62,74,79,86,98,107 and younger11,49,87 patients. 
  
n<500 n=500-1000 n>1000
0% 20% 40% 60% 80%
Prevalence rate
0% 20% 40% 60% 80%
Prevalence rate
0% 20% 40% 60% 80%
Prevalence rate
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Table 8.5 Risk factors associated with psychiatric disorders post-TBI* 
Disorder Patient-related Injury-related Follow-up related 
Axis I Younger age (18–64 year)49,87 (2|8) More severe TBI43 (1|7) Shorter44, longer80 time 
post-injury (2|2) 
 Less education49,87 (2|6)  Poorer GOS49,87 (2|2) 
 Pre-injury unemployment5 (1|3)  Lower MMSE score49,87 
(2|2) 
 History of psychiatric disorders43,49,80,87 
(4|5) 
  
 History of alcohol consumption49,87 (2|2)   
Anxiety Older age5,79,86 (3|6) 
 
Less66, more (symptoms)68 
severe TBI (1|4) 
 
 Female gender43,44 (2|6)   
 Pre-injury unemployment86 (1|2)   
 Pre-injury anxiety disorders5,85,86 (3|4)   
ASD History of psychiatric disorders89 (1|2)  Shorter89, longer56 
hospitalisation (2|2) 
PTSD Older age74 (1|9) 
 
Higher LOC69 (PTSD severity)75 
(2|2) 
Shorter time post-
injury44 (1|4) 
 Female gender44 (PTSD severity)75 (2|5) Shorter PTA duration83 (1|8) PCS/PCD59,92,97 (3|3) 
 History of psychiatric disorders74,83 (PTSD 
severity)75 (3|4) 
 Memory of traumatic 
event65,74,76 (3|3) 
   Poorer GOSE83 (1|1), 
Lower QOLI83 (1|1) 
Depression Older age62,98 (2|12) Lesion location62,100,102 (3|3) Shorter44, longer85 time 
post-injury (2|5) 
 Female gender44,85 (2|11) Abnormal CT result98 (1|3)  
 Less education85 (1|11)   
 History of psychiatric disorders99,103 (2|6),  
depression85 (1|2) 
  
 History of substance abuse99 (1|4)   
MD Older107, younger (16–59 year)11 age (2|6) MVA10 (1|3) PCS/PCD59,97 (2|2) 
 Pre-injury unemployment60 (1|4) Lesion location51,60,100 (3|3)  
 (No)43 History of psychiatric disorders51 
(2|2), depression51,60,107 (3|3) 
  
 History of substance abuse11 (1|6)   
Axis I also includes disorders other than anxiety or depressive disorders (e.g. substance use, schizophrenia, psychotic disorders, dementia, 
etc.). 
* Only risk factors which appear to be significant in 2 or more studies were presented. 
In brackets: Number of studies in which the risk factor reached significance | Number of studies in which the risk factor was assessed. 
ASD: acute stress disorder; GOS: Glasgow Outcome Scale; MMSE: Mini-Mental State Examination; LOC: loss of consciousness; MD: major 
depression; MVA: motor vehicle accident; PCS/PCD: post-concussion symptoms/disorder (e.g. concentration deficits, dizziness, fatigue, 
headaches, sensitivity to sound, and visual disturbances); PTSD: post-traumatic stress disorder. 
 
8.4 DISCUSSION 
 
Our systematic review aimed to provide insight into the prevalence of, and risk factors for, anxiety 
disorders and depressive disorders post-TBI, collected with structured diagnostic interviews. Our 
findings showed that a substantial number of patients had a history of anxiety disorders (19%) or 
depressive disorders (13%) pre-TBI or were diagnosed with those disorders in the first year post-TBI 
(21% and 17%). Pooled prevalence estimates of psychiatric disorders increased over time and indicated 
that years post-TBI, half of the participants (54%) were diagnosed with Axis I disorders, including anxiety 
disorders (36%) or depressive disorders (43%). Females, those without employment, and those with a 
history of psychiatric disorders or substance abuse pre-TBI seem to be at higher risk for anxiety or 
depressive disorders post-TBI. 
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Quality of the evidence 
Several limitations of the included studies need to be considered. First, the studies faced difficulties in 
differential diagnosis of overlapping disorders (e.g. ASD and post-concussive effects) and overlapping 
symptoms between TBI and disorders, which may have led to higher89 or lower108 prevalence rates of 
disorders. The included studies, however, all used structured diagnostic interviews to examine the 
presence of psychiatric disorders according to standard criteria like the DSM or ICD. The use of 
structured diagnostic interviews by clinical experts (e.g. one trained psychiatrist or psychologist) enables 
more stringent assessment of psychiatric outcomes post-TBI than self-report measures.18 However, 
regardless of the method of assessment, patients may report more symptoms because of concerns 
about pending litigations.109 
Second, the history of psychiatric disorders pre-TBI was often retrospectively assessed (e.g. with use of 
the structured interview), in some studies even years post-TBI. Relying on recall of symptoms over such 
long periods may be less reliable.110  
Third, several studies reported on a small number of subjects,6,24,62,66,68,73,90,92 and their conclusions may 
not apply to all patients with TBI. Although most of the 34 included studies had difficulties in contacting 
and interviewing all eligible patients, there is a need for a thorough and reliable assessment of the 
psychiatric outcome in all survivors of a TBI. Participation rates may be increased by using face-to-face 
recruitment and data collection, using mail and Internet for contacting and informing patients, and 
lowering the participant burden (e.g. by conducting interviews at home).111  
 
Prevalence rates 
Consistent with findings in the literature,1-3 anxiety disorders (mainly PTSD) and depressive disorders 
(mainly MD) were the most common, frequently studied disorders post-TBI. 
There was considerable variation in the post-injury prevalence rates of disorders among the patient 
samples of the included studies. The wide variation in prevalence rates of pre- and post-injury 
prevalence rates of anxiety and depressive disorders between studies has been reported 
previously1,3,15,112 and can be explained by differences in study design, characteristics of the patients, 
definitions, methods of assessment, and measures used to assess the psychiatric outcomes. 
Our findings indicate that a history of psychiatric disorders before the TBI was common in TBI survivors, 
given that approximately 1 in 3 adults (38%) had pre-injury Axis I disorders (often including substance 
abuse disorder), 1 in 5 (19%) a history of anxiety disorders, and 1 in 8 (13%) a history of depressive 
disorders pre-TBI. According to our pooled prevalence estimates, prevalence rates of anxiety disorders 
were lower pre-TBI (19%) than in the first year post-TBI (21%). In contrast, three studies that reported 
on pre- and post-injury prevalence rates of depressive disorders, indicated prevalence of depressive 
disorders to be higher pre-TBI than in the first year post-TBI.5,57,58 In line with these findings, the included 
studies in our review that also reported on the community base rate of psychiatric disorders showed 
that patients with TBI had lower pre-injury rates of anxiety disorders than the general population (e.g. 
PTSD: 6% pre-TBI vs 8% in US adults43; 2% pre-TBI versus 6% in Australian population80), but higher pre-
injury rates of depressive disorders (e.g. MD: 17–20% pre-TBI versus 6% in US adults43,44; 14% pre-TBI 
versus 11% in Australian population80).  
Although a history of psychiatric disorders pre-TBI was common, several studies reported a substantial 
share of novel disorders.2,45,54 These studies showed that numerous participants experienced Axis I 
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disorders (78%), including anxiety disorders (74%) or depressive disorders (72%) for the first time post-
injury.45,54 However, a history of psychiatric disorders pre-TBI was significantly associated with a higher 
risk for psychiatric disorders in the aftermath of a TBI.5,43,49,51,60,74,75,80,85-87,89,99,103,107 
A few of the included studies reported on the prevalence of comorbid psychiatric disorders and 
indicated that 72–77% of those with a post-injury depressive disorder also had a comorbid anxiety 
disorder and 69% of those with an anxiety disorder also had a comorbid depressive disorder.54,60,80 
According to findings of Gould and colleagues, anxiety disorders tended to precede or emerge at the 
same time as depressive disorders.80 
Pooled prevalence estimates of psychiatric disorders indicated that psychiatric disorders did increase 
over time, even after mild TBI. The increase of prevalence rates of disorders over time was a 
phenomenon that was also found within some of the included studies.2,5 This may be explained by the 
ongoing stressors and problems that may occur after the traumatic event, which may add to the 
maintenance of disorders post-TBI.2,113 Additionally, the delayed onset of psychiatric disorders may 
occur because of psychosocial changes, given that after the physical recovery insight into social, 
cognitive, and emotional disability develops.80,114,115 Another explanation may be that a greater 
cognitive resource (e.g. higher education level before a TBI) may decrease the vulnerability to cognitive 
deficits post-TBI and may have a protective role in the development of psychiatric disorders.116 Although 
the included studies in our review assessed education level5,6,11,24,44,49,51,60-63,68,74,76,86,88,93,98 and pre-
morbid IQ24,68,107 as risk factors for psychiatric disorders post-TBI, only few of them reached significance 
showing less education to be associated with higher prevalence of anxiety and depressive disorders 
post-TBI.49,85,87 In contrast, longitudinal results of Ashman and colleagues showed that the risk of having 
an Axis I disorder decreased 3–6 years post-injury.44 However, Koponen and colleagues found high rates 
of current psychiatric disorders 30 years post-TBI,45 which suggests that the vulnerability of developing 
psychiatric disorders may remain throughout the life of a person with TBI. 
Our pooled estimates of depressive disorders (MD: 15% first year, 27% >1 year; dysthymia: 3% and 1%) 
were in line with those of a recent review of Osborn and colleagues, in which 27% of the TBI survivors 
were clinically diagnosed with MD and/or dysthymia post-TBI.18 We, however, computed pooled 
prevalence estimates over time, showing lower estimates of MD and dysthymia in the first year post-
TBI (15% and 3%), but higher estimates in the long-term (27% and 1%). Additionally, a review of Van 
Reekum and colleagues overall reported higher mean prevalence rates of MD and PTSD compared to 
our pooled estimates: MD 44%22 versus 15% in the first year and 27% after one year in our review; PTSD 
14%22 versus 14% and 7% in our review. Their review, however, did not specify prevalence of disorders 
over time, and included data from both structured diagnostic interviews and self-report measures.22 
Osborn and colleagues showed that, in comparison to structured diagnostic interviews, use of self-
report measures leads to far higher prevalence rates.18 
 
Risk factors 
The included studies in our review reported different directions of risk factors such as the patients’ 
age,11,107 TBI severity level,43,66,68 time post-injury,44,80,85 and length of stay in the hospital.56,89 However, 
these findings are not necessarily inconsistent. For example, in the studies that reported that younger 
people were more at risk of having a psychiatric disorder post-TBI, the younger group comprised all 
those aged 18–64 years,49,87 or 16–59 years.11 However, the relationship between age and psychiatric 
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disorders post-TBI is controversial, with studies showing contrasting findings on whether62,98 or not11 
older patients are at increased risk of psychiatric disorders post-TBI. 
Additionally, inconsistent findings were reported on TBI severity, because more-severe TBI was related 
to a higher risk for Axis I disorders43 and the number of anxiety symptoms,68 whereas less-severe TBI 
was related to higher risk for anxiety disorders.66 
The studies in our review tended towards higher prevalence rates of MD among patients with more-
severe TBI, as 8–18% of the patients with mild TBI received this diagnosis versus 7–63% in patients with 
all TBI severity levels. However, the severity of TBI has not emerged as a significant risk factor for 
depressive disorders in previous studies.5,18,61,63,66,86,96,99,105 
Female gender was identified as a risk factors for psychiatric disorders post-TBI in several studies.43,44,85 
This is underpinned by the fact that the included studies with a high share of women (≥70%, n=5) tended 
to report somewhat higher prevalence rates of anxiety disorders than the samples with relatively more 
men (on average 6–12% higher rates), OCD (2–6%), PTSD (3–8%), depressive disorders (4–12%), and 
MD (<1–5%). 
Finally, several studies included in this review reported depressive disorders being associated with 
lesion location, with higher rates of disorders in patients with left frontal abnormality,51,60,62,99,102 left 
anterior lesions,51,99,100,102 left51 or right hemisphere lesions,51,102 cortical lesions,51 and parieto-occipital 
lesions.51 Although investigations determining the relationship between lesion location and depressive 
symptoms have proven inconsistent,1 lesion site may influence the nature of depression, but does not 
fully explain the occurrence and severity of depressive disorders.117 
 
Strengths and limitations 
Our review adds to the knowledge on psychiatric outcomes of TBI in civilian adults, by providing pooled 
prevalence estimates over time and insight into the risk factors associated with the full spectrum of 
anxiety disorders and depressive disorders. Our findings are based on evidence from structured 
diagnostic interviews and emphasise that the prevalence of anxiety and depressive disorders post-TBI 
is high and persists over time. 
This review has limitations. First, because of our decision to only include studies on anxiety and 
depressive disorders post-TBI, other psychiatric outcomes (e.g. including substance use disorders, 
schizoaffective disorders, or psychotic disorders) were not specifically taken into account. Second, the 
review solely focused on the prevalence of psychiatric disorders post-TBI in civilian adults aged 16 years 
or older. Therefore, information on the prevalence of anxiety and depressive disorders among children 
or adolescents and military personnel is missing. Military personnel and veterans have a higher 
exposure to emotional trauma,25 and therefore show higher rates of psychiatric disorders (e.g. PTSD) 
than the civilian populations.26 Third, this review did not elaborate on the cognitive impairments (e.g. 
deficits in attention, processing speed, and working memory) or post-concussion symptoms (e.g. 
dizziness, fatigue, and headaches) which may contribute or interact with psychiatric outcome post-
TBI.79,107 Fourth, only a few of the studies included in this review reported on the percentage of novel 
disorders post-TBI.2,45,54,70 Research is needed to gain more insight into the prevalence of new versus 
recurrent anxiety disorders and depressive disorders post-TBI. Finally, it was difficult to compare study 
results because of the differences in study objectives, design, methodology, and study population, 
including differences in definitions of TBI, inclusion and exclusion criteria, and interviews used to assess 
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psychiatric disorders. Some of the studies in this review included participants with self-reported TBI (not 
medically documented) or from a variety of outpatient or rehabilitation settings. The studies assessed 
disorders in patients with varying TBI severity levels. Because mild TBI is likely to be very different from 
severe TBI on many aspects, pooling of the data across these TBI severity levels may lead to an under- 
or overestimation of the prevalence rates amongst different cohorts. In addition, some studies (n=3) 
reported prevalence over a period of time instead of point prevalence and sometimes used different 
diagnostic criteria. Research showed that the latter variation in diagnostic criteria surprisingly provided 
different prevalence estimates, despite the overlap between these criteria.18 All the previous factors 
might have influenced the prevalence estimates of anxiety disorders and depressive disorders provided 
in this review. To enable comparisons between studies, consensus should be reached on standard 
definitions (e.g. for TBI and TBI severity levels), study methods (e.g. which structured interview to use 
and which time points), and reporting styles (e.g. how to report on pre- and post-injury prevalence 
rates). 
 
Implications for practice and research 
Our review showed that, even years post-TBI, a substantial number of patients experience psychiatric 
disorders. This underscores the need for recognition and treatment of anxiety and depressive disorders 
in all health care settings.10,11,68 Ideally, the routine treatment of patients with TBI should include a 
psychiatric evaluation and follow-up. Overall, early identification and treatment of psychiatric disorders 
may enhance the recovery of TBI survivors, their capacity to work, their HRQL and functional outcome, 
and may reduce the high costs associated with disability in TBI.118-120 
As only a few of the studies included in this review reported on the percentage of novel disorders post-
TBI,2,45,54,70 research is needed to gain more insight into the prevalence of new versus recurrent anxiety 
and depressive disorders post-TBI. 
Additionally, because of the increased risk of psychiatric disorders over time, it is recommended to 
assess the psychiatric outcome of patients soon after TBI (within 1 month), and after 3, 6, 12, and 24 
months. 
Future studies on the psychiatric outcomes of TBI survivors should assess the prevalence of the full 
range of anxiety disorders and depressive disorders, with use of structured diagnostic interviews, and 
should investigate the increased risk for these disorders among females, the unemployed, and those 
with a history of psychiatric disorders pre-TBI.  
 
Conclusions 
Research conducted with the best available assessment instruments shows that a substantial number 
of patients encounter anxiety and depressive disorders pre- and post-TBI and that prevalence rates 
increase with time post-injury. The pooled prevalence estimates provide insight into the magnitude of 
anxiety disorders and depressive disorders post-TBI and indicate that these disorders persist over time. 
All health care settings should pay attention to the occurrence of psychiatric symptoms in the aftermath 
of TBI, especially in females, those without employment, and those with a history of psychiatric 
disorders or substance abuse pre-TBI. 
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APPENDIX 
 
Appendix 8.A Literature search strategies 
Date: January 15, 2015 
Update: November 2, 2015 
 January 15, 2015 November 2, 2015 
Database Records Unique records Records Unique, new records 
Embase.com  3623 3606 307  
Medline (OvidSP)  2288 511 173  
PsycINFO (OvidSP) 1448 461 107  
PubMed publisher  161 114 174  
Cochrane   69 15 2  
Google scholar 200 93 –  
Total  7782 4800 763 539 
 
Embase.com 
('brain injury'/exp OR 'brain injury assessment'/exp OR 'head injury'/exp OR concussion/exp OR coma/exp OR (((brain OR 
head OR crani* OR intracrani* OR skull* OR cerebr* OR capitis OR hemisphere*) NEAR/3  (injur* OR trauma* OR 
posttrauma* OR damag* OR lesion* OR fracture*)) OR concus* OR contus* OR neurotraum* OR tbi OR mtbi  OR 
coma*):ab,ti) AND (injury/exp OR 'posttraumatic stress disorder'/exp  OR accident/exp  OR emergency/exp OR 
'emergency care'/exp  OR 'emergency ward'/exp OR violence/exp  OR (trauma* OR posttrauma* OR injur* OR tbi OR mtbi 
OR accident* OR emergen* OR violen*):ab,ti) AND (anxiety/exp OR 'mood disorder'/de OR 'anxiety disorder'/exp OR 
depression/exp OR 'mental health'/de OR 'psychological well being'/de OR "Diagnostic and Statistical Manual of Mental 
Disorders" OR  (anxi* OR ((mood OR affective) NEAR/3 (disorder* OR disturb*)) OR phobi* OR agoraphobi* OR panic OR 
ocd OR (obsessi* NEAR/3 compulsi*) OR depress* OR ((posttraumatic  OR post-traumatic OR postconcussion* OR post-
concussional OR post-concussion) NEAR/3 (stress* OR syndrom*)) OR dysthymi* OR ptsd OR ((psychologic* OR 
neuropsychologic* OR emotion*) NEAR/3 (outcome* OR develop* OR well-being OR wellbeing OR disabil* OR progres* 
OR adjust* OR function* OR consequenc* OR sequel*)) OR 'mental health' OR dsm ):ab,ti) AND (prevalence/exp OR 
incidence/exp OR 'prediction and forecasting'/exp OR interview/exp OR epidemiology/de OR 'risk factor'/exp OR 
(incidenc* OR prevalen*  OR predict* OR prognos* OR interview* OR (risk NEAR/3 factor*) OR epidemiolog* OR 
((indicator* OR variable* OR characteristic* OR examination* OR assessment* OR measure* OR association* OR 
determinant*) NEAR/3 psycholog*) OR psychometric*):ab,ti ) NOT ([Conference Abstract]/lim OR [Letter]/lim OR 
[Note]/lim OR [Conference Paper]/lim OR [Editorial]/lim) AND [english]/lim NOT ([animals]/lim NOT [humans]/lim) 
 
Medline (OvidSP) 
(exp Craniocerebral Trauma/ OR Glasgow Coma Scale/ OR coma/ OR (((brain OR head OR crani* OR intracrani* OR skull* 
OR cerebr* OR capitis OR hemisphere*) ADJ3  (injur* OR trauma* OR posttrauma* OR damag* OR lesion* OR fracture*)) 
OR concus* OR contus* OR neurotraum* OR tbi OR mtbi  OR coma*).ab,ti.) AND (exp Wounds and Injuries/ OR exp Stress 
Disorders, Traumatic/  OR exp accidents/  OR exp Emergencies/ OR exp Emergency Treatment/  OR exp Emergency 
Service, Hospital/ OR exp violence/  OR (trauma* OR posttrauma* OR injur* OR tbi OR mtbi OR accident* OR emergen* 
OR violen*).ab,ti.) AND (exp anxiety/ OR exp mood disorders/ OR exp anxiety disorder/ OR exp depression/ OR exp 
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mental health/ OR Personal Satisfaction/ OR "Diagnostic and Statistical Manual of Mental Disorders" OR  (anxi* OR 
((mood OR affective) ADJ3 (disorder* OR disturb*)) OR phobi* OR agoraphobi* OR panic OR ocd OR (obsessi* ADJ3 
compulsi*) OR depress* OR ((posttraumatic  OR post-traumatic OR postconcussion* OR post-concussional OR post-
concussion) ADJ3 (stress* OR syndrom*)) OR dysthymi* OR ptsd OR ((psychologic* OR neuropsychologic* OR emotion*) 
ADJ3 (outcome* OR develop* OR well-being OR wellbeing OR disabil* OR progres* OR adjust* OR function* OR 
consequenc* OR sequel*)) OR mental health OR dsm ).ab,ti.) AND (exp prevalence/ OR exp incidence/ OR Prognosis/ OR 
exp Interviews as Topic/ OR epidemiology/ OR epidemiology.xs. OR exp risk factors/ OR (incidenc* OR prevalen*  OR 
predict* OR prognos* OR interview* OR (risk ADJ3 factor*) OR epidemiolog* OR ((indicator* OR variable* OR 
characteristic* OR examination* OR assessment* OR measure* OR association* OR determinant*) ADJ3 psycholog*) OR 
psychometric*).ab,ti. ) NOT (letter OR news OR comment OR editorial OR congresses OR abstracts).pt. AND english.la. 
NOT (exp animals/ NOT humans/) 
 
PsycINFO (OvidSP) 
(exp Head Injuries/ OR Brain Damage/ OR coma/ OR (((brain OR head OR crani* OR intracrani* OR skull* OR cerebr* OR 
capitis OR hemisphere*) ADJ3  (injur* OR trauma* OR posttrauma* OR damag* OR lesion* OR fracture*)) OR concus* OR 
contus* OR neurotraum* OR tbi OR mtbi  OR coma*).ab,ti.) AND (exp Injuries/ OR exp Posttraumatic Stress Disorder/  OR 
exp accidents/  OR exp trauma/ OR exp Emergency Services/ OR exp Emergency Management/  OR exp violence/  OR 
(trauma* OR posttrauma* OR injur* OR tbi OR mtbi OR accident* OR emergen* OR violen*).ab,ti.) AND (exp anxiety/ OR 
exp affective disorders/ OR exp anxiety disorders/ OR exp "Depression (Emotion)"/ OR exp mental health/ OR 
Satisfaction/ OR "Diagnostic and Statistical Manual" OR  (anxi* OR ((mood OR affective) ADJ3 (disorder* OR disturb*)) OR 
phobi* OR agoraphobi* OR panic OR ocd OR (obsessi* ADJ3 compulsi*) OR depress* OR ((posttraumatic  OR post-
traumatic OR postconcussion* OR post-concussional OR post-concussion) ADJ3 (stress* OR syndrom*)) OR dysthymi* OR 
ptsd OR ((psychologic* OR neuropsychologic* OR emotion*) ADJ3 (outcome* OR develop* OR well-being OR wellbeing 
OR disabil* OR progres* OR adjust* OR function* OR consequenc* OR sequel*)) OR mental health OR dsm ).ab,ti.) AND 
(Prognosis/ OR exp Interviews/ OR exp epidemiology/ OR exp risk factors/ OR (incidenc* OR prevalen*  OR predict* OR 
prognos* OR interview* OR (risk ADJ3 factor*) OR epidemiolog* OR ((indicator* OR variable* OR characteristic* OR 
examination* OR assessment* OR measure* OR association* OR determinant*) ADJ3 psycholog*) OR 
psychometric*).ab,ti. ) NOT book.pt. AND english.la. NOT (exp animals/ NOT humans/) 
 
PubMed publisher 
(Craniocerebral Trauma[mh] OR Glasgow Coma Scale[mh] OR coma[mh] OR (((brain OR head OR crani*[tiab] OR 
intracrani*[tiab] OR skull*[tiab] OR cerebr*[tiab] OR capitis OR hemisphere*[tiab]) AND  (injur*[tiab] OR trauma*[tiab] OR 
posttrauma*[tiab] OR damag*[tiab] OR lesion*[tiab] OR fracture*[tiab])) OR concus*[tiab] OR contus*[tiab] OR 
neurotraum*[tiab] OR tbi OR mtbi  OR coma*[tiab])) AND (Wounds and Injuries[mh] OR Stress Disorders, Traumatic[mh]  
OR accidents[mh]  OR Emergencies[mh] OR Emergency Treatment[mh]  OR Emergency Service, Hospital[mh] OR 
violence[mh]  OR (trauma*[tiab] OR posttrauma*[tiab] OR injur*[tiab] OR tbi OR mtbi OR accident*[tiab] OR 
emergen*[tiab] OR violen*[tiab])) AND (anxiety[mh] OR mood disorders[mh] OR anxiety disorder[mh] OR depression[mh] 
OR mental health[mh] OR Personal Satisfaction[mh] OR "Diagnostic and Statistical Manual of Mental Disorders" OR  
(anxi*[tiab] OR ((mood OR affective) AND (disorder*[tiab] OR disturb*[tiab])) OR phobi*[tiab] OR agoraphobi*[tiab] OR 
panic OR ocd OR (obsessi*[tiab] AND compulsi*[tiab]) OR depress*[tiab] OR ((posttraumatic  OR post-traumatic OR 
postconcussion*[tiab] OR post-concussional OR post-concussion) AND (stress*[tiab] OR syndrom*[tiab])) OR 
dysthymi*[tiab] OR ptsd OR ((psychologic*[tiab] OR neuropsychologic*[tiab] OR emotion*[tiab]) AND (outcome*[tiab] OR 
develop*[tiab] OR well-being OR wellbeing OR disabil*[tiab] OR progres*[tiab] OR adjust*[tiab] OR function*[tiab] OR 
consequenc*[tiab] OR sequel*[tiab])) OR mental health OR dsm )) AND (prevalence[mh] OR incidence[mh] OR 
Prognosis[mh] OR Interviews as Topic[mh] OR epidemiology[mh] OR epidemiology[sh] OR risk factors[mh] OR 
(incidenc*[tiab] OR prevalen*[tiab]  OR predict*[tiab] OR prognos*[tiab] OR interview*[tiab] OR (risk AND factor*[tiab]) 
OR epidemiolog*[tiab] OR ((indicator*[tiab] OR variable*[tiab] OR characteristic*[tiab] OR examination*[tiab] OR 
assessment*[tiab] OR measure*[tiab] OR association*[tiab] OR determinant*[tiab]) AND psycholog*[tiab]) OR 
psychometric*[tiab]) ) NOT (letter[pt] OR news[pt] OR comment[pt] OR editorial[pt] OR congresses[pt] OR abstracts[pt]) 
AND english[la] NOT (animals[mh] NOT humans[mh]) AND publisher[sb] 
 
Cochrane 
((((brain OR head OR crani* OR intracrani* OR skull* OR cerebr* OR capitis OR hemisphere*) NEAR/3  (injur* OR trauma* 
OR posttrauma* OR damag* OR lesion* OR fracture*)) OR concus* OR contus* OR neurotraum* OR tbi OR mtbi  OR 
coma*):ab,ti) AND ((trauma* OR posttrauma* OR injur* OR tbi OR mtbi OR accident* OR emergen* OR violen*):ab,ti) 
AND ((anxi* OR ((mood OR affective) NEAR/3 (disorder* OR disturb*)) OR phobi* OR agoraphobi* OR panic OR ocd OR 
(obsessi* NEAR/3 compulsi*) OR depress* OR ((posttraumatic  OR post-traumatic OR postconcussion* OR post-
concussional OR post-concussion) NEAR/3 (stress* OR syndrom*)) OR dysthymi* OR ptsd OR ((psychologic* OR 
neuropsychologic* OR emotion*) NEAR/3 (outcome* OR develop* OR well-being OR wellbeing OR disabil* OR progres* 
OR adjust* OR function* OR consequenc* OR sequel*)) OR 'mental health' OR dsm ):ab,ti) AND ((incidenc* OR prevalen*  
OR predict* OR prognos* OR interview* OR (risk NEAR/3 factor*) OR epidemiolog* OR ((indicator* OR variable* OR 
characteristic* OR examination* OR assessment* OR measure* OR association* OR determinant*) NEAR/3 psycholog*) 
OR psychometric*):ab,ti )  
 
Google scholar 
"brain|head|cranial|cerebral injury|trauma|fracture"|concussion|contussion|coma 
trauma|traumatic|posttraumatic|injury|accident anxiety|"mood disorder"|depression|"mental 
health"|psychological|dsm prevalence|incidence|epidemiology|"risk factor"|prognosis
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ABSTRACT 
 
Background While major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) 
are prevalent after traumatic brain injury (TBI), little is known about which patients are at risk 
of developing these psychiatric conditions. This systematic review examined predictors of and 
prognostic models for MDD and PTSD after TBI.  
 
Methods We searched EMBASE, MEDLINE, Cochrane Central, PubMed, PsycINFO, and Google 
Scholar in September 2015. We sought to include studies in adults with TBI reporting on 
predictors or prognostic models for MDD and/or PTSD, using structured diagnostic interviews. 
Risk of bias of individual studies was assessed using the QUIPS tool. Overall quality of the 
evidence underpinning predictors was assessed using a modified GRADE framework.  
 
Results We included 24 observational studies assessing predictors or prognostic models for 
MDD (n=14), PTSD (n=8) or both (n=2). Risk of bias ratings for most studies were acceptable 
although studies that developed a prognostic model (n=9) were at risk for statistical 
overfitting. MDD was probably predicted by pre-injury depression and may also be predicted 
by female gender, higher Glasgow Coma Scale and post-injury unemployment. PTSD was 
probably predicted by a shorter post-traumatic amnesia and a memory of the traumatic 
event. The effect of other possible predictors was uncertain due to low or very low quality 
evidence.   
 
Conclusions The overall evidence on predictors of MDD and PTSD after TBI is weak, and 
currently available prognostic models suffer from methodological shortcomings. Future 
prognostic models for PTSD and MDD should be developed with adequate sample size and 
solid methodology.   
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9.1 INTRODUCTION 
 
There is growing awareness that traumatic brain injury (TBI) may result in post-injury psychiatric 
disorders1,2 among which major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) 
are the most frequently reported.2-5 A recent systematic review reported pooled prevalence estimates 
of 21% for MDD and 17% for PTSD in the first year after TBI.5 
MDD and PTSD after TBI are associated with functional impairments1,6,7 and a decrease in health-related 
quality of life (HRQL).7 They subsequently interfere with rehabilitative interventions and negatively 
affect recovery from TBI.1 Moreover, they are associated with high direct and indirect costs,8-10 resulting 
in a tremendous individual and societal burden.  
Although the significance of MDD and PTSD after TBI is well established, the literature yields limited 
information about which patients are at risk of developing these psychiatric conditions. This knowledge 
could be used to flag patients who might benefit from additional monitoring or (preventive) therapeutic 
interventions, which have shown to be effective in people at risk for MDD and PTSD.11-13 Prognostic 
models, which combine a number of characteristics to predict MDD or PTSD, are particularly useful for 
this purpose.  
To our knowledge, there is currently no systematic review investigating prognostic models for MDD or 
PTSD in patients with TBI. There is one systematic review assessing psychological and psychosocial 
predictors of PTSD.14 The authors found that comorbid depression and anxiety, acute stress disorder 
(ASD), psychological processes (coping styles and attribution) and psychosocial variables (role 
impairment and reintegration) were associated with PTSD post-TBI.14 The authors however included all 
factors associated with PTSD, rather than factors predicting PTSD. It is therefore unclear whether these 
specific factors predicted PTSD or were predicted by PTSD. Moreover, they included self-reported 
measurements to diagnose PTSD. Self-reported measurements might not be reliable in a TBI population 
due to overlap between psychiatric symptoms and TBI symptoms, memory deficits, low self-awareness, 
attention problems and evidence that TBI patients tend to underestimate their problems.15-18 
Structured diagnostic interviews, such as the Structured Clinical Interview for Diagnostic and Statistical 
Manual of mental disorders (SCID), constitute a better alternative as these interviews distinguish 
psychopathology symptoms from TBI symptoms and are less influenced by TBI-related problems such 
as memory deficits.16  Potential predictors of MDD and PTSD are further discussed in three narrative 
reviews of psychiatric sequelae after TBI.1,6,16 However, these reviews did not include systematic 
searches nor analyses to identify predictors.  
The objective of this systematic review and meta-analysis was to examine predictors of and prognostic 
models for MDD and/or PTSD following TBI using structured diagnostic interviews. 
 
9.2 METHODS 
 
Information sources 
We conducted a comprehensive literature search on September 1st 2015. The search strategy was 
developed in consultation with a search expert using a combination of subheadings and text words 
(Appendix 9.A). The following databases were searched: EMBASE, MEDLINE, Cochrane Central, 
PubMed, PsycINFO and Google Scholar. Reference lists and citation indices of included papers and 
180 | Outcome after traumatic brain injury 
relevant reviews were further inspected to identify any additional publications. The search strategy was 
restricted to studies published in peer-reviewed English language journals. We did not use any date 
restrictions.  
 
Study selection 
We selected studies examining predictors of and/or prognostic models for MDD and PTSD after TBI. We 
used the following inclusion and exclusion criteria to determine eligibility of a study:  
Participants – Civilian adults (age ≥16) who sustained TBI. TBI was defined as “an alteration in brain 
function or other evidence of brain pathology, caused by an external force”.19 We included patients with 
mild, moderate and severe TBI (as defined by the study authors). 
Outcome measurement – MDD and/or PTSD according to the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) or International Classification of Diseases (ICD) classification systems. We 
restricted our inclusion criteria to studies that used a structured diagnostic interview to diagnose MDD 
and PTSD, as structured diagnostic interviews are regarded as the gold standard in diagnosing 
psychopathology.17 Moreover, structured diagnostic interviews are less influenced by potential memory 
deficits, low self-awareness and over- or underestimation by TBI patients.   
Predictors – We selected studies that examined at least one predictor of or prognostic model for MDD 
or PTSD after TBI. To be included, studies had to report at least one of the following: 1) baseline 
differences between the diagnosed and undiagnosed groups, 2) descriptive statistics (e.g. results t-test, 
chi square test, p-value) or 3) results of the prognostic model (e.g. odds ratio, Nagelkerke R2). To be 
included as a predictor, these factors must have preceded the diagnosis of MDD or PTSD. Preceding was 
defined as either 1) being measured earlier than the psychiatric diagnose or 2) obviously preceding the 
diagnosis such as gender, age and computed tomography (CT) abnormalities. Prognostic models were 
defined as models that combined at least two factors to predict a clinical outcome,20,21 in our case MDD 
or PTSD. 
Study design – We included retrospective- and prospective cohort studies, cross-sectional studies, and 
case-control studies. 
  
Data extraction and assessment of risk of bias 
One author (MC or ASc) screened citations on title and abstract, and then again on full-text, excluding 
those that did not meet the inclusion criteria. Any doubts were resolved by consulting a senior member 
of the team (JH or SP). As an audit of performance, a random 20% of the full text screening was repeated 
by the other reviewer (MC or ASc) and concordance rates were calculated accordingly. The search 
process was documented according to the Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) flowchart.22  
We developed a data extraction form based on the Critical Appraisal and Data Extraction for Systematic 
Reviews of Prediction Modelling Studies (CHARMS) checklist23 and subsequently extracted information 
on type of prediction modelling study, target population, participants, outcome measurements, 
candidate predictors, sample size, handling of missing values and model development methods. We 
additionally extracted baseline information on univariable associations between predictors and 
outcome by collecting means and standard deviation (SD) for MDD+/PTSD+ and MDD-/PTSD- group 
(continuous predictors) or number of patients with and without the predictor in MDD+/PTSD+ and 
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MDD-/PTSD- groups (categorical predictors). We further extracted univariable and multivariable 
statistics and effect measurements, if available.  
Risk of bias was assessed using the Quality in Prognostic Studies (QUIPS) risk of bias tool. The QUIPS has 
been recommended by the Cochrane Prognosis Methods Groups and has acceptable inter-rater 
reliability.24 We included information on the following domains: study participation, study attrition, 
prognostic factor measurement, outcome measurement, study confounding and statistical analysis and 
presentation. Each domain was subsequently rated as ‘low’, ‘moderate’ or ‘high’ risk of bias. A domain 
obtained the score ‘low risk’ if all individual items of the domain were rated as ‘low risk’. A domain was 
rated as ‘moderate risk’ if at least one and maximum 50% of the items implied a high risk of bias or an 
unknown risk of bias, and a study received a score of high risk if >50% of the items implied a high risk of 
bias or an unknown risk of bias. We applied a quality threshold for study inclusion in the meta-analyses; 
i.e. studies were omitted from the meta-analyses if they obtained a high score on at least two out of six 
QUIPS domains. Such a strategy is recommended by Cochrane.25  Since we performed the meta-analyses 
with univariable predictors, we omitted studies with a high score on at least two out of five QUIPS 
domains, excluding study confounding. Study confounding indicates whether the effect of the 
predictor(s) studied might be explained by other variables and is therefore not relevant for univariable 
associations.  
The data extraction and risk of bias were done independently by one author (MC) with the data and 
decisions checked by a second author (ASc). Any discrepancies were resolved by discussion with a senior 
member of the team (SP).  
 
Data synthesis  
We performed meta-analyses of univariable predictors of MDD and PTSD. Predictors were included in 
the meta-analysis if univariable data (mean (SD) or numbers in MDD+/PTSD+ and MDD-/PTSD- groups) 
were reported in two or more studies measuring the same predictor. Predictors were excluded from 
the meta-analyses if a study measured the predictor differently from any other study (e.g. age 
dichotomised into two age groups instead of continuous) or obtained a high risk of bias on at least two 
QUIPS domains (excluding confounding). Predictors that were not included in the meta-analyses were 
narratively described and their results were included in the overall rating of the effect. If a study 
assessed predictors for multiple time points or multiple outcomes (e.g. chronic depression, late onset 
depression and recovered depression) scores were combined, or if this was not possible, the time point 
or outcome that was closest to that in the other studies in the same meta-analysis was chosen. We used 
Review manager (Revman) version 5.326 to perform the meta-analyses. For all analyses, random effect 
models were used as we expected heterogeneity in time span and measurements. For dichotomous 
predictors, we reported the pooled odds ratio (pOR) and confidence interval (CI) and for continuous 
predictors, we reported the mean difference (MD) and CI. Heterogeneity was determined using I2. 
Heterogeneity was defined as high when I2 was ≥ 50% (substantial heterogeneity according to 
Cochrane27). In that case, pooled results should not be calculated, or at the very least, be interpreted 
with caution.  
Prognostic models of MDD and PTSD were narratively described by comparing model performance (e.g. 
Area Under the Receiver Operating Curve (AUC) / Nagelkerke R2 / calibration) and methods (e.g. number 
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of candidate predictors). We also narratively described the effect of individual predictors corrected for 
other variables in the model.  
 
Assessing the quality of evidence  
We used an approach modified from the GRADE framework28 to assess the overall quality of evidence 
underpinning the identified predictors of and prognostic models for MDD or PTSD.29,30 For every 
predictor that was assessed in at least two studies including at least 200 patients in total, we provided 
summary information from the meta-analysis, narrative synthesis and multivariable analysis, together 
with a GRADE rating of the overall quality. The quality of predictors that were studied in less than two 
studies or less than 200 patients in total, was on forehand rated as ‘very low’ and therefore not included 
in the GRADE assessment.   
According to the GRADE approach, quality of the evidence can be rated as high, moderate, low or very 
low. Since we included predominately exploratory studies that identified potential prognostic factors, 
which may be vulnerable to type I errors,29  we started our GRADE rating at ‘moderate quality’ instead 
of ‘high quality’. The GRADE rating was subsequently upgraded or downgraded according to the 
evaluation of study limitations, inconsistencies, indirectness, imprecision, publication bias, effect size 
and dose-response effects. See Huguet and colleagues29 and Iorio and colleagues30 for more information 
about these criteria. GRADE rating was performed by one review author (MC) and checked by a second 
review author (ASy), both of whom were trained in the GRADE approach. The pooled results and 
narrative syntheses for each predictor, along with its GRADE rating (with reasons), were presented in 
table form.  
 
Multiple publications 
Multiple publications refer to more than one article that has been written based on the same study 
data.31 Multiple publications were dealt with by selecting one main study based on the following criteria: 
1) the study that uses multivariable analyses or developed a prognostic model; 2) the study with the 
largest number of patients included; 3) the study with the largest numbers of predictors. Any other 
articles based on the same study database were used to extract any additional predictors. 
 
9.3 RESULTS 
 
Study selection 
A total of 8,449 citations were identified through the electronic search strategy (Figure 9.1). After 
removing duplicates, 5,374 were screened on title and abstract and 5,075 citations were excluded. We 
obtained 299 citations in full-text of which 270 were subsequently excluded. The most common reason 
for exclusion was using self-reported measurements instead of a structured diagnostic interview 
(n=140). The 20% audit on full-text screening obtained a concordance rate of 100% between two review 
authors. Five additional citations were found via reference lists and citation indices. We included 24 
studies (reported in 34 publications) in the narrative synthesis. Of these, 17 studies were included in 
the meta-analysis. 
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Figure 9.1 PRISMA flowchart of the selection process 
 
Figure is adapted from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
MDD: Major Depressive Disorder; PTSD: Posttraumatic Stress Disorder; TBI: traumatic brain injury. 
 
Study characteristics 
Of the 24 studies included, the majority (n=15) were prospective cohort studies.17,32-45 Four studies used 
a retrospective cohort,46-49 three a cross-sectional design,50-52 and two were case-control studies.3,53 
Studies were published between 1992 and 2015 and were conducted all over the globe, but mainly in 
high-income countries such as the United States (n=7) and Australia (n=4). The large majority of studies 
derived their patients from a single hospital or rehabilitation center (n=20).3,17,32-39,41-44,46-50,52  
Fourteen studies examined predictors of MDD,3,17,33,37-39,41-43,47,48,51-53 eight studies examined predictors 
of PTSD32,34-36,44-46,49 and two studies examined both.40,50 Nine studies included multiple predictors in a 
prognostic model to predict MDD (n=5), PTSD (n=3) or both (n=1).  
Studies included on average 117 patients (range 16 to 402). Studies that assessed predictors of MDD 
included on average 24 (range 9 to 48) patients with MDD (‘cases’) and 67 patients without MDD. 
Studies that assessed predictors of PTSD included on average 32 (range 7 to 127) patients with PTSD 
(‘cases’) and 132 patients without PTSD. The majority of studies included predominately male patients 
with a mean age between 30 and 40 years. Motor vehicle accidents (MVA) were the most reported 
cause of injury.  
Most predictors were measured during emergency department (ED) visit or very soon after discharge. 
Outcome was measured between one month and six years post-injury with the majority of studies 
measuring MDD/PTSD between three months and one year post-injury (Table 9.1).  
Papers identified through 
database searching 
(n=8449)
Papers after duplicates 
removed (n=5374)
Papers excluded
(n=3075)
Papers screened title and 
abstract (n=5374)
Papers excluded
(n=5075)
Papers where full-text 
assessed for eligibility 
(n=299)
Papers excluded after full-text 
assessed (n=270), with reasons
No TBI (n= 51)
No PTSD/MDD (n=19)
Study design (n=16)
No civilians (n=1)
No adults (n=1)
No structured interview (n=140)
No predictors (n=42)
Papers included in 
qualitative synthesis
(n=34; 24 unique studies)
Additional papers identified 
through reference lists and 
citation indices (n=5)
Papers included in meta-
analysis
(n=17; 17 unique studies)
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Risk of bias of the studies 
The majority of studies (n=16)3,17,33,35,37,38,40,43-45,47,49,51-54 were scored as high risk of bias for study 
confounding because they only assessed the effect of predictors in univariable analyses (Table 9.2). It is 
therefore unknown whether the effect of the predictor is independent of other factors. As we sought 
to perform a meta-analysis with univariable data, we did not exclude any studies based on a high risk of 
study confounding from the meta-analysis.  
Except for the high risk of study confounding, methodological quality of the included studies was 
acceptable. Study participation17,40,51 and attrition37,43,49 were rated at high risk of bias in three studies. 
Additionally, one study was judged at high risk of bias for prognostic factor measurement3 and outcome 
measurement49, and five studies were rated at high risk of bias on statistical analysis and 
reporting.3,39,44,46,49 Nevertheless, the majority of studies obtained a moderate risk of bias score for two 
or three domains. Two studies3,49 were rated at high risk on two out of five (excluding study 
confounding) domains and were therefore omitted from the meta-analyses. 
 
Table 9.2 Risk of bias assessment 
Study 
Study 
participation 
Study 
attrition 
Prognostic 
factor 
measurement 
Outcome 
measurement 
Study 
confounding 
Statistical 
analyses and 
presentation 
Alway, Y. (2015) Moderate Moderate Low Low Low Low 
Ashman, T.A. (2004) Moderate Moderate Moderate Low Low Moderate 
Barker-Collo, S. (2013) Moderate Moderate Low Low High Low 
Bryant, R.A. (1998) Low Low Low Low High Low 
Bryant, R.A. (2000) Low Moderate Low Low High Low 
Caspi, Y. (2006) Low Moderate Low Low Low High 
Deb, S. (2007) Low High Low Moderate High Low 
Diaz, A.P.  (2012) Low Low Low Low High Low 
Federoff, J.P. (1992) Low Low Low Low High Low 
Gil, S. (2005) Low Moderate Low Low Low Low 
Gould, K.R. (2011) Low Moderate Low Low Low High 
Hibbard, M.R. (1998) High Moderate Moderate Low High Moderate 
Jorge, R.E. (2004) Low Low Low Low High Low 
Kennedy, R.E. (2005) High Moderate Low Low High  Low 
Koponen, S. (2002) Moderate Moderate Moderate Low High Low 
Levin, H.S. (2005) Low Moderate Low Low Low Low 
Mauri, M.C. (2014) Moderate Low High Low High High 
Rao, V. (2010) High Low Low Low High Moderate 
Rapoport, M.J. (2003) Moderate Low Moderate Low Low Low 
Rapoport, M.J. (2005) Moderate Low Moderate Low High Low 
Reekum, R. (1996) Moderate High Low Low High Low 
Roitman, P. (2013) Moderate Low Moderate Low High High 
Turnbull, S.J. (2001) Moderate High Moderate High High High 
Whelan-Goodinson, R. 
(2010) 
Moderate Low Low Low Moderate Moderate 
Table presents risk of bias assessment according to the Quality in Prognostic Studies (QUIPS) tool. 
  
Predictors of MDD and PTSD  
The included studies examined a total of 109 predictors of MDD and 54 predictors of PTSD (Figure 9.2). 
Age and gender were most often assessed. The majority of predictors were assessed in only one study. 
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Figure 9.2 Frequency of predictors of MDD and PTSD following TBI 
  
Figure shows how frequent predictors were studied across the included studies. For example, for MDD one predictor (age) is studied in 
fourteen studies and one predictor (gender) is studied in thirteen studies. The majority of predictors (e.g. MRI abnormalities) were 
assessed in one study. 
 
Predictors of MDD 
In the meta-analysis of univariable data, we found that the presence of a pre-injury depression was 
associated with a higher odds of developing MDD in five studies of 470 patients (pOR=3.86; 95%CI [2.26 
– 6.59], moderate quality evidence, Table 9.3). This was confirmed by one of the studies in the narrative 
synthesis. Two studies42,48 included pre-injury depression in a multivariable model. One study48 reported 
that the odds of MDD was more than five times higher in those with a pre-injury depression compared 
to those without a pre-injury depression (OR=6.5, p<0.01), while the other study42 reported an opposite 
effect (OR=0.28, p>0.05, Table 9.3 and 9.4). Overall, the evidence for pre-injury depression as a 
predictor for MDD was rated as moderate, meaning that pre-injury depression probably predicts MDD 
and that we are moderately confident in the effect estimate.  
Three other predictors were found to be associated with MDD based on their pooled results. These 
include female gender (pOR=1.78; 95%CI [1.22 – 2.60], 9 studies, 786 participants, low quality 
evidence), higher GCS (MDadmission GCS=0.49; 95%CI [0.02 – 0.97]; MD24h GCS=0.13; 95%CI [–1.29 – 1.56], 4 
studies, 289 participants, very low quality evidence) and post-injury unemployment (pOR=2.04; 95%CI 
[1.10 – 3.79], 3 studies, 211 participants, very low quality evidence). For GCS, we found that MDD is 
more common in those with moderate TBI (GCS 9–12) compared to those with severe TBI (GCS 3–8, 
Appendix 9.B). However, the quality of the evidence underpinning all these associations was judged as 
low or very low, meaning that we are (very) uncertain about these estimates and therefore cannot make 
firm conclusions about the role of female gender, higher GCS and post-injury unemployment in the 
prediction of MDD. 
Other possible predictors of MDD studied were: age, education, race, marital status, income, pre-injury 
psychiatric disorder, pre-injury alcohol or substance abuse, pre-injury unemployment, family history of 
psychiatric disorders, pre-injury TBI, mechanism of injury, posttraumatic amnesia (PTA), bodily injuries, 
computed tomography (CT) abnormalities and post-injury litigation situation (Table 9.3). None of these 
predictors showed a significant association with MDD on pooled or narratively synthesised estimates. 
In addition, the quality of the evidence for these predictors was rated as either low or very low, meaning 
that we are (very) uncertain about these estimates. This means that, while we have no evidence to 
suggest they play a role in the development of MDD, it would be premature at this stage to conclude 
that they do not. The forest plots of the meta-analyses and narrative synthesis are presented in 
Appendix 9.B and 9.C. 
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Predictors of PTSD 
In the meta-analysis of univariable data, PTA was associated with PTSD in three studies of 477 patients 
(MD –8.07;95%CI [–15.46 – –0.69], moderate quality evidence, Table 9.3). The association was also 
found in one study34 that used a multivariable model, although the association was no longer statistically 
significant (OR=0.98; p>0.05). Patients with a memory of the traumatic event were more likely to 
develop PTSD than those without a memory of the event in two studies in both univariable analysis 
(pOR=5.15; 95%CI [2.37 – 11.21], 240 patients, moderate quality evidence) and in a multivariable model 
(ORs 2.2 and 2.8, both p<0.05). Evidence for PTA and memory of the traumatic event were rated as 
moderate quality, meaning that they probably predict PTSD and that we are moderately confident in 
the effect estimates.  
Other possible predictors include age, education, pre-injury psychiatric disorders and loss of 
consciousness (Table 9.3). The quality of evidence underpinning these predictors was rated as either 
low or very low. This means that we are (very) uncertain about these estimates and it would be 
premature to conclude that any of these predictors do or indeed, do not play a role in the development 
of MDD. The forest plots of the meta-analyses and narrative synthesis are presented in Appendix 9.B 
and 9.C. 
 
Prognostic models of MDD and PTSD  
Six studies used a multivariable model to predict MDD (Table 9.4). On average, models included 6.3 
(range 1.2–22) cases for every predictor in the model. None of the studies described whether there 
were missing values in predictors and if so, how they were handled. Nagelkerke R2 was calculated in 
three models,39,42,48 and ranged from 0.18–0.35. The Area Under the Receiver Operating Curve (AUC) 
was calculated in one study41 and indicated good discriminative ability (AUC=0.86). This model included 
age, depressive symptoms after one week post-injury and CT results.  
Four studies used a multivariable model to predict PTSD (Table 9.4). Models included on average 7.7 
(range 1.1–19) cases per predictor. Again, none of the studies described how they handled missing 
values in predictors. Nagelkerke R2 was reported for two models32,46 and ranged from 0.38–0.42. Both 
models included memory of the traumatic event and history of psychiatric disorders.  
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9.4 DISCUSSION 
 
This systematic review provides an overview of predictors of and prognostic models for MDD and PTSD 
following TBI. We included 24 studies and found that pre-injury depressive disorder is a probable 
predictor of MDD. Additionally, female gender, higher GCS and post-injury unemployment may also be 
predictors of MDD but the low or very low quality of the evidence precludes firm conclusions. PTSD was 
probably predicted by a shorter PTA and a memory of the traumatic event. Only a few studies used a 
multivariable model to predict MDD or PTSD, of which the majority was of limited quality. All other 
studied predictors were non-significant and graded as low or very low quality, precluding firm 
conclusions.  
 
Quality of the evidence 
This systematic review included studies over the last 23 years from all over the globe and therefore 
provides a complete overview of current knowledge about predictors and prognostic models for MDD 
and PTSD following TBI. Some notes should however be made regarding the completeness and 
applicability of the evidence. Firstly, the large majority of predictors were examined in only one study 
and therefore could not be included in our meta-analyses. For many predictors, we consequently cannot 
draw conclusions. A possible solution might have been to include studies with all self-reported outcome 
measurements since these studies are more common and usually include more patients. However, self-
reported measurements are less reliable in TBI patients.14-16 A 2006 study found that the diagnosis of 
PTSD varied from 59–3% when using self-reported measurements and structured diagnostic interviews 
respectively.18  
Secondly, as only a minority of studies used a multivariable model, the majority of our results are based 
on univariable associations. As a consequence, we cannot exclude the possibility that some of the 
associations we found were influenced by other factors. Lastly, the majority of studies included patients 
from a single site, limiting generalisability of results in prognostic research.55 
The risk of bias of most studies developing prognostic models was high. Models included on average six 
to eight cases for every predictor, while it is recommended to include at least ten.56,57 Including too 
many predictors enhances the risk of finding too extreme estimates (‘statistical overfitting’), limiting 
generalisability of findings.58 Additionally, the majority of studies did not report how they handled 
missing data and how they selected candidate predictors. Although this is common in prognostic studies 
in TBI,55 it may have resulted in bias, further limiting generalisability. For the studies on predictors, the 
risk of bias of included studies was acceptable, except for the high risk of study confounding.  
In terms of quality of the evidence for each predictor, the majority was rated as ‘very low’, indicating 
that we are very uncertain about the estimates. This was mainly due to study limitations, inconsistencies 
in results across studies, small number of studies and small sample sizes. It would however be difficult 
to obtain high evidence ratings in this research area since studies are usually underpowered due to 
relatively low prevalences of psychiatric disorders in combination with the use of labor-intensive 
structured diagnostic interviews. Three predictors obtained a moderate quality score. In all cases this 
was because we upgraded for a moderate or high effect size according to the GRADE criteria. It can 
however be debated whether the evidence of studies with a moderate or large effect size is indeed 
stronger than that of studies with a smaller effect size. Large effect sizes can also indicate random errors 
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or biases. Whether the size of an effect indicates high quality merely depends on whether the effect 
size is commensurate with prior knowledge rather than whether the effect size is above a certain cut-
off point.59   
 
Predictors of MDD and PTSD  
We found that MDD was probably associated with the presence of a pre-injury depression, which might 
be due to the high recurrence rates in MDD. A large prospective study reported that even 85% of the 
patients with prior MDD developed a new MDD episode during a 15 years follow-up period.60 
Recurrence of MDD can be triggered by a stressful life event, such as a TBI, although causation is usually 
multifactorial.61,62  
We further found a possible association between female gender and the likelihood of developing MDD. 
This is in line with systematic reviews about gender and depression in the general population; females 
approximately have a twice as high risk of developing major depression as males.63,64 Higher GCS, 
referring predominately to moderate TBI patients compared to severe TBI patients, might also be 
associated with a higher odds of MDD. A recent study about HRQL after TBI also reported a lower quality 
of life in patients with moderate TBI than in patients with severe TBI.65 The authors elaborated that this 
might be caused by severe TBI patients’ appreciation about being alive, which might outweigh 
difficulties caused by the TBI and thereby influence their quality of life to a lesser extent compared to 
patients with moderate TBI. It could however also be explained by potential selective lost to follow-up 
among severe TBI patients with severe psychopathology or differences in rehabilitative treatment 
interventions between moderate and severe TBI patients. Lastly, MDD was more prevalent among those 
reporting post-injury unemployment. This has also been shown in systematic reviews in the general 
population.66,67 Unemployment can results in reduced social interactions and status which may 
subsequently result in depression.68 Unemployment is also related to a lower socio-economic status, 
which is also associated with a higher risk of depression.69  
PTSD was more likely among patients with a shorter PTA and those with a memory of the traumatic 
event. It is suggested that amnesia for the traumatic events minimises the establishment of cognitive 
representations and so reduces the likelihood of intrusive symptoms.46 There are no other studies yet 
investigating this association.  
 
Strengths and limitations 
Strengths of this systematic review include the comprehensive search strategy, the restriction to 
structured diagnostic interviews and the use of GRADE to evaluate the quality of the evidence. This 
novel approach provides an explicit, transparent and rigorous assessment of the strength of the 
evidence of predictors.30 Additionally, we combined results from the meta-analyses, narrative syntheses 
and multivariable models to obtain conclusions about the significance of predictors. We thereby 
integrated all available sources of evidence.  
The use of meta-analytic techniques might have been a limitation in this review since there was 
between-study variation in time span, TBI severity and outcome measurement. This might have resulted 
in estimates that are difficult to interpret. However, a meta-analysis is the most adequate and efficient 
possibility to provide insight in prognosis of psychiatric sequelae after TBI. A second limitation concerns 
our screening process, which was conducted by one study author. We however performed an audit and 
202 | Outcome after traumatic brain injury 
found a 100% concordance rate between study authors, indicating that screening by two independent 
reviewers would probably not have resulted in the inclusion of any additional studies. A last limitation 
is that we only included studies published in peer-reviewed English language journals.  
 
Implications for practice and research 
The results of this systematic review imply that there is still limited knowledge about which patients 
develop MDD and PTSD after TBI. We therefore cannot recommend yet which patients should receive 
additional follow-up or preventive treatment and advise physicians to be aware in all patients that 
sustained TBI. Physicians could be extra aware in those with a pre-injury history of depression. 
Additionally, female patients, those with a higher GCS (predominately moderate TBI patients) and those 
who are unemployed, might be at enhanced risk of developing MDD. Furthermore, patients with a 
shorter PTA and a clear memory of the traumatic event might be at higher risk of developing PTSD post-
TBI.  
 
More research is needed to confirm the relevance of these predictors of MDD and PTSD after TBI, and 
develop a prognostic model that could be implemented in hospitals and rehabilitation centers. Future 
prognostic studies should ideally include a large sample size and a limited set of candidate predictors. 
Selection of candidate predictors could be based on current review, theory or clinical knowledge about 
aetiology of psychiatric disorders. Additionally, the confirmation of specific predictions among different 
patient samples is critically important to increase our knowledge about predictors of psychiatric 
sequelae post-TBI.  
 
Conclusions 
Our systematic review showed that MDD after TBI was predicted by gender, pre-injury depressive 
disorder, GCS and post-injury unemployment while PTSD was predicted by PTA and memory of the 
traumatic event.  However, currently available prognostic models of MDD and PTSD after TBI suffer 
from methodological shortcomings. These findings, together with clinical knowledge about aetiology of 
psychiatric disorders, could form the basis for future development of a prognostic model from a large 
sample of TBI patients using solid methodology.  
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APPENDIX 
 
Appendix 9.A Literature search strategy 
Date: September 1, 2015 
 
Embase.com  
('brain injury'/exp OR 'brain injury assessment'/exp OR 'head injury'/exp OR concussion/exp OR coma/exp OR (((brain OR 
head OR crani* OR intracrani* OR skull* OR cerebr* OR capitis OR hemisphere*) NEAR/3  (injur* OR trauma* OR 
posttrauma* OR damag* OR lesion* OR fracture*)) OR concus* OR contus* OR neurotraum* OR tbi OR mtbi  OR 
coma*):ab,ti) AND (injury/exp OR 'posttraumatic stress disorder'/exp  OR accident/exp  OR emergency/exp OR 
'emergency care'/exp  OR 'emergency ward'/exp OR violence/exp  OR (trauma* OR posttrauma* OR injur* OR tbi OR mtbi 
OR accident* OR emergen* OR violen*):ab,ti) AND (anxiety/exp OR 'mood disorder'/de OR 'anxiety disorder'/exp OR 
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depression/exp OR 'mental health'/de OR 'psychological well being'/de OR "Diagnostic and Statistical Manual of Mental 
Disorders" OR  (anxi* OR ((mood OR affective) NEAR/3 (disorder* OR disturb*)) OR phobi* OR agoraphobi* OR panic OR 
ocd OR (obsessi* NEAR/3 compulsi*) OR depress* OR ((posttraumatic  OR post-traumatic OR postconcussion* OR post-
concussional OR post-concussion) NEAR/3 (stress* OR syndrom*)) OR dysthymi* OR ptsd OR ((psychologic* OR 
neuropsychologic* OR emotion*) NEAR/3 (outcome* OR develop* OR well-being OR wellbeing OR disabil* OR progres* 
OR adjust* OR function* OR consequenc* OR sequel*)) OR 'mental health' OR dsm ):ab,ti) AND (prevalence/exp OR 
incidence/exp OR 'prediction and forecasting'/exp OR interview/exp OR epidemiology/de OR 'risk factor'/exp OR 
(incidenc* OR prevalen*  OR predict* OR prognos* OR interview* OR (risk NEAR/3 factor*) OR epidemiolog* OR 
((indicator* OR variable* OR characteristic* OR examination* OR assessment* OR measure* OR association* OR 
determinant*) NEAR/3 psycholog*) OR psychometric*):ab,ti ) NOT ([Conference Abstract]/lim OR [Letter]/lim OR 
[Note]/lim OR [Conference Paper]/lim OR [Editorial]/lim) AND [english]/lim NOT ([animals]/lim NOT [humans]/lim) 
 
Medline (OvidSP)   
(exp Craniocerebral Trauma/ OR Glasgow Coma Scale/ OR coma/ OR (((brain OR head OR crani* OR intracrani* OR skull* 
OR cerebr* OR capitis OR hemisphere*) ADJ3  (injur* OR trauma* OR posttrauma* OR damag* OR lesion* OR fracture*)) 
OR concus* OR contus* OR neurotraum* OR tbi OR mtbi  OR coma*).ab,ti.) AND (exp Wounds and Injuries/ OR exp Stress 
Disorders, Traumatic/  OR exp accidents/  OR exp Emergencies/ OR exp Emergency Treatment/  OR exp Emergency 
Service, Hospital/ OR exp violence/  OR (trauma* OR posttrauma* OR injur* OR tbi OR mtbi OR accident* OR emergen* 
OR violen*).ab,ti.) AND (exp anxiety/ OR exp mood disorders/ OR exp anxiety disorder/ OR exp depression/ OR exp 
mental health/ OR Personal Satisfaction/ OR "Diagnostic and Statistical Manual of Mental Disorders" OR  (anxi* OR 
((mood OR affective) ADJ3 (disorder* OR disturb*)) OR phobi* OR agoraphobi* OR panic OR ocd OR (obsessi* ADJ3 
compulsi*) OR depress* OR ((posttraumatic  OR post-traumatic OR postconcussion* OR post-concussional OR post-
concussion) ADJ3 (stress* OR syndrom*)) OR dysthymi* OR ptsd OR ((psychologic* OR neuropsychologic* OR emotion*) 
ADJ3 (outcome* OR develop* OR well-being OR wellbeing OR disabil* OR progres* OR adjust* OR function* OR 
consequenc* OR sequel*)) OR mental health OR dsm ).ab,ti.) AND (exp prevalence/ OR exp incidence/ OR Prognosis/ OR 
exp Interviews as Topic/ OR epidemiology/ OR epidemiology.xs. OR exp risk factors/ OR (incidenc* OR prevalen*  OR 
predict* OR prognos* OR interview* OR (risk ADJ3 factor*) OR epidemiolog* OR ((indicator* OR variable* OR 
characteristic* OR examination* OR assessment* OR measure* OR association* OR determinant*) ADJ3 psycholog*) OR 
psychometric*).ab,ti. ) NOT (letter OR news OR comment OR editorial OR congresses OR abstracts).pt. AND english.la. 
NOT (exp animals/ NOT humans/) 
 
PsycINFO (OvidSP)   
(exp Head Injuries/ OR Brain Damage/ OR coma/ OR (((brain OR head OR crani* OR intracrani* OR skull* OR cerebr* OR 
capitis OR hemisphere*) ADJ3  (injur* OR trauma* OR posttrauma* OR damag* OR lesion* OR fracture*)) OR concus* OR 
contus* OR neurotraum* OR tbi OR mtbi  OR coma*).ab,ti.) AND (exp Injuries/ OR exp Posttraumatic Stress Disorder/  OR 
exp accidents/  OR exp trauma/ OR exp Emergency Services/ OR exp Emergency Management/  OR exp violence/  OR 
(trauma* OR posttrauma* OR injur* OR tbi OR mtbi OR accident* OR emergen* OR violen*).ab,ti.) AND (exp anxiety/ OR 
exp affective disorders/ OR exp anxiety disorders/ OR exp "Depression (Emotion)"/ OR exp mental health/ OR 
Satisfaction/ OR "Diagnostic and Statistical Manual" OR  (anxi* OR ((mood OR affective) ADJ3 (disorder* OR disturb*)) OR 
phobi* OR agoraphobi* OR panic OR ocd OR (obsessi* ADJ3 compulsi*) OR depress* OR ((posttraumatic  OR post-
traumatic OR postconcussion* OR post-concussional OR post-concussion) ADJ3 (stress* OR syndrom*)) OR dysthymi* OR 
ptsd OR ((psychologic* OR neuropsychologic* OR emotion*) ADJ3 (outcome* OR develop* OR well-being OR wellbeing 
OR disabil* OR progres* OR adjust* OR function* OR consequenc* OR sequel*)) OR mental health OR dsm ).ab,ti.) AND 
(Prognosis/ OR exp Interviews/ OR exp epidemiology/ OR exp risk factors/ OR (incidenc* OR prevalen*  OR predict* OR 
prognos* OR interview* OR (risk ADJ3 factor*) OR epidemiolog* OR ((indicator* OR variable* OR characteristic* OR 
examination* OR assessment* OR measure* OR association* OR determinant*) ADJ3 psycholog*) OR 
psychometric*).ab,ti. ) NOT book.pt. AND english.la. NOT (exp animals/ NOT humans/) 
 
Cochrane    
((((brain OR head OR crani* OR intracrani* OR skull* OR cerebr* OR capitis OR hemisphere*) NEAR/3  (injur* OR trauma* 
OR posttrauma* OR damag* OR lesion* OR fracture*)) OR concus* OR contus* OR neurotraum* OR tbi OR mtbi  OR 
coma*):ab,ti) AND ((trauma* OR posttrauma* OR injur* OR tbi OR mtbi OR accident* OR emergen* OR violen*):ab,ti) 
AND ((anxi* OR ((mood OR affective) NEAR/3 (disorder* OR disturb*)) OR phobi* OR agoraphobi* OR panic OR ocd OR 
(obsessi* NEAR/3 compulsi*) OR depress* OR ((posttraumatic  OR post-traumatic OR postconcussion* OR post-
concussional OR post-concussion) NEAR/3 (stress* OR syndrom*)) OR dysthymi* OR ptsd OR ((psychologic* OR 
neuropsychologic* OR emotion*) NEAR/3 (outcome* OR develop* OR well-being OR wellbeing OR disabil* OR progres* 
OR adjust* OR function* OR consequenc* OR sequel*)) OR 'mental health' OR dsm ):ab,ti) AND ((incidenc* OR prevalen*  
OR predict* OR prognos* OR interview* OR (risk NEAR/3 factor*) OR epidemiolog* OR ((indicator* OR variable* OR 
characteristic* OR examination* OR assessment* OR measure* OR association* OR determinant*) NEAR/3 psycholog*) 
OR psychometric*):ab,ti )  
 
PubMed publisher   
(Craniocerebral Trauma[mh] OR Glasgow Coma Scale[mh] OR coma[mh] OR (((brain OR head OR crani*[tiab] OR 
intracrani*[tiab] OR skull*[tiab] OR cerebr*[tiab] OR capitis OR hemisphere*[tiab]) AND  (injur*[tiab] OR trauma*[tiab] OR 
posttrauma*[tiab] OR damag*[tiab] OR lesion*[tiab] OR fracture*[tiab])) OR concus*[tiab] OR contus*[tiab] OR 
neurotraum*[tiab] OR tbi OR mtbi  OR coma*[tiab])) AND (Wounds and Injuries[mh] OR Stress Disorders, Traumatic[mh]  
OR accidents[mh]  OR Emergencies[mh] OR Emergency Treatment[mh]  OR Emergency Service, Hospital[mh] OR 
206 | Outcome after traumatic brain injury 
violence[mh]  OR (trauma*[tiab] OR posttrauma*[tiab] OR injur*[tiab] OR tbi OR mtbi OR accident*[tiab] OR 
emergen*[tiab] OR violen*[tiab])) AND (anxiety[mh] OR mood disorders[mh] OR anxiety disorder[mh] OR depression[mh] 
OR mental health[mh] OR Personal Satisfaction[mh] OR "Diagnostic and Statistical Manual of Mental Disorders" OR  
(anxi*[tiab] OR ((mood OR affective) AND (disorder*[tiab] OR disturb*[tiab])) OR phobi*[tiab] OR agoraphobi*[tiab] OR 
panic OR ocd OR (obsessi*[tiab] AND compulsi*[tiab]) OR depress*[tiab] OR ((posttraumatic  OR post-traumatic OR 
postconcussion*[tiab] OR post-concussional OR post-concussion) AND (stress*[tiab] OR syndrom*[tiab])) OR 
dysthymi*[tiab] OR ptsd OR ((psychologic*[tiab] OR neuropsychologic*[tiab] OR emotion*[tiab]) AND (outcome*[tiab] OR 
develop*[tiab] OR well-being OR wellbeing OR disabil*[tiab] OR progres*[tiab] OR adjust*[tiab] OR function*[tiab] OR 
consequenc*[tiab] OR sequel*[tiab])) OR mental health OR dsm )) AND (prevalence[mh] OR incidence[mh] OR 
Prognosis[mh] OR Interviews as Topic[mh] OR epidemiology[mh] OR epidemiology[sh] OR risk factors[mh] OR 
(incidenc*[tiab] OR prevalen*[tiab]  OR predict*[tiab] OR prognos*[tiab] OR interview*[tiab] OR (risk AND factor*[tiab]) 
OR epidemiolog*[tiab] OR ((indicator*[tiab] OR variable*[tiab] OR characteristic*[tiab] OR examination*[tiab] OR 
assessment*[tiab] OR measure*[tiab] OR association*[tiab] OR determinant*[tiab]) AND psycholog*[tiab]) OR 
psychometric*[tiab]) ) NOT (letter[pt] OR news[pt] OR comment[pt] OR editorial[pt] OR congresses[pt] OR abstracts[pt]) 
AND english[la] NOT (animals[mh] NOT humans[mh]) AND publisher[sb] 
 
Google scholar 
"brain|head|cranial|cerebral injury|trauma|fracture"|concussion|contussion|coma 
trauma|traumatic|posttraumatic|injury|accident anxiety|"mood disorder"|depression|"mental 
health"|psychological|dsm prevalence|incidence|epidemiology|"risk factor"|prognosis 
 
Appendix 9.B Meta-analyses of univariable predictors of MDD and PTSD 
 
MDD 
Demographics 
1. Age (continuous, in years) as predictor of MDD 
 
2. Female gender as predictor of MDD 
 
3. Education (continuous, in years) as predictor of MDD 
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4. Caucasian race as predictor of MDD 
 
5. Marital status (married / relationship vs. unattached) as predictor of MDD 
 
6. Socio-economic status (Hollinghead classes IV and V vs. lower) as predictor of MDD 
 
Pre-injury variables 
7. Pre-injury depression as predictor of MDD 
 
8. Pre-injury psychiatric disorders as predictor of MDD  
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9. Pre-injury alcohol abuse as predictor of MDD 
 
10. Pre-injury substance abuse as predictor of MDD 
 
11. Pre-injury unemployment as predictor of MDD 
 
12. Family history of psychiatric disorders as predictor of MDD 
 
Clinical variables and imaging 
13. Admission GCS as predictor of MDD 
 
14. GCS after 24h post-injury as predictor of MDD 
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15. CT abnormalities as predictor of MDD 
 
16. Brain Contusion as predictor of MDD 
 
17. Total brain volume as predictor of MDD 
 
Post-injury variables 
18. Post-injury unemployment as predictor of MDD 
 
19. Post-injury litigation situation as predictor of MDD 
 
PTSD 
Demographics 
1. Age (continuous) as predictor of PTSD 
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2. Female gender as predictor of PTSD 
 
3. Education (continuous) as predictor of PTSD 
 
Pre-injury variables 
4. Pre-injury psychiatric disorder as predictor of PTSD 
 
Clinical variables  
5. PTA (continuous) as predictor of PTSD 
 
Post-injury variables 
6. Memory of the traumatic event as predictor of PTSD 
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ABSTRACT 
 
Background The impact of disability following traumatic brain injury (TBI), assessed by 
functional measurement scales for TBI or by health-related quality of life (HRQL), may vary 
because of a number of factors, including presence of depression or post-traumatic stress 
disorder (PTSD). The aim of this study was to assess prevalence and impact of depression and 
PTSD on functional outcome and HRQL six and 12 months following mild TBI.  
 
Methods We selected a sample of 1,919 TBI patients who presented to the emergency 
department (ED) followed by either hospital admission or discharge to the home 
environment. The sample received postal questionnaires six and 12 months after treatment 
at the ED. The questionnaires included items regarding socio-demographics, the 36-item 
Short-Form Health Survey (SF-36), the Perceived Quality of Life Scale (PQoL), the Beck 
Depression Inventory, and the Impact of Event Scale. 
 
Results A total of 797 (42%) TBI patients completed the 6 month follow-up survey. Depression 
and PTSD prevalence rates at both the 6 and 12 month follow-up were 7% and 9%, 
respectively. Living alone was an independent predictor of depression and/or PTSD at 6 and 
12 month follow-up. Depression and PTSD were associated with a significantly decreased 
functional outcome (measured with Glasgow Outcome Scale Extended) and HRQL (measured 
using the SF-36 and the PQoL).  
 
Conclusions We conclude that depression and/or PTSD are relatively common in our sample 
of TBI patients and associated with a considerable decrease in functional outcome and HRQL. 
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10.1 INTRODUCTION 
 
Traumatic brain injury (TBI) is an important cause of mortality and disability in modern Western 
societies. In Europe annually, 1.6 million patients with TBI are admitted to the hospital.1 About half of 
these patients experience some level of disability caused by TBI.2 The impact of disability following TBI 
may be assessed by functional measurement scales that have been designed for TBI specifically (e.g. 
the Glasgow Outcome Scale (GOS) or the GOS Extended (GOSE)) or by health-related quality of life 
(HRQL). HRQL reflects an individual’s perception of how a disorder and its treatment affect the physical, 
mental, and social aspects of his or her life. HRQL has been recognised as a potentially important 
outcome variable in TBI, because it provides well-standardised information on recovery patterns and 
frequency, nature, and predictors of disabilities. 
Functional outcome and HRQL may vary because of a number of factors, including the severity of the 
brain injury, time since injury and comorbid sequelae due to the injury, such as presence of depression 
or post-traumatic stress disorder (PTSD). Depression and PTSD frequently occur among TBI patients. 
Among TBI patients, depression prevalence rates have been assessed that vary from 17–61%3,4 and 
PTSD prevalence rates from 0–50%.5 
Recently, a study of injury patients by O’Donnell and colleagues6 revealed that psychiatric symptoms 
play a substantial role in the development and maintenance of long-term disability measured with the 
World Health Organisation Disability Assessment Schedule. Among TBI patients, research has shown 
that depression and PTSD have a substantial effect on functioning and HRQL.7-11 
The current study focused on a comprehensive population of adult patients with mild TBI and on the 
impact of depression and PTSD on both functional outcome and HRQL. The aims of this study were to 
1) assess the prevalence and predictors of depression and PTSD among patients with mild TBI, 2) assess 
the association between depression and PTSD and functional outcome measured with the GOSE, and 
3) assess the association between depression and PTSD and HRQL measured by the SF-36 and the PQoL. 
 
10.2 METHODS 
 
Study design 
The data for this study was obtained from the Radboud University Brain Injury Cohort Study (RUBICS).12-
14
 RUBICS is a prospective observational cohort study on the association between demographic and 
clinical variables, post-traumatic complaints, and functional outcome. The RUBICS database included 
information for all patients with TBI admitted to the emergency department (ED) of the Radboud 
University Nijmegen Medical Centre (RUNMC), a Level I trauma center, between January 1998 and 
December 2010. Approval for this study was obtained from the ethical standards committee of the 
RUNMC. Clinical data was registered by a neurologist and/or neurosurgeon at the ED, and thereafter 
collected by a research nurse and registered on prespecified forms and entered into the RUBICS 
databank. 
The RUBICS databank comprised demographic data (age and sex), trauma mechanism, hospital 
admission and length of hospitalisation, clinical injury variables, and comorbidities. Mild TBI was defined 
by a Glasgow Coma Scale (GCS) score in the ED of 13–15 after initial resuscitation or followed by 
sedation and intubation during resuscitation for a non-neurological cause. The injury diagnosis was 
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verified at the individual level with information from the hospital discharge register according to the 
Abbreviated Injury Scale (AIS), 1990 Revision, update 1998.15 The AIS is used to assess patients’ Injury 
Severity Score (ISS), which indicates the risk of mortality. Further, the GCS score, the Abbreviated Injury 
Scale of the Head score, the ISS, and GOSE were recorded. Initially, several sub-studies were conducted, 
in which TBI patients registered in the RUBICS database received a survey. Later on, all patients in the 
RUBICS database received postal follow-up surveys six months and 12 months after initial treatment. 
 
Study participants 
In the current study, 3,631 patients with mild TBI admitted to the ED of the RUNMC between June 2003 
and June 2010 were eligible for inclusion. Of these patients, 1,919 were sent a questionnaire. Exclusion 
criteria were age younger than 16 years, no informed consent given for previous RUBICS sub-studies, 
alcohol or drug abuse or dementia, no possibility of follow-up (unknown address), and inability to speak 
or write Dutch.Written informed consent was obtained from all patients (or guardians of patients) 
participating in the study. 
 
Functional outcome 
The GOSE assesses functional outcome via eight questions that cover consciousness, independence 
inside and outside the home, major social roles (work, social and leisure activities, family and 
friendships), and return to normal life.16 Aggregating these questions results in an 8-point scale that 
classifies functional outcome from 1 (dead) to 8 (complete recovery). The GOSE was assessed using a 
structured interview during regular visits to the outpatient clinic or during consultation by telephone.17 
Assessment of the GOSE often took place at six (70%) and 12 (66%) months post-injury. If GOSE scores 
at six months post-TBI were missing, the six month GOSE was composed by taking the mean of GOSE 
scores assessed at five or seven months (25%), or at four or eight months (4%). In case of missing GOSE 
scores at 12 months post-TBI, the 12 month GOSE was composed by taking the mean of GOSE scores 
assessed at 11 or 13 months (29%), or at 10 or 14 months (5%). 
 
Health-related quality of life 
Generic HRQL was determined using the SF-3618 and the Perceived Quality of Life Scale (PQoL). 
The SF-36 is one of the HRQL instruments recommended by the TBI consensus groups.19 The SF-36 is a 
36-item questionnaire that covers eight domains of health status: physical functioning, role limitations 
related to physical health problems, bodily pain, general health perception, vitality, social functioning, 
role limitations related to emotional problems, and mental health.18 The SF-36 has been used previously 
to evaluate HRQL in TBI patients.20,21 For each domain, a summation of item responses is linearly 
transformed into a score ranging from 0–100. 
The physical (PCS) and mental health summary component scores (MCS) are calculated by first 
standardising the patients’ scores, specifically by subtracting the subscale means for the general United 
States population sample from each individual’s subscale scores and dividing the result by the standard 
deviation of the US sample to generate Z-scores. Second, Z-scores are multiplied by the subscale factor 
coefficients for PCS and MCS of the US sample and summed over all eight subscales into the PCS and 
MCS summary scores. Finally, the obtained PCS and MCS sums were re-scaled into T-scores, with a mean 
of 50 and standard deviation of 10 for the US norm.22 
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The PQoL was initially developed as a cognitive appraisal of life satisfaction for patients after intensive 
medical care.23 The instrument has been used for adults with chronic neurologic disability, including 
stroke and TBI.24,25 The PQoL measures the degree to which the individual is satisfied with his/her 
functioning on an 11-point scale ranging from 0 (“extremely dissatisfied”) to 10 (“extremely satisfied”). 
The measurement consists of 19 items that assess 10 different areas of functioning, including physical 
health, thinking and remembering, family relationships, community participation and leisure, work and 
income, and meaning and purpose of life. The overall PQoL score based on the mean of the 19 item 
scores may be considered a measure of global life satisfaction, where a score <7.5 is “Dissatisfied” and 
a score >7.5 is “Satisfied”.26 We used the mean score (range of 0 to 10) in our analyses. The PQoL showed 
to have good internal reliability in a sample of 97 people who had sustained a TBI at least six months 
previously and who are living in the community.27 
 
Self-report inventories on depression and anxiety 
Symptoms of depression were assessed with the Beck Depression Inventory (BDI). The BDI consists of 
21 items that measure symptoms relating to depression (e.g. hopelessness and irritability), cognitions 
(e.g. guilt), and physical symptoms. By combining the items the total BDI score can be calculated. The 
total BDI score can range from 0 through 63. For TBI patients, a cut-off score of 19 for depression is 
recommended.28 
The Impact of Event Scale (IES) was used to assess symptoms of post-traumatic stress indicative of 
PTSD.29 The IES consists of 15 items, which measure intrusive re-experiences of the trauma and 
avoidance of trauma-related stimuli. By combining the 15 items the total IES score, ranging from 0 
through 75, can be calculated. Wohlfarth and colleagues30 showed that a cut-off score of 34 on the 
total IES score produced a sensitivity of .89, and a specificity of .94 against the Diagnostic and Statistical 
Manual of Mental Disorders, 4th. Edition (DSM-IV) criteria for PTSD as the gold standard.30 Therefore, 
we assumed that an IES score of 35 or higher (IES ≥35) represents symptoms of post-traumatic stress 
indicative of PTSD. 
 
Data and statistical analysis 
For analysis of the data the Statistical Package for the Social Sciences version 21 was used (SPSS Inc, 
Chicago, IL). The BDI and IES scores can be calculated if all items are completed. If one or two items of 
the BDI or IES were missing, the missing item was estimated using a hot deck imputation technique. The 
missing data was then imputed by the estimated values.31 If more than two of the BDI or IES items were 
missing, data was not imputed. Chi-square statistics (dichotomous variables) and Student’s t-tests 
(continuous variables) were used to test for differences between TBI patients with IES scores higher or 
lower than 35 and for TBI patients with BDI scores higher or lower than 19. 
We used univariate logistic regression analysis to explore the association between patient 
demographics, presence of comorbid diseases and health care with regard to depression (BDI ≥19) and 
PTSD (IES ≥35) at six and 12 months post-trauma. Secondly, multiple logistic regression analyses (enter 
method) was applied to further investigate the association between socio-demographics (block 1), 
hospitalisation and comorbidity (block 2), and depression (BDI ≥19) and PTSD (IES ≥35). 
For the analysis of the association between BDI ≥19 and/or IES ≥35 and functional outcome and HRQL, 
we selected participants that filled in the GOSE, SF-36, and the PQoL. We used the Mann-Whitney U 
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test to assess differences with and without depression and/or PTSD and GOSE. To test differences 
between participants with and without depression and/or PTSD, SF-36 and PQoL summary scores were 
analyzed with a one-way ANOVA. Because two outcome measures were tested against four variables, a 
Bonferroni adjusted significance level of 0.00625 was calculated to account for the increased possibility 
of type I error. A p value of less than 0.00625 was considered to indicate statistical significance. 
 
10.3 RESULTS 
 
Study population 
During the study period, 3,631 patients with mild TBI aged 16 years and older were admitted to the 
RUNMC. The average age of the TBI patients was 43 years (interquartile range (IQR), 25–61). Of these 
patients, 1,919 were sent a questionnaire. The response rates were 41.5% (n=797) at six months post-
injury and 15% (n=282) at 12 months post-injury. A flow chart of study participants demonstrates the 
number of respondents and the number of respondents that completed the BDI and IES at each time-
point (Figure 10.1). 
 
Figure 10.1 Flow-chart of study participants and the number of respondents that completed the BDI and IES 
 
RUNMC, Radboud University Nijmegen Medical Centre; BDI, Beck Depression Inventory; IES, Impact of Event Scale. 
 
With regard to the respondents of the 6 month follow-up questionnaire, the average age was 45 years 
old and 63% were male (Table 10.1). Almost one-half (47%) of TBI patients was injured due to traffic 
accidents and one in three (34%) was injured due to home and leisure accidents. After treatment at the 
ED, 51% of the respondents were admitted to the hospital and 4% were admitted to the intensive care 
unit.  
Comparison of the characteristics of responders and non-responders to the 6 month follow-up survey 
showed that respondents who filled in the 6 month questionnaire were significantly older (non-
responders, 38 years (IQR, 25–54); responders, 45 tears (IQR, 28–57). 
Patients (16+ years) atmitted to RUNMC 
between June 1 2003 and June 30 2010
N=3631
Eligible patients
N=3330
T1: 6 month follow-up
N=797
BDI completed n=736 (92%)
IES completed n=764 (96%)
T1: 12 month follow-up
N=282
BDI completed n=274 (97%)
IES completed n=278 (99%)
301 patients excluded
(149 patients died
152 patients unable to speak Dutch or foreigner)
Study sample
N=1919
1411 patients not sent a questionnaire
(reasons: no study at the time, unwillingness to 
participate, address unknown, dementia)
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Respondents who also filled in the 12 month follow-up questionnaire were significantly more often 
admitted to hospital (Chi2=8.8; p<0.05), compared with non-respondents. Further, comparison of the 
characteristics of responders and non-responders to the 12 month follow-up survey showed that 
respondents who filled in both the 6 and 12 month questionnaire were older and more likely to be 
female, though these differences were not significant. 
 
Table 10.1 Characteristics of the study population  
 
Patients (16+ years) 
admitted to RUNMC 
6 month follow-up 12 month follow-up 
 Respondents Filled in  
BDI and IES 
Respondents Filled in 
BDI and IES 
N 3,631 797 721 282 270 
Patient demographics      
Age 43 [25–61] 45 [28–57] 45 [28–57] 48.5 [33–58] 48.5 [32.8–58] 
Male sex  62.6 62.3 58.8 58.5 
Injury mechanism      
Road traffic accident  47.1 46.0 42.6 42.6 
Fall   34.3 35.0 35.1 35.9 
Sports  10.3 11.0 11.7 11.9 
Assault  5.4 5.3 5.3 4.8 
Other/unknown  3.0 2.8 5.3 4.8 
Injury characteristics      
ISS1   6 [4–14] 6 [4–14] 8 [5–14] 8 [5–14] 
AISH2      
Head AIS 0–1 27.5 25.2 25.2 24.5 23.7 
Head AIS 2–3 65.8 65.5 65.6 67.0 67.8 
Head AIS 4–5 6.7 9.3 9.2 8.5 8.5 
CT scan2      
No CT scan   6.6 6.5 7.4 7.0 
CT scan, no abnormalities  81.1 80.7 78.0 78.5 
CT scan, abnormalities  12.3 12.8 14.5 14.4 
Admitted to hospital3  51.1 51.4 58.2 58.5 
Admitted to IC2  4.4 4.7 5.3 5.6 
1Data is displayed as median, with the first and third quartile given within brackets. 
2 p < 0.05 (comparison between respondents 6 month and respondents 12 month follow-up questionnaire). 
3 p < 0.001 (comparison between non-respondents and respondents 6 month and respondents 12 month follow-up questionnaire). 
RUNMC, Radboud University Nijmegen Medical Centre; BDI, Beck Depression Inventory; IES, Impact of Event Scale; ISS injury Severity Score; 
AISH, Abbreviated Injury Scale of the Head; AIS, Abbreviated Injury Scale; CT, computed tomography; IC, intensive care. 
 
Prevalence of depression and PTSD 
With reference to the respondents that completed the 6 month follow-up questionnaire, BDI and IES 
scores were available for 92% and 96% of the patients (Figure 10.1). At the 12 month follow-up, BDI and 
IES scores were available for 97% and 99% of the patients, respectively. Table 10.2 shows the 
characteristics of the respondents with a BDI score of 19 or higher, which indicates the likely presence 
of depression, and respondents with an IES score of 35 or higher, which indicates the likely presence of 
PTSD. At 6 month follow-up, 6.5% of the respondents had depression and 8.7% of the respondents had 
probable PTSD. A total of 3.4% of the patients met the criteria of both depression and probable PTSD. 
At 12 month follow-up, the prevalence rates of depression and PTSD were 6.8% and 8.5%, respectively 
and 2.5% met the criteria for both depression and PTSD. In total, this means that at six months, 11.8% 
had and IES and/or BDI score that indicated PTSD and/or depression, and at 12 month follow-up, 12.8% 
had depression and/or PTSD. 
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Risk factors for developing depression and PTSD 
Univariate logistic regression analyses showed that lower educational level, living alone, comorbid 
disease, and hospital admission (all, p<0.006) were significantly associated with depression and/or 
probable PTSD at 6 month follow-up. At 12 month follow-up, lower education was significantly 
associated with depression and/or probable PTSD. Multivariate logistic regression analysis, including 
socio-demographic, physical and health care variables, indicated that living alone was an independent 
predictor of depression and/or probable PTSD (6 month OR=3.8; 95%CI [1.4 – 9.9]; p<0.006; 12 month 
OR=10.2; 95%CI [2.2 – 47.4]; p<0.006). 
 
Functional outcome 
TBI patients with depression and/or PTSD had significantly lower GOSE scores, compared with TBI 
without depression and probable PTSD (6 month Z=-9.3, p<0.001; 12 month Z=-3.9; p<0.001). The 
outcomes on the GOSE 6 and 12 months after sustaining the injury are presented in Figure 10.2. 
To examine the correlation between depression and PTSD and functional outcome, we performed a 
logistic regression analysis of admission variables (age, sex, GCS, number of days in hospital) and BDI 
and IES scores against GOSE. The results showed that apart from number of days in hospital, BDI score 
is correlated with unfavorable outcome at 6 and 12 month follow-up (6 month OR=1.15; 95%CI [1.11 – 
1.21]; 12 month OR=1.06; 95%CI [1.02 – 1.11]). IES score is correlated with unfavorable outcome at 6 
month follow-up (OR=1.03; 95%CI [1.01 – 1.04]). 
 
Figure 10.2 Mean Glasgow Outcome Scale Extended (GOSE) scores at 6 and 12 month follow-up of mild TBI 
patients with and without depression and post-traumatic stress disorder (PTSD) 
 
No D/P: no depression and/or PTSD; D: depression but no PTSD; P: PTSD but no depression; D&P: depression and PTSD. 
 
Health-related quality of life 
SF-36 
At 6 and 12 month follow-up, TBI patients with depression and/or probable PTSD had significantly lower 
scores in all SF-36 categories. At 6 and 12 month follow-up, TBI patients with depression and/or PTSD 
had lowest mean scores on the role emotional (difference in mean score six months (Δ, 22–81), social 
functioning (Δ, 21–57), and role physical (Δ, 25–47). The mean physical and mental health summary 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
No D/P D P D&P No D/P D P D&P
6 months 12 months
3
4
5
6
7
8
GOSE
Chapter 10 | 229 
 
scores of TBI patients without depression/PTSD were 49 and 53, respectively, whereas for patients with 
depression/PTSD the mean summary scores ranged from 41–42 for physical health and 30–44 for 
mental health. Figure 10.3 illustrates the SF-36 scores for TBI patients with and without depression 
and/or PTSD at six and 12 months post-injury, and the US norm scores.18 
 
Figure 10.3 Mean scores on the 36-item Short-Form Health Survey (SF-36) at 6 and 12 month follow-up of 
mild TBI patients with and without depression and post-traumatic stress disorder (PTSD) 
 
No D/P: no depression and/or PTSD; D: depression but no PTSD; P: PTSD but no depression; D&P: depression and PTSD; PF: physical 
functioning; RP: role physical; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role emotional; MH: mental health. 
 
PQoL 
At 6 month follow-up the mean PQoL score for TBI patients without depression/PTSD was 8.1, with 28% 
of patients who were dissatisfied with their functioning (PQoL <7.5). For TBI patients with depression, 
PTSD, or both, the mean PQoL scores were 4.6, 6.9, and 4.2 respectively (F=49.3; p<0.001). Of these 
patients, 53% to 100% were dissatisfied with their functioning. At 12 month follow-up, the mean PQoL 
scores for TBI patients without depression, with depression, without PTSD, and with PTSD were 8.1, 5.8, 
6.4, 3.9 respectively (F=16.2; p<0.001), with 25%, 90%, 64%, and 100% of patients who were dissatisfied 
with their functioning. 
 
10.4 DISCUSSION 
 
Depression and PTSD are common in a comprehensive population of Dutch patients with mild TBI. Six 
months after sustaining the injury 12% had an IES and/or BDI score that indicated PTSD and/or 
depression. At 12 month follow-up, 13% had depression and/or PTSD. The depression and PTSD 
prevalence rates found in this study were higher than the depression (5.2–5.8%) and PTSD (3.3–3.8%) 
prevalence rates in the general Dutch population.32-35 
Reported prevalence rates of PTSD and depression following TBI vary widely. Depression prevalence 
rates vary from 17–61%,3,4 and PTSD prevalence rates range from 0–50%.5 The prevalence rates that 
were found are dependent on many aspects, including cause and severity of the TBI, patient subgroup, 
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methods used to assess depression, and PTSD and follow-up time.36 The majority of studies that focused 
on PTSD following TBI found prevalence rates lower than 20%.37 The PTSD prevalence rates that we 
found are comparable to those reported by studies that included a self-report inventory to assess PTSD 
symptoms at 6 month follow-up.38-42 Bombardier and colleagues38 found that 11% of 124 TBI patients 
of all severity levels met PTSD criteria some time during the first six months, however, point prevalence 
at six months was between 2% and 3%, which is much lower than the PTSD prevalence rates we found. 
Greenspan and colleagues,41 on the other hand, found a point prevalence of 11% at 6 month follow-up 
among 198 TBI patients. Williams and colleagues42 reported a PTSD prevalence rate of 18% among a 
sample of 66 injury patients and Ohry and colleagues40 found a much higher prevalence rate of 33% 
among a sample of severe brain injury patients. Depression prevalence rates assessed with the BDI 
varied even more. Three studies reported depression prevalence rates of 11%,43 24%,44 and 46%,45 
respectively. 
Detection of depression and PTSD in patients with traumatic brain injury is complicated, because several 
symptoms that result from TBI are similar to those of PTSD or depression.46 As a result, a patient with 
TBI and depression or PTSD may be diagnosed with only one of the two conditions, or with both 
conditions while there is only one condition.47-50 In addition, patients with TBI may have difficulty 
answering questions from the questionnaire used to diagnose depression and PTSD. Therefore, it is of 
great importance that accurate screening tools are used with acceptable sensitivity and specificity. 
An independent predictor of depression was living alone. Previous research has shown that living alone 
increases the likelihood of depressive symptoms both among TBI patients and the general population, 
as well as in certain other subgroups, such as the elderly, immigrants or patients who suffer the 
consequences of a stroke or myocardial infarction. Insight into the predictors of depression and PTSD 
may help health care providers identify TBI patients at risk for depression and/or PTSD. Further 
investigation of predictors of depression and PTSD among TBI patients, particularly of subgroups of TBI 
patients (e.g. young adults or adults), may provide opportunities for prevention and early treatment of 
depression and PTSD. 
Risk factors for psychiatric illness following TBI that are often reported are female sex, young age, lower 
educational level, lower GCS scores, and previous psychiatric illness or alcohol abuse.51-53 In our study, 
previous psychiatric illness may be captured in the variable comorbidity. Unfortunately, the data on 
comorbidity did not allow the identification of TBI patients with psychiatric comorbidity for a more 
detailed analysis of the relationship between psychiatric comorbidity and depression and/or PTSD. 
However, it should be noted that psychiatric illness and TBI may share risk factors.53 
Regarding functional outcome and HRQL, we found that among respondents, depression and/or PTSD 
was associated with a significantly lower mean GOSE, SF-36 and PQoL summary score. Previous studies 
showed similar significant effects of PTSD and depression on functional outcome and HRQL among 
injury patients.10,11,21,52,54-58 Although these studies used different instruments to measure functional 
outcome or HRQL (e.g. SF-36, Quality of Well Being Self-Administered Scale, the EuroQOL five 
dimensions questionnaire, etc.), each of these studies reported a considerable decrease of HRQL at 
each time-point of measurement, even after correction for possible confounders, such as comorbidity 
and hospitalisation. This concurs with the findings by O’Donnell and colleagues,6 who found that 
psychiatric symptoms play a substantial role in the development and maintenance of longterm disability 
measured with the World Health Organisation Disability Assessment Schedule. However, it should be 
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noted that in the current study, it was not possible to ascertain a cause-effect relationship between 
depression and/or PTSD and impaired functional outcome and HRQL. Depression and PTSD may raise a 
barrier for physical recovery or conversely, severe injury, and no or a slow recovery may induce 
depression and/or PTSD. 
 
Strengths and limitations 
A main limitation of our study was the low response rate of 15% at 12 month follow-up and that there 
may be selection bias at the two follow-up moments of the study. Therefore, the finding that depression 
and PTSD prevalence rates among TBI patients are higher, compared with the general population, 
cannot be extrapolated to the mild TBI population. Comparison of the characteristics of responders and 
non-responders to the 12 month follow-up survey showed that respondents who filled in both the 6 
and 12 month questionnaire were older and more likely to be female, though these differences were 
not significant. The low response rates may have led to selection bias and in turn, to underestimation 
or overestimation of the prevalence of depression and PTSD.32 In our study, there was the risk of 
underestimation of depression, since patients who met the threshold for depression at 6 month follow-
up were significantly less likely to respond to the 12 month questionnaire. 
In the current study, a large number of outcome measures were included in the follow-up 
questionnaire. This may affect statistical power, because there is an increased risk of attaining a 
significant finding. To adjust for this, the use of adjusted p values has been recommended, though other 
researchers have debated that this may lead to incorrect conclusions.59,60 In this study, the p values 
were adjusted for the multiple outcome measurement. 
This study used a self-report questionnaire to identify cases of depression and PTSD. It should be noted 
that self-report questionnaires are not designed to diagnose mental disorders according to the DSM-IV. 
As a result, cases identified with symptoms of depression or PTSD may not meet the DSM-IV criteria of 
clinical depression or PTSD, and conversely. In our study, the IES was used to measure PTSD. The IES 
measures symptoms of two of the three main PTSD criteria.61 To avoid over-diagnosing PTSD in a 
comprehensive population with a relative low PTSD prevalence, we used a high IES cut-off to increase 
specificity. 
Another issue with the use of self-report instruments to measure functional outcome, HRQL, 
depression, and PTSD is that TBI patients had to fill out lengthy and complex questions. It has been 
debated whether TBI patients have the skills to provide useful and complete answers to complex 
questions.62 The more complex HRQL instruments, such as the SF-36, have been shown to be difficult 
to complete by the general population,63 let alone by TBI patients who may have cognitive problems. 
The use of self-report questionnaires may have led to an underestimation of impact on functional 
outcome and HRQL, since patients with a higher degree of cognitive problems may not have been able 
to fill in the questionnaire. Comparison of the response rate of patients with a GSC >8 and GSC ≤8 
showed that the latter group of patients were significantly less likely to respond to the 6 month follow-
up questionnaire. Further, because the SF-36 and PQoL were self-reported by patients, it is unclear if 
and to what extent the self-reported assessments of HRQL are biased by depression and/or PTSD and 
consequently, resulted in lower HRQL. 
Unlike the PQoL and the SF-36, the GOSE was assessed by health care professionals and may therefore 
have been less prone to subjectivity. A limitation of the GOSE, however, is that it measures functional 
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outcome with eight rather broad categories that are insensitive to subtle changes in functional outcome 
and quality of life.17 
 
Conclusions 
We conclude that among respondents with mild TBI, depression and/or PTSD are associated with a 
considerable decrease in functional outcome and HRQL. The cause-effect relationship between 
depression and/or PTSD and impaired functional outcome and HRQL should be further investigated, as 
well as predictors of depression and PTSD to enhance early diagnosis and treatment. 
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ABSTRACT 
 
Background Guidelines aim to improve the quality of medical care and reduce treatment 
variation. The extent to which guidelines are adhered to in the field of traumatic brain injury 
(TBI) is unknown. The objectives of this systematic review were to (1) quantify adherence to 
guidelines in adult patients with TBI, (2) examine factors influencing adherence, and (3) study 
associations of adherence to clinical guidelines and outcome. 
 
Methods We searched EMBASE, MEDLINE, Cochrane Central, Pubmed, Web of Science, 
PsycINFO, SCOPUS, CINAHL, and grey literature in October 2014. We included studies of 
evidence-based (inter)national guidelines that examined the acute treatment of adult TBI 
patients. Methodological quality was assessed using the Research Triangle Institute item bank 
and Quality in Prognostic Studies Risk of Bias Assessment Instrument. 
 
Results Twenty-two retrospective and prospective observational cohort studies, reported in 
25 publications, were included, describing adherence to 13 guideline recommendations. 
Guideline adherence varied considerably between studies (range 18–100%) and was higher in 
guideline recommendations based on strong evidence compared to those based on lower 
evidence, and lower in recommendations of relatively more invasive procedures such as 
craniotomy. A number of patient-related factors, including age, Glasgow Coma Scale and 
intracranial pathology, were associated with greater guideline adherence. Guideline 
adherence to Brain Trauma Foundation guidelines seemed to be associated with lower 
mortality. 
 
Conclusions Guideline adherence in TBI is suboptimal and wide variation exists between 
studies. Guideline adherence may be improved through the development of strong evidence 
for guidelines. Further research specifying hospital and management characteristics that 
explain variation in guideline adherence is warranted.  
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11.1 INTRODUCTION 
 
Traumatic brain injury (TBI) is a major public health concern affecting approximately 150–300 per 
100,000 people annually in Europe.1 The World Health Organisation has predicted that TBI will be one 
of the leading causes of death and disability worldwide by the year 2020.2 
The care for TBI patients is often complex and multidisciplinary. Guidelines, protocols and care pathways 
have been developed to improve quality of care, to reduce variation in practice and to ensure that 
evidence-based care is optimally implemented.3 
A 2013 systematic review4 found that the use of protocols in the management of severe TBI in the 
intensive care unit (ICU) led to improved patient outcomes. However, the findings were based on 
observational studies that did not report on adherence rates. Without an understanding of adherence 
rates, the improved outcomes stated in the review cannot be directly attributed to the use of protocols. 
Guideline adherence can be defined as the proportion of patients treated according to a guideline 
recommendation, which often represents evidence-based or best practice care. Previous studies have 
found that guideline adherence in medicine is generally low5-7 and varies widely across centers,7,8 
medical condition,9 types of guideline,10,11 and time period.8,10 As a result, many patients do not receive 
evidencebased care, while others receive unnecessary care that may even be harmful.5 To date, no 
systematic review of the literature about guideline adherence in TBI has been conducted. 
The aim of this systematic review was to provide a comprehensive overview of professionals’ adherence 
to guidelines in adult TBI patients. The objectives were to 1) quantify adherence to guidelines in adult 
patients with TBI, 2) explore factors influencing adherence to TBI guidelines in those studies reporting 
on adherence, and 3) examine the association between adherence to guidelines and outcome in 
patients with TBI in those studies reporting on adherence. 
 
11.2 METHODS 
 
This review was conducted and reported in line with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) Statement.12 Details of the protocol for this systematic review 
were registered on PROSPERO (registration number CRD42014012863) and can be accessed at 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014012863. 
This review is being prepared as a ‘living systematic review’ as part of the CENTER-TBI project13 
(www.center-tbi.eu). A living systematic review is a high quality, up-to-date, online summary of health 
research that is updated as new research becomes available.14 This means that the searches will be re-
run frequently and new studies will be incorporated into the review, with revisions to recommendations 
as appropriate. We will seek to publish regular updates. 
 
Information sources 
A comprehensive literature search was conducted on October 22nd 2014. Search strategies were 
developed in consultation with search experts using a combination of subheadings and text words 
(Appendix 11.A). The databases EMBASE, MEDLINE (via Ovid SP), Cochrane Central, Pubmed as supplied 
by publisher, Web of Science, PsycINFO, SCOPUS and CINAHL were searched. In addition, grey literature 
was examined via Google Scholar, opengrey.eu and dissertation databases (openthesis.org, 
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dissertation.com). Reference lists and citation indices of the included papers and relevant reviews were 
inspected to identify additional relevant citations. All selected studies were downloaded to the 
reference management database Endnote X515 and duplicates were removed. We restricted the search 
to original articles published in English. There was no date restriction. 
 
Inclusion and exclusion criteria and study selection 
We used the following inclusion and exclusion criteria to select studies: 
Study designs: We included retrospective and prospective cohort studies, cross-sectional studies, time 
series and controlled clinical trials. Reviews, qualitative studies, case reports and editorials were 
excluded. 
Participants: Studies were included if they were conducted in adult patients with suspected or 
confirmed TBI. Studies including a mixed population (e.g. all trauma patients) were only included if they 
presented their results for TBI patients separately. Studies solely about children were excluded as other 
factors, such as radiation, might play a role in guideline adherence in this group. If studies presented 
results for children and adults separately, only the information on adults was extracted. 
Guidelines: Evidence-based international and national clinical TBI guidelines were included. Evidence-
based guidelines were defined as guidelines for which evidence was found in quantitative research. We 
included studies analysing adherence to a complete guideline or protocol as well as studies analysing 
adherence to one or more single guideline recommendations. Local and regional guidelines, and 
guidelines based on expert opinion were excluded. Studies were further excluded if they assessed 
adherence to guidelines not published or implemented during the study period. 
Adherence: Adherence or compliance was conceptualised as the percentage of patients that were 
treated according to a guideline, a subset of guidelines or an individual recommendation of a guideline. 
This definition was chosen to enable comparison of adherence to different guidelines or guideline 
recommendations. Studies using self-reported adherence were excluded due to the risk of 
overestimation.16 
Setting: Studies were included if they examined the acute curative care of TBI patients, in the 
prehospital setting, emergency department (ED), hospital ward care and intensive care unit (ICU). 
The first review author (MC) screened all titles and abstracts and deleted obviously irrelevant citations. 
After the initial selection, two independent reviewers (MC and ACS) screened the remaining citations 
on title and abstract and obtained those selected in full text. Results were compared and any 
disagreement was resolved by discussion or consulting a third author (SP). The search process was 
documented according to the PRISMA flowchart.12 
 
Data collection and assessment of methodological quality 
Two reviewers (MC and ACS) independently extracted data and assessed the risk of bias of included 
studies. Any discrepancies were resolved by discussion or consulting a third author (SP). 
A data extraction form was developed based on the Effective Practice and Organisation of Care 
Cochrane Review Group (EPOC) data collection checklist,17 and the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement.18 Additionally, topic-relevant criteria about 
guidelines, adherence, and influencing factors were extracted. Guideline recommendations were 
classified as ‘strong’ or ‘weak/moderate’ recommendations. Strong recommendations were defined as 
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being based on good quality randomised controlled trials (RCTs). Weak or moderate recommendations 
were defined as being based on moderate or poor quality RCTs, cohort studies, case control studies or 
case series. 
We developed three risk of bias forms to rate the risk of bias in quantifying adherence (objective 1), 
exploring factors influencing adherence (objective 2) and examining the association between adherence 
and outcome (objective 3). Risk of bias forms were based on items from the Research Triangle Institute 
(RTI) Item Bank for observational studies19,20 (objective 1 and 3) and the Quality in Prognostic Studies 
(QUIPS) risk of bias tool21 (objective 2). The risk of bias was assessed for each of the three objectives 
separately as different risks are relevant in the three objectives. Moreover, it was possible that studies 
assessing more than one review objective had a low risk of bias for one objective but a high risk for 
another. 
Risk of bias items were subdivided into six categories for every objective: selection bias/confounding, 
performance bias, attrition bias, detection bias, reporting bias and information bias19,22 (Appendix 11.B). 
For every category, individual items were scored as high, low or unclear risk of bias. 
If at least one item in a bias category was scored as high, the risk of bias within this category was scored 
as ‘moderate risk’. If at least 50% of the items in a bias category were scored as high, the risk of bias 
category was scored as ‘high risk’. Every study received a total risk of bias score for every objective 
which was equal to the highest score obtained in all risk of bias criteria. 
Risk of bias was presented with a table divided by objective. Attrition and detection bias were not 
reported for objective 1 since these were considered irrelevant for the percentage adherence obtained. 
We accounted for risk of bias by narratively describing studies with a low (none of the criteria was rated 
as high risk of bias) and moderate (<50% of the criteria was rated as high risk of bias) risk of bias 
separately for the three objectives. 
In order to enhance inter-rater reliability, data extraction and risk of bias forms were pilot-tested on 
three studies that were likely to be included in the review. Inter-rater reliability was assessed by 
calculating concordance rates between the two independent reviewers in data screening, data 
extraction and risk of bias assessment. 
 
Data synthesis 
Due to heterogeneity in settings, guidelines, populations, statistical methods and outcomes, meta-
analytic techniques were not used. Instead, we conducted a narrative synthesis of results stratified by 
objective. 
For every guideline recommendation that was examined in at least two studies, mean guideline 
adherence was calculated by adding up the total number of patients treated according to the guideline 
recommendation and subsequently dividing them by the total number of patients eligible for the 
guideline. In addition, the percentage adherence was presented separately for strong and 
moderate/weak recommendations. We also compared the differences in percentage adherence for 
relatively more invasive (e.g. intracranial pressure monitoring and intracranial operation) and less 
invasive (e.g. computer tomography scanning and anti-seizure prophylaxis) procedures separately. A 
total percentage adherence was not calculated, as there was considerable variation in guidelines and 
patient severity. 
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An overview of factors influencing adherence was conducted. We examined whether associations 
between predictive factors and adherence were positively or negatively directed and whether they 
were statistically significant (p<0.05). Additionally, we conducted an overview of the association 
between adherence and outcome and reported whether associations were positively or negatively 
directed and statistically significant. 
All eligible studies were used for objective 1. Those that also reported factors influencing adherence 
and/or outcome were further analyzed for objective 2 and/or 3. There were no further specific inclusion 
criteria for these objectives. All results are presented before and after the exclusion of studies that were 
judged as high risk of bias. 
 
Treatment of studies with multiple publications 
Multiple publications refer to the situation where more than one article has been written based on the 
same dataset.23 Multiple publications assessing the same guideline in an overlapping time period and 
setting were dealt with by extracting information from the study that could be used for the most study 
objectives. If the number of objectives was similar across studies with multiple publications, the article 
that included the largest number of patients was chosen. Articles from the same dataset that assessed 
different guidelines or that were conducted during a different study period or in a different setting, 
were analysed separately. 
 
11.3 RESULTS 
 
Study selection 
A total of 1,903 citations were identified through the extensive search strategy (Figure 11.1). After 
removing duplicates, 912 were screened on citation and 518 obviously irrelevant records (determined 
on title) were removed. We screened 394 citations on title and abstract and excluded 310. We obtained 
84 citations in full text of which 62 were excluded. Three additional citations were found via reference 
lists and citation indices. For an overview of related studies excluded at the full text stage, see Appendix 
11.C. The concordance rates between the two independent reviewers were generally high in screening 
of title and abstract (91%), screening of full text (81%), and data extraction (93%). 
 
Study characteristics 
We included 22 studies, reported in 25 publications (Table 11.1). Three articles were removed from the 
analyses because of multiple publications.10,24,25 Two more studies were based on the same dataset,26,27 
but the study describing the least number of objectives26 was still included for extracting the amount of 
adherence to another guideline recommendation. 
All included studies used an observational cohort design with fourteen being retrospective28-41 and eight 
being prospective.26,27,42-47 Twelve studies described multicentre studies26-31,34,36,40,41,44,46 with a median 
of eight (range 2–155) hospitals included. All studies were conducted in North America (n=9) or Europe 
(n=13) and were published between 2002 and 2014. Six of the included studies33,40,41,43,44,46 examined 
adherence to more than one guideline recommendation (mean number of guideline recommendations 
in studies describing more than one guideline recommendation: 3.6; range 2–6). The sample size in the 
included studies ranged from n=2738 to n=10,62828 patients. 
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Adherence to a total of thirteen guideline recommendations was assessed, including those from the 
Brain Trauma Foundation (BTF),48 National Institute of Health and Clinical Excellence (NICE)49 and 
Scandinavian guidelines for the initial management of minimal, mild and moderate head injury.50 The 
most frequently studied guideline recommendation was the BTF guideline for Incracranial Pressure (ICP) 
monitoring (n=9). Other guidelines that were studied in more than one study were the NICE guidelines 
for CT scanning (n=5), the BTF guidelines for prehospital intubation (n=7), transport (n=2), steroids (n=2) 
and resuscitation (n=2), and the Scandinavian guidelines for computer tomography (CT) scanning and 
hospital admission (n=2). 
Six studies were performed during ICU admission, seven during an emergency department (ED) visit and 
three during the prehospital phase. The remainder (six studies) reported on a combination of these 
settings. The majority of studies reported on guideline recommendations that were judged as 
weak/moderate. Only seven studies included strong recommendations. The majority of studies were 
funded by government organisations. One study29 was funded by the BTF. 
 
Figure 11.1 PRISMA flowchart of the selection process 
 
Reasons for exclusion full text: Study design: the study was no prospective or retrospective cohort study, RCT, clinical trial, cross-sectional 
study or time series; Guideline: the study did not describe a guideline, the guideline was local or not evidence-based, the guideline was not 
implemented or disseminated before the study period; Adherence: the study did not measure adherence per patient, adherence was self-
reported; TBI: the study was not about TBI patients; Setting: the study was not conducted during the hospital and prehospital setting; 
Language: the study was not published in English; Solely about children: the study did not include adults.  
TBI: traumatic brain injury. 
Figure is adapted from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097.  
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Methodological quality 
Overall, the methodological quality of studies was good, with the majority of studies judged at low risk 
of bias in most domains (Table 11.2). For studies measuring the amount of adherence to guidelines 
(objective 1, n=22), 19 had an overall low risk of bias. The remainder (n=3)34,36,38 received a high risk of 
bias score, due to high scores on selection bias / confounding. 
For studies exploring factors influencing adherence to guidelines (objective 2, n=10), respectively three 
and four studies received a low and moderate overall risk of bias score. Three studies34,43,44 were judged 
as being at high risk of bias due to selection bias / confounding. 
None of the studies examining the association between adherence to guidelines and outcome (objective 
3, n=11) had an overall low risk of bias. Nine studies received a moderate risk of bias score and two 
studies42,46 a high risk of bias score. This was due to selection bias / confounding, performance bias and 
information bias. None of the studies sufficiently isolated the impact of the guideline studied from 
concurrent interventions. In addition, some studies used inappropriate control groups or did not adjust 
for confounders while others calculated adherence- or quality scores that were based on non-validated 
scoring mechanisms or partly based on guideline recommendations that were not evidence-based nor 
(inter)national. 
Concordance rates between independent reviewers in assessing risk of bias was high (92%) and any 
discrepancies were resolved by discussion or consulting a third author. 
 
Amount of adherence to guidelines 
The amount of guideline adherence was reported in all included studies (Table 11.1) and varied 
considerably between (range 18%–100%) and within (range 0%–100%) studies. Excluding studies with 
a high risk of bias34,36,38 did not influence this variation. 
Among the guidelines that were examined by more than one study, adherence was the highest in NICE 
CT-scan guidelines35-39 (mean 87%, range 70–100%) and the lowest in BTF Intracranial Pressure (ICP) 
monitoring guidelines10,26,28-30,32,40,41,46,47 (mean 31%, range 18–83%). Studies about the NICE CT scan 
guidelines were all performed at the ED in the United Kingdom and included patients with head injury. 
The majority had a single-center design. Studies about ICP monitoring were performed in Europe and 
Northern America and performed during ICU admission. Most studies used a multi-center design. The 
studies with the lowest and highest percentage adherence to ICP monitoring guidelines were 
comparable multi-center studies performed in Northern America. The study with the highest 
percentage adherence was based on the TBI-Trac database, which is a database from the BTF aiming to 
track and improve adherence, while the study with the lowest percentage was based on general trauma 
databases. A visual display of adherence per guideline is provided in Figure 11.2. After removing studies 
with a high risk of bias (n=3), adherence to the NICE guidelines was 75%. Adherence to other guidelines 
did not differ substantially. 
To assess whether strength of recommendation was related to guideline adherence, we divided 
guidelines into strong, and moderate/weak recommendations. Strong recommendations consisted of 
NICE CT scan guidelines, reported in five studies, and BTF steroids guidelines, reported in two studies. 
All other guideline recommendations were based on low levels of evidence. Mean adherence to strong 
recommendations was 93% (range 70%–100%) while adherence to moderate/weak recommendations 
was considerable lower (mean 49%, range 18%–94%). Percentages did not differ substantially after 
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removing studies that were found to be at high risk of bias. One study42 was excluded from this analysis 
as it reported adherence to an ICU protocol that was based on both strong and moderate/weak 
recommendations. 
In addition, we considered whether the invasiveness of the intervention was related to adherence. 
Across studies, relatively invasive interventions such as ICP monitoring and intracranial operations 
obtained a mean adherence rate of 30% (range: 8–83%), while less invasive interventions such as CT 
scanning and anti-seizure prophylaxis obtained a much higher adherence rate (mean: 79%, range 51–
100%). 
 
Figure 11.2 Percentage guideline adherence for various guideline recommendations 
 
Figure displays lowest, highest and mean percentages adherence for various guideline recommendations. Numbers correspond with number 
of guideline recommendation and not to individual studies since some studies reported on multiple guideline recommendations. “Other” is 
a summary measure of following: BTF ICU protocol for patients with severe TBI,42 BTF hyperventilation,46 BTF barbiturates,46 BTF anti-seizure 
prophylaxis,46 BTF ICP directed therapy40 and BTF craniotomy.41 BTF: Brain Trauma Foundation; ICP: intracranial pressure; NICE: National 
Institute for Health and Care Excellence; CT: computer tomography. 
 
Factors influencing guideline adherence 
Ten studies identified factors influencing adherence (Table 11.3). Most studies assessed patient 
demographics and clinical characteristics. Three studies assessed treatment, hospital or country 
characteristics. Taking the results together, the BTF guidelines, in particular the ICP monitoring 
recommendations, were consistently more often adhered to in younger patients with extracranial injury 
and more severe TBI (indicated by Glasgow Coma Scale (GCS), Head Abbreviated Injury Scale (HAIS), 
abnormal pupillary reactions and intracranial pathology). The Scandinavian guidelines were more often 
adhered to in older patients with moderate head injury in comparison to mild and minimal head injuries. 
Among studies with a relatively low risk of bias that assessed factors influencing adherence using 
multivariable analyses, age was significantly associated with adherence in all studies (younger age is 
associated with greater adherence in severe TBI patients; older age is associated with greater adherence 
in minimal, mild and moderate TBI patients). Studies about ICP monitoring further reported that 
adherence was more often accomplished in patients with a lower GCS and the occurrence of intracranial 
pathology. 
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Factors that were studied but not significantly associated with adherence included race,28,40 certain 
severity indices (GCS motor score28; Acute Physiology and Chronic Health Evaluation (APACHE) II 
score32), certain laboratory values (international normalised ratio and prothrombin time47; blood 
alcohol level33) certain complications (tachycardia47; hypoxia47), referral status27 and structural hospital 
characteristics (hospital type28; number of beds28; trauma center designation28). For an overview of 
factors significantly associated with adherence in at least one study see Table 11.3. For a complete 
overview of all factors studied, see Appendix 11.D. 
 
The association between guideline adherence and outcome 
Eleven studies examined the association between guideline adherence and outcome (Table 11.4). All 
studies examined the BTF guidelines with six studies investigating ICP monitoring guidelines, one study 
examining direct transfer, and the remainder combining various BTF recommendations into a 
compliance or quality score. 
Outcome measurements included in-hospital mortality,28,29,32,40,42,47 two-week mortality,30,34 28-day 
mortality,32 six-month mortality,27 Glasgow Outcome Scale (GOS) and Rancho Los Amigos Scale (RLAS) 
at discharge,42 90-day Extended Glasgow Outcome Scale (GOSE),46 six-month GOSE,27 ICU survival,44,46 
and ICU and hospital length of stay (LOS).27,29,42,47 
The majority of studies (n=8) analysed the adherence-outcome association with multiple regression 
adjusted for relevant confounders30,34,40,44,46 or for propensity scores.27,32,47 Two multi-center studies 
analysed the association on hospital level by dividing hospitals into quartiles based on their percentage 
adherence28 or by dividing hospitals into having an aggressive or nonaggressive approach.29 One study 
univariately assessed the association.42 
Eight out of eleven studies reported a statistically significant association between adherence and a 
reduction in mortality with odds ratios ranging from 0.15 to 0.96.28-30,34,40,42,44,47 One study additionally 
described an association between adherence and higher scores on GOSE and RLAS.42 One study 
reported increased in-hospital mortality in those treated according to the guideline but no significant 
differences between groups in 28-day mortality.32 
For ICU and hospital LOS, three studies27,32,47 reported an association with longer LOS and one study 
reported an association with shorter LOS.42 All other associations were non-significant. 
After adjusting for the risk of bias by removing studies with a high risk of bias on at least one of the 
criteria and outcomes that have been univariately assessed, all but one of the nine remaining studies32 
reported an association between adherence and a reduction in mortality. Functional outcome was 
assessed in one study,27 showing non-significant results. The association with LOS was assessed with 
multivariable analyses in two studies29,47 showing contradictory results. Statistical methods and results 
can be found in Appendix 11.E. 
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Table 11.4 The association between adherence to guidelines and patient outcome 
Study ID Outcome variables Direction of association1 
Alali (2013) In-hospital mortality  –– 
Biersteker (2012) 6 month mortality  – 
6 month unfavorable outcome  + 
ICU LOS ++* 
Hospital LOS ++* 
Bulger (2002) In-hospital mortality  –– 
Hospital LOS – 
Fakhry (2004) Mortality  ––* 
ICU LOS ––* 
Hospital LOS ––* 
Unfavorable outcome (GOSE) at discharge ––* 
Lower RLAS at discharge ––* 
Farahvar (2012) 
Gerber (2013) 
2-weeks mortality –– 
 
Griesdale (2010) In-hospital mortality  ++ 
28-days mortality  + 
ICU LOS ++* 
Härtl (2006) 2-weeks mortality –– 
Mauritz (2008) ICU mortality –/–– 
Rusnak (2007) ICU mortality – 
 90 days unfavorable outcome (GOS) – 
 ICU LOS +* 
 Hospital LOS –* 
Shafi (2014) In-hospital mortality –– 
Talving (2013) In-hospital mortality –– 
 ICU LOS ++ 
 Hospital LOS ++ 
1 + = Positive, non-significant effect; – = negative, non-significant effect; ++ = positive, significant effect;  –– = negative, significant effect. The 
direction of the multivariable analyses were noted. If there was no multivariable analysis performed, the univariate analysis was reported 
and a * was noted. 
* Univariate association adherence – outcome. 
 
11.4 DISCUSSION 
 
This systematic review provides an overview of adherence to guidelines, its determinants and 
association with outcomes in TBI patients. We included 22 studies, reported in 25 publications. 
Guideline adherence in TBI was found to be suboptimal overall, and varied widely between studies (from 
18–100%) and within multi-center studies. Guideline recommendations based on strong evidence were 
more often adhered to in comparison with recommendations based on lower level evidence. Guideline 
adherence was also influenced by age and severity (indicated by intracranial pathology and lower GCS). 
Importantly, guideline adherence appears related to patient outcomes, as adherence to BTF (especially 
ICP monitoring) guidelines was associated with a reduction in mortality in all but one study after 
correction for risk of bias. 
This systematic review included three objectives, and thereby provided an overview of the entire scope 
of adherence to guidelines in TBI. However, four important notes should be made regarding the 
completeness and applicability of the evidence. Firstly, despite the existence of over 100 evidence-
based guideline recommendations,51 adherence was assessed for only thirteen recommendations. 
Results can therefore not be generalised to all guideline recommendations. Similarly, the variability in 
adherence might have been confounded by the invasiveness of the recommended intervention. We 
found a lower adherence rate in studies about invasive interventions such as ICP monitoring and 
craniotomy in comparison to studies with less invasive interventions. Invasive interventions require 
more experience and skills within the institution and therefore may face greater barriers to be 
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implemented than less invasive interventions. Thirdly, no definitive conclusion about the efficacy of 
guidelines can be drawn from this review as we did not include any cluster RCTs. These results should 
encourage the conduct of cluster RCTs to more rigorously examine the efficacy of guidelines for TBI. 
Additionally, all included studies were conducted in Europe and North America. Hence, our findings are 
not generalisable to non-Western countries since lack of resources restricts the routine use of 
aggressive treatment strategies in these countries.52 Related, our findings cannot be generalised to 
children as it is known that guideline adherence in children varies from guideline adherence in adults36 
and might also be influenced by other factors such as concern about radiation. Lastly, the majority of 
current TBI guidelines are not based on high quality evidence. TBI is however emerging as an important 
topic in research with large-scaled, high-quality multicenter studies conducted all over the globe.13 
These are likely to result in revised guidelines based on more rigorous evidence.13 The findings of this 
review might not be generalisable to a situation in which TBI guidelines are based on robust evidence, 
which underlines the importance of keeping this systematic review, as well as other systematic reviews 
in the field of TBI, ‘living’. 
Overall, the methodological quality of the studies was good. The association between adherence to 
guidelines and outcome was however highly suspect for performance bias, as none of the studies 
sufficiently isolated the impact of the guideline studied from concurrent interventions. It is nevertheless 
plausible that patients who had, for example, an ICP monitoring inserted, also had a higher chance of 
receiving ICP lowering treatment, and that this therapy might have caused the association with 
outcome. 
Although selection bias / confounding did not seem a major threat to validity in the association between 
adherence and outcome, the risk of bias form we used did not account for confounding by indication. 
Observational studies in critical care may easily suffer from confounding by indication, i.e. a different a 
priori risk of unfavourable outcome between those treated and those not treated according to the 
guideline.53,54 Although the majority of studies made attempts to reduce the risk of confounding by 
multivariable analysis or propensity score adjustment, these methods may still insufficiently resolve the 
problem of confounding by indication as they do not account for unmeasured confounders.54-56 This is 
in contrast to an RCT, where comparability between groups is achieved on measured and unmeasured 
characteristics. In this review, two studies defined guideline adherence at the level of the hospital, which 
is more likely to provide a valid estimate of the effect of adherence on outcome. 
Suboptimal adherence and between center variation have been reported in other systematic reviews 
about guideline adherence in critical care.6,57 Ebben6 reported a variation as large as 0 to 98% in a 
systematic review about guideline adherence in the prehospital and emergency care. 
The large between-center variation suggests that guideline adherence is a management or structural 
characteristic, which is consistent with a qualitative study about guideline adherence in the ICU.58 These 
authors reported that unit culture and communication were among the most important factors in 
guideline adherence. Furthermore, the availability of electronic protocols, education, reminders and an 
audit-feedback system were identified by participants as important determinants of guideline 
adherence. Surprisingly, only one of the included studies in this review assessed the association 
between hospital characteristics and adherence.28 
In this review we found that strong recommendations were more often adhered to than 
recommendations based on lower level evidence. This is consistent with the findings of a study about 
 254 | Guidelines and adherence 
oncology guidelines.59 This may imply that clinicians are not convinced by the benefit of moderate and 
weak guideline recommendations, which is supported by our finding that intracranial pathology is 
associated with adherence to ICP monitoring guidelines. The recommendation to place an ICP 
monitoring in patients without CT abnormalities but with additional risk factors stems from one 
prospective study published in 1982,60 while the recommendation to place an ICP monitor in patients 
with an abnormal head CT is, albeit still controversial, based on more robust evidence. 
Other clinical characteristics that were associated with guideline adherence were age and GCS. The 
negative association between age and adherence in severe TBI patients is conceivable as older age is 
associated with medical comorbidity and premorbid anticoagulant- or antiplatelet use.61 It has been 
suggested that these patients should not be treated aggressively,62 although the BTF guidelines do not 
specify any subgroups in their recommendations. 
The positive association between lower GCS and adherence to BTF guidelines is in line with findings 
from methodological studies about confounding by indication in critical care, which describe that the 
most intensive treatments, such as ICP monitoring, are often reserved for the most ill.53,63 
The association between adherence and a reduction in mortality is consistent with a systematic review 
of protocolised management of patients with TBI in the ICU4 and a cost-benefit analysis about the 
effectiveness of the BTF guidelines.64 Although these findings are consistent, they should be interpreted 
with caution because of the high risk of confounding by indication and performance bias in these 
studies. 
 
Strengths and limitations 
Strengths of this systematic review include the use of a comprehensive search strategy and independent 
screening, data extraction and quality assessment by two review authors. As there is no gold standard 
for risk of bias assessment in observational studies,65 we developed and piloted our own form. This 
could be considered a review limitation, however, we attempted to describe the six threats to validity 
as described by the Cochrane Collaboration and used two validated forms. In addition, concordance 
rates in assessing bias were high suggesting unambiguous items. Finally, despite an extensive search 
strategy, we found no unpublished studies. Although the performance of audits to test and improve 
guideline adherence is well practiced,66 these reports are seldom published in international journals. 
Combined with the fact that we excluded non-English language studies, it is likely that some publication 
bias exists within this review. 
The results of this review imply that guideline adherence in TBI is suboptimal. Certain subgroups, such 
as older patients or severe TBI patients with a relatively high GCS are even less likely to be treated 
according to the guidelines. One solution may be for guideline developers to take into account specific 
subgroups of patients and tailor their recommendations accordingly. 
The fact that strong guideline recommendations were more often followed than those based on less 
robust evidence, speaks to the need for adequate investment in high-quality research to evaluate 
treatment efficacy and effectiveness, and for this research to be incorporated rapidly into guidelines. 
We would recommend high quality RCTs and large-scale comparative effectiveness design using robust 
methods to adjust for confounding by indication for this purpose. 
The large variation found in this systematic review highlights the importance of hospital characteristics 
and/or management strategies in guideline adherence. Although this has been reported in qualitative 
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studies, further quantitative research may shed greater light on its importance and elucidate which 
characteristics inhibit clinicians from adhering to guidelines. 
In this systematic review, we found an association between adherence to current guidelines and 
reduced mortality. These results should be interpreted as preliminary because only two studies 
accounted for confounding by indication and none could eliminate the effect of concurrent 
interventions. It is important that future studies investigating guideline adherence or treatment 
effectiveness use robust methods to adjust for confounding by indication and concurrent treatment 
interventions to estimate effectiveness. 
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APPENDIX 
 
Appendix 11.A Search strategy 
Date: October 22, 2014 
 
Embase.com  
('protocol compliance'/de OR (((adher* OR complian* OR conform* OR deviat* OR nonadher* OR noncomplian* OR 
nonconform* OR nondeviat*) NEAR/11 (protocol* OR guideline* OR pathway* OR 'good clinical practice' OR polic* OR 
procedure* OR recommend* OR definition* OR rule* OR 'evidence based'))):ab,ti) AND ('brain injury'/exp OR 'head 
injury'/de OR concussion/exp OR 'nervous system injury'/de OR (((brain OR head OR crani* OR cerebr* OR capitis OR 
hemisphere*) NEAR/3 (injur* OR trauma* OR posttrauma* OR damag*)) OR concus* OR contus* OR neurotraum* OR tbi 
OR mtbi):ab,ti) 
 
Medline (OvidSP)  
("Guideline Adherence"/ OR (((adher* OR complian* OR conform* OR deviat* OR nonadher* OR noncomplian* OR 
nonconform* OR nondeviat*) ADJ11 (protocol* OR guideline* OR pathway* OR "good clinical practice" OR polic* OR 
procedure* OR recommend* OR definition* OR rule* OR "evidence based"))).ab,ti.) AND (exp "Brain Injuries"/ OR 
"Craniocerebral Trauma"/ OR "Trauma, Nervous System"/ OR exp "Cerebrovascular Trauma"/ OR (((brain OR head OR 
crani* OR cerebr* OR capitis OR hemisphere*) ADJ3 (injur* OR trauma* OR posttrauma* OR damag*)) OR concus* OR 
contus* OR neurotraum* OR tbi OR mtbi).ab,ti.) 
 
Cochrane central  
((((adher* OR complian* OR conform* OR deviat* OR nonadher* OR noncomplian* OR nonconform* OR nondeviat*) 
NEAR/11 (protocol* OR guideline* OR pathway* OR 'good clinical practice' OR polic* OR procedure* OR recommend* OR 
definition* OR rule* OR 'evidence based'))):ab,ti) AND ((((brain OR head OR crani* OR cerebr* OR capitis OR 
hemisphere*) NEAR/3 (injur* OR trauma* OR posttrauma* OR damag*)) OR concus* OR contus* OR neurotraum* OR tbi 
OR mtbi):ab,ti) 
 
Web-of-science   
TS=(((((adher* OR complian* OR conform* OR deviat* OR nonadher* OR noncomplian* OR nonconform* OR nondeviat*) 
NEAR/11 (protocol* OR guideline* OR pathway* OR "good clinical practice" OR polic* OR procedure* OR recommend* 
OR definition* OR rule* OR "evidence based")))) AND ((((brain OR head OR crani* OR cerebr* OR capitis OR hemisphere*) 
NEAR/3 (injur* OR trauma* OR posttrauma* OR damag*)) OR concus* OR contus* OR neurotraum* OR tbi OR mtbi))) 
 
Scopus   
TITLE-ABS-KEY(((((adher* OR complian* OR conform* OR deviat* OR nonadher* OR noncomplian* OR nonconform* OR 
nondeviat*) W/11 (protocol* OR guideline* OR pathway* OR "good clinical practice" OR polic* OR procedure* OR 
recommend* OR definition* OR rule* OR "evidence based")))) AND ((((brain OR head OR crani* OR cerebr* OR capitis OR 
hemisphere*) W/3 (injur* OR trauma* OR posttrauma* OR damag*)) OR concus* OR contus* OR neurotraum* OR tbi OR 
mtbi))) 
 
PsycINFO (OvidSP) 
((((adher* OR complian* OR conform* OR deviat* OR nonadher* OR noncomplian* OR nonconform* OR nondeviat*) 
ADJ11 (protocol* OR guideline* OR pathway* OR "good clinical practice" OR polic* OR procedure* OR recommend* OR 
definition* OR rule* OR "evidence based"))).ab,ti.) AND (exp "Brain Damage"/ OR (((brain OR head OR crani* OR cerebr* 
OR capitis OR hemisphere*) ADJ3 (injur* OR trauma* OR posttrauma* OR damag*)) OR concus* OR contus* OR 
neurotraum* OR tbi OR mtbi).ab,ti.)  
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Cinahl   
(MH "Guideline Adherence+" OR (((adher* OR complian* OR conform* OR deviat* OR nonadher* OR noncomplian* OR 
nonconform* OR nondeviat*) N11 (protocol* OR guideline* OR pathway* OR "good clinical practice" OR polic* OR 
procedure* OR recommend* OR definition* OR rule* OR "evidence based")))) AND (MH "Brain Injuries+" OR MH "Head 
Injuries+" OR (((brain OR head OR crani* OR cerebr* OR capitis OR hemisphere*) N3 (injur* OR trauma* OR posttrauma* 
OR damag*)) OR concus* OR contus* OR neurotraum* OR tbi OR mtbi)) 
 
PubMed publisher   
((((adher*[tiab] OR complian*[tiab] OR conform*[tiab] OR deviat*[tiab] OR nonadher*[tiab] OR noncomplian*[tiab] OR 
nonconform*[tiab] OR nondeviat*[tiab]) AND (protocol*[tiab] OR guideline*[tiab] OR pathway*[tiab] OR good clinical 
practice*[tiab]  OR polic*[tiab] OR procedure*[tiab] OR recommend*[tiab] OR definition*[tiab] OR rule*[tiab] OR 
evidence based*[tiab] )))) AND ((((brain[tiab]  OR head[tiab]  OR crani*[tiab] OR cerebr*[tiab] OR capitis[tiab]  OR 
hemisphere*[tiab]) AND (injur*[tiab] OR trauma*[tiab] OR posttrauma*[tiab] OR damag*[tiab])) OR concus*[tiab] OR 
contus*[tiab] OR neurotraum*[tiab] OR tbi[tiab]  OR mtbi[tiab] )) AND publisher[sb] 
 
Google scholar 
adherence|compliance|nonadherence|noncompliance  protocol|protocols|guideline|guidelines "brain|head 
injury|injuries|trauma"|concussion|tbi|mtbi 
 
Opengrey.eu 
Handsearch (use criteria google scholar) 
 
Dissertations 
Handsearch (use criteria google scholar) 
 
Reference lists of included papers / relevant reviews 
Handsearch after the initial selections of papers 
 
ISI web of science  
Handsearch after the initial selections of papers 
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 262 | Guidelines and adherence 
Appendix 11.C Table of related studies that were excluded  
Reason exclusion Studies 
Study measured guideline adherence in a group of 
patients of which a part did not fit the guideline criteria  
Arabi (2010); Frohlich (2011); Myburgh (2008); Raj 
(2013); Watts (2012) 
 
Study was about a local guideline Crandall (2010); Mossop (2009) 
Study had a qualitative design (survey) Duus (1997); Strand (2012) 
Study included all trauma patients and results for TBI 
patients were not reported separately 
Gage (2012) 
 
Study examined how many CT scans would have been 
performed if guidelines were implemented  
Harris (2006); Hassan (2005)  
Study examined adherence to more than one guideline 
of which none was implemented 
Gupta (2014); Kerr (2010); Korley (2013); Melnick (2012) 
Study included all patients with blunt force trauma above 
the neck (including facial injuries) 
Kerr (2005); Kerr (2010) 
Study measured adherence not per patient but per 
measurement 
Neumann (2008); Griesdale (2014); Thompson (2006) 
Study did not measure adherence Palmer (2001) 
Study measured deviations from the protocol in clinical 
characteristics (e.g. hypotension, hypocapnia) and did 
not measure whether patients have been treated 
adequately 
Schirmer-Mikalsen (2012); Schirmer-Mikalsen (2013) 
Study is about a consensus guideline Thomas (2002) 
Study measured whether neurological observations were 
prescribed according to the guidelines; but not if they 
were conducted (while authors describe that they could 
have been performed if they weren’t prescribed)  
Qureshi (2005) 
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1
3
 U
SD
; 
U
M
I =
 u
p
p
e
r 
m
id
d
le
 in
co
m
e
, G
D
P
 =
 7
7
2
4
 a
n
d
 8
8
0
3
 U
SD
; 
LM
I =
 lo
w
e
r 
gu
id
e
lin
e
s 
(H
I =
 h
ig
h
e
r 
in
co
m
e
, G
D
P
 =
 3
7
2
1
3
 U
SD
; 
U
M
I =
 u
p
p
e
r 
m
id
d
le
 in
co
m
e
, G
D
P
 =
 7
7
2
4
 a
n
d
 8
8
0
3
 U
SD
; 
LM
I =
 lo
w
e
r 
m
id
d
le
 in
co
m
e
, G
D
P
 =
 2
1
8
3
 a
n
d
 2
6
3
7
 U
SD
)
m
id
d
le
 in
co
m
e
, G
D
P
 =
 2
1
8
3
 a
n
d
 2
6
3
7
 U
SD
)
m
id
d
le
 in
co
m
e
, G
D
P
 =
 2
1
8
3
 a
n
d
 2
6
3
7
 U
SD
)
m
id
d
le
 in
co
m
e
, G
D
P
 =
 2
1
8
3
 a
n
d
 2
6
3
7
 U
SD
)    
*
 
*
 *
 
*
 P
re
h
o
sp
it
al
 in
tu
b
at
io
n
 (
%
):
 H
I 3
3
4
P
re
h
o
sp
it
al
 in
tu
b
at
io
n
 (
%
):
 H
I 3
3
4
P
re
h
o
sp
it
al
 in
tu
b
at
io
n
 (
%
):
 H
I 3
3
4
P
re
h
o
sp
it
al
 in
tu
b
at
io
n
 (
%
):
 H
I 3
3
4
    (
8
2
%
);
 U
M
I 1
1
8
 (
3
5
%
);
 L
M
I =
 2
2
1
 (
5
2
%
) 
(8
2
%
);
 U
M
I 1
1
8
 (
3
5
%
);
 L
M
I =
 2
2
1
 (
5
2
%
) 
(8
2
%
);
 U
M
I 1
1
8
 (
3
5
%
);
 L
M
I =
 2
2
1
 (
5
2
%
) 
(8
2
%
);
 U
M
I 1
1
8
 (
3
5
%
);
 L
M
I =
 2
2
1
 (
5
2
%
) 
    
U
n
ad
ju
st
e
d
 (
C
h
i s
U
n
ad
ju
st
e
d
 (
C
h
i s
U
n
ad
ju
st
e
d
 (
C
h
i s
U
n
ad
ju
st
e
d
 (
C
h
i s
q
u
ar
e
):
 p
 <
 0
.0
0
0
1
q
u
ar
e
):
 p
 <
 0
.0
0
0
1
q
u
ar
e
):
 p
 <
 0
.0
0
0
1
q
u
ar
e
):
 p
 <
 0
.0
0
0
1
    
*
 
*
 *
 
*
 D
ir
e
ct
 t
ra
n
sp
o
rt
: H
I 3
4
3
 (
8
4
%
);
 U
M
I 2
0
1
 (
6
0
%
);
 L
M
I 2
3
5
 (
5
5
%
)
D
ir
e
ct
 t
ra
n
sp
o
rt
: H
I 3
4
3
 (
8
4
%
);
 U
M
I 2
0
1
 (
6
0
%
);
 L
M
I 2
3
5
 (
5
5
%
)
D
ir
e
ct
 t
ra
n
sp
o
rt
: H
I 3
4
3
 (
8
4
%
);
 U
M
I 2
0
1
 (
6
0
%
);
 L
M
I 2
3
5
 (
5
5
%
)
D
ir
e
ct
 t
ra
n
sp
o
rt
: H
I 3
4
3
 (
8
4
%
);
 U
M
I 2
0
1
 (
6
0
%
);
 L
M
I 2
3
5
 (
5
5
%
)    
U
n
ad
ju
st
e
d
 (
C
h
i s
U
n
ad
ju
st
e
d
 (
C
h
i s
U
n
ad
ju
st
e
d
 (
C
h
i s
U
n
ad
ju
st
e
d
 (
C
h
i s
q
u
ar
e
):
 p
 <
 0
.0
0
0
1
q
u
ar
e
):
 p
 <
 0
.0
0
0
1
q
u
ar
e
):
 p
 <
 0
.0
0
0
1
q
u
ar
e
):
 p
 <
 0
.0
0
0
1
    
*
 
*
 *
 
*
 S
te
ro
id
s 
n
o
t 
u
se
d
: 
H
I 3
8
9
 (
9
6
%
);
 U
M
I 3
1
8
 (
9
4
%
);
 L
M
I 1
5
3
 (
3
6
%
)
St
e
ro
id
s 
n
o
t 
u
se
d
: 
H
I 3
8
9
 (
9
6
%
);
 U
M
I 3
1
8
 (
9
4
%
);
 L
M
I 1
5
3
 (
3
6
%
)
St
e
ro
id
s 
n
o
t 
u
se
d
: 
H
I 3
8
9
 (
9
6
%
);
 U
M
I 3
1
8
 (
9
4
%
);
 L
M
I 1
5
3
 (
3
6
%
)
St
e
ro
id
s 
n
o
t 
u
se
d
: 
H
I 3
8
9
 (
9
6
%
);
 U
M
I 3
1
8
 (
9
4
%
);
 L
M
I 1
5
3
 (
3
6
%
)    
U
n
ad
ju
st
e
d
 (
C
h
i s
U
n
ad
ju
st
e
d
 (
C
h
i s
U
n
ad
ju
st
e
d
 (
C
h
i s
U
n
ad
ju
st
e
d
 (
C
h
i s
q
u
ar
e
):
  p
 <
 0
.0
0
0
1
q
u
ar
e
):
  p
 <
 0
.0
0
0
1
q
u
ar
e
):
  p
 <
 0
.0
0
0
1
q
u
ar
e
):
  p
 <
 0
.0
0
0
1
 
B
o
ld
 =
 s
ta
ti
st
ic
al
ly
 s
ig
n
if
ic
an
t 
as
so
ci
at
io
n
; I
ta
lic
 =
 s
ta
ti
st
ic
al
ly
 n
o
n
-s
ig
n
if
ic
an
t 
as
so
ci
at
io
n
.  
B
TF
: 
B
ra
in
 T
ra
u
m
a 
Fo
u
n
d
at
io
n
; 
IC
P
: 
in
tr
ac
ra
n
ia
l 
p
re
ss
u
re
; 
IQ
R
: 
in
te
rq
u
ar
ti
le
 r
an
ge
; 
IC
P
+
: 
p
at
ie
n
ts
 i
n
 w
h
ic
h
 I
C
P
 m
o
n
it
o
ri
n
g 
gu
id
e
lin
e
s 
w
e
re
 a
d
h
e
re
d
 t
o
; 
IC
P
-:
 p
at
ie
n
ts
 i
n
 w
h
ic
h
 I
C
P
 m
o
n
it
o
ri
n
g 
gu
id
e
lin
e
s 
w
e
re
 n
o
t 
ad
h
e
re
d
 t
o
; 
O
R
: 
o
d
d
s 
ra
ti
o
; 
E
V
D
: 
e
xt
e
rn
al
 v
e
n
tr
ic
u
la
r 
d
ra
in
; 
C
T
: 
co
m
p
u
te
d
 t
o
m
o
gr
ap
h
y;
 H
IS
S:
 H
e
ad
 I
n
ju
ry
 S
e
ve
ri
ty
 S
co
re
; 
B
A
C
: 
b
lo
o
d
 a
lc
o
h
o
l c
o
n
ce
n
tr
at
io
n
; 
SB
P
: 
sy
st
o
lic
 b
lo
o
d
 p
re
ss
u
re
; 
IS
S:
 I
n
ju
ry
 S
e
ve
ri
ty
 S
co
re
; 
G
C
S:
 G
la
sg
o
w
 C
o
m
a 
Sc
al
e
; 
A
IS
: 
A
b
b
re
vi
at
e
d
 I
n
ju
ry
 S
co
re
; 
IP
H
: 
in
tr
ap
ar
e
n
ch
ym
al
 h
e
m
o
rr
h
ag
e
; 
 P
T:
 p
ro
th
ro
m
b
in
 t
im
e
; 
IN
R
: 
in
te
rn
at
io
n
al
 n
o
rm
al
is
e
d
 r
at
io
; 
 P
TT
: 
p
ar
ti
al
 t
h
ro
m
b
o
p
la
st
in
g 
ti
m
e
; 
SA
H
: 
su
b
ar
ac
h
n
o
id
 
h
e
m
o
rr
h
ag
e
; 
H
A
IS
: 
H
e
ad
 A
b
b
re
vi
at
e
d
 I
n
ju
ry
 S
co
re
; 
A
P
A
C
H
E
: 
A
cu
te
 P
h
ys
io
lo
gy
 a
n
d
 C
h
ro
n
ic
 H
e
al
th
 E
va
lu
at
io
n
; 
C
V
A
: 
ce
re
b
ro
va
sc
u
la
r 
ac
ci
d
e
n
t;
 S
D
H
: 
su
b
d
u
ra
l 
h
e
m
o
rr
h
ag
e
; 
G
D
P
: 
gr
o
ss
 d
o
m
e
st
ic
 p
ro
d
u
ct
; 
H
I:
 h
ig
h
 
in
co
m
e
; 
U
M
I:
 u
p
p
e
r 
m
id
d
le
 in
co
m
e
; 
 L
M
I:
 lo
w
e
r 
m
id
d
le
 in
co
m
e
. 
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A
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d
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 1
1
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A
p
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d
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 1
1
.E
 
A
p
p
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d
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 1
1
.E
 
A
p
p
en
d
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 1
1
.E
 A
d
h
e
re
n
ce
 a
n
d
 o
u
tc
o
m
e
 
St
u
d
y 
ID
St
u
d
y 
ID
St
u
d
y 
ID
St
u
d
y 
ID
    
St
at
is
ti
ca
l m
e
th
o
d
 (
o
u
tc
o
m
e
)
St
at
is
ti
ca
l m
e
th
o
d
 (
o
u
tc
o
m
e
)
St
at
is
ti
ca
l m
e
th
o
d
 (
o
u
tc
o
m
e
)
St
at
is
ti
ca
l m
e
th
o
d
 (
o
u
tc
o
m
e
)    
O
u
tc
o
m
e
 v
ar
ia
b
le
s
O
u
tc
o
m
e
 v
ar
ia
b
le
s
O
u
tc
o
m
e
 v
ar
ia
b
le
s
O
u
tc
o
m
e
 v
ar
ia
b
le
s    
St
at
is
ti
cs
 
St
at
is
ti
cs
 
St
at
is
ti
cs
 
St
at
is
ti
cs
     
A
la
li 
(2
0
1
3
) 
Tw
o
 r
an
d
o
m
 in
te
rc
e
p
t 
m
u
lt
ile
ve
l l
o
gi
st
ic
 r
e
gr
e
ss
io
n
 m
o
d
e
ls
 w
it
h
 
re
sp
e
ct
iv
e
ly
 IC
P
 m
o
n
it
o
ri
n
g 
as
 a
 p
at
ie
n
t-
le
ve
l f
ac
to
r 
an
d
 a
 h
o
sp
it
al
-
sp
e
ci
fi
c 
IC
P
 u
ti
lis
at
io
n
 r
at
e
 (
ca
te
go
ri
se
d
 in
to
 q
u
ar
ti
le
s)
 a
d
ju
st
e
d
 f
o
r 
p
at
ie
n
t-
 a
n
d
 h
o
sp
it
al
-l
e
ve
l c
o
va
ri
at
e
s 
In
-h
o
sp
it
al
 m
o
rt
al
it
y 
 
P
at
ie
n
t 
le
ve
l m
o
d
e
l (
ad
j.
) 
O
R
 d
e
at
h
 IC
P
+
 0
.4
4
 (
9
5
%
C
I:
 
0
.3
1
–
0
.6
3
);
 
H
o
sp
it
al
-l
e
ve
l m
o
d
e
l (
ad
j.
):
 O
R
 d
e
at
h
 IC
P
+
 (
h
ig
h
e
st
 –
 
lo
w
e
st
 q
u
ar
ti
le
):
 0
.5
2
 (
9
5
%
C
I:
 0
.3
5
–
0
.7
8
) 
B
ie
rs
te
ke
r 
(2
0
1
2
) 
C
h
i2
 a
n
d
 t
w
o
 m
u
lt
iv
ar
ia
te
 lo
gi
st
ic
 r
e
gr
e
ss
io
n
 a
n
a
ly
se
s 
w
it
h
 6
 m
o
n
th
 
o
u
tc
o
m
e
 d
ic
h
o
to
m
is
e
d
 a
s 
d
e
ad
 (
ye
s/
n
o
) 
an
d
 u
n
fa
vo
ra
b
le
 o
u
tc
o
m
e
 
(y
e
s 
=
 G
O
SE
 1
–
4
/n
o
 =
 G
O
SE
 5
–
8
) 
ad
ju
st
e
d
 f
o
r 
p
at
ie
n
t’
s 
p
ro
p
e
n
si
ty
 
sc
o
re
 o
f 
re
ce
iv
in
g 
an
 IC
P
 m
o
n
it
o
r 
in
se
rt
e
d
 
6
 m
o
n
th
 m
o
rt
al
it
y 
(n
, %
) 
 6
 m
o
n
th
 u
n
fa
vo
ra
b
le
 o
u
tc
o
m
e
 
(n
, %
) 
IC
U
 L
O
S 
(m
e
d
ia
n
, 
IQ
R
) 
M
o
rt
al
it
y 
IC
P
+
 5
9
 (
4
8
%
);
  I
C
P
- 
5
2
 (
3
7
%
),
 p
 =
 .0
7
 
O
R
 d
e
at
h
 (
ad
j.
) 
0
.9
3
 (
9
5
%
C
I:
 0
.4
7
–
1
.8
5
) 
IC
P
+
 8
1
 (
7
4
%
),
 IC
P
- 
6
7
 (
5
3
%
),
 p
<
 .0
0
1
 
O
R
 u
n
fa
v 
(a
d
j.
) 
1
.8
1
 (
9
5
%
C
I:
 0
.8
8
–
3
.7
3
) 
IC
P
+
 1
0
.8
 (
4
.2
–
2
1
);
 IC
P
- 
2
.6
5
 (
1
.0
0
–
6
.9
),
 p
<
.0
0
1
 
 
 
H
o
sp
it
al
 L
O
S 
(m
e
d
ia
n
, I
Q
R
) 
IC
P
+
 2
2
.0
 (
8
.3
–
4
4
),
 IC
P
- 
7
.4
8
 (
1
.9
–
2
0
),
 p
<
.0
0
1
 
B
u
lg
e
r 
(2
0
0
2
) 
A
gg
re
ss
iv
e
 c
e
n
te
rs
 (
IC
P
 m
o
n
it
o
ri
n
g 
in
 >
 5
0
%
 o
f 
p
at
ie
n
ts
 w
it
h
 a
 B
TF
 
in
d
ic
at
io
n
) 
ar
e
 c
o
m
p
ar
e
d
 w
it
h
 n
o
n
-a
gg
re
ss
iv
e
 c
e
n
te
rs
 (
IC
P
 m
o
n
it
o
ri
n
g 
≤
 5
0
%
 o
f 
th
e
 p
at
ie
n
ts
 w
it
h
 a
 B
T
F 
in
d
ic
at
io
n
) 
u
si
n
g 
a 
C
o
x 
p
ro
p
o
rt
io
n
al
 
h
az
ar
d
s 
m
o
d
e
l a
d
ju
st
e
d
 f
o
r 
b
as
e
lin
e
 c
h
ar
ac
te
ri
st
ic
s 
an
d
 t
re
at
m
e
n
t 
ch
ar
ac
te
ri
st
ic
s.
 T
h
e
 a
ss
o
ci
at
io
n
 w
it
h
 L
O
S 
w
as
 c
al
cu
la
te
d
 u
si
n
g 
lin
e
ar
 
re
gr
e
ss
io
n
 c
o
n
tr
o
lli
n
g 
fo
r 
IS
S<
 h
e
ad
 A
IS
, a
ge
, a
n
d
 h
yp
o
te
n
si
o
n
 o
n
 
ad
m
is
si
o
n
 
In
-h
o
sp
it
al
 m
o
rt
al
it
y 
 
H
az
ar
d
 R
at
io
 =
 0
.4
3
 (
9
5
%
C
I:
 0
.2
7
–
0
.6
6
) 
H
o
sp
it
al
 L
O
S 
 
M
e
an
 d
if
fe
re
n
ce
 =
 –
6
 (
9
5
%
C
I:
 (
–
1
4
) 
–
 2
),
 p
 =
 .1
4
3
 
Fa
kh
ry
 
(2
0
0
4
) 
C
o
m
p
ar
is
o
n
 o
f 
a 
h
is
to
ri
ca
l c
o
n
tr
o
l g
ro
u
p
 (
1
9
9
1
–
9
4
),
 lo
w
 a
d
h
e
re
n
ce
 
(1
9
9
5
–
9
6
, 5
0
%
 a
d
h
e
re
n
ce
) 
an
d
 h
ig
h
 a
d
h
e
re
n
ce
 (
1
9
9
7
–
0
0
, 8
8
%
 
ad
h
e
re
n
ce
) 
u
si
n
g 
F 
te
st
 a
n
d
 T
u
ke
ys
 h
o
n
e
st
 s
ig
n
if
ic
an
t 
d
if
fe
re
n
ce
 
m
u
lt
ip
le
 c
o
m
p
ar
is
o
n
 (
p
o
st
 h
o
c)
 f
o
r 
si
gn
if
ic
an
t 
re
su
lt
s 
M
o
rt
al
it
y 
(%
) 
9
1
–
9
4
: 
1
7
.8
%
; 
9
5
–
9
6
: 
1
8
.6
%
; 
9
7
–
0
0
: 
1
3
.8
%
, p
 =
 .0
4
7
 
IC
U
 L
O
S 
(m
e
an
) 
9
1
–
9
4
: 
9
.7
; 
9
5
–
9
6
: 
8
.4
; 
9
7
–
0
0
: 
7
.9
, p
 =
 .0
2
1
 
H
o
sp
it
al
 L
O
S 
(m
e
a
n
) 
9
1
–
9
4
: 
2
1
.2
; 
9
5
–
9
6
: 
1
6
.7
; 
9
7
–
0
0
: 
1
5
.8
, p
 =
 .0
0
1
 
Fa
vo
ra
b
le
 o
u
tc
o
m
e
 (
G
O
SE
, %
 
go
o
d
 r
e
co
ve
ry
) 
at
 d
is
ch
ar
ge
 
9
1
–
9
4
:4
3
.4
%
; 
9
5
–
9
6
: 
5
0
.3
%
; 
9
7
–
0
0
: 
6
1
.5
%
, p
<
.0
0
1
 
 
R
LA
S 
(%
 a
p
p
ro
p
ri
a
te
) 
at
 
d
is
ch
ar
ge
 
9
1
–
9
4
: 
4
3
.9
%
; 
9
5
–
9
6
: 
4
4
.0
%
; 
9
7
–
0
0
: 
5
6
.6
%
, p
 =
 .
0
0
4
 
Fa
ra
h
va
r 
(2
0
1
2
) 
G
e
rb
e
r 
(2
0
1
3
) 
C
h
i2
 a
n
d
 m
u
lt
iv
ar
ia
te
 lo
gi
st
ic
 r
e
gr
e
ss
io
n
 a
n
al
ys
is
 t
o
 a
d
ju
st
 f
o
r 
ag
e
, 
h
yp
o
te
n
si
o
n
 s
ta
tu
s 
o
n
 d
ay
 1
, p
u
p
ill
ar
y 
st
at
u
s 
o
n
 d
ay
 1
, i
n
it
ia
l G
C
S 
sc
o
re
, a
n
d
 C
T 
re
su
lt
s 
w
it
h
 2
 w
e
e
ks
 m
o
rt
al
it
y 
as
 d
e
p
e
n
d
e
n
t 
va
ri
ab
le
 
Tw
o
-w
e
e
ks
 m
o
rt
al
it
y 
(n
, %
) 
IC
P
+
 2
1
2
 (
1
9
.6
%
);
 IC
P
- 
7
4
 (
3
3
.2
%
);
 p
<
.0
0
1
 
O
R
 =
 0
.6
4
 (
.4
1
–
1
.0
0
),
 p
 =
 .0
5
 
G
ri
e
sd
al
e
 
(2
0
1
0
) 
Fi
sh
e
r’
s 
e
xa
ct
 t
e
st
, t
-t
e
st
, W
ilc
o
xo
n
 r
an
k-
su
m
 t
e
st
s 
an
d
 m
u
lt
iv
ar
ia
te
 
lo
gi
st
ic
 r
e
gr
e
ss
io
n
 a
n
al
ys
is
 a
d
ju
st
e
d
 f
o
r 
G
C
S 
an
d
 t
h
e
 p
ro
p
e
n
si
ty
 s
co
re
 
o
f 
h
av
in
g 
an
 E
V
D
 m
o
n
it
o
r 
in
se
rt
e
d
 
In
-h
o
sp
it
al
 m
o
rt
al
it
y 
(n
, %
) 
IC
P
+
 2
8
 (
2
8
.6
%
),
 IC
P
- 
9
 (
1
2
.3
%
),
 p
 <
 .
0
1
 
O
R
 (
ad
j.
):
 2
.8
 (
1
.1
–
7
.1
) 
2
8
-d
ay
 m
o
rt
al
it
y 
(m
e
an
, S
D
) 
IC
P
+
 2
2
 (
2
2
.4
%
),
 IC
P
- 
9
 (
1
2
.3
%
),
 p
 =
 .0
7
 
O
R
 (
ad
j.
):
 2
.1
 (
0
.8
0
–
5
.6
) 
IC
U
 L
O
S 
(m
e
d
ia
n
, S
D
) 
IC
P
+
 1
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ABSTRACT 
 
Background Acute pain in trauma patients in emergency care is still undertreated. Early pain 
treatment is assumed to effectively reduce pain in patients and improve long-term outcomes. 
In order to improve pain management in the chain of emergency care, a national evidence-
based guideline was developed. The aim of this study was to assess whether current practice 
is in compliance with the guideline ‘Pain management for trauma patients in the chain of 
emergency care’ from the Netherlands Association for Emergency Nurses (in Dutch NVSHV), 
and to evaluate early and initial pain management for adult trauma patients in emergency 
care. 
 
Methods Chart reviews were conducted in three regions of the Netherlands using electronic 
patient files of trauma patients from the chain of emergency care. We included one after-
hours General Practitioner Co-operation (GPC), one ambulance Emergency Medical Services 
(EMS), two Helicopter Emergency Medical Services (HEMS), and three Emergency 
Departments (EDs). Organisation of pain management, pain assessment, and pain treatment 
was examined and compared with national guideline recommendations, including quality 
indicators. 
 
Results We assessed a random sample of 1,066 electronic patient files. The use of 
standardised tools to assess pain was registered in zero to 52% of the electronic patient files 
per organisation. Registration of (non-)pharmacological pain treatment was found in less than 
half of the files. According to the files, pharmacological pain treatment deviated from the 
guideline in 73–99% of the files. Time of administration of medication was missing in 73–
100%. Reassessment of pain following pain medication was recorded in half of the files by the 
HEMS, but not in files of the other organisations. 
 
Conclusions The (registration of) current pain management in trauma patients in the chain of 
emergency care varies widely between health care organisation, and deviates from national 
guideline recommendations. Although guideline compliance differs across groups of health 
care professionals, maximum compliance rate with indicators registered is 52%. In order to 
improve pain management and evaluate its effectiveness, we recommend to improve pain 
registration in patient files. Furthermore, we advise to identify barriers and facilitators related 
to the implementation of the national guideline in all emergency care organisations. 
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12.1 INTRODUCTION 
 
Treatment of acute pain in emergency care still gets insufficient attention.1 Acute pain and trauma are 
often closely related to one another, as pain is induced by noxious stimuli at the site of tissue damage.2 
Recent studies show that the prevalence of pain in trauma patients in the Dutch (pre-hospital) 
emergency care setting is 70–91%.1,3 In contrast to the improved treatment of postoperative and 
chronic pain,4,5 the treatment of acute pain in emergency care is low;1 only 19–30% of trauma patients 
receive pharmacological pain treatment.1,3 
Emergency care for trauma patients encompasses the care for patients with recent (within 24h) 
suspected injuries caused by blunt or penetrating forces, falls, explosions, heat/cold or chemical 
toxicants. In the Netherlands, emergency care is provided by General Practitioners (Co-operations) 
(GP(C)s), ambulance Emergency Medical Services (EMS), Helicopter Emergency Medical Services 
(HEMS), and Emergency Departments (EDs). Collaboration between health care professionals in the 
chain of emergency care with respect to pain management is not optimal, making it very difficult to 
guarantee continuity of care. As a consequence, pain treatment is not always applied, not continued or 
contradicts the pain management by the preceding professional partner in the chain.6 The 
undertreatment of acute pain can have an adverse effect on the outcome of the treatment, e.g. a delay 
in wound healing, and causes a longer period of recovery.7 Furthermore, poorly treated acute pain can 
result in chronic pain.8 Early pain treatment is therefore of great importance. 
To improve pain management in trauma patients, a national evidence-based guideline ‘Pain 
management for trauma patients in the chain of emergency care’ was developed in 2010.9 This 
multidisciplinary guideline from the Netherlands Association for Emergency Nurses (in Dutch NVSHV) 
provides clear recommendations and quality indicators for early pain management in evaluable, adult 
trauma patients in the chain of emergency care, concerning pain assessment, (non-)pharmacological 
pain treatment, and the organisation of pain management. 
The objective of this study is to 1) assess whether current practice is in compliance with the Dutch 
guideline recommendations, and 2) evaluate early and initial pain management for adult trauma 
patients in the chain of emergency care. The evaluation provides insight into the extent to which the 
guideline is already used by health care professionals in the chain of emergency care. It identifies the 
adherence and deviations in current practice from the quality indicators in the guideline, and provides 
a starting point for the implementation of the guideline. 
 
12.2 METHODS 
 
Design 
Between January and March 2012 (HEMS from October 2011 to March 2012) chart reviews were 
conducted, assessing electronic patient files of trauma patients from seven organisations in the chain 
of emergency care, in three regions of the Netherlands; one after-hours GPC (suburban), one EMS 
(suburban), two HEMS (suburban and urban), and three EDs (rural/suburban, suburban and urban). 
Trauma patients were defined as patients with (suspected) injuries, due to mechanisms of blunt or 
penetrating forces, falls, explosions, heat/cold or chemical toxicants.10 Patient files were used to assess 
whether current practice is in compliance with the guideline ‘Pain management for trauma patients in 
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the chain of emergency care’ from the NVSHV and to evaluate pain assessment and current pain 
management for adult trauma patients in emergency care. 
 
Setting 
The target group of the guideline consists of GPs, physicians and nurses in ambulance EMS and the ED, 
and team members of the HEMS. Dutch GPs organise their after hours primary care – weekdays 5PM 
to 8AM and weekend – in large-scale GPCs.11 Telephone triage nurses assess the urgency of patient’s 
health problem and decide – based on triage protocols12 and guidelines – the appropriate action to be 
taken,11 e.g. using paracetamol. In addition, out-of-hospital emergency care is also provided by nurses 
in EMS; registered nurses who followed a national training programme and deliver pre-hospital care 
autonomously, based on national protocols. These national protocols assist the nurses in the limited 
use of Fentanyl, Ketanest (S-Ketamine), and Midazolam in case of a trauma.13 However, nurses may 
decide to deviate from the protocol (stating reasons) based on the patient’s condition and 
circumstances, or follow advices from regional protocols, e.g. using paracetamol. Care provided by EMS 
nurses can be complemented by team members of a HEMS. Four HEMS, which are available on a 24/7 
basis for the whole country, are equipped with a specially trained team including a HEMS physician 
(trauma surgeon or anaesthesiologist), a registered flight nurse, and a pilot. This team is capable of 
delivering hospital-level medical care and advanced pain management at the accident site, including 
the use of anaesthesia and certain analgesics. At the ED, a triage nurse assigns an urgency level to the 
patient’s health problem,14 and may decide to give a patient certain pain medications before treatment 
by a physician. Care at the ED is provided by registered physicians and nurses who followed additional 
training in emergency medicine. 
 
Guideline 
The national evidence-based guideline was developed in 2010 by a multidisciplinary working group 
consisting of representatives from all relevant professionals working in emergency care: general 
practitioners, EMS nurses, HEMS physicians and nurses, physicians and nurses working in the ED, nurse 
practitioners, physician assistants, anaesthesiologists and physicians of surgical and orthopaedic 
traumatology departments. The guideline offers professionals recommendations and indicators, 
concerning pain assessment, initial (non-)pharmacological pain treatment, and the organisation of pain 
management in the chain of emergency care. The guideline has been distributed among these 
organisations, but has not yet been actively implemented nationwide. 
The guideline recommends to register pain scores, initial (non- )pharmacological pain treatment and 
time of administration of medication in the medical records. The guideline suggests to use the verbal 
Numeric Rating Scale (NRS), a scale from zero to ten with zero as no pain and ten as unbearable pain, 
to assess pain score. Pain needs to be assessed at least three times; at arrival, after (non-
)pharmacological intervention, and at the end of the medical visit. Non-pharmacological treatment of 
patients with fractures, contusions, and soft tissue injuries should be delivered according to the RICE#-
criteria – Rest, Ice, Compression and Elevation. 
According to the guideline, initial pharmacological pain management should be given as indicated by 
algorithms, designed specifically for ambulance EMS, HEMS, GP(C) and ED (Figure 12.1 to 12.3). 
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Figure 12.1 Algorithm for pharmacological pain management in ambulance EMS 
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Figure 12.2 Algorithm for pharmacological pain management in HEMS 
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Figure 12.3 Algorithm for pharmacological pain management in GP(C) and ED 
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These algorithms consist of several routes concerning pain treatment for mild (NRS <4), moderate to 
severe (NRS 4–7) and unbearable pain (NRS >7). In the guideline, paracetamol is the pharmacological 
treatment of first choice, if necessary with additional use of non-steroidal anti-inflammatory drugs 
(NSAIDs) or opioids. Fentanyl and Morphine can be given for severe to unbearable pain during 
emergency care. Administering Ketanest can be considered in case of severe or unbearable pain in 
combination with hypovolemia. 
In order to measure pain management performance by professionals and organisations in emergency 
care, the recommendations in the guideline are translated into essential indicators (Table 12.1).  
 
Table 12.1 Indicators of guideline ‘Pain management for trauma patients in the chain of emergency care’ 
Indicator Numerator /Denominator 
Organisation of pain management   
Pain treatment within 10 min after  
ABCD assessment 
Number of patients pain treatment started ≤10 min after triage or 
intake 
/ Patients with pain 
Registration of pain score Number of patients with registered pain score 
/ Total number of patients 
Registration of non-pharmacological 
pain treatment 
Number of patients with registered non pharmacological pain treatment 
/ Total number of patients 
Registration of pharmacological  
pain treatment 
Number of patients with registered pharmacological pain treatment 
/ Total number of patients 
Registration of time administration of 
medication 
Number of patients with registered time of administration of 
medication 
/ Total number of patients 
Pain assessment   
Using Numeric Rating Score (NRS) Number of patients pain assessed with NRS 
/ Total number of patients 
Using NRS after administration of 
analgesics 
Number of patients with pain score after pain medication  
/ Patients with pain medication 
Acceptable pain level after treatment Number of patients acceptable pain NRS <4 after medication  
/ Patients pain score after medication 
Using NRS three times during treatment Number of patients pain assessed at least three times  
/ Total number of patients 
Pharmacological treatment   
Paracetamol for moderate to severe pain 
(NRS≥4) 
Number of patients with NRS 4–10 receiving paracetamol  
/ Patients with NRS 4–10 
Treatment according to algorithms in 
guideline 
Number of patients receiving treatment according to guideline 
flowcharts 
/ Total number of patients 
 
Data collection and selection of patient files 
Patient files were handled anonymously – without patient identification, e.g. name or address. For each 
organisation, databases were preselected before a random sample for analysis was drawn. The 
preselection was based on the following inclusion criteria: patient in need of emergency care due to a 
recent trauma – less than 24h before admission – aged 18 or older, ABCD-stabile, and verbally 
responsive (Glasgow Coma Scale  ≥14) at least once during treatment. Due to the severity of trauma 
treated by the HEMS and the lower number of HEMS calls (on average 45 non-cancelled flights per 
month in the study period), the preselection of the HEMS included patients with a Glasgow Coma Scale  
≥8. This included also unresponsive patients, in contrast to the other organisations. Exclusion criteria 
were: patients that had drowning injuries, had attempted suicide, were victim of domestic violence, and 
visited ED for wound inspection or removal of stitches. After pre-selecting the electronic patient files, 
around 150 cases were randomly selected from each database. 
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In order to assess the electronic patient files for essential indicators, the quality indicators and 
recommendations from the guideline were translated into a measuring tool which was used to screen 
information in the patient files. The quality indicator ‘treatment according to guideline algorithms’ was 
assessed through a step by step analysis of the information per patient on pain as measured by the NRS, 
followed by the advised pharmacological treatment (dose not taken into account). 
 
Data analysis 
We used descriptive statistics (percentages, means and standard deviations (SDs)) to analyse the 
results. Data was analysed using SPSS 21 (SPSS Inc., Chicago, IL).  
 
12.3 RESULTS 
 
This study included a random sample of 1,066 files out of the 12,407 assessed electronic files of patients 
treated by the seven organisations in the emergency care, including 155 files of GPC, 176 of EMS, 238 
of HEMS, and 497 of ED (Table 12.2). 
 
Table 12.2 Pre-selection, inclusion and random sample per organisation 
Region1 Organisation Period Patient files Sample 
Rural/suburban ED - general January – March 2012 8,741 195 
Suburban GPC January – March 2012 1,224 155 
 EMS January – March 2012 807 176 
 HEMS October 2011 – March 2012 287 120 
 ED – academic January – March 2012 690 157 
Urban HEMS January – March 2012 245 118 
 ED – academic2 January – March 2012 413 145 
Total   12,407 1,066 
1 Defined by number of inhabitants per agglomeration: rural/suburban 159.000; suburban 168.000, urban 1.000.000.15 
2 Selection of patients with primary transport by EMS to the ED. 
 
Characteristics of patients 
Table 12.3 shows the characteristics of the 1,066 trauma patients, of whom most were men (51.1% at 
EMS to 73.1% at HEMS). The age of the trauma patients ranged from 18 to 100, and varied from a mean 
age of 41.9 (SD 17.2) in the GPC to 57.3 (SD 23.2) in the EMS. Most patients treated in the GPC had 
injuries due to sports, while patients treated by the (H)EMS or ED often had injuries that occurred at 
home or during leisure, or in traffic. Mechanism of injuries often included a fall or collision (data not 
shown). 
Most patients had injuries to their extremities (up to 72.1% in the GPC). Patients treated by the (H)EMS 
and ED often had injuries to head/neck (up to 29.4%). The GPC often treated patients with superficial 
injury (24.5%), while the (H)EMS and ED often treated patients with fractures (up to 52.7%). In 1.3% 
(GPC) to 10.1% (ED) of the electronic patient files it was registered that patients were under the 
influence of alcohol and/or drugs. Most electronic patient files did not contain information about the 
mental state of patients (data not shown). 
 
Guideline adherence and current practice of pain management 
Adherence to the guideline is presented in Table 12.4 and 12.5 reports current pain management 
practice based on the chart review.  
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Table 12.3 Characteristics of trauma patients 
Organisation 
(N electronic patient files) 
GPC, N(%) 
n=155 
EMS, N(%) 
n=176 
HEMS, N(%) 
n=238 
ED, N(%) 
n=497 
Gender     
Men 96 (61.9) 90 (51.1) 174 (73.1) 303 (61.0) 
Women 59 (38.1) 86 (48.9) 64 (26.9) 194 (39.0) 
Age     
Mean (SD) 41.9 (17.2) 57.3 (23.2) 45.1 (18.9) 45.1 (20.8) 
18–19 10 (6.5) 5 (2.8) 17 (7.1) 31 (6.2) 
20–39 62 (40.0) 44 (25.0) 95 (39.9) 209 (42.1) 
40–59 59 (38.1) 41 (23.3) 75 (31.5) 121 (24.3) 
60 or older 24 (15.5) 86 (48.8) 51 (21.4) 136 (27.4) 
Cause of injury     
Home and leisure 7 (16.7) 77 (55.4) 37 (23.6) 218 (47.7) 
Traffic 5 (11.9) 41 (29.5) 95 (60.5) 103 (22.5) 
Sports 20 (47.6) 15 (10.8) 10 (6.4) 50 (10.9) 
Work 10 (23.8) 2 (1.4) 9 (5.7) 54 (11.8) 
Violence 0 (0.0) 4 (2.9) 6 (3.8) 32 (7.0) 
Unknown/Not registered 113 36 81 40 
Location of injury     
Head/neck 10 (6.8) 41 (20.1) 130 (29.4) 100 (18.6) 
Face 24 (16.3) 6 (2.9) 63 (14.3) 61 (11.3) 
Thorax 7 (4.8) 17 (8.3) 71 (16.1) 27 (5.0) 
Abdomen 0 (0.0) 10 (4.9) 39 (8.8) 10 (1.9) 
Spinal cord 0 (0.0) 19 (9.3) 28 (6.3) 26 (4.8) 
Extremities 106 (72.1) 111 (54.4) 111 (25.1) 315 (58.4) 
Unknown/Not registered 8 11 21 52 
Observed assumed injury     
Fracture 9 (5.8) 48 (52.7) 109 (23.8) 146 (29.0) 
Dislocation/luxation 21 (13.5) 20 (22.0) 7 (1.5) 39 (7.8) 
Intracranial injury 0 (0.0) 0 (0.0) 69 (15.1) 35 (7.0) 
Internal injury1 3 (1.9) 0 (0.0) 31 (6.8) 17 (3.4) 
Open wound 16 (10.3) 9 (9.9) 26 (5.7) 53 (10.5) 
Injury to blood vessel 17 (11.0) 6 (6.6) 31 (6.8) 7 (1.4) 
Superficial injury 38 (24.5) 1 (1.1) 63 (13.8) 77 (15.3) 
Contusion 0 (0.0) 2 (2.2) 71 (15.5) 64 (12.7) 
Other 51 (32.9) 5 (5.5) 51 (11.1) 65 (12.9) 
Unknown/Not registered 0 93 24 80 
Under influence      
Alcohol 2 (1.3) 8 (4.5) 19 (8.0) 50 (10.1) 
Drugs 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) 
Alcohol and drugs 0 (0.0) 1 (0.6) 1 (0.4) 5 (1.0) 
Unknown/Not registered 153 167 218 441 
1 Internal injury of thorax, abdomen and/or pelvis. 
 
Organisation of pain management 
According to the registration in patient files, one fifth of patients of the HEMS and ED received pain 
treatment within 10 min after the ABCD assessment. For the GPC and the EMS this indicator could not 
be calculated due to missing time and pain score registrations. Registration of pain scores was lacking 
in the GPC, and varied from 15% in the EMS up to 52% in the ED. The registration of non-
pharmacological pain treatment varied from 14% in the EMS up to 49% in the HEMS. Pharmacological 
pain treatment was registered in 13% in the GPC up to 48% in the (H)EMS. Finally, the registration of 
the time of administration of analgesia was not or poorly reported in the GPC (0%), EMS (1%) and HEMS 
(13%). However, over one in four electronic files in the ED contained a time of administration of 
analgesia (27%). 
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Table 12.4 Guideline adherence 
Organisation 
(N electronic patient files) 
GPC, N(%) 
n=155 
EMS, N(%) 
n=176 
HEMS, N(%) 
n=238 
ED, N(%) 
n=497 
Organisation of pain treatment     
Pain treatment within 10 min after ABCD assessment1 * * 10 (18) 23 (20) 
Registration of pain score (any scoring instrument) 0 (0) 26 (15) 68 (29) 259 (52) 
Registration of non-pharmacological pain treatment 47 (30) 24 (14) 117 (49) 50 (46) 
Registration of pharmacological pain treatment 20 (13) 84 (48) 115 (48) 228 (46) 
Registration of time administration of medication 0 (0) 2 (1) 31 (13) 132 (27) 
Pain assessment     
Using Numeric Rating Score (NRS) 0 (0) 26 (15) 68 (29) 126 (25) 
After administration of pain medication2 * * 27 (48) * 
Acceptable pain level after treatment3 * * 14 (52) * 
At least three times during treatment * 3 (2) 25 (11) 13 (3) 
Pharmacological treatment     
Paracetamol for moderate to severe pain (NRS≥4)4 * 6 (32) 1 (3) 37 (50) 
Treatment according to algorithms in guideline * 22 (13) 3 (1) 132 (27) 
Percentages are presented and calculated by the number divided by the total number of patients per organisation. 
1 Divided by number of patients with pain (HEMS: 56, ED: 115). 2 Divided by number of patients with pain medication (HEMS: 56). 3 Divided 
by number of patients with a pain score after medication (HEMS: 27). 4 Divided by number of patients with NRS 4-10 (EMS: 19, HEMS: 39, 
ED: 74). 
* Cannot be calculated due to missing, not registered or unknown data. 
 
Pain assessment 
The files of the GPC and one HEMS indicated that a systematic pain score with the NRS was not used. 
In the EMS professionals registered the NRS in 15% of the patients, while for the ED in 25% and the 
other HEMS in 57% of the files a pain score was reported. If pain was assessed, it was mostly registered 
as assessed once during treatment. Indicators on the effectiveness of pain management (pain 
assessment after medication, and acceptable pain level after treatment) could not be calculated for the 
GPC, EMS and ED, due to the missing time registrations of the pain score and administration of 
pharmacological pain treatment. For the HEMS half of the patients (52%) had an acceptable pain score 
registered after pharmacological interventions. 
 
(Non-)pharmacological treatment 
Non-pharmacological treatment of patients treated by the GPC often consisted of a bandage (57.4%), 
while treatment at the ED (64.5%) and HEMS (77.8%) often consisted of immobilisation by splint or cast 
(Table 12.5). Pharmacological pain treatment was administered and registered in accordance to the 
algorithms of the guideline in 1% (HEMS) up to 27% (ED) of the patients. Guideline adherence for the 
GPC could not be assessed, because the recommendations regarding pain management in the guideline 
are based on intensity of pain, and the GPs reported no pain scores in the files. 
 
In general, only the registered pain treatment at the ED often included paracetamol (35.5%) or a 
combination with paracetamol (49.6%). Half of the patients with severe or unbearable pain in the ED 
received paracetamol (50%); this was in contrast with the HEMS, where no or hardly any paracetamol 
was (registered to be) administered to patients in severe or unbearable pain. Due to the often life-
threatening injuries, patients in the HEMS were mostly treated without paracetamol (51.3%), and were 
provided with more stronger analgesia like Ketanest or anaesthesia. The files indicated that patients of 
all severities received paracetamol (45.0%), NSAID (40.0%) or a combination of medications including 
paracetamol (15.0%) in the GPC, and Fentanyl in the EMS (36.9%) and HEMS (47.0%). 
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Overall, the chart review showed that the current registration of pain management mainly (but poorly) 
focused on the administration of analgesia and not on the pain assessment and evaluation, with a 
maximum compliance rate of 52%.  
 
Table 12.5 Current practice of pain management 
Organisation 
(N electronic patient files) 
GPC, N(%) 
n=155 
EMS, N(%) 
n=176 
HEMS, N(%) 
n=238 
ED, N(%) 
n=497 
Type of scale     
NRS 0 (0.0) 26 (100) 68 (100) 126 (47.5) 
VRS 0 (0.0) 0 (0.0) 0 (0.0) 117 (44.2) 
NRS and VRS 0 (0.0) 0 (0.0) 0 (0.0) 16 (6.0)  
Other 0 (0.0) 0 (0.0) 0 (0.0) 6 (2.3) 
No/Unknown/Not registered1 155 150 170 232 
Number of assessments     
Once 0 (0.0) 18 (69.2) 28 (35.4) 229 (88.4) 
Twice 0 (0.0) 5 (19.2) 26 (32.9) 17 (6.6) 
3 times 0 (0.0) 3 (11.5) 25 (31.6) 13 (5.0) 
Unknown/Not registered1 155 150 159 238 
Non-pharmacological     
No 1 (2.1) 6 (25.0) 22 (18.8) 2 (0.9) 
Immobilisation 0 (0.0) 10 (41.7) 91 (77.8) 149 (64.5) 
Ice 5 (10.6) 0 (0.0) 0 (0.0) 1 (0.4) 
Compression 8 (17.0) 0 (0.0) 0 (0.0) 35 (15.2) 
Elevation 1 (2.1) 1 (4.2) 0 (0.0) 11 (4.8) 
Bandage 27 (57.4) 7 (29.2) 2 (1.7) 18 (7.8) 
Other 5 (10.6) 0 (0.0) 2 (1.7) 15 (6.5) 
Unknown/Not registered1 108 152 121 266 
Pharmacological     
Paracetamol 9 (45.0) 15 (17.9) 0 (0.0) 81 (35.5) 
NSAID 8 (40.0) 0 (0.0) 0 (0.0) 6 (2.6) 
Fentanyl 0 (0.0) 31 (36.9) 54 (47.0) 13 (5.7) 
Morfine 0 (0.0) 2 (2.4) 0 (0.0) 9 (3.9) 
Nitrous 50%/ oxygen 50% 0 (0.0) 3 (3.6) 0 (0.0) 0 (0.0) 
Other 0 (0.0) 6 (7.1) 0 (0.0) 0 (0.0) 
Combination with paracetamol 3 (15.0) 14 (16.7) 2 (1.7) 113 (49.6) 
Combination without paracetamol 0 (0.0) 13 (15.5) 59 (51.3)* 6 (2.6) 
Unknown/Not registered1 135 92 123 269 
1 Missing information can have several meanings; assessment/treatment has not been done/provided unfairly, has not been done/provided 
with good reasons, was not needed at all, or has been done/provided but not registered. 
* HEMS provides advanced pain treatment, while the guideline is limited to initial pain treatment. 
 
12.4 DISCUSSION 
 
Our study showed that (registration of) current pain management in trauma patients in the chain of 
emergency care varies widely between health care organisations, and is suboptimal. The assessment of 
pain scores using standardised tools was only registered in zero to 52% of the electronic patient files 
per organisation. Registration of (non-)pharmacological pain treatment was found in less than half of 
the files. According to the available information in the electronic patient files, pharmacological pain 
treatment was not in accordance with the guideline in 73–99% of the files. The time of administration 
of medication was missing in 73–100% of the patient files. Reassessment of pain following 
administration of pain medication was recorded in half of the patient files by the HEMS, but not in any 
of the patient files of the other organisations. 
Although the Dutch guideline has been distributed among the organisations in emergency care, it has 
not yet been actively implemented nationwide. As a first step in the implementation of the guideline, 
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this study assessed where current practice deviates from the guideline recommendations. It is 
important to note that any differences found are not interpreted as violations, but rather as issues for 
which the reasons need to be explored. Thus, a next step is to explore reasons for deviations from the 
guideline, which may depend on the circumstances, patient characteristics and injury severity. For 
example, the HEMS provides care to patients with often life-threatening injuries and unstable vital signs, 
and their advanced pain management often does not start with the administration of paracetamol and 
reaches beyond the algorithm for initial pain management in the guideline. Before deciding on an 
implementation strategy, barriers and facilitators for guideline adherence in the chain of emergency 
care need to be identified. 
A limitation of this study was the use of chart review to assess current practice. The data registered by 
the emergency care organisations was not primarily gathered for research purposes, and not all 
organisations had the ability to register all relevant data on pain management in their electronic patient 
files, because their databases were not designed for this purpose. For example, the GPC had no pain 
scores registered in their electronic patient files. Guideline adherence for the GPC could therefore not 
be assessed, because the guideline recommendations regarding pain management are based on 
intensity of pain. 
In addition, it is known that chart reviews are prone to underreporting. It is therefore highly plausible 
that missing registration on certain factors of pain assessment or pain treatment does not mean that 
these proceedings did not occur in practice; i.e. not performed or not registered. The lack of registration 
of information can have several meanings; assessment and treatment has not been done but should 
have been provided, has not been done and has not been provided with good reasons, was not needed 
at all, or has been done and is provided but not registered. This challenges the determination of 
guideline adherence. Overall, compliance with the guideline in practice, particularly with regard to 
registration of pain management, could be higher. Uniform registration of data by all organisations on 
the organisation of pain, pain assessment, and pain treatment, is key to accurately evaluate early pain 
management in the chain of emergency care. 
With these limitations in mind, our study is to our knowledge the first to report on pain management in 
trauma patients in a comprehensive sample of organisations in the chain of emergency care. Most 
studies on pain management in trauma patients focused on one specific organisation in the emergency 
care setting. 
The finding that (registration of) current practice of pain management in trauma patients in emergency 
care is suboptimal, is not new. Earlier retrospective document and prospective cohort studies among 
respectively 1,407 and 450 patient of the EMS and ED showed that in the ambulance only 30% of the 
patients receive pain medication,3 and in the ED this is even less (19%),1 and 69–86% still report pain at 
discharge.1 Furthermore, a high prevalence of oligoanalgesia (40%) was identified in adult trauma 
victims transported by the HEMS.16 Although pain is the major complaint for patients seeking 
emergency care,17 research showed that only 20% of the patients with minor trauma actually received 
adequate pain management, while 40% of these patients expected to receive analgesia in the ED.18 In 
contrast, our study shows a much larger amount of patients for whom pain medication is registered at 
admission; GPC (15%), EMS (48%), HEMS (48%), and ED (46%). Although compliance with the guideline 
differs across groups of health care professionals, the maximum compliance rate with the indicators 
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registered is 52%. The deviations in current practice from the quality indicators of the guideline were 
however expected, as the guideline has not yet been implemented nationwide. 
The pain guideline requires professionals in the chain of emergency care to collaborate and synchronise 
their pain management strategies. This might pose a problem as these professionals are used to work 
autonomously. Their differences in professional background, working culture, organisation and financial 
incentives may influence their guideline adherence.19,20 As with all guidelines, it is not self-evident that 
the guideline will implement itself. Therefore, the development of a tailored implementation strategy 
for the multidisciplinary pain guideline is necessary. This implementation strategy should be based on a 
thorough analysis of the specific setting of the chain of emergency care and the different organisations 
involved in pain management. 
 
Conclusions 
In conclusion, this study showed that (registration of) current pain management in trauma patients in 
the chain of emergency care varies widely between health care organisations, and deviates from the 
Dutch guideline recommendations. In order to improve pain management and evaluate its 
effectiveness, we recommend to improve pain registration in electronic patient files and to identify 
barriers and facilitators related to the implementation of the Dutch national guideline in all emergency 
care organisations. 
 
Acknowledgements 
We would like to thank all organisations in the emergency care that participated in this study, and 
especially the participants of the ‘Emergency Pain Study Group’ for their support, which are: F. van 
Eenennaam, P. van Grunsven, W. Heutz, W. Breeman, D. den Hartog, N. Hoogerwerf, S. van Vliet, E. de 
Vaal, D. Pols, D. Kuster, M. Edwards, P. Rood, C. Doggen, L. Schoonhoven, S. Berben, A. Westmaas, A. 
Scholten. We would also like to acknowledge ZonMw, The Netherlands Organisation for Health 
Research and Development, for their funding to make this study possible (project number 171203004). 
 
REFERENCES 
 
1. Berben SA, Meijs TH, van Dongen RT, et al. Pain prevalence and pain relief in trauma patients in the Accident & Emergency 
department. Injury. May 2008;39(5):578-585. 
2. Liu M, Ferrante F. Overview of pain mechanisms and neuroanatomy. In: Rosenber AD, Grande CM, Bernstein RL, eds. Pain 
management and regional anesthesia in trauma. London: WB Saunders; 2000:29–46. 
3. Berben SA, Schoonhoven L, Meijs TH, van Vugt AB, van Grunsven PM. Prevalence and relief of pain in trauma patients in 
emergency medical services. The Clinical journal of pain. Sep 2011;27(7):587-592. 
4. Gramke HF, Marcus MA, Sommer M, van Kleef M. [Postoperative pain management: guidelines, organization and 
techniques]. Nederlands tijdschrift voor geneeskunde. May 16 2009;153(20):975-979. 
5. Steegers MA, Wilder-Smith OH. [Late chronic pain after surgery is prevented with good perioperative analgesics]. Nederlands 
tijdschrift voor geneeskunde. Mar 21 2009;153(12):562-566. 
6. Berben SA, Kemps HH, van Grunsven PM, Mintjes-de Groot JA, van Dongen RT, Schoonhoven L. [Guideline 'Pain management 
for trauma patients in the chain of emergency care']. Nederlands tijdschrift voor geneeskunde. 2011;155(18):A3100. 
7. Lewis KS, Whipple JK, Michael KA, Quebbeman EJ. Effect of analgesic treatment on the physiological consequences of acute 
pain. American journal of hospital pharmacy. Jun 15 1994;51(12):1539-1554. 
8. Dunwoody CJ, Krenzischek DA, Pasero C, Rathmell JP, Polomano RC. Assessment, physiological monitoring, and 
consequences of inadequately treated acute pain. Pain management nursing : official journal of the American Society of Pain 
Management Nurses. Mar 2008;9(1 Suppl):S11-21. 
9. Netherlands Association for Emergency Nurses. Pain management in trauma patients in the chain of emergency care (in 
Dutch). 2011; 
http://www.cbo.nl/Downloads/1307/Richtlijn%20Pijnbehandeling%20bij%20traumapatienten%20in%20de%20spoedzorgk
eten.pdf. 
10. National Association of Emergency Medical Technicians. PHTLS: Basic and Advanced Prehospital Trauma Life Support. St. 
Louis: Mosby Elsevier; 2007. 
Chapter 12 | 291 
 
11. Giesen P, Smits M, Huibers L, Grol R, Wensing M. Quality of after-hours primary care in the Netherlands: a narrative review. 
Annals of internal medicine. Jul 19 2011;155(2):108-113. 
12. van Ierland Y, van Veen M, Huibers L, Giesen P, Moll H. Validity of telephone and physical triage in emergency care: The 
Netherlands Triage System Family Practice. 2011(28):334-341. 
13. Dutch Ambulance Institute. National Protocols for Paramedics, version 7.2 (in Dutch). Zwolle: Dutch Ambulance Institute; 
2011. 
14. Huibers L, Thijssen W, Koetsenruijter J, Giesen P, Grol R, Wensing M. GP cooperative and emergency department: an 
exploration of patient flows. Journal of evaluation in clinical practice. Apr 2013;19(2):243-249. 
15. Bevolkingsontwikkeling; regio per maand. 2013. http://statline.cbs.nl/. Accessed 05.02.2014. 
16. Albrecht E, Taffe P, Yersin B, Schoettker P, Decosterd I, Hugli O. Undertreatment of acute pain (oligoanalgesia) and medical 
practice variation in prehospital analgesia of adult trauma patients: a 10 yr retrospective study. British journal of anaesthesia. 
Jan 2013;110(1):96-106. 
17. Cordell WH, Keene KK, Giles BK, Jones JB, Jones JH, Brizendine EJ. The high prevalence of pain in emergency medical care. 
The American journal of emergency medicine. May 2002;20(3):165-169. 
18. Whiteley J, Goodacre S. Patient expectations of minor injury care: a cross-sectional survey. Emergency medicine journal : 
EMJ. Apr 10 2013. 
19. Berben SA, Meijs TH, van Grunsven PM, Schoonhoven L, van Achterberg T. Facilitators and barriers in pain management for 
trauma patients in the chain of emergency care. Injury. Sep 2012;43(9):1397-1402. 
20. Ebben RH, Vloet LC, Verhofstad MH, Meijer S, Mintjes-de Groot JA, van Achterberg T. Adherence to guidelines and protocols 
in the prehospital and emergency care setting: a systematic review. Scand J Trauma Resusc Emerg Med. 2013;21:9. 
 
 
  
 
 
 
  
Chapter 12 | 293 
 
 
 
 
 
 
General discussion and summary 
 
 
  
 
 
 
Chapter 13 
 
General discussion
  
296 | General discussion 
GENERAL DISCUSSION 
 
The aim of this thesis was to study the incidence, health-related quality of life (HRQL), psychiatric 
consequences and costs of traumatic brain injury (TBI), and to contribute to the improvement of 
outcome assessment in the injury field. This chapter will describe the main findings of the papers in this 
thesis and consequently will address the possible shortcomings and methodological considerations. The 
chapter ends with the implications of the papers and recommendations based on the findings. 
 
13.1 MAIN FINDINGS 
 
Part I - Epidemiology of traumatic brain injury 
The first part of this thesis studies the epidemiology of TBI, addressing research question 1: 
1. What are the incidence, health impact and costs of TBI, and which risk groups in TBI can be 
identified?  
In the Netherlands, yearly about 35,000 patients visit the emergency department (ED) due to a TBI, 
equal to an incidence of 214/100,000 person years. Most cases of TBI in the Netherlands are caused by 
a fall or traffic accident, the latter often involving cyclists. Over the past decade, Dutch numbers of ED 
visits and hospital admissions due to bicycle-related TBI strongly increased (54% and 92%), especially 
among older cyclists aged 55+ (151% and 186%, Chapter 3). Overall, TBI imposes a substantial disease 
burden (patients loose on average 7 disability-adjusted life years due to ill-health, disability or early 
death) and huge economic costs (in total €315 million per year, on average €18,000 per patient). Our 
integrated approach of assessing incidence, health impact and costs of TBI identified different risk 
groups for each indicator. Children and adolescents (up to 24 years) had high incidence and disease 
burden but low economic costs, whereas 25–64-year-olds had relatively low incidence but high 
economic costs. Overall, patients aged 65+ (often involving cyclists and fallers) had highest incidence, 
leading to considerable health care costs. 
 
Part II - Methodological challenges in assessing outcome after injury 
The second part of this thesis addresses some methodological challenges in assessing outcome after 
injury, answering research question 2: 
2. How can the assessment of outcomes after injury be improved? 
In Chapter 4, evidence from the international literature was reviewed to study and clarify the 
differences between the methods which are currently used to assess the pre-injury HRQL of injury 
patients. Retrospectively assessment (recall) showed consistently higher pre-injury HRQL scores than 
population norms and a recovery that lags behind that of prospective assessments, implying a 
systematic overestimation of the change in HRQL from pre- to post-injury due to an injury. Researchers 
should be aware of the bias that may arise when pre-injury HRQL is assessed retrospectively or when 
population norms are applied, and should use prospectively derived HRQL scores wherever possible to 
estimate the impact of injury on HRQL. 
Overall, the assessment of outcome after injury has become increasingly important, due to the growing 
number of injury patients that survives their injury.1 Although trauma registries were initially developed 
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to improve preventable mortality after trauma, our research shows the possibilities of extending these 
registries with valuable follow-up data on the consequences of injuries beyond mortality, and 
incorporating these outcomes in the evaluation of trauma care (Chapter 5). This way, insight in the 
outcome of trauma survivors can be obtained, and comparisons of the consequences of trauma across 
patient subgroups can be made.  
Estimates of the outcomes after injury may further be improved by choosing the right elements in, for 
example, calculating the healthy time that is lost due to living with disability (YLD) due to TBI. An 
essential component of these YLD calculations is the disability weight.2 YLD estimates can be derived 
using different methods, involving the use of a set of standard disability weights (e.g. from the Global 
Burden of Disease study) or disability weights derived from HRQL follow-up data of individual TBI 
patients. As described in Chapter 6, both methods yield similar estimates of the YLD due to TBI in the 
Netherlands. Although researchers increasingly recommend the use of HRQL disability weights,3-6 as 
these capture the heterogeneity within TBI patients and match with the epidemiological data of the 
sample under study,7 HRQL data might be affected by factors like the patient’s comorbidity, age, sex 
and adaptation to a certain health state, and the follow-up time or instrument used to assess HRQL.  
 
Part III - Outcome after traumatic brain injury  
The third part of this thesis studies the health outcome after TBI, addressing research question 3: 
3. What is the impact of TBI on HRQL, and what is the prevalence of psychiatric disorders after TBI? 
Historically, studies on the impact of TBI on HRQL primarily have focused on the consequences of 
moderate and severe TBI instead of mild TBI, due to a lack of consensus on the diagnosis of mild TBI and 
limited methods for detecting and classifying less severe grades of TBI.8 Over time, studies have 
advanced our knowledge on the outcomes and recovery patterns after mild TBI,8,9 although studies 
often still focus on the outcomes after either mild TBI or moderate and severe TBI.10 As described in 
Chapter 7, data from a longitudinal cohort study indicates that TBI of all severities strongly affects HRQL, 
showing different recovery patterns between TBI severity levels with only patients with mild TBI 
reaching outcomes comparable to population norms at one year follow-up. Consistent with risk factors 
identified in general injury populations,11 our results show that poor HRQL after TBI is predicted by 
female gender, older age, comorbidity and a higher injury severity. 
Our results emphasise that TBI has a more negative association with patients’ mental functioning than 
physical functioning.10 As described in Chapter 8, review of the international literature shows that a high 
number of patients encounter anxiety and depressive disorders following TBI, often involving post-
traumatic stress disorder (PTSD) and major depression disorder (MDD). These problems persist over 
time, as over one third of the patients are diagnosed with an anxiety or depressive disorder more than 
one year after TBI. The meta-analysis described in Chapter 9 shows that patients with a shorter post-
traumatic amnesia and those with a memory of the traumatic event are at higher risk to be diagnosed 
with PTSD after TBI. Moreover, MDD after TBI is associated with pre-injury depression, female gender, 
moderate TBI, and post-injury unemployment. 
These psychiatric consequences, in their turn, have a great impact on the HRQL in TBI patients. It was 
shown in Chapter 10 that both PTSD and MDD are associated with significantly decreased objective 
clinical outcomes as well as subjective HRQL. 
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Part IV - Guidelines and adherence 
The fourth part of this thesis addresses the adherence to guidelines in the field of injury, answering 
research question 4: 
4. What is the extent of adherence to guidelines in injury patients? 
Our findings indicate that TBI, and injury in general, is not just an acute event, but can result in long-
term consequences. Although our knowledge on the epidemiology and impact of injuries has increased 
over time, guideline adherence remained suboptimal. Review of the international literature (Chapter 
11) and medical charts (Chapter 12) shows that guideline adherence in injury patients is generally low 
and varies widely between studies and between health care organisations. In case of TBI, adherence is 
found to be higher in guideline recommendations that are based on strong evidence rather than lower 
level evidence. Guidelines are also more often adhered to in younger patients and those with more 
severe TBI. Adherence to guidelines is associated with more favorable patient outcomes, showing a 
reduction in mortality. The clinical management and trauma care for injury patients and evaluation of 
its effectiveness can be improved by a complete registration of guideline recommendations and quality 
indicators in patient files. 
 
In summary, the studies in this thesis clearly indicate that TBI has a substantial impact on both 
individuals and society. TBI has large and often long-term consequences for the persons’ functioning 
and HRQL, resulting in a high disease burden. Subsequently, TBI imposes huge economic costs due to 
the often long-term need for specialised medical care and loss of productivity. 
 
13.2 METHODOLOGICAL CONSIDERATIONS 
 
Considerable methodological variation exists in the methods to measure outcome after TBI10 as well as 
injury in general,11 including differences in settings, study populations, instruments, follow-up periods 
and timings of assessments. These design choices limit the comparability between study results, and 
limit our insight into the national, regional, and global burden of injuries. 
 
Clinical outcome 
Over the past decades, our knowledge on the causes and consequences of injuries has rapidly grown, 
especially in case of TBI. This resulted in the recognition of the impact of milder injuries and the 
development of criteria to diagnose and classify TBI.8,12 
TBI severity is often classified with use of scores on the Glasgow Coma Scale (GCS). Since 1974, the GCS 
is the most common scoring system used to describe the level of consciousness after TBI.13 The GCS can 
be translated into three severity categories: mild, moderate, and severe TBI. There is however 
considerable variation within these severity categories, especially at the ends of the scale.14 Research 
shows that the GCS as a single variable may have limited value as a predictor of outcome after TBI, and 
suggests the use of other variables for this purpose (e.g. the duration of post-traumatic amnesia).15,16 
Only recently, an expert group published a position statement including a clear-cut definition of TBI and 
related diagnostic criteria.12 Notwithstanding, research on the epidemiology of TBI still lacks 
standardisation and does not incorporate all TBI cases. 
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Most estimates on the incidence of TBI are based on data from only a sample of hospitals in a certain 
nation or region, and include only TBI cases that warranted treatment at an ED or admission to a 
hospital. As a consequence, these estimates do not include the thousands of persons with TBI who 
consult their general physician17 or another specialists (e.g. physiotherapist), or those not seeking 
medical help but experiencing a change in their ability to function after the injury. 
Epidemiological data is known to be incomplete, as patients with mild injuries may be missed in current 
epidemiologic monitors. Combination of data from prospective and retrospective surveillance systems 
in New Zealand shows that the incidence of TBI, especially mild TBI, may be substantially greater than 
would be estimated from previous findings.18 To get full insight into the true size of the TBI problem, 
data from multiple overlapping sources (e.g. surveillance systems, national registries, study databases, 
medical records, etc.) that hold information on TBI cases treated by health care professionals need to 
be combined. These data sources should also comprise accurate information on the TBI-related 
mortality. 
Beyond mortality, outcome following TBI is generally assessed with the Glasgow Outcome Scale 
Extended (GOSE).19 This 8-point scale enables clinicians to objectively score the patient’s recovery.19 
Data from the Radboud University Brain Injury Cohort Study (RUBICS) showed that HRQL levels 
significantly increased with more favorable GOSE categories (Chapter 7), in line with other studies.20,21 
However, we found discrepancies between the objective perspective of clinicians on the patient’s 
recovery on the one hand, and the subjective perspective of patients on certain aspects of their HRQL 
on the other hand. Specifically, one third of the patients showed poor outcomes on the domains general 
health, mental health or vitality, while being assigned good recovery levels by the clinician on the GOSE. 
Research on the observer variation in GOSE scores shows that clinicians may tend to rate patients as 
less disabled than indicated by the GOSE criteria.22 If correctly rated, the GOSE does however 
incorporate the pre-injury health status of patients, by ignoring areas in which there has been no change 
with respect to the situation before the injury. 
 
Functional outcome 
Our insight into the impact of injuries on individuals can be improved by incorporating the patients’ 
subjective perception of how an injury and its treatment affect physical, mental and social aspects of 
his/her life, by assessing their HRQL.23 Data on these domains of functioning make it possible to obtain 
insight into the recovery patterns after injuries and the disability that injury patients experience over 
time. This provides ways to quantify the impact of injury on population health over time and enables 
comparison of health outcome between injury patients, different types of injuries, and between injuries 
and other diseases. However, measuring the impact of injuries remains challenging. 
A recent systematic review shows considerable variation in the HRQL instruments that are used to 
assess the HRQL of patients with TBI.10 Depending on the study setting and injury population, 
researchers may choose different HRQL instruments. This makes it difficult to compare the outcomes 
of studies, as different HRQL instruments measure different domains of HRQL and may result in 
different valuations of similar health states. Guidelines and recommendations are required to 
standardise the follow-up studies on the HRQL after TBI. 
Moreover, the patient’s HRQL after an injury may be influenced by factors other than the injury. 
Research shows that HRQL scores are for example associated with injury severity, injury type, gender, 
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patients’ mental health and comorbidity.11 For instance, pre-existing comorbidity may contaminate our 
estimates of the injury-related disability, since HRQL scores might incorporate the impact of one or 
more comorbid diseases instead of solely reflecting the impact of the injury. Consequently, these factors 
may all influence our measurement of what the impact of an injury is on the patient’s HRQL.  
Therefore, information on the pre-injury HRQL is needed to make valid estimates of the change from 
pre- to post-injury HRQL due to the injury. Studies may compare the HRQL reported by patients after 
an injury with general population norms. This way, we were able to show that TBI of all severities 
strongly affects HRQL (Chapter 7). However, general population norms may not reflect the pre-injury 
health status of injury patients, as pre-injury HRQL scores of injury patients often deviate from the HRQL 
scores in general populations. An alternative can be to use retrospective assessment (recall) to assess 
pre-injury HRQL. Retrospectively assessment however showed consistently higher pre-injury HRQL 
scores than the general population norms and a recovery that lags behind that of prospective 
assessments (Chapter 4). Users should be aware of the bias these methods may have on their estimate 
of the impact of injury on the HRQL of patients. 
Measuring the effects of serious injuries, like TBI, on the mental functioning of patients may be even 
more challenging. On the one hand, there is overlap in symptoms caused by TBI and symptoms caused 
by psychiatric disorders. Patients with TBI may for example experience fatigue or difficulties in 
concentrating or social functioning, which are symptoms of TBI as well as psychiatric disorders. This 
impedes attribution of symptoms after TBI to the brain injury or other frequently comorbid conditions 
such as anxiety or depression. Differential diagnosis of the psychiatric consequences of TBI may be 
enhanced by using structured diagnostic interviews. In contrast to self-report measures, structured 
diagnostic interviews enable the clinical diagnosis of psychiatric disorders according to standard criteria. 
However, structured diagnostic interviews are time consuming for health care professionals as well as 
patients, and require specific training and experience. Although self-report measures are not designed 
to diagnose psychiatric disorders according to standard criteria, and their use may lead to less accurate 
prevalence estimates,24-27 self-report questionnaires can be used as a screening tool to detect 
psychiatric symptoms. Consequently, only screening tools that have proven to be sensitive and specific 
in measuring psychiatric symptoms should be used. In addition, high cut-off scores need to be used to 
avoid over-diagnosing of psychiatric symptoms and the prevalence of probable psychiatric disorders. 
On the other hand, it is difficult to determine causality between TBI, psychiatric disorders and impaired 
functioning. Our results show that a history of psychiatric disorders before a TBI is strongly related to 
the presence of psychiatric disorders after TBI (Chapter 8 and 9). In their turn, psychiatric disorders are 
associated with decreased functioning and HRQL (Chapter 8 and 10). According to previous research, 
post-injury psychiatric symptoms may be caused by the history of pre-injury psychiatric disorders, rather 
than due the TBI.28 Moreover, psychiatric disorders may be caused directly by the injury, but may also 
occur as a consequence of the experienced disability after TBI.29-31 Further research is necessary to 
determine the cause-effect relationship between the development of psychiatric disorders and 
impaired outcome after TBI. 
 
Economic outcomes 
The clinical and functional implications of injuries have a huge economic impact on both individuals and 
society. Generally, considerable methodological variation exists between studies that report on the 
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economic outcomes after injury. For example, cost calculations may be limited to inpatient costs or may 
also include the extramural health care costs. These differences in cost calculations make it difficult to 
compare the economic burden of injuries between countries or health care settings. 
In this thesis we were able to assess both the direct medical costs and indirect productivity costs due to 
TBI, using the Dutch Burden of Injury Model. This model includes data on the medical expenses from 
pre-hospital care (e.g. emergency medical care) to out-of-hospital care (e.g. physiotherapy and home 
care) that is needed to estimate the direct health care costs of injuries. This information is, however, 
based on ED treated and/or hospitalised injury cases, and does not contain information on the costs of 
patients who seek care outside the hospital or did not use medical care. 
Besides information on the direct health care costs, the applied cost model also includes data on the 
costs due to lost productivity. These indirect productivity costs represent the indirect economic burden 
of injuries resulting from absence from work due to an injury. To date, only a few population-based 
studies have included both the direct medical costs and indirect productivity costs of injuries. Their 
results underpin our findings that, especially in serious injuries like TBI, the productivity costs constitute 
a considerable proportion of the total economic burden (Chapter 2 and 3).32-34 This indicates that 
information on the productivity costs is essential input for policy decision making and the development 
of preventive strategies. 
Notwithstanding, the economic burden of injuries is expected to be even higher if other potential 
sources of indirect costs are included. Specifically in TBI, the occurrence of such a severe injury imposes 
a substantial financial burden to family members and caregivers, who are often confronted with loss of 
work productivity and financial issues in taking care of their injured relative.35,36 
 
Patient follow-up data 
Overall, we were able to use data from patient surveys from multiple studies in this thesis. There are, 
however, methodological considerations with respect to administering questionnaires to injury 
patients, especially in case of severe injuries like TBI. 
There has been debate whether patients with cognitive impairments, like in TBI, have the skills to 
complete questionnaires, answering complex questions and providing useful information on their 
health outcome.37,38 This may affect the measurement of constructs such as HRQL in severely impaired 
persons, and may have led to biased estimates of the health impact of TBI. Despite this, research 
indicated that lack of awareness is expected among patients with severe TBI soon after the injury, 
though most people are aware of those deficits six months after injury.39  
Specifically in long-term conditions like TBI, questionnaire response may be affected by the adaptation 
of patients to a certain health state. Patients who live with certain conditions for some time may 
perceive their health state as being less severe.40 This may lead to an underestimation of the true injury-
related disability. 
The most commonly threat to longitudinal studies on the outcomes after TBI is the loss due to follow-
up.41 The loss of subjects to follow-up may affect the generalisability of the findings, when those lost 
differ from those found and responding. These differences may occur in the outcomes themselves (e.g. 
higher response among older patients, reporting poorer HRQL) as well as in the factors affecting 
outcomes (e.g. higher response among those with a higher socio-economic status, reporting better 
HRQL). 
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Moreover, low response rates may affect the representativeness of the study findings to other patients. 
Response rates may be affected by the use of lengthy follow-up questionnaires, that are often used to 
assess a large number of outcome measures. However, contradictory findings have been published on 
the effect of questionnaire length on response rates and data quality.42-44 
 
13.3 IMPLICATIONS AND FUTURE RESEARCH 
 
In this thesis we estimated the incidence, disease burden and economic costs of TBI based on an 
extrapolation of data from the Dutch National Injury Surveillance System (ED treated cases, 12-15% 
coverage Dutch EDs) and the Dutch Hospital Registry (hospitalised cases, all Dutch hospitals) between 
2007 and 2012. This way, we were able to generate national estimates of the incidence, disease burden 
and costs of TBI in the Netherlands (Chapter 2 and 3). In addition, we used regional data from a trauma 
registry (Chapter 5), longitudinal cohort study (Chapter 6, 7 and 10) and medical charts (Chapter 12) 
from an academic trauma center and health care organisations in the Eastern part of the Netherlands. 
The results of these studies do not necessarily apply to patients treated at other hospitals or health care 
settings. Additionally, thorough reviews of the available evidence from different countries and health 
care settings were used to provide an overview of the pre-injury HRQL in injury populations (Chapter 
4), the prevalence and predictors of anxiety and/or depression following TBI (Chapter 8 and 9), and the 
adherence to TBI guidelines (Chapter 11). Although these systematic reviews included all eligible studies 
published in peer-reviewed English language journals, most studies reported on findings from high-
income countries such as the United States, Australia, the UK or Canada. However, their findings may 
also be of use in developing countries. Overall, the studies presented in this thesis have important 
implications for policy makers, health care professionals and researchers. 
 
Implications for policy and health care 
Education and communication 
TBI is often described as an silent epidemic, with patients and families who experienced a TBI knowing 
how devastating its effects can be, yet awareness among the public and even health care specialist 
remains low.45 Prevention programmes are needed to inform the public on the devastating 
consequences a TBI can have, even in case of milder injuries, and should educate the population about 
how injuries can be avoided. Victims of a TBI seeking medical care should be clearly informed by their 
health care professional on the symptoms that may occur in the period after their injury, and their 
recovery should be closely monitored. Special attention should be given to the outcomes of injuries in 
patients with milder injuries, as patients but also health care professionals might underestimate the 
consequences a mild TBI can have. Overall, early recognition, treatment and monitoring of the physical 
as well as psychiatric consequences of TBI may enhance the recovery of TBI survivors, their capacity to 
work, and may reduce the high costs associated with disability after TBI.30,46 
 
Setting priorities for prevention 
Our research shows that TBI imposes a substantial disease burden and huge economic costs to 
individuals and society, supporting findings from other countries.32,33,47 Our studies provide directions 
on how the burden of TBI can be reduced by identifying important risk groups in TBI that should be 
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targeted in prevention programmes. Worldwide, TBI is still highly prevalent among children, 
adolescents and older adults aged 55 years and older,18,48-50 with falls and traffic accidents being its 
leading causes.51,52 Especially in children, TBI can have a tremendous lifelong impact. The younger brain 
is more flexible and modifiable, and it was thought that healthy tissue could take over the functions of 
damaged tissue. It was only recently acknowledged that TBI can have a more devastating impact on 
children and adolescents than similar injuries may have on adults.53,54 Children and young adults may 
face lifetime physical and psychological challenges, and experience problems in functioning and learning 
due to their TBI. Beyond the high incidence and disease burden among children, our findings show that 
TBI imposes a substantial loss of productivity among the working population leading to considerable 
productivity costs, and high health care costs among the elderly cyclists and fallers. Overall, this calls for 
the development of preventive strategies to reduce the number of serious injuries in these risk groups 
in order to reduce the TBI-related burden. 
 
Patient’s perspective 
The studies in this thesis provide evidence that it is important to assess the subjective perspective of 
patients on their functioning and recovery following the injury. Information from patient-reported 
outcome measures (e.g. HRQL instruments) can be used in clinical decision making and may enable 
clinicians to detect unrecognised problems, monitor the impact of injuries and evaluate the provided 
care. Research shows that incorporation of the patient’s perspective may lead to improvements in HRQL 
and satisfaction with care.55 
 
Implications for future research 
Data linkage 
For future research, one of the challenges in assessing the outcomes after injury remains that 
epidemiological data on all TBI cases and data on the long-term medical events resulting from injury 
(e.g. long-term rehabilitation or even death) is often not readily available. Generally, multiple 
registration systems and databases exist that contain information on injuries and injury patients (e.g. 
national injury surveillance systems, national hospital discharge registries, trauma registries, hospital 
records, or cause of death registries). These registries all have their own purposes (e.g. prevention of 
injuries, or evaluation of trauma care) and therefore may document only specific information of the 
injury (e.g. data on the acute phase of trauma care, the number and cause of death, or the long-term 
outcomes after injury). As a consequence, none of these registries provides the full picture of medical 
events resulting from injury. Linkage of data from multiple sources may overcome these problems. 
Future research may benefit from data linkage to obtain full insight into the incidence, risk groups, costs, 
and impact of injuries on population health over time. 
 
Long-term follow-up 
Data on the long-term outcomes of trauma is often not available, or limited to a certain period of follow-
up. Our research shows that most patients do not recover in the first year after TBI. TBI symptoms may 
persist for many years and may even cause growing problems over time.56,57 This emphasises the need 
for longitudinal follow-up studies in TBI patients to obtain insight into the long-term consequences and 
recovery patterns after TBI. Additionally, challenges remain in rehabilitation research. To date, there is 
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only limited understanding of the rehabilitation process after TBI and the effectiveness of 
interventions.58 The rehabilitation process plays an important role in the long-term outcomes of TBI 
survivors, as early and continuous rehabilitation improves long-term functional outcomes and reduces 
the economic burden of TBI.59,60 
 
Productivity costs 
Our results showed that the productivity costs dominate the economic burden after TBI, especially in 
men of the working age. However, the productivity costs related to paid work are not systematically 
included in injury research, and there is ongoing debate on whether and how indirect productivity costs 
should be included in economic evaluations.61 Productivity costs strongly affect economic outcomes 
after injury, accounting for on average 75% of the total costs of TBI per patient (Chapter 2). On average 
20% of the injury survivors, especially victims of severe injury like TBI, are unable to work or to return 
to full employment and become depended on social security.62-64 Consequently, the productivity costs 
of injuries are often several times higher than the direct medical costs of injuries.32 Future research 
should incorporate the productivity costs in their assessment of the economic burden of injuries, as 
information on the magnitude of productivity losses is important input for policy decisions and enables 
priority setting based on the total direct and indirect expenses due to injuries. 
 
Integrated outcome assessment 
Overall, studies on the incidence and outcomes after injury or other diseases should apply an integrated 
approach in assessing the incidence, health impact and economic costs. Incorporation of all three 
dimensions of outcome is essential to gain a comprehensive insight into the size of the injury or disease 
problem, to identify high-risk groups and to set priorities for prevention and treatment. 
 
Standardisation of research 
TBI is considered to be the most complex disease in our most complex organ. It is characterised by large 
heterogeneity, in terms of mechanisms, severity, and treatment, with a large range of outcomes. Our 
findings indicate that TBI of all severities strongly affects outcome after injury, which endorses the 
assessment of the outcomes after all severity levels of TBI in future research.10,47 The heterogeneity 
imposes several methodological challenges, and endorse the need for standardisation in TBI research. 
Consensus should be reached on definitions, classifications, methodology (including timings of 
assessments and follow-up), and reporting of study results to enable comparisons between studies and 
to obtain insight into the true size of the TBI problem. 
According to our findings, it is important to incorporate information on the patients pre-injury HRQL 
before the injury to assess the change between pre- and post-injury HRQL. Researchers should be aware 
of the bias that may arise when pre-injury HRQL is assessed retrospectively or when population norms 
are applied, and should use prospectively derived HRQL scores wherever possible to estimate the 
impact of injury on HRQL. 
 
Financial support 
Without support for research on the outcomes of TBI, there will be limited knowledge on the recovery 
patterns after TBI, the associated disease burden and costs, and the way to improve prevention and 
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rehabilitation of TBI victims. The growing number of TBI victims due to falls in the aging population and 
road traffic injuries in developing countries, endorses the need for financial support and funding of TBI 
research. Like the treatment for TBI patients, research should be a collaborative effort. 
 
13.4 CONCLUSIONS 
 
To conclude, the papers in this thesis quantified the incidence, health impact and costs of TBI, and 
contributed to the improvement of outcome assessment in the injury field. The incidence data, HRQL 
data, and cost data provided in this thesis is essential input for policy makers to set priorities in health 
care policy and prevention, and enables health care professionals to develop effective treatments, 
rehabilitation services and guideline recommendations. In addition, the findings of our papers and the 
methodological considerations presented in this thesis may enable researchers to further improve the 
assessment of outcomes after TBI. A collaborative effort of policy makers, health care professionals and 
researchers may tame the globally growing numbers of TBI victims, and improve the care and outcomes 
for injury patients. 
 
13.5 RECOMMENDATIONS 
 
Based on this thesis some specific recommendations can be made for policy makers, health care 
professionals and researchers who work in the injury field, especially related to TBI. 
 
Policy makers 
• Inform the public on the substantial consequences TBI may have, and educate the population about 
how injuries can be avoided. 
• Develop preventive strategies to reduce TBI, targeting 0–24-year-olds, men in the working 
population aged 25–64 years, and elderly cyclists and fallers. 
• Provide funding and support for research to assess the size and impact of the TBI problem. 
 
Health care professionals 
• Inform patients on the physical and mental symptoms that may occur after a TBI. 
• Closely monitor the recovery of TBI victims over a long time of follow-up as TBI symptoms may 
persist for many years and may cause growing problems over time. 
• Pay attention to the psychiatric consequences TBI may have. 
• Do not underestimate the consequences of mild TBI. 
• Incorporate the subjective perspective of patients on their functioning and recovery following injury 
in clinical decision making. 
• Use guidelines in providing care to patients, and register all necessary items of the guideline 
recommendations and quality indicators in patient files. 
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Researchers 
• Apply an integrated approach to assess the clinical, functional and economic outcomes after injuries 
and diseases, including the health-related quality of life (HRQL) and psychiatric consequences. 
• Link data from multiple sources to obtain full insight into the size and impact of injuries and diseases. 
• Incorporate the productivity costs to assess the economic burden of injuries and diseases. 
• Assess the pre-injury HRQL of patients to estimate the change in health status due to an injury. 
• Assess the long-term consequences and recovery patterns after TBI. 
• Use multiple follow-up measurements over time (preferably lifelong), as recovery patterns and 
occurrence of symptoms may vary over time. 
• Standardise TBI research by using uniform definitions, classifications, methodology (e.g. timings of 
assessments and follow-up), and reporting of study results to enable comparisons between studies. 
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INTRODUCTION 
 
Injuries are among the leading causes of death and disability in the world, often imposing great personal 
suffering and economic costs. An important severe injury that often affects young people is a traumatic 
brain injury (TBI). TBI occurs when a sudden trauma causes damage to the brain. Globally, the incidence 
of TBI has rapidly grown in scale over the past decade due to increasing motor vehicle use in low- and 
middle income countries and the growing number of falls among elderly in higher income countries. 
TBI is often described as a silent epidemic, with patients and families who experienced a TBI knowing 
how devastating its effects can be, yet awareness among the public and even health care specialist 
remains low. Almost all TBI survivors experience some level of short-term or long-term impairment or 
disability, which disrupts the lives of victims and relatives, reduces their health-related quality of life 
(HRQL), complicates their recovery and rehabilitation, and imposes a huge economic burden to both 
individuals and society.  
Over the past decades, the number of survivors of severe TBI has rapidly grown, though the disability 
due to TBI has not appreciably reduced. This has resulted in a shift in attention from mortality towards 
disability. Policymakers and clinicians are recognising the importance of quantifying the outcomes after 
TBI to assess the effects of prevention strategies and treatments. Consequently, insight into the 
incidence, health impact and costs of TBI is essential in order to compare the burden of injuries between 
patient subgroups and with other diseases, optimise health care policy and prevention, and develop 
effective health care and rehabilitation services. 
 
Aims and research questions 
In this thesis we assessed the incidence, health-related quality of life, psychiatric consequences and 
costs of injuries, especially TBI, and the possible improvements of outcome assessment in the injury 
field. The thesis consists of four parts, including eleven studies, that each address a specific research 
question: 
• What are the incidence, health impact and costs of TBI, and which risk groups in TBI can be 
identified? 
• How can the assessment of outcomes after injury be improved? 
• What is the impact of TBI on HRQL, and what is the prevalence of psychiatric disorders after TBI? 
• What is the extent of adherence to guidelines in injury patients? 
 
Part I - Epidemiology of traumatic brain injury 
In part I the incidence, costs and disease burden of TBI in the Netherlands were studied, and important 
risk groups in TBI were identified, using data from the Dutch Injury Surveillance System and National 
Hospital discharge. In Chapter 2, we demonstrated that yearly about 35,000 patients in the Netherlands 
visit the emergency department (ED) due to a TBI, equal to an incidence of 214/100,000 person years. 
We found that TBI imposes a substantial disease burden (TBI patients loose on average 7 disability-
adjusted life years due to ill-health, disability or early death) and huge economic costs (in total €315 
million per year in the Netherlands, on average €18,000 per patient). By applying an integrated 
approach of assessing incidence, health impact and costs of TBI, we identified different risk groups for 
each indicator. Children and adolescents (up to 24 years) had high incidence and disease burden but 
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low economic costs, whereas 25–64-year-olds had relatively low incidence but high economic costs. 
Overall, patients aged 65+ (often involving cyclists and fallers) had highest incidence, leading to 
considerable health care costs. In Chapter 3, we further explored the incidence and impact of TBI due 
to cycling. We identified a strong increase in the number of hospital treatments due to bicycle-related 
TBI over the past decade (55%), especially among older cyclists (55+, 151%). 
 
Part II - Methodological issues in assessing outcome after injury 
Part II addresses ways to improve outcome assessment in the injury field. The literature review in 
Chapter 4 reviewed the methods that are currently used to assess pre-injury health status. We found 
that retrospectively assessment (recall) showed consistently higher pre-injury HRQL scores than 
population norms and a recovery that lags behind that of prospective assessments, implying a 
systematic overestimation of the change in HRQL from pre- to post-injury due to an injury. Researchers 
should be aware of the bias that may arise when pre-injury HRQL is assessed retrospectively or when 
population norms are applied, and should use prospectively derived HRQL scores wherever possible to 
estimate the impact of injury on HRQL. 
In Chapter 5 we performed a pilot study, linking trauma data from complementary registers to patient 
follow-up data. We showed the opportunities of expanding trauma registries with follow-up data on the 
consequences of injuries beyond mortality. This way, insight in the outcome of injury survivors can be 
obtained, enabling comparisons of the consequences of trauma across patient subgroups. Information 
on the (long-term) outcomes of injury survivors should be incorporated in the evaluation of trauma 
care. 
In Chapter 6 we compared two methods to derive disability weights for several TBI health states: a set 
of standard disability weights from the Global Burden of Disease (GBD) study and disability weights 
derived from HRQL follow-up data of individual TBI patients. A disability weight is a weight factor that 
reflects the severity of the health losses due to an injury or disease on a scale from 0 (implying no loss 
of health) to 1 (implying a health loss equivalent to death). These disability weights are used to calculate 
the number of years lost due to disability (YLD) after TBI. We showed that both methods yield similar 
disability weights for TBI health states, except for long-term consequences of severe TBI, for which the 
GBD disability weight was much higher (more severe), which will ultimately result in higher YLD.  
 
Part III - Outcome after traumatic brain injury  
In Part III the impact of TBI on HRQL, and the psychiatric consequences of TBI were studied. In Chapter 
7 we assessed the recovery pattern differences between mild, moderate, and severe TBI and examined 
the relationship between clinicians’ outcome assessment and patient-reported outcomes in a cohort of 
TBI patients. We found that TBI of all severities strongly affects HRQL, showing different recovery 
patterns between TBI severity levels. Poor HRQL was predicted by female gender, older age, 
comorbidity and a higher injury severity. Patient-reported outcomes were generally poorer than 
clinicians’ outcome assessments, showing the importance of the patient’s perspective on functioning 
and HRQL in assessing disability. 
The literature review in Chapter 8 provides insight into the prevalence and risk factors of anxiety and 
depression after TBI. We found that prevalence rates of psychiatric disorders after TBI varied widely, 
often involving post-traumatic stress disorder (PTSD) and major depression disorder (MDD). About one 
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fifth of all patients with TBI had a history of anxiety (19%) or depressive disorders (13%) before the 
injury, and slightly more were diagnosed with these disorders in the year after TBI (respectively 21% 
and 17%). Pooled prevalence estimates increased over time, and indicated high long-term prevalence 
of anxiety (36%) and depressive disorders (43%). 
The meta-analysis in Chapter 9 provides an overview of the predictors of PTSD and MDD after TBI. We 
found that patients with a shorter post-traumatic amnesia and those with a memory of the traumatic 
event are at higher risk to be diagnosed with PTSD after TBI. MDD after TBI is associated with pre-injury 
depression, female gender, moderate TBI, and post-injury unemployment. 
In Chapter 10 the impact of PTSD and MDD on patients’ functioning and HRQL was assessed, using data 
from a longitudinal cohort study among TBI patients. We found that PTSD and MDD both are associated 
with significantly decreased functioning and HRQL after TBI. 
 
Part IV - Guidelines and adherence 
Part IV studied the adherence to guidelines in injury patients. The literature review in Chapter 11 
quantifies the guideline adherence in TBI, explores the factors influencing adherence, and examines the 
associations between guideline adherence and outcome. In Chapter 12 chart reviews of health care 
organisations involved in the emergency care of injury patients are used to assess whether current 
practice is in compliance with a new guideline on pain management for injury patients. In both studies, 
guideline adherence was generally low and varied widely between health care organisations. In case of 
TBI, adherence was found to be higher in younger patients, more severe TBI, and in guideline 
recommendations that are based on strong evidence rather than lower level evidence. Review of the 
international evidence showed guideline adherence to be associated with more favorable patient 
outcomes, including reduced mortality. 
 
DISCUSSION 
 
The aim of this thesis was to study the incidence, HRQL, psychiatric consequences and costs of TBI, and 
to contribute to the improvement of outcome assessment in the injury field. 
We found that TBI has a substantial impact on both individuals and society. TBI has large and often long-
term consequences for the persons’ functioning and HRQL, resulting in a high disease burden. 
Subsequently, TBI imposes huge economic costs due to the often long-term need for specialised medical 
care and loss of productivity. Current epidemiological data is, however, known to be incomplete, as 
epidemiologic monitors do not incorporate all cases of TBI (e.g. milder injuries treated outside the 
hospital are missed). Moreover, data on long-term medical events resulting from injury (e.g. 
rehabilitation or even death) is often not readily available. This limits our insight into the actual size of 
the TBI problem. 
Our analyses showed that research on the epidemiology and outcomes of TBI is seriously challenging 
due to the large heterogeneity in causes, severity, treatment, and outcome, and still lacks 
standardisation. Considerable methodological variation exists in the methods to measure outcome after 
TBI, including differences in settings, study populations, instruments, follow-up periods and timings of 
assessments. These design choices limit the comparability between study results. Moreover, we found 
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that different methods may result in different valuations of similar health states, and may yield different 
estimates of the change in health status.  
 
Implications 
Our findings have several implications for policy makers, health care professionals and future research. 
From a policy perspective, prevention programmes are needed to inform the public on the 
consequences that TBI can have, even in case of milder injuries, and to educate them on how such 
injuries can be avoided. Based on our findings, preventive strategies should be developed to reduce the 
incidence and impact of TBI in children, adolescents, men in the working age, and victims from falls 
(children and elderly) or traffic injury (especially cyclists). The growing number of TBI victims due to falls 
in the aging population and traffic injuries endorses the need for financial support and funding of TBI 
research. Without this support for research, there will be limited knowledge on the outcomes and 
recovery after TBI, and ways to improve prevention and rehabilitation of TBI victims. 
Health care professionals should be aware of the consequences TBI may have and should inform their 
patients on the symptoms that may occur after a TBI. They should closely monitor the recovery of TBI 
victims, including those with milder injuries. Health care professionals may benefit from the use of 
patient-reported outcome measures (e.g. HRQL instruments), which enable them to detect 
unrecognised problems and monitor the impact of injuries. Incorporation of patient’s perspective on 
their functioning and recovery in clinical decision making, may enhance the patient’s rehabilitation and 
HRQL. Overall, as guideline adherence is associated with better outcomes, health care professionals 
should use guideline recommendations in their care for injury patients. The trauma care for injury 
patients and evaluation of its effectiveness can be improved by a complete registration of guideline 
recommendations and quality indicators in patient files. 
 
Future research 
Future research should apply an integrated approach of assessing incidence, health impact and 
economic consequences of injuries, to identify important risk groups. Incorporation of all three 
dimensions of outcome is essential to gain insight into the size of the injury problem, to identify high-
risk groups and to set priorities for prevention and treatment. Researchers may benefit from linkage of 
data from multiple registries to obtain full insight into the incidence and impact of injuries on population 
health over time. Assessments of outcome of injury, especially TBI, should incorporate the productivity 
losses due to the injury and the associated costs, as productivity costs dominate the economic burden 
of severe injuries like TBI. These assessments should also incorporate information on the patients‘ pre-
injury HRQL, as HRQL may be influenced by a range of factors (e.g. comorbidity). Researchers should 
however be aware of the bias that may arise when pre-injury HRQL is assessed retrospectively or when 
population norms are applied, and should use prospectively derived HRQL scores wherever possible to 
estimate the impact of injury on HRQL.  
Further insight into the long-term consequences and recovery patterns after TBI is needed and 
longitudinal follow-up studies can provide this valuable information. These studies should use multiple 
follow-up measures over time, as TBI symptoms may aggravate or vary over time. TBI research should 
be standardised in terms of the use of uniform definitions, classifications, and methodology. It is 
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however also important for researchers to uniformly report on study results to improve comparison of 
results of studies. 
 
Recommendations 
To call attention to the devastating consequences a TBI may have, and to improve prevention, 
treatment and outcomes research in TBI, some specific recommendations can be made based on this 
thesis: 
 
Policy makers 
• Inform the public on the substantial consequences TBI may have, and educate the population about 
how injuries can be avoided. 
• Develop preventive strategies to reduce TBI, targeting 0–24-year-olds, men in the working 
population aged 25–64 years, and elderly cyclists and fallers. 
• Provide funding and support for research to assess the size and impact of the TBI problem. 
 
Health care professionals 
• Inform patients on the physical and mental symptoms that may occur after a TBI. 
• Closely monitor the recovery of TBI victims over a long time of follow-up as TBI symptoms may 
persist for many years and may cause growing problems over time. 
• Pay attention to the psychiatric consequences TBI may have. 
• Do not underestimate the consequences of mild TBI. 
• Incorporate the subjective perspective of patients on their functioning and recovery following injury 
in clinical decision making. 
• Use guidelines in providing care to patients, and register all necessary items of the guideline 
recommendations and quality indicators in patient files. 
 
Researchers 
• Apply an integrated approach to assess the clinical, functional and economic outcomes after injuries 
and diseases, including the health-related quality of life (HRQL) and psychiatric consequences. 
• Link data from multiple sources to obtain full insight into the size and impact of injuries and diseases. 
• Incorporate the productivity costs to assess the economic burden of injuries and diseases. 
• Assess the pre-injury HRQL of patients to estimate the change in health status due to an injury. 
• Assess the long-term consequences and recovery patterns after TBI. 
• Use multiple follow-up measurements over time (preferably lifelong), as recovery patterns and 
occurrence of symptoms may vary over time. 
• Standardise TBI research by using uniform definitions, classifications, methodology (e.g. timings of 
assessments and follow-up), and reporting of study results to enable comparisons between studies.  
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INTRODUCTIE 
 
Letsels vormen wereldwijd een groot probleem voor de volksgezondheid. Ze behoren tot de 
belangrijkste doodsoorzaken en hebben vaak ernstige gevolgen, wat leidt tot hoge kosten voor de 
samenleving. Traumatisch hersenletsel is een letsel met een relatief hoge sterftekans en een aanzienlijk 
risico op blijvende lichamelijke beperkingen. Deze vorm van niet-aangeboren hersenletsel ontstaat 
plotseling door een oorzaak buiten het lichaam, bijvoorbeeld een verkeersongeval of val van de trap. 
Traumatisch hersenletsel wordt vaak beschreven als een stille epidemie. Patiënten en familieleden die 
ervaring hebben met dit letsel weten hoe ernstig de gevolgen kunnen zijn. In de samenleving en zelfs 
onder zorgaanbieders is dit bewustzijn echter nog steeds laag. Bijna alle overlevenden van een 
traumatisch hersenletsel ondervinden lichamelijke of mentale beperkingen. Deze beperkingen hebben 
een grote impact op de kwaliteit van leven van patiënten en hun herstel. Daarnaast hebben 
hersenletselpatiënten vaak moeite om hun werk of studie volledig te hervatten. De langdurige zorg en 
verminderde productiviteit brengen hoge kosten met zich mee voor de patiënt en de samenleving. 
De afgelopen decennia is een sterke stijging zichtbaar van het aantal patiënten dat een ernstig 
traumatisch hersenletsel overleeft. De beperkingen en ziektelast ten gevolge van dit letsel zijn echter 
niet aanzienlijk afgenomen. Hierdoor is er meer aandacht gekomen voor het meten van de (lange-
termijn) uitkomsten na letsels, in aanvulling op sterfte. Er is een toegenomen belangstelling onder 
beleidsmakers en zorgaanbieders om de uitkomsten na letsels te kwantificeren om de effecten van 
preventieprogramma’s en behandelingen te kunnen meten. Inzicht in de incidentie, gezondheidsimpact 
en economische gevolgen van letsels, zoals traumatisch hersenletsel, is noodzakelijk om de ziektelast 
van letselpatiënten onderling of met andere aandoeningen te vergelijken, gezondheidsbeleid en 
preventie te optimaliseren en effectieve (revalidatie)zorg te ontwikkelen. 
 
In dit proefschrift worden de incidentie, gezondheidsgerelateerde kwaliteit van leven, psychische 
gevolgen en kosten van traumatisch hersenletsel en de mogelijkheden voor verbetering van 
uitkomstmeting na letsel onderzocht. Daarbij staan de volgende onderzoeksvragen centraal: 
• Wat zijn de incidentie, gezondheidsimpact en kosten van traumatisch hersenletsel en welke 
risicogroepen kunnen geïdentificeerd worden? 
• Hoe kan het meten van uitkomsten na letsel worden verbeterd? 
• Wat is de impact van traumatisch hersenletsel op de kwaliteit van leven van patiënten en hoe vaak 
komen psychiatrische stoornissen voor na traumatisch hersenletsel? 
• In welke mate worden richtlijnen opgevolgd in de zorgverlening aan letselpatiënten? 
 
Deel I - Epidemiologie van traumatisch hersenletsel 
In deel I wordt de omvang van het hersenletselprobleem in Nederland onderzocht. Op basis van 
informatie over de incidentie, kosten en ziektelast van traumatisch hersenletsel worden belangrijke 
risicogroepen voor preventie geïdentificeerd. Uit de gegevens van het Nederlandse Letsel Informatie 
Systeem (patiënten gezien op de Spoedeisende Hulp-afdeling van een ziekenhuis) en de Landelijke 
Medische Registratie (patiënten opgenomen in het ziekenhuis) in hoofdstuk 2 blijkt dat jaarlijks 35.000 
patiënten met traumatisch hersenletsel op de Spoedeisende Hulp behandeld worden: een incidentie 
van 214 per 100.000 persoonsjaren. Traumatisch hersenletsel leidt tot een aanzienlijke ziektelast: 
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hersenletselpatiënten verliezen gemiddeld 7 levensjaren door ziekte, beperkingen of vroegtijdige 
sterfte. Daarnaast brengt dit type letsel hoge kosten met zich mee: in totaal €315 miljoen per jaar in 
Nederland, met een gemiddelde van €18.000 per patiënt. Het risico op traumatisch hersenletsel en 
diens gezondheids- en economische gevolgen waren het hoogst in kinderen en jongvolwassenen (tot 
24 jaar), mannen (25–64 jaar) en slachtoffers van privé-ongevallen (met name valincidenten bij 0–5 
jarigen en ouderen) en verkeersongevallen (in het bijzonder fietsers). In hoofdstuk 3 onderzochten we 
de incidentie en gevolgen van hersenletsel onder fietsers. We vonden dat het aantal patiënten dat 
opgenomen werd naar aanleiding van een hersenletsel door een fietsongeval de afgelopen tien jaar 
sterk is gestegen, met name onder oudere fietsers (55+). 
 
Deel II - Methodologische uitdagingen in uitkomstmeting na letsel 
Deel II gaat in op de mogelijkheden voor verbetering van uitkomstmeting na letsel. De systematische 
literatuurstudie in hoofdstuk 4 onderzoekt hoe de gezondheidsgerelateerde kwaliteit van leven 
voorafgaand aan een letsel gemeten wordt. Aangezien het vaak niet mogelijk is om deze informatie 
vóór een ongeval te meten, wordt veelal na het ongeval (retrospectief) aan patiënten gevraagd hoe zij 
hun gezondheidstoestand van vóór het ongeval herinneren. Een andere methode is om de algemene 
populatie als norm te gebruiken voor de gezondheidstoestand van patiënten vóór het ongeval. De 
retrospectieve methode levert echter voor de meeste letseltypen een hogere waardering van de 
kwaliteit van leven vóór het ongeval op in vergelijking met de algemene populatienorm. Daarnaast blijft 
het herstel in de gezondheidsgerelateerde kwaliteit van leven na het ongeval in de retrospectieve 
metingen achter op de prospectieve metingen, wat duidt op een systematische overschatting van de 
verandering in de gezondheidsgerelateerde kwaliteit van leven als gevolg van een letsel. Onderzoekers 
moeten bedacht zijn op de bias die gepaard gaat met het gebruik van deze retrospectieve methode en 
het toepassen van algemene populatienormen en moeten waar mogelijk de gezondheidsgerelateerde 
kwaliteit van leven voorafgaand aan een ongeval prospectief meten om de impact van een letsel op de 
gezondheidsgerelateerde kwaliteit van leven van een patiënt te bepalen. 
In de pilot studie in hoofdstuk 5 hebben we data van meerdere registraties gekoppeld aan gegevens van 
een vervolgvragenlijst onder patiënten. We lieten hiermee zien wat uitbereiding van traumaregistraties 
met follow-up gegevens over de uitkomsten na letsels verder dan alleen sterfte kan opleveren. Deze 
koppeling van gegevens biedt inzicht in de uitkomsten van letselpatiënten en maakt het mogelijk om de 
gevolgen van letsels onderling en tussen patiënten te vergelijken. Informatie over de (lange-termijn) 
uitkomsten na letsels zouden geïntegreerd moeten worden in de evaluatie van traumazorg. 
In hoofdstuk 6 vergeleken we twee methoden om wegingsfactoren van traumatisch hersenletsel te 
bepalen. Een wegingsfactor is een maat voor de ernst van de gevolgen van het letsel voor het 
functioneren van patiënten, uitgedrukt op een schaal van 0 (geen nadelige gevolgen) tot 1 (zeer ernstige 
nadelige gevolgen). Door de wegingsfactor voor de ernst van de gevolgen van het letsel te 
vermenigvuldigen met het aantal mensen dat letsel heeft en het aantal mensen dat blijvende 
beperkingen heeft door letsel, kan het aantal verloren levensjaren door het letsel worden berekend 
(ziektejaarequivalenten). In deze studie vergeleken we standaard wegingsfactoren vastgesteld in de 
Global Burden of Disease (GBD) studie 2013 met wegingsfactoren vastgesteld op basis van follow-up 
gegevens over de kwaliteit van leven van individuele patiënten met traumatisch hersenletsel. Beide 
methoden leveren vergelijkbare schattingen op van het aantal ziektejaarequivalenten door traumatisch 
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hersenletsel in Nederland, behalve voor de lange-termijn gevolgen van zwaar traumatisch hersenletsel, 
die veel zwaarder meewogen in de GBD wegingsfactoren, wat zal resulteren in een hoger aantal 
verloren levensjaren. 
 
Deel III - Uitkomsten na traumatisch hersenletsel  
In deel III onderzochten we de impact van traumatisch hersenletsel op de kwaliteit van leven van 
patiënten en het voorkomen van psychiatrische stoornissen na traumatisch hersenletsel. In hoofdstuk 
7 brachten we de herstelpatronen na licht, middelzwaar en zwaar hersenletsel in kaart en onderzochten 
we het verband tussen de functionele uitkomsten na letsel volgens clinici en de patiënt-gerapporteerde 
uitkomsten. We vonden dat hersenletsel van alle ernstniveaus sterk de gezondheidsgerelateerde 
kwaliteit van leven beïnvloedt en dat het herstelpatroon verschilt per ernstniveau. Vrouwelijk geslacht, 
oudere leeftijd, comorbiditeit en een zwaarder letsel bleken voorspellers te zijn voor een lagere 
kwaliteit van leven. Patiënt-gerapporteerde uitkomsten vielen over het algemeen slechter uit dan de 
meting van clinici. Het is daarom belangrijk om het patiënt perspectief mee te nemen in de 
uitkomstmeting na letsels. 
De systematische literatuurstudie in hoofdstuk 8 geeft inzicht in de prevalentie van angst- en 
depressieve stoornissen na traumatisch hersenletsel. We vonden een grote variatie in de prevalentie 
van psychische stoornissen tussen de verschillende studies. Posttraumatische stress (PTSS) en depressie 
waren de meest voorkomende stoornissen ten gevolge van traumatisch hersenletsel. Ongeveer één op 
de vijf patiënten had een geschiedenis van een angst- (19%) of depressieve stoornis (13%) vóór het 
ongeval en bij een groter aantal patiënten werden deze stoornissen gediagnosticeerd in het jaar na het 
letsel (respectievelijk 21% en 17%). De gepoolde prevalenties uit de verschillende studies namen toe 
over tijd met een hoge prevalentie van angst- (36%) en depressieve stoornissen (43%) in de lange 
termijn. 
De meta-analyse in hoofdstuk 9 geeft inzicht in de risicofactoren van PTSS en depressie ten gevolge van 
traumatisch hersenletsel. We vonden dat patiënten met een kortere toestand van verwarring (post-
traumatische amnesie) en patiënten die zich het ongeval kunnen herinneren een hoger risico hebben 
op een diagnose van PTSS na traumatisch hersenletsel. Depressie werd geassocieerd met een 
geschiedenis van een depressieve stoornis vóór het ongeval, vrouwelijk geslacht, middelzwaar 
hersenletsel en werkloosheid na het ongeval. 
In hoofdstuk 10 onderzochten we de impact van PTSS en depressie op de gezondheidsgerelateerde 
kwaliteit van leven van patiënten met hersenletsel. Zowel PTSS als depressie werden geassocieerd met 
een significante daling in de functionele uitkomsten en kwaliteit van leven na traumatisch hersenletsel. 
 
Deel IV - Opvolging van richtlijnen 
Deel IV onderzoekt de opvolging van richtlijnen in de behandeling van letselpatiënten. In de 
systematische literatuurstudie in hoofdstuk 11 onderzochten we de mate waarin richtlijnen worden 
opgevolgd bij patiënten met traumatisch hersenletsel, de factoren die het opvolgen van richtlijnen 
beïnvloeden en de relatie tussen het opvolgen van richtlijnen en de uitkomsten voor de patiënt. In 
hoofdstuk 12 onderzochten we medische dossiers van zorginstellingen in de acute zorg om na te gaan 
in welke mate de huidige hulpverlening overeenkomt met een nieuwe richtlijn over pijnbehandeling bij 
traumapatiënten in de spoedzorgketen. Uit beide studies bleek dat de richtlijnen over het algemeen 
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matig werden opgevolgd en dat de mate van opvolging sterk varieerde tussen zorginstellingen. We 
vonden dat bij traumatisch hersenletsel de opvolging van richtlijnen hoger was bij jongere patiënten, 
zwaarder hersenletsel en bij aanbevelingen uit richtlijnen die onderbouwd waren met overtuigend 
wetenschappelijk bewijs dan bewijs van een lager niveau. Opvolging van richtlijnen werd geassocieerd 
met betere uitkomsten voor de patiënt, onder andere lagere sterfte. 
 
DISCUSSIE 
 
Het doel van dit proefschrift was om de incidentie, gezondheidsgerelateerde kwaliteit van leven, 
psychische gevolgen en kosten van traumatisch hersenletsel en de mogelijkheden voor verbetering van 
uitkomstmeting na letsel te onderzoeken. 
Onze studies toonden aan dat traumatisch hersenletsel een substantiële impact heeft op zowel de 
individuele patiënt als de samenleving. Traumatisch hersenletsel heeft grote en veelal langdurige 
gevolgen voor het functioneren en de gezondheidsgerelateerde kwaliteit van leven van patiënten, wat 
leidt tot een hoge ziektelast. Daarnaast brengt traumatisch hersenletsel hoge kosten met zich mee door 
de lange-termijn behoefte aan specialistische zorg en het verlies aan productiviteit. Echter, de huidige 
epidemiologische gegevens zijn niet volledig aangezien niet alle hersenletselpatiënten worden 
geregistreerd in de bestaande registraties. Deze registraties missen bijvoorbeeld de patiënten met licht 
hersenletsel die  buiten het ziekenhuis worden behandeld, of geen medische hulp zoeken. Daarnaast 
zijn gegevens over de lange-termijn gevolgen en hulpverlening na letsels (zoals revalidatie of zelfs 
sterfte) niet altijd gemakkelijk beschikbaar. Hierdoor is ons inzicht in de daadwerkelijke omvang van het 
hersenletselprobleem nog niet volledig. 
We vonden dat het onderzoek naar de epidemiologie en gevolgen van traumatisch hersenletsel 
belemmerd wordt door de sterke heterogeniteit in oorzaken, ernst, behandeling en uitkomsten van 
hersenletsel en dat onderzoek naar traumatisch hersenletsel nog steeds niet gestandaardiseerd is. Er 
zijn aanzienlijke verschillen in methoden om uitkomsten na traumatisch hersenletsel te meten, zoals 
verschillende studie populaties, meetinstrumenten en de periode en timing van vervolgonderzoek. Dit 
beperkt de vergelijkbaarheid van resultaten tussen studies. Daarnaast kunnen verschillende methoden 
leiden tot verschillende waarderingen van dezelfde gezondheidstoestanden en daarmee verschillende 
schattingen van de letsel-gerelateerde ziektelast tot gevolg hebben. 
 
Implicaties 
Onze resultaten hebben implicaties voor beleidsmakers, zorgaanbieders en toekomstig onderzoek. 
Preventieprogramma’s zijn nodig om de samenleving te informeren over de gevolgen die traumatisch 
hersenletsel kan hebben, ook de lichtere letsels, en hoe deze letsels voorkomen kunnen worden. 
Preventiemaatregelen zouden zich moeten richten op het verlagen van de incidentie en impact van 
hersenletsel onder kinderen, jongvolwassenen, mannen (25–64 jaar) en slachtoffers van privé-
ongevallen (valincidenten onder kinderen en ouderen) en verkeersongevallen (fietsers). De toename 
van het aantal hersenletselpatiënten door verkeersongevallen en valincidenten in de vergrijzende 
samenleving benadrukken de noodzaak voor financiële steun van hersenletselonderzoek. Zonder deze 
steun zal er beperkt inzicht zijn in de uitkomsten en het herstel van deze patiënten, evenals in de manier 
waarop preventie en revalidatie van traumatisch hersenletsel kan worden verbeterd. 
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Zorgaanbieders moeten bedacht zijn op de gevolgen die traumatisch hersenletsel kan hebben en 
moeten hun patiënten informeren over de symptomen en klachten die na dit letsel zouden kunnen 
ontstaan. Het herstel van patiënten zou nauwkeurig gevolgd moeten worden, ook na licht hersenletsel. 
Zorgaanbieders kunnen hierbij gebruik maken van patiënt-gerapporteerde uitkomsten, bijvoorbeeld uit 
kwaliteit van leven instrumenten. Deze informatie maakt het hen mogelijk om functionele problemen 
bij patiënten op te sporen en de gevolgen van letsels te monitoren. Door dit patiënt perspectief op het 
functioneren en herstel na het letsel onderdeel te laten uitmaken van de besluitvorming over de 
behandeling, kunnen zorgaanbieders de uitkomsten voor patiënten verbeteren. De uitkomst voor de 
patiënt kan tevens worden verbeterd door aanbevelingen uit wetenschappelijk onderbouwde 
richtlijnen toe te passen in de dagelijkse zorg aan patiënten. Om het effect van deze zorg te kunnen 
evalueren is het van belang om een complete registratie van de aanbevelingen uit richtlijnen en 
kwaliteitsindicatoren bij te houden. 
 
Toekomstig onderzoek 
Het meten van zowel de incidentie, functionele uitkomsten als kosten van letsels is noodzakelijk om 
inzicht te krijgen in de omvang van het letselprobleem en om prioriteiten te kunnen stellen voor de 
preventie en behandeling van letsels. Daarom is het cruciaal dat onderzoekers een integrale aanpak 
toepassen en alle drie uitkomsten na letsels meten om belangrijke risicogroepen voor preventie te 
identificeren. Daarbij kan gebruik worden gemaakt van het koppelen van bestaande gegevens uit 
verschillende registraties. Daarnaast is het van belang, zeker in geval van traumatisch hersenletsel, om 
niet alleen de directe medische kosten van letsels te bepalen, maar ook de kosten in kaart te brengen 
die gepaard gaan met het verlies aan productiviteit door letsels. Deze productiviteitskosten bepalen 
namelijk het overgrote deel van de totale economische gevolgen van zware letsels zoals traumatisch 
hersenletsel. Om de invloed van andere factoren op het functioneren (zoals comorbiditeit) uit te sluiten 
is informatie nodig over de gezondheidstoestand van de patiënt vóór het ongeval. Verschillende 
methoden kunnen gebruikt worden om de gezondheidsgerelateerde kwaliteit van leven vóór een 
ongeval te meten, bijvoorbeeld door retrospectief te meten of de algemene populatie als norm te 
gebruiken. Onderzoekers moeten echter bedacht zijn op het effect dat deze methoden kunnen hebben 
op hun schatting van de impact van een letsel op de gezondheidsgerelateerde kwaliteit van leven van 
patiënten. 
 
Er is meer longitudinaal onderzoek nodig naar de lange-termijn gevolgen en herstelpatronen na 
traumatisch hersenletsel. Daarbij zijn meerdere follow-up momenten over tijd nodig, aangezien 
symptomen van hersenletsel kunnen toenemen en variëren over tijd. Hersenletselonderzoek zou 
gestandaardiseerd moeten worden door gelijke definities, classificaties en methoden te gebruiken. 
Daarbij is het van belang om resultaten op een uniforme manier te rapporteren om zo de 
vergelijkbaarheid van resultaten tussen studies te verhogen. Tot slot moet de belasting van onderzoek 
voor patiënten worden gereduceerd, zeker in geval van zware letsels. 
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Aanbevelingen 
Om meer aandacht te vragen voor de aanzienlijke gevolgen die traumatisch hersenletsel kan hebben 
en om de preventie, behandeling en uitkomstmeting na hersenletsel te verbeteren, doen wij enkele 
aanbevelingen op basis van dit proefschrift: 
 
Beleidsmakers 
• Informeer de samenleving over de gevolgen die traumatisch hersenletsel kan hebben en hoe deze 
letsels voorkomen kunnen worden. 
• Ontwikkel preventiemaatregelen om de incidentie en impact van hersenletsel te verlagen, gericht 
op 0–24-jarigen, mannen in de leeftijd 25–64 jaar en slachtoffers van verkeersongevallen en 
valincidenten. 
• Bied financiële ondersteuning voor onderzoek om inzicht te krijgen in de omvang en impact van 
het hersenletselprobleem. 
 
Zorgaanbieders 
• Informeer patiënten over de fysieke en mentale klachten die kunnen ontstaan na een traumatisch 
hersenletsel. 
• Volg nauwkeurig het herstel van slachtoffers van een traumatisch hersenletsel op de lange 
termijn, aangezien klachten meerdere jaren kunnen aanhouden en problemen kunnen variëren 
over tijd. 
• Wees bedacht op de psychische gevolgen die een traumatisch hersenletsel kan hebben. 
• Onderschat de gevolgen van licht traumatisch hersenletsel niet. 
• Laat het perspectief van de patiënt over diens functioneren en herstel na het letsel onderdeel 
uitmaken van de besluitvorming over de behandeling. 
• Pas aanbevelingen uit wetenschappelijk onderbouwde richtlijnen toe in de dagelijkse zorg aan 
patiënten en registreer de aanbevelingen uit richtlijnen en kwaliteitsindicatoren. 
 
Onderzoekers 
• Pas een integrale aanpak toe en onderzoek zowel de incidentie, functionele uitkomsten als kosten 
van letsels en ziekten, inclusief de kwaliteit van leven en psychische gevolgen. 
• Koppel data van verschillende registraties om inzicht te krijgen in de omvang en impact van letsels 
en ziekten. 
• Onderzoek ook de productiviteitskosten om de economische impact van letsels en ziekten te 
bepalen. 
• Meet de gezondheidstoestand van patiënten vóór het ongeval om de letsel-gerelateerde 
ziektelast te bepalen. 
• Onderzoek de lange-termijn uitkomsten en herstelpatronen na traumatisch hersenletsel. 
• Gebruik meerdere follow-up moment over tijd, aangezien symptomen van hersenletsel kunnen 
toenemen en variëren over tijd. 
• Standaardiseer hersenletselonderzoek en verhoog de vergelijkbaarheid tussen studies door 
uniforme definities, classificaties, methoden en rapportage van studieresultaten te gebruiken. 
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Gevolgen voor en volgens de patiënt: verbreding uitkomstmetingen, 
LNAZ Symposium 2015, Utrecht, the Netherlands 
2015 1.0 
National and international conferences   
WEON 2014, Leiden, the Netherlands 2014 0.6 
LNAZ Symposium 2014, Amersfoort, the Netherlands 2014 0.1 
ISOQOL 2014, Berlin, Germany 2014 1.2 
Healthy Living Conference 2015, Maastricht, the Netherlands 2015 0.9 
LNAZ Symposium 2015, Utrecht, the Netherlands 2015 0.1 
Seminars and workshops   
Research seminars, Dep. Public Health, Erasmus MC, Rotterdam, the 
Netherlands 
2013–2015 3.0 
CMB/Club Meth, Rotterdam, the Netherlands 2013–2015 1.0 
2. Teaching activities   
Supervisor medical students theme 3.C.4 (community projects) 2013–2015 4.5 
Lecturer medical students course ‘From Problem to Solution in Public Health’ 2014 0.3 
Checking examinations course ‘GEN3C1 - Arts en volksgezondheid (REG)’ 2014 0.3 
CMB: Medical Decision Making; ISOQOL: International Society for Quality of Life Research; LNAZ: Dutch Network for Emergency Care; NIHES: 
National Institute for Health Sciences; WEON: Working Group on Epidemiological Research Netherlands. 
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